1 00:00:05,440 --> 00:00:09,640 >>WE'D LIKE TO WELCOME THE 2 00:00:09,640 --> 00:00:15,000 MEMBERS OF THE BSA AND NATIONAL 3 00:00:15,000 --> 00:00:17,480 CANCER ADVISORY BOARD, NCAB, EX 4 00:00:17,480 --> 00:00:18,240 OFFICIO MEMBERS, PANEL MEMBERS, 5 00:00:18,240 --> 00:00:20,400 STAFF AND GUESTS. 6 00:00:20,400 --> 00:00:28,560 TODAY WE'RE GOING TO START WITH 7 00:00:28,560 --> 00:00:29,520 A PRESENTATION FROM IRENE 8 00:00:29,520 --> 00:00:33,480 GHOBRIAL, PROFESSOR OF MEDICINE 9 00:00:33,480 --> 00:00:36,920 AT HARVARD, LEVINE FAMILY CHAIR, 10 00:00:36,920 --> 00:00:42,360 PREVENTIVE CANCER THERAPY, 11 00:00:42,360 --> 00:00:43,680 DANA-FARBER CANCER INSTITUTE. 12 00:00:43,680 --> 00:00:45,800 DO WE HAVE IRENE? 13 00:00:45,800 --> 00:00:47,960 >>I'M CHECKING TO SEE. 14 00:00:47,960 --> 00:00:50,440 >>SHE DOESN'T APPEAR TO BE ON, 15 00:00:50,440 --> 00:00:51,880 WE'LL CHECK. 16 00:00:51,880 --> 00:01:02,080 >>HMM. 17 00:01:16,160 --> 00:01:18,040 AN AREA NEAR AND DEAR TO MY 18 00:01:18,040 --> 00:01:22,120 HEART, I CAN GIVE A 19 00:01:22,120 --> 00:01:22,440 PRESENTATION. 20 00:01:22,440 --> 00:01:22,800 [LAUGHTER] 21 00:01:22,800 --> 00:01:24,560 AND SO CAN KAREN. 22 00:01:24,560 --> 00:01:27,920 [LAUGHTER] 23 00:01:27,920 --> 00:01:30,760 24 00:01:30,760 --> 00:01:32,320 >>THIS IS A FIRST. 25 00:01:32,320 --> 00:01:39,560 BUT WE ARE PATIENT. 26 00:01:39,560 --> 00:01:44,000 >>I'M ASSUMING SHE WAS SENT 27 00:01:44,000 --> 00:01:44,360 REMINDERS. 28 00:01:44,360 --> 00:01:49,800 >>SHE'S SCHEDULED TO BEGIN AT 29 00:01:49,800 --> 00:01:50,000 1:05. 30 00:01:50,000 --> 00:01:58,160 WE STILL HAVE THREE MINUTES. 31 00:01:58,160 --> 00:02:01,080 >>I'M ALWAYS LOOKING FOR YOUR 32 00:02:01,080 --> 00:02:07,680 CUE, PAULETTE. 33 00:02:07,680 --> 00:02:12,520 >>I THINK SHE JUST JOINED. 34 00:02:12,520 --> 00:02:13,760 SHE IS ON. 35 00:02:13,760 --> 00:02:17,360 YES, I JUST SAW HER. 36 00:02:17,360 --> 00:02:17,800 >>GREAT. 37 00:02:17,800 --> 00:02:19,880 IRENE, DO WE HAVE YOU? 38 00:02:19,880 --> 00:02:25,120 >>YES, I'M HERE. 39 00:02:25,120 --> 00:02:25,440 >>AWESOME. 40 00:02:25,440 --> 00:02:29,280 WE CAN SHARE YOUR SLIDES. 41 00:02:29,280 --> 00:02:30,920 I'VE ALREADY INTRODUCED YOU, AND 42 00:02:30,920 --> 00:02:32,560 THE TITLE OF YOUR PRESENTATION. 43 00:02:32,560 --> 00:02:36,200 SO WHENEVER YOU'RE READY TO 44 00:02:36,200 --> 00:02:36,400 START. 45 00:02:36,400 --> 00:02:38,880 >>ALL RIGHT. 46 00:02:38,880 --> 00:02:43,720 47 00:02:43,720 --> 00:02:46,480 NEXT SLIDE. 48 00:02:46,480 --> 00:02:49,080 49 00:02:49,080 --> 00:02:51,240 SO JUST TO REMIND EVERYONE 50 00:02:51,240 --> 00:02:53,280 MULTIPLE MYELOMA IS A BLOOD 51 00:02:53,280 --> 00:02:54,800 MALIGNANCY IN 35,000 NEW CASES 52 00:02:54,800 --> 00:02:57,760 PER YEAR IN THE UNITED STATES. 53 00:02:57,760 --> 00:03:00,040 EVERY PATIENT WHO IS DIAGNOSED 54 00:03:00,040 --> 00:03:01,560 RIGHT NOW WITH MULTIPLE MYELOMA 55 00:03:01,560 --> 00:03:08,480 MUST HAVE HAD THE PRECURSOR 56 00:03:08,480 --> 00:03:10,000 CONDITION, MGUS OR SMOLDER 57 00:03:10,000 --> 00:03:12,320 MULTIPLE MYELOMA WITH A HIGH 58 00:03:12,320 --> 00:03:13,720 CHANCE OF DEVELOPING MYELOMA, 59 00:03:13,720 --> 00:03:16,560 10% PER YEAR, AND IN SOME 60 00:03:16,560 --> 00:03:21,720 PATIENTS WE CONSIDER THEM HIGH 61 00:03:21,720 --> 00:03:23,240 RISK SMOLDERS, 50% CHANCE OF 62 00:03:23,240 --> 00:03:25,200 PROGRESSION WITHIN TWO YEARS. 63 00:03:25,200 --> 00:03:27,280 IT'S THE END ORGAN DAMAGE, 64 00:03:27,280 --> 00:03:28,160 PATIENTS HAVE THE MALIGNANT 65 00:03:28,160 --> 00:03:31,000 CANCER CELLS IN THEIR BONE 66 00:03:31,000 --> 00:03:38,000 MARROW BUT ALSO HAVE THE 67 00:03:38,000 --> 00:03:39,640 CRITERIA, HYPER CALCEMIA, AND IF 68 00:03:39,640 --> 00:03:42,280 WE THINK ABOUT INCIDENCE OF MGUS 69 00:03:42,280 --> 00:03:44,280 IN THE POPULATION, IT'S ABOUT 3% 70 00:03:44,280 --> 00:03:45,880 IN THE POPULATION OVER THE AGE 71 00:03:45,880 --> 00:03:47,760 OF 50, AND THAT'S NOT ACCOUNTING 72 00:03:47,760 --> 00:03:50,680 FOR THE HIGH RISK OF THAT 73 00:03:50,680 --> 00:03:51,520 HAPPENING IN AFRICAN AMERICANS 74 00:03:51,520 --> 00:03:54,560 OR IN PEOPLE WITH THE FIRST 75 00:03:54,560 --> 00:03:57,280 DEGREE RELATIVE WITH MYELOMA OR 76 00:03:57,280 --> 00:03:58,560 ANY B CELL MALIGNANCY, TWO TO 77 00:03:58,560 --> 00:04:01,520 THREE TIMES HIGHER CHANCE OF 78 00:04:01,520 --> 00:04:02,200 DEVELOPING MGUS. 79 00:04:02,200 --> 00:04:03,080 NEXT SLIDE. 80 00:04:03,080 --> 00:04:05,920 IF WE START THINKING ABOUT THIS, 81 00:04:05,920 --> 00:04:09,440 WHAT ARE THE NUMBERS FOR 82 00:04:09,440 --> 00:04:16,000 MULTIPLE MYELOMA IN THE 83 00:04:16,000 --> 00:04:17,440 POPULATION, TWO TO THREE TIMES, 84 00:04:17,440 --> 00:04:19,160 EVERY CASE HIGHER IN THE AFRICAN 85 00:04:19,160 --> 00:04:20,160 AMERICAN POPULATION IS BECAUSE 86 00:04:20,160 --> 00:04:22,240 THEY HAVE AN EARLIER PRECURSOR 87 00:04:22,240 --> 00:04:23,160 CONDITION. 88 00:04:23,160 --> 00:04:26,080 IT'S NOT BECAUSE USUALLY THEY 89 00:04:26,080 --> 00:04:29,920 PROGRESS MUCH MORE RAPIDLY FROM 90 00:04:29,920 --> 00:04:32,160 MGUS TO MYELOMA, NOT RAPID BUT A 91 00:04:32,160 --> 00:04:34,040 HIGHER CHANCE AT DEVELOPING AT 92 00:04:34,040 --> 00:04:36,400 EARLIER STAGE EVEN AT AGE 30 AND 93 00:04:36,400 --> 00:04:36,600 ABOVE. 94 00:04:36,600 --> 00:04:44,000 IF YOU LOOK AT CURRENT NUMBERS 95 00:04:44,000 --> 00:04:45,880 WE HAVE ONE OUT OF FIVE 96 00:04:45,880 --> 00:04:48,680 DIAGNOSED, AFRICAN AMERICANS OR 97 00:04:48,680 --> 00:04:53,440 BLACK 98 00:04:53,440 --> 00:04:53,640 BLACK. 99 00:04:53,640 --> 00:04:58,320 BY 2034 WE EXPECTED TO BE 24%. 100 00:04:58,320 --> 00:05:00,320 MYELOMA IS MORE COMMON IN 101 00:05:00,320 --> 00:05:01,600 AFRICAN AMERICANS AT YOUNGER 102 00:05:01,600 --> 00:05:01,960 AGE. 103 00:05:01,960 --> 00:05:03,560 AGAIN, LIKELY THAT'S BECAUSE 104 00:05:03,560 --> 00:05:05,560 THEY GET DIAGNOSED WITH MGUS OR 105 00:05:05,560 --> 00:05:06,880 DEVELOP MGUS AT YOUNGER AGE SO 106 00:05:06,880 --> 00:05:10,160 CHANCES OF IT GOING ON TO 107 00:05:10,160 --> 00:05:11,240 DEVELOP MYELOMA HAPPENS AT 108 00:05:11,240 --> 00:05:12,600 YOUNGER AGE. 109 00:05:12,600 --> 00:05:15,360 THINK ABOUT MEDIAN AGE OF 110 00:05:15,360 --> 00:05:17,240 DEVELOPING MYELOMA IT'S 65 TO 111 00:05:17,240 --> 00:05:21,240 70, YOU A INDICATION AT -- YOU A 112 00:05:21,240 --> 00:05:22,200 INDICATIONS AT OLDER AGE, 113 00:05:22,200 --> 00:05:23,240 AFRICAN AMERICANS AND HISPANICS 114 00:05:23,240 --> 00:05:23,920 AT YOUNGER AGE. 115 00:05:23,920 --> 00:05:25,280 THE PROBLEM THOUGH IS OUR 116 00:05:25,280 --> 00:05:26,520 PATIENTS ARE NOT BEING DIAGNOSED 117 00:05:26,520 --> 00:05:28,000 AT THAT EARLIER STAGE. 118 00:05:28,000 --> 00:05:29,400 IN FACT, BY THE TIME THEY HAVE 119 00:05:29,400 --> 00:05:31,720 SYMPTOMS TO THE TIME THEY ARE 120 00:05:31,720 --> 00:05:33,240 DIAGNOSED WITH MYELOMA, THERE'S 121 00:05:33,240 --> 00:05:35,680 A HUGE DELAY IN THE AFRICAN 122 00:05:35,680 --> 00:05:37,600 AMERICAN POPULATION, COMPARED TO 123 00:05:37,600 --> 00:05:38,160 THE CAUCASIAN POPULATION. 124 00:05:38,160 --> 00:05:42,560 AND THAT DELAY COULD BE FROM 125 00:05:42,560 --> 00:05:45,480 MANY FACTORS, ONE ACCESS TO GOOD 126 00:05:45,480 --> 00:05:46,600 HEALTHCARE AND SYSTEM OF CARE 127 00:05:46,600 --> 00:05:49,120 FOR PATIENTS WHO ARE OF AFRICAN 128 00:05:49,120 --> 00:05:51,400 DESCENT, BUT TWO, COULD BE 129 00:05:51,400 --> 00:06:01,880 BECAUSE THEY HAVE UNDERLYING 130 00:06:05,040 --> 00:06:09,560 RENAL INSUFFICIENCY, 131 00:06:09,560 --> 00:06:10,440 MISDIAGNOSED, UNDIAGNOSED, 132 00:06:10,440 --> 00:06:10,720 DIABETES. 133 00:06:10,720 --> 00:06:12,760 YOU EXPECT BY THE TIME THEY GET 134 00:06:12,760 --> 00:06:14,200 DIAGNOSED THEY SHOULD ACTUALLY 135 00:06:14,200 --> 00:06:15,480 RECEIVE THERAPY EQUALLY AND 136 00:06:15,480 --> 00:06:17,440 EQUITABLY COMPARED TO THE 137 00:06:17,440 --> 00:06:18,200 CAUCASIAN POPULATION. 138 00:06:18,200 --> 00:06:19,440 UNFORTUNATELY, THAT'S NOT TRUE. 139 00:06:19,440 --> 00:06:24,880 SO IF WE LOOK AT THE SURVIVAL OF 140 00:06:24,880 --> 00:06:28,040 OUR PATIENTS WHO ARE AFRICAN 141 00:06:28,040 --> 00:06:28,280 AMERICAN 142 00:06:28,280 --> 00:06:28,800 [AUDIO DISTORTION] 143 00:06:28,800 --> 00:06:32,040 ALL OF THE AMAZING DRUGS RIGHT 144 00:06:32,040 --> 00:06:33,800 NOW FOR MYELOMA, OVER 15 NEW 145 00:06:33,800 --> 00:06:34,960 FDA-APPROVED DRUGS OVER THE LAST 146 00:06:34,960 --> 00:06:37,320 10 YEARS OR SO AND IT'S 147 00:06:37,320 --> 00:06:38,600 IMPRESSIVE THE SURVIVAL WE HAVE 148 00:06:38,600 --> 00:06:41,760 NOW OF PEOPLE LIVING INSTEAD OF 149 00:06:41,760 --> 00:06:45,280 3 TO 5 YEARS, 10 TO 15 YEARS IN 150 00:06:45,280 --> 00:06:45,600 MYELOMA. 151 00:06:45,600 --> 00:06:47,480 WE GOT AN ANTIBODY APPROVED A 152 00:06:47,480 --> 00:06:49,320 FEW WEEKS AGO, AND YET IF YOU 153 00:06:49,320 --> 00:06:50,960 THINK ABOUT IT, ACCESS TO THOSE 154 00:06:50,960 --> 00:06:53,920 GREAT DRUGS THAT WE HAVE IN 155 00:06:53,920 --> 00:06:57,000 MYELOMA IS VERY DISMAL IN OUR 156 00:06:57,000 --> 00:06:57,560 AFRICAN AMERICAN POPULATION. 157 00:06:57,560 --> 00:06:59,880 SOME OF THOSE SLIDES ARE FROM MY 158 00:06:59,880 --> 00:07:02,680 FRIEND WHO CALLS IT THE THREE 159 00:07:02,680 --> 00:07:04,120 Ts, DON'T HAVE ACCESS TO 160 00:07:04,120 --> 00:07:08,160 TRIPLE THERAPY, NOW WE EVEN HAVE 161 00:07:08,160 --> 00:07:09,480 FOUR DRUG COMBINATIONS, DON'T 162 00:07:09,480 --> 00:07:10,960 HAVE ACCESS TO TRANSPLANT, DON'T 163 00:07:10,960 --> 00:07:12,560 HAVE ACCESS TO CAR T THERAPY, 164 00:07:12,560 --> 00:07:15,160 AND THE FOURTH ONE THEY DON'T 165 00:07:15,160 --> 00:07:17,960 HAVE ACCESS TO CLINICAL TRIALS. 166 00:07:17,960 --> 00:07:20,320 THIS WAS REALLY HIGHLIGHTED BY 167 00:07:20,320 --> 00:07:23,280 DR. GORMLEY SHOWING LESS THAN 8% 168 00:07:23,280 --> 00:07:24,720 OF OUR POPULATION WHO ARE 169 00:07:24,720 --> 00:07:27,120 AFRICAN AMERICAN HAVE ACCESS TO 170 00:07:27,120 --> 00:07:28,320 CLINICAL TRIALS OR ARE ENROLLED 171 00:07:28,320 --> 00:07:30,480 IN CLINICAL TRIALS, THAT SHOWS 172 00:07:30,480 --> 00:07:31,480 THERE'S A HUGE DISCREPANCY 173 00:07:31,480 --> 00:07:33,480 BETWEEN WHAT WE HAVE ACCESS TO 174 00:07:33,480 --> 00:07:36,560 AND WHAT OUR PATIENTS WHO ARE OF 175 00:07:36,560 --> 00:07:37,840 AFRICAN AMERICAN DESCENT ARE 176 00:07:37,840 --> 00:07:39,360 INDEED GETTING TO ACHIEVE OR 177 00:07:39,360 --> 00:07:42,800 RECEIVE IN OUR CURRENT CARE. 178 00:07:42,800 --> 00:07:43,320 NEXT SLIDE. 179 00:07:43,320 --> 00:07:45,160 NOW, IF YOU THINK ABOUT HOW TO 180 00:07:45,160 --> 00:07:47,440 IMPROVE ON THAT, YOU ACTUALLY 181 00:07:47,440 --> 00:07:48,680 TREAT THE PATIENTS THE SAME WAY, 182 00:07:48,680 --> 00:07:53,480 AND THIS WAS DONE IN EMORY, 183 00:07:53,480 --> 00:07:54,480 ENROLLED AFRICAN AMERICANS ON 184 00:07:54,480 --> 00:07:56,560 CLINICAL TRIALS WITH EQUITABLE 185 00:07:56,560 --> 00:07:57,280 CARE, INDEED THE SURVIVAL 186 00:07:57,280 --> 00:07:58,520 EXACTLY IS THE SAME. 187 00:07:58,520 --> 00:08:01,080 IF WE IMPROVE OUR CARE TO OUR 188 00:08:01,080 --> 00:08:02,240 PATIENTS, IN FACT THEIR SURVIVAL 189 00:08:02,240 --> 00:08:04,680 WOULD BE BETTER OR THE SAME AS 190 00:08:04,680 --> 00:08:06,800 CAUCASIAN POPULATION. 191 00:08:06,800 --> 00:08:07,720 NEXT SLIDE. 192 00:08:07,720 --> 00:08:11,240 AND THAT COMES BECAUSE THEIR 193 00:08:11,240 --> 00:08:12,240 UNDERLYING BIOLOGY, BIOLOGICAL 194 00:08:12,240 --> 00:08:13,440 CHANGES OF MULTIPLE MYELOMA OF 195 00:08:13,440 --> 00:08:15,520 THE TUMOR CELLS THEMSELVES ARE 196 00:08:15,520 --> 00:08:17,080 LIKELY ACTUALLY BETTER IN A 197 00:08:17,080 --> 00:08:19,560 PATIENT WHO IS AFRICAN AMERICAN 198 00:08:19,560 --> 00:08:20,880 THAN CAUCASIAN POPULATION. 199 00:08:20,880 --> 00:08:23,360 THE NUMBERS ARE SMALL AND WE'RE 200 00:08:23,360 --> 00:08:28,000 NOT SURE INDEED THOSE ARE EXACT, 201 00:08:28,000 --> 00:08:30,000 NEED MORE TRIALS TO UNDERSTAND 202 00:08:30,000 --> 00:08:31,720 UNDERLYING BIOLOGY WHY SOMEONE 203 00:08:31,720 --> 00:08:33,040 OF AFRICAN DESCENT, TUMOR CELLS 204 00:08:33,040 --> 00:08:35,320 MAY BE DIFFERENT THAN CAUCASIAN 205 00:08:35,320 --> 00:08:36,720 POPULATION, WE'RE LOOKING AT 206 00:08:36,720 --> 00:08:37,840 GERMLINE SEQUENCING DATA IN 207 00:08:37,840 --> 00:08:40,040 THOSE PATIENTS BUT WE THINK THAT 208 00:08:40,040 --> 00:08:46,120 INDEED AFRICAN AMERICANS MAY 209 00:08:46,120 --> 00:08:50,160 HAVE A BETTER PROGNOSIS, LESS OF 210 00:08:50,160 --> 00:08:53,040 17P AND 13Q DELETION WE MAY GIVE 211 00:08:53,040 --> 00:08:55,360 WORSE PROGNOSIS IN OUR PATIENTS 212 00:08:55,360 --> 00:08:55,880 WITH MYELOMA. 213 00:08:55,880 --> 00:08:57,760 AND THIS WAS FURTHER CONFIRMED 214 00:08:57,760 --> 00:08:59,080 IN MULTIPLE OTHER STUDIES EVEN 215 00:08:59,080 --> 00:09:03,800 IN EMORY UNIVERSITY WHERE THEY 216 00:09:03,800 --> 00:09:05,080 TREATED EVERYONE WITH RVD, WHERE 217 00:09:05,080 --> 00:09:08,160 WE HAVE NOW THE NOVEL THERAPIES 218 00:09:08,160 --> 00:09:12,880 SO THE EFFECT OF CYTOGENETICS 219 00:09:12,880 --> 00:09:14,920 WOULD BE CRITICAL, THOSE 220 00:09:14,920 --> 00:09:17,120 PATIENTS HAVE BETTER COMPARED TO 221 00:09:17,120 --> 00:09:19,520 CAW CAUTION POPULATION, LESS OF 222 00:09:19,520 --> 00:09:25,920 THE 1Q GAIN, MORE 1:14, LESS 17P 223 00:09:25,920 --> 00:09:27,960 DELETION, LESS 13Q DELETION. 224 00:09:27,960 --> 00:09:29,600 WITH THAT IN MIND, WE TRY ASK 225 00:09:29,600 --> 00:09:31,040 THE QUESTION WHAT CAN WE DO TO 226 00:09:31,040 --> 00:09:32,560 CHANGE ALL OF THIS? 227 00:09:32,560 --> 00:09:34,640 HOW CAN WE IMPROVE ON EARLY 228 00:09:34,640 --> 00:09:36,960 DETECTION OF OUR PATIENTS 229 00:09:36,960 --> 00:09:38,680 ESPECIALLY AFRICAN AMERICAN 230 00:09:38,680 --> 00:09:40,800 COMMUNITY THAT HAS HIGHER 231 00:09:40,800 --> 00:09:43,640 INCIDENCE TO DEVELOP MGUS AT 232 00:09:43,640 --> 00:09:46,480 YOUNGER AGE, EMPOWER THEM TO BE 233 00:09:46,480 --> 00:09:48,160 DIAGNOSED EARLY TO INTERCEPT 234 00:09:48,160 --> 00:09:50,440 BEFORE END ORGAN DAMAGE, KIDNEY 235 00:09:50,440 --> 00:09:51,960 DAMAGE, BROKEN FRACTURES, AND 236 00:09:51,960 --> 00:09:53,080 BRING THE BEST CLINICAL TRIAL 237 00:09:53,080 --> 00:09:55,720 DRUGS AND BEST DRUGS WE HAVE 238 00:09:55,720 --> 00:09:57,560 INCLUDING IMMUNOTHERAPY TO THE 239 00:09:57,560 --> 00:09:58,960 EARLIER SETTING TO PREVENT 240 00:09:58,960 --> 00:10:00,280 FURTHER PROGRESSION OF THE 241 00:10:00,280 --> 00:10:01,720 PATIENT AND POTENTIALLY IMPROVE 242 00:10:01,720 --> 00:10:03,240 SURVIVAL IN GENERAL OF OUR 243 00:10:03,240 --> 00:10:06,200 PATIENTS SO THE SPECTRUM IS 244 00:10:06,200 --> 00:10:07,200 EARLY DETECTION AND EARLY 245 00:10:07,200 --> 00:10:09,480 INTERCEPTION BUT IS MUCH BETTER 246 00:10:09,480 --> 00:10:12,000 AND GIVES US CONFIDENCE ENOUGH 247 00:10:12,000 --> 00:10:13,640 TO APPLY TO THE AFRICAN AMERICAN 248 00:10:13,640 --> 00:10:15,000 COMMUNITY BECAUSE THAT CAN MAKE 249 00:10:15,000 --> 00:10:17,160 A HUGE DIFFERENCE IN THEIR 250 00:10:17,160 --> 00:10:17,440 SURVIVAL. 251 00:10:17,440 --> 00:10:17,920 NEXT SLIDE. 252 00:10:17,920 --> 00:10:19,560 SO HOW DO WE DO THAT? 253 00:10:19,560 --> 00:10:22,520 AGAIN, I USE HERE BREAST CANCER 254 00:10:22,520 --> 00:10:23,080 AS EXAMPLE TO REALLY 255 00:10:23,080 --> 00:10:24,480 DIFFERENTIATE HOW WHAT WE'RE 256 00:10:24,480 --> 00:10:25,840 DOING FOR MYELOMA COMPARED TO 257 00:10:25,840 --> 00:10:28,000 BREAST CANCER. 258 00:10:28,000 --> 00:10:31,240 LOOK AT BREAST CANCER, WE 259 00:10:31,240 --> 00:10:33,280 SCREEN, YET IN MULTIPLE MYELOMA 260 00:10:33,280 --> 00:10:43,800 A BLOOD TEST IS SPECIFIC, SERUM 261 00:10:53,120 --> 00:10:53,680 ELECTROPHORESIS, EASIER THAN 262 00:10:53,680 --> 00:10:54,480 BREAST SCREENING. 263 00:10:54,480 --> 00:10:56,880 WE TELL THEM WAIT UNTIL YOU HAVE 264 00:10:56,880 --> 00:10:59,080 DAMAGE IN YOUR ORGANS, UNTIL YOU 265 00:10:59,080 --> 00:11:00,560 HAVE FRACTURES IN YOUR BONES, 266 00:11:00,560 --> 00:11:02,360 AND THEN I TREAT YOU. 267 00:11:02,360 --> 00:11:03,480 WE HAVE PROBABLY AMAZING DRUGS 268 00:11:03,480 --> 00:11:05,880 IF WE JUST USE THEM EARLIER WE 269 00:11:05,880 --> 00:11:07,600 MAY CHANGE COMPLETELY THE 270 00:11:07,600 --> 00:11:08,600 SURVIVAL OF MYELOMA. 271 00:11:08,600 --> 00:11:12,120 IT'S SIMILAR TO TELLING A WOMAN 272 00:11:12,120 --> 00:11:12,800 WITH BREAST CANCER YOU'RE 273 00:11:12,800 --> 00:11:14,520 ASYMPTOMATIC, WAIT UNTIL YOU 274 00:11:14,520 --> 00:11:16,800 HAVE METASTASIS AND THEN I TREAT 275 00:11:16,800 --> 00:11:17,000 YOU. 276 00:11:17,000 --> 00:11:18,560 AGAIN, THAT CONCEPT NEEDS TO BE 277 00:11:18,560 --> 00:11:21,520 CHANGED, WE NEED TO THINK OF 278 00:11:21,520 --> 00:11:22,520 EARLY SCREENING AND EARLY 279 00:11:22,520 --> 00:11:24,480 INTERVENTION IN PATIENTS WITH 280 00:11:24,480 --> 00:11:28,720 MYELOMA TO CHANGE THEIR 281 00:11:28,720 --> 00:11:29,000 SURVIVAL. 282 00:11:29,000 --> 00:11:32,560 WE STARTED BY STAND UP TO CANCER 283 00:11:32,560 --> 00:11:34,960 DREAM TEAM GRANT, THE PROMIS 284 00:11:34,960 --> 00:11:38,920 STUDY, A NATIONWIDE EFFORT THAT 285 00:11:38,920 --> 00:11:41,640 WE STARTED SCREENING EARLY TO 286 00:11:41,640 --> 00:11:42,960 DETECT MGUS IN THE COMMUNITY, 287 00:11:42,960 --> 00:11:43,960 SPECIFICALLY HIGH RISK 288 00:11:43,960 --> 00:11:46,000 COMMUNITY, PEOPLE WHO ARE OF 289 00:11:46,000 --> 00:11:47,560 AFRICAN AMERICAN DESCENT OR 290 00:11:47,560 --> 00:11:50,000 FIRST DEGREE FAMILY MEMBER WITH 291 00:11:50,000 --> 00:11:52,840 MULTIPLE MYELOMA OR OTHER B CELL 292 00:11:52,840 --> 00:11:53,360 MALIGNANCIES. 293 00:11:53,360 --> 00:11:55,440 THE EFFORT WAS DIRECTED TO 294 00:11:55,440 --> 00:11:56,640 PATIENT NATIONWIDE, LIKE ALL OF 295 00:11:56,640 --> 00:11:59,160 US, UNLIKE MANY OTHER EFFORTS, 296 00:11:59,160 --> 00:12:00,480 PATIENTS ARE THE PARTICIPANTS, 297 00:12:00,480 --> 00:12:02,120 ARE EMPOWERED TO BE PART OF THIS 298 00:12:02,120 --> 00:12:04,680 AND IT'S NOT COMING FROM THE 299 00:12:04,680 --> 00:12:06,920 PHYSICIANS, IT'S ALL OVER THE 300 00:12:06,920 --> 00:12:08,000 WEBSITES SO PATIENTS CAN CLICK 301 00:12:08,000 --> 00:12:11,200 ON IT OR LOOK AT THE URL AND GO 302 00:12:11,200 --> 00:12:13,560 ON AND SIGN UP FOR THEIR OWN 303 00:12:13,560 --> 00:12:17,360 CARE OR THEIR OWN SCREENING. 304 00:12:17,360 --> 00:12:18,640 NEXT SLIDE. 305 00:12:18,640 --> 00:12:19,800 OUR QUESTIONS WERE REALLY WHY 306 00:12:19,800 --> 00:12:21,520 DOES IT HAPPEN AT AN EARLIER 307 00:12:21,520 --> 00:12:23,040 STAGE AND WHY DOES IT HAPPEN IN 308 00:12:23,040 --> 00:12:25,120 A HIGH RISK POPULATION AS IN 309 00:12:25,120 --> 00:12:25,880 AFRICAN AMERICANS OR FIRST 310 00:12:25,880 --> 00:12:27,200 DEGREE FAMILY MEMBERS? 311 00:12:27,200 --> 00:12:30,040 YOU CAN SEE WE'RE DOING WITH 312 00:12:30,040 --> 00:12:31,800 MANY OTHER MEMBERS FROM THE 313 00:12:31,800 --> 00:12:34,200 BROAD INSTITUTE, M.I.T., MEMBERS 314 00:12:34,200 --> 00:12:37,280 FROM THE COMMUNITY IN MYELOMA 315 00:12:37,280 --> 00:12:38,880 ASKING QUESTIONS OF GENETICS AND 316 00:12:38,880 --> 00:12:40,520 GERMLINE SEQUENCING, WHY IT 317 00:12:40,520 --> 00:12:41,720 HAPPENS, IMMUNE CELL SEQUENCING 318 00:12:41,720 --> 00:12:44,360 TRYING TO UNDERSTAND IS IT 319 00:12:44,360 --> 00:12:46,120 IMMUNE CELL DYSREGULATION, TUMOR 320 00:12:46,120 --> 00:12:47,240 TELL SEQUENCING DEFINING WHETHER 321 00:12:47,240 --> 00:12:55,880 INDEED PATIENTS OF AFRICAN 322 00:12:55,880 --> 00:12:57,320 DESCENT HAVE DIFFERENT PROGRESS, 323 00:12:57,320 --> 00:12:59,600 IF WE DON'T INTERVENE THERE'S NO 324 00:12:59,600 --> 00:13:02,560 BENEFIT, WE'RE ONLY CAUSING 325 00:13:02,560 --> 00:13:03,200 WORRY. 326 00:13:03,200 --> 00:13:04,200 IT'S NOT JUST TAKING WHAT 327 00:13:04,200 --> 00:13:09,240 HAPPENS IN MYELOMA BUT ASKING 328 00:13:09,240 --> 00:13:11,080 WHAT ARE ALTERATIONS IN THE 329 00:13:11,080 --> 00:13:15,800 TUMOR AND IMMUNE CELLS AT THE 330 00:13:15,800 --> 00:13:16,480 MGUS AND SMOLDERING STATES. 331 00:13:16,480 --> 00:13:17,120 [AUDIO DISTORTION] 332 00:13:17,120 --> 00:13:18,960 SPECIFIC FOR THEM. 333 00:13:18,960 --> 00:13:19,760 NEXT SLIDE. 334 00:13:19,760 --> 00:13:22,640 AGAIN I SHOWED YOU THE INCLUSION 335 00:13:22,640 --> 00:13:23,680 CRITERIA, SIMPLE, ANYONE OVER 336 00:13:23,680 --> 00:13:25,960 THE AGE OF 30, WE CHANGED FROM 337 00:13:25,960 --> 00:13:28,560 AGE 40 TO 30 WHEN WE FOUND SO 338 00:13:28,560 --> 00:13:31,000 MANY AFRICAN AMERICANS SCREENING 339 00:13:31,000 --> 00:13:33,200 WITH EARLIER DISEASE STAGE AND 340 00:13:33,200 --> 00:13:37,800 WITH EARLIER AGE IN GENERAL SO 341 00:13:37,800 --> 00:13:40,560 WE SCREEN OF AGE 30, PEOPLE WHO 342 00:13:40,560 --> 00:13:45,240 IDENTIFY OF AFRICAN DESCENT, 343 00:13:45,240 --> 00:13:46,800 FIRST DEGREE FAMILY MEMBERS, 344 00:13:46,800 --> 00:13:48,520 THOSE ARE AT HIGH RISK, WE 345 00:13:48,520 --> 00:13:50,920 WANTED TO CAPTURE THE WHOLE 346 00:13:50,920 --> 00:13:52,920 FAMILY, ESPECIALLY WITH GERMLINE 347 00:13:52,920 --> 00:13:53,680 SEQUENCING, ENCOURAGED SECOND 348 00:13:53,680 --> 00:13:56,280 DEGREE AND THIRD DEGREE FAMILY 349 00:13:56,280 --> 00:14:02,400 MEMBERS WITH AGE OVER 18 AND 350 00:14:02,400 --> 00:14:02,640 ABOVE. 351 00:14:02,640 --> 00:14:03,760 NEXT SLIDE. 352 00:14:03,760 --> 00:14:06,880 I LOST MY SLIDES. 353 00:14:06,880 --> 00:14:07,440 PERFECT. 354 00:14:07,440 --> 00:14:08,000 THANK YOU. 355 00:14:08,000 --> 00:14:10,520 THIS IS SHOWING YOU THE EFFORT, 356 00:14:10,520 --> 00:14:12,600 IT'S EASY, THEY SIGN UP ONLINE 357 00:14:12,600 --> 00:14:14,560 ON TABLETS, ON THEIR PHONE, 358 00:14:14,560 --> 00:14:16,280 AGREE TO THE TERMS, LESS THAN 359 00:14:16,280 --> 00:14:19,280 FIVE MINUTES, RECEIVE A BLOOD 360 00:14:19,280 --> 00:14:19,800 KIT. 361 00:14:19,800 --> 00:14:20,920 WE WORKED WITH QUEST, THEY CAN 362 00:14:20,920 --> 00:14:23,200 GO TO ANY QUEST LAB AND SCHEDULE 363 00:14:23,200 --> 00:14:24,840 [AUDIO DISTORTION] 364 00:14:24,840 --> 00:14:28,720 THEY RECEIVE THE RESULTS WHETHER 365 00:14:28,720 --> 00:14:29,360 POSITIVE OR NEGATIVE. 366 00:14:29,360 --> 00:14:31,400 AND IF THEY ARE POSITIVE WE CALL 367 00:14:31,400 --> 00:14:33,240 THEM, WE HAVE A TEAM INCLUDING 368 00:14:33,240 --> 00:14:34,360 MYSELF, CALL THE PATIENTS, TELL 369 00:14:34,360 --> 00:14:36,440 THEM WHAT IT IS AND PROVIDE THEM 370 00:14:36,440 --> 00:14:36,640 CARE. 371 00:14:36,640 --> 00:14:38,640 IF IT'S NEGATIVE, OF COURSE WE 372 00:14:38,640 --> 00:14:40,920 E-MAIL THEM AND FOLLOW THEM AND 373 00:14:40,920 --> 00:14:44,240 RESCREEN IN THREE YEARS. 374 00:14:44,240 --> 00:14:44,680 NEXT SLIDE. 375 00:14:44,680 --> 00:14:47,240 SO THIS IS SHOWING SOME OF THE 376 00:14:47,240 --> 00:14:48,840 EFFORTS, REALLY A NATIONWIDE 377 00:14:48,840 --> 00:14:51,880 EFFORT, IT WAS BOOTS ON THE 378 00:14:51,880 --> 00:14:53,680 GROUND EFFORT. 379 00:14:53,680 --> 00:14:57,120 WE GOT HURT IN COVID BECAUSE WE 380 00:14:57,120 --> 00:14:58,680 WOULDN'T DO THAT BUT WE'VE DONE 381 00:14:58,680 --> 00:15:05,360 HEALTH FAIR EVENTS, IN MANY 382 00:15:05,360 --> 00:15:09,760 STATES, WORKED WITH CONGRESS 383 00:15:09,760 --> 00:15:10,840 REPRESENTATIVES INCLUDING AYANNA 384 00:15:10,840 --> 00:15:15,440 PRESSLEY AND MANY OTHERS. 385 00:15:15,440 --> 00:15:16,960 POST-COVID WE JOINED THE 2022 386 00:15:16,960 --> 00:15:20,520 INDIANA BLACK AND MINORITY 387 00:15:20,520 --> 00:15:21,880 HEALTH FAIR, 177 PARTICIPANTS 388 00:15:21,880 --> 00:15:23,280 OVER 4 CASE ACCRUED ON THE 389 00:15:23,280 --> 00:15:24,280 PROMISE STUDY INCLUDING ONE 390 00:15:24,280 --> 00:15:27,240 PATIENT WHO DID NOT WANT TO BE 391 00:15:27,240 --> 00:15:29,560 ON THE STUDY DECIDED SHE WOULD 392 00:15:29,560 --> 00:15:34,920 GIVE A BLOOD SAMPLE, FOUND TO 393 00:15:34,920 --> 00:15:37,320 HAVE HIGH LEVEL, LIKELY TO GET 394 00:15:37,320 --> 00:15:38,320 RENAL FAILURE, GOT HER TO SEE A 395 00:15:38,320 --> 00:15:40,800 PHYSICIAN IN THE WEEK. 396 00:15:40,800 --> 00:15:43,200 THAT'S ONE CASE, DIAGNOSED EARLY 397 00:15:43,200 --> 00:15:44,560 WITHOUT HAVING END ORGAN DAMAGE. 398 00:15:44,560 --> 00:15:50,160 WE HAVE A LOT OF CASES WITH MGUS 399 00:15:50,160 --> 00:15:52,120 SMOLDERING EARLY STAGE DESCRIBED 400 00:15:52,120 --> 00:15:52,320 LATER. 401 00:15:52,320 --> 00:15:53,200 NEXT SLIDE. 402 00:15:53,200 --> 00:15:56,160 DURING COVID WE HAD MANY EFFORTS 403 00:15:56,160 --> 00:15:57,680 ON ZOOM, INCLUDING ALSO 404 00:15:57,680 --> 00:15:58,720 EDUCATIONAL SESSIONS. 405 00:15:58,720 --> 00:16:00,000 THAT'S CRITICAL BECAUSE YOU HAVE 406 00:16:00,000 --> 00:16:01,520 TO LEARN TO GAIN TRUST, TO LEARN 407 00:16:01,520 --> 00:16:03,920 TO WORK WITH THE COMMUNITY AND 408 00:16:03,920 --> 00:16:05,240 REALLY UNDERSTAND WHAT IS THE 409 00:16:05,240 --> 00:16:06,760 NEED, HOW CAN YOU GAIN TRUST, 410 00:16:06,760 --> 00:16:08,520 HOW CAN YOU REALLY WORK TOGETHER 411 00:16:08,520 --> 00:16:10,160 WITH THE COMMUNITY TO PROVIDE 412 00:16:10,160 --> 00:16:12,560 THE CARE. 413 00:16:12,560 --> 00:16:13,200 NEXT SLIDE. 414 00:16:13,200 --> 00:16:15,320 SO THIS IS JUST PROMISE BY THE 415 00:16:15,320 --> 00:16:15,760 NUMBERS. 416 00:16:15,760 --> 00:16:17,280 WE'RE ONGOING. 417 00:16:17,280 --> 00:16:27,560 WE HAVE 12,592. 418 00:16:30,120 --> 00:16:32,640 THE PROMISE POSITIVE CASES ARE 419 00:16:32,640 --> 00:16:36,080 ABOVE 1,000 CASES. 420 00:16:36,080 --> 00:16:37,120 NEXT SLIDE. 421 00:16:37,120 --> 00:16:38,720 AND WE'RE ACCRUING IN THE UNITED 422 00:16:38,720 --> 00:16:41,320 STATES, JUST OPENED SOUTH 423 00:16:41,320 --> 00:16:43,080 AFRICA, HOPING TO OPEN KENYA, 424 00:16:43,080 --> 00:16:44,840 GHANA, ISRAEL AND MANY OTHERS. 425 00:16:44,840 --> 00:16:48,360 WE'VE RECEIVED MANY SAMPLES FROM 426 00:16:48,360 --> 00:16:50,640 OUR MASS GENERAL AT BRIGHAM NEW 427 00:16:50,640 --> 00:16:52,600 ENGLAND AREA, THE MGB BIOBANK WE 428 00:16:52,600 --> 00:16:55,120 CALL IT. 429 00:16:55,120 --> 00:16:57,440 WE HAVE 3,866 PEOPLE OF AFRICAN 430 00:16:57,440 --> 00:16:59,240 DESCENT SCREENED TO DATE, THE 431 00:16:59,240 --> 00:17:01,040 LARGEST NUMBER THAT HAS BEEN 432 00:17:01,040 --> 00:17:04,560 SCREENED FOR MYELOMA, AND FAMILY 433 00:17:04,560 --> 00:17:07,040 MEMBERS 8,653, A HUGE AGGREGATE 434 00:17:07,040 --> 00:17:11,400 OF VERY CLOSE FAMILY MEMBERS TO 435 00:17:11,400 --> 00:17:12,520 UNDERSTAND BETTER THE GENETICS 436 00:17:12,520 --> 00:17:14,160 OF THESE PATIENTS. 437 00:17:14,160 --> 00:17:14,920 NEXT SLIDE. 438 00:17:14,920 --> 00:17:18,520 I JUST WANT TO GIVE SOME 439 00:17:18,520 --> 00:17:20,400 HIGHLIGHTS, IT MATTERS TO SEE 440 00:17:20,400 --> 00:17:21,960 AMAZING PARTICIPANTS, A FAMILY 441 00:17:21,960 --> 00:17:23,360 OF NINE SIBLINGS JOINED, 442 00:17:23,360 --> 00:17:25,400 NUMEROUS SETS OF TWINS, A TEAM 443 00:17:25,400 --> 00:17:26,760 OF JANITORS AT A PUBLIC HIGH 444 00:17:26,760 --> 00:17:28,400 SCHOOL WHO DECIDED TO GO 445 00:17:28,400 --> 00:17:28,840 TOGETHER. 446 00:17:28,840 --> 00:17:31,440 WE HAD ONE PATIENT WHO WAS AT 447 00:17:31,440 --> 00:17:32,760 THE FURTHEST PART OF ALASKA, IT 448 00:17:32,760 --> 00:17:34,960 TOOK TWO OR THREE PLANES TO GET 449 00:17:34,960 --> 00:17:36,480 THAT BLOOD SAMPLE, BUT HE WAS 450 00:17:36,480 --> 00:17:38,040 INSISTING HE WANTED TO BE PART 451 00:17:38,040 --> 00:17:38,880 OF THE PROMISE STUDY. 452 00:17:38,880 --> 00:17:40,320 THESE ARE THE CASES THAT REALLY 453 00:17:40,320 --> 00:17:42,600 MATTER FOR US TO SEE IT DOES 454 00:17:42,600 --> 00:17:43,560 MATTER FOR EVERY PARTICIPANT AND 455 00:17:43,560 --> 00:17:44,680 FOR EVERYONE WHO WANTS TO BE 456 00:17:44,680 --> 00:17:47,640 PART OF THE PROMISE STUDY. 457 00:17:47,640 --> 00:17:48,880 NEXT SLIDE. 458 00:17:48,880 --> 00:17:53,200 NOW I'LL SHOW SOME OF 459 00:17:53,200 --> 00:17:56,480 [AUDIO DISTORTION] 460 00:17:56,480 --> 00:17:57,920 WE'VE PUBLISHED, 3866 AFRICAN 461 00:17:57,920 --> 00:18:03,000 AMERICANS, AND THEN -- SORRY, 462 00:18:03,000 --> 00:18:04,040 2439 AFRICAN AMERICANS, AND 463 00:18:04,040 --> 00:18:05,840 3,086 FIRST DEGREE FAMILY 464 00:18:05,840 --> 00:18:06,240 MEMBERS. 465 00:18:06,240 --> 00:18:07,040 NEXT SLIDE. 466 00:18:07,040 --> 00:18:09,640 AND WHAT WE FOUND WAS VERY 467 00:18:09,640 --> 00:18:10,200 INTERESTING. 468 00:18:10,200 --> 00:18:11,480 WE SCREENED BY MASS 469 00:18:11,480 --> 00:18:12,560 SPECTROMETRY, INSTEAD OF 470 00:18:12,560 --> 00:18:15,120 SCREENING BY HAIR AND PROTEIN 471 00:18:15,120 --> 00:18:18,120 ELECTROPHORESIS ONLY BECAUSE 472 00:18:18,120 --> 00:18:20,280 IT'S MORE SENSITIVE. 473 00:18:20,280 --> 00:18:21,160 IT'S A 50-YEAR-OLD TECHNOLOGY, 474 00:18:21,160 --> 00:18:23,120 NOT SENSITIVE IN SMALL NUMBERS. 475 00:18:23,120 --> 00:18:25,160 MASS SPECTROMETRY BY BINDING 476 00:18:25,160 --> 00:18:27,400 SITE ALLOWS US TO IDENTIFY MGUS 477 00:18:27,400 --> 00:18:32,080 AND ABOVE, WHICH IS ON YOUR LEFT 478 00:18:32,080 --> 00:18:33,840 SIDE HERE, THE NUMBERS THAT ARE 479 00:18:33,840 --> 00:18:38,960 ABOVE 1 GRAM, YOU CAN IDENTIFY 480 00:18:38,960 --> 00:18:40,080 IMMUNOFIXATION POSITIVE ABOVE .2 481 00:18:40,080 --> 00:18:44,800 GRAMS, FOUND ANOTHER 20% OF 482 00:18:44,800 --> 00:18:46,880 CASES HAVING MONOCLONAL BELOW 483 00:18:46,880 --> 00:18:48,840 THE FRACTION WE LEVEL WE FIND IN 484 00:18:48,840 --> 00:18:49,920 IMMUNOFIXATION SO WE WANTED TO 485 00:18:49,920 --> 00:18:51,800 MAKES SURE WE DON'T CALL THOSE 486 00:18:51,800 --> 00:18:53,560 MGUS, OTHERWISE IT WILL CHANGE 487 00:18:53,560 --> 00:18:55,840 THE PREVALENCE WE SEE IN GENERAL 488 00:18:55,840 --> 00:19:03,600 AND TERM THIS A NEW TERM, 489 00:19:03,600 --> 00:19:04,400 MONOCLONAL OF INDETERMINATE 490 00:19:04,400 --> 00:19:06,360 POTENTIAL, AND I CAN SHOW HERE 491 00:19:06,360 --> 00:19:09,200 THOSE ARE ALL CONFIRMED BY MASS 492 00:19:09,200 --> 00:19:13,040 SPECTROMETRY, INDICATING INDEED 493 00:19:13,040 --> 00:19:15,320 THEY WERE TRUE MONOCLONAL 494 00:19:15,320 --> 00:19:17,720 PROTEINS, I'LL TALK ABOUT THAT 495 00:19:17,720 --> 00:19:19,160 IN A SECOND. 496 00:19:19,160 --> 00:19:23,320 SO AS WE SEE HERE THE 497 00:19:23,320 --> 00:19:25,320 INCIDENCE -- PREVALENCE OF THOSE 498 00:19:25,320 --> 00:19:26,520 PATIENTS INCREASED WITH AGE, AS 499 00:19:26,520 --> 00:19:30,560 YOU CAN SEE, AND NUMBERS WERE 500 00:19:30,560 --> 00:19:32,560 INCREASING WITH AGE BUT MGUS 501 00:19:32,560 --> 00:19:34,600 KEEPS INCREASING MORE WITH AGE 502 00:19:34,600 --> 00:19:36,040 AS WELL AS IN THE AFRICAN 503 00:19:36,040 --> 00:19:36,920 AMERICAN COMMUNITY. 504 00:19:36,920 --> 00:19:41,920 IF YOU LOOK AT NUMBERS WE'RE 505 00:19:41,920 --> 00:19:44,040 SCREENING HIGH RISK POPULATION 506 00:19:44,040 --> 00:19:45,840 GENERAL POPULATION HAS 3% OF 507 00:19:45,840 --> 00:19:50,200 DEVELOPING MGUS AT AGE 50, 508 00:19:50,200 --> 00:19:52,480 PEOPLE AT RISK HAVE DOUBLE THAT, 509 00:19:52,480 --> 00:19:54,680 IF YOU LOOK BY MASS 510 00:19:54,680 --> 00:19:55,520 SPECTROMETRY, MORE SENSITIVE, 511 00:19:55,520 --> 00:20:00,360 EVEN AT THE SAME LEVEL OF MGUS, 512 00:20:00,360 --> 00:20:03,880 .2 GRAMS, 13% OF PEOPLE WE 513 00:20:03,880 --> 00:20:11,400 SCREENED ARE POSITIVE. 514 00:20:11,400 --> 00:20:13,680 THAT'S NOT EVEN COUNTING OTHER 515 00:20:13,680 --> 00:20:14,480 CASES. 516 00:20:14,480 --> 00:20:16,680 THE QUESTION IS WHAT CAN WE DO 517 00:20:16,680 --> 00:20:22,880 TO PREVENT MYELOMA IN THOSE 518 00:20:22,880 --> 00:20:23,080 CASES? 519 00:20:23,080 --> 00:20:25,680 NEXT SLIDE. 520 00:20:25,680 --> 00:20:28,080 521 00:20:28,080 --> 00:20:32,760 IN GENERAL WHEN WE LOOK AT MGB 522 00:20:32,760 --> 00:20:35,160 CO-COURT WORSE OVERALL SURVIVAL 523 00:20:35,160 --> 00:20:37,680 ASSOCIATED WITH ALSO CHANGES OR 524 00:20:37,680 --> 00:20:40,600 ASSOCIATED WITH MORBIDITY, NOT 525 00:20:40,600 --> 00:20:42,040 JUST MORTALITY, INCLUDING 526 00:20:42,040 --> 00:20:43,720 HEMATOLOGIC MALIGNANCY AND 527 00:20:43,720 --> 00:20:44,600 AUTOIMMUNE DISEASES, FOUND 528 00:20:44,600 --> 00:20:47,560 INDEED IT WAS MUCH MORE COMMON 529 00:20:47,560 --> 00:20:52,360 IN AFRICAN AMERICANS EVEN MGIB 530 00:20:52,360 --> 00:20:52,560 CASES. 531 00:20:52,560 --> 00:20:53,240 NEXT SLIDE. 532 00:20:53,240 --> 00:20:54,760 THIS IS PRELIMINARY DATA THAT 533 00:20:54,760 --> 00:21:05,320 CAME OUT LAST WEEK WHY IGI IS A 534 00:21:09,720 --> 00:21:13,600 REAL MALIGNANCY THOSE WITH M GIP 535 00:21:13,600 --> 00:21:19,880 AND MGUS, THEY ALL HAD INDEED 536 00:21:19,880 --> 00:21:24,440 LYMPHOID MALIGNANCY WITH COPY 537 00:21:24,440 --> 00:21:25,880 NUMBER ALTERATIONS, SO THIS 538 00:21:25,880 --> 00:21:27,440 OPENS THE DOOR THAT WE'RE 539 00:21:27,440 --> 00:21:29,080 SCREENING NOT ONLY FOR MYELOMA 540 00:21:29,080 --> 00:21:31,320 BUT FOR MANY OTHER B CELL 541 00:21:31,320 --> 00:21:32,920 MALIGNANCIES AND ASKING THE 542 00:21:32,920 --> 00:21:35,520 QUESTION WHETHER WE'RE DETECTING 543 00:21:35,520 --> 00:21:37,280 EARLY SOME AUTOIMMUNE DISEASES 544 00:21:37,280 --> 00:21:44,360 PEOPLE HAVE WITH IMMUNE 545 00:21:44,360 --> 00:21:44,720 DYSREGULATION. 546 00:21:44,720 --> 00:21:46,800 IF WE DO NOTHING WE'RE REALLY 547 00:21:46,800 --> 00:21:47,760 MAKING PEOPLE WORRY FOR A LONG 548 00:21:47,760 --> 00:21:50,800 TIME AND WE'RE NOT MAKING ANY 549 00:21:50,800 --> 00:21:52,360 BENEFIT FOR THOSE PATIENTS. 550 00:21:52,360 --> 00:21:53,480 SCREENING SHOULD ONLY MATTER IF 551 00:21:53,480 --> 00:21:55,560 WE CAN CHANGE SURVIVAL OF THOSE 552 00:21:55,560 --> 00:21:57,520 PATIENTS SO BY DOING THAT ONE WE 553 00:21:57,520 --> 00:22:01,360 WANT TO MAKE SURE WE'RE NOT 554 00:22:01,360 --> 00:22:04,200 DETECTING MGUS THAT WILL BE NOT 555 00:22:04,200 --> 00:22:05,760 CAUSING HARM VERSUS MGUS IN 556 00:22:05,760 --> 00:22:07,080 SMOLDERING PATIENTS WHO WOULD 557 00:22:07,080 --> 00:22:09,920 PROGRESS TO MYELOMA IN THEIR 558 00:22:09,920 --> 00:22:10,720 LIFETIME, RISK STRATIFICATION, 559 00:22:10,720 --> 00:22:15,720 AND SECOND THING OF COURSE IS 560 00:22:15,720 --> 00:22:16,560 INTERCEPTION. 561 00:22:16,560 --> 00:22:18,960 RISK STRATIFICATION IS CRITICAL 562 00:22:18,960 --> 00:22:19,440 LOOKING AT GENOMIC 563 00:22:19,440 --> 00:22:19,880 [AUDIO DISTORTION] 564 00:22:19,880 --> 00:22:21,480 YOU CAN SEE WE HAVE PUBLICATION 565 00:22:21,480 --> 00:22:27,640 A FEW YEARS AGO USING WHOLE 566 00:22:27,640 --> 00:22:29,640 EXOME SEQUENCING, THREE GENOMIC 567 00:22:29,640 --> 00:22:33,880 ALTERATIONS LEAD TO RAPID 568 00:22:33,880 --> 00:22:35,000 PROGRESSION TO MYELOMA. 569 00:22:35,000 --> 00:22:37,400 AND BY DOING THAT WE KNOW WE CAN 570 00:22:37,400 --> 00:22:38,160 POTENTIALLY SCREEN OUR PATIENTS 571 00:22:38,160 --> 00:22:40,240 FOR THOSE AND IF THEY DO HAVE IT 572 00:22:40,240 --> 00:22:42,960 WE CAN CONSIDER THERAPY IN THEM. 573 00:22:42,960 --> 00:22:44,320 NEXT SLIDE. 574 00:22:44,320 --> 00:22:46,960 THIS IS A NEW METHOD THAT WE 575 00:22:46,960 --> 00:22:49,200 JUST DEVELOPED, IT'S ONLINE 576 00:22:49,200 --> 00:22:51,520 TODAY IN CANCER DISCOVERY. 577 00:22:51,520 --> 00:22:53,360 [AUDIO DISTORTION] 578 00:22:53,360 --> 00:23:00,640 BLOOD SAMPLES AND ISOLATING CAN 579 00:23:00,640 --> 00:23:01,520 DO WHOLE GENOME SEQUENCING AND 580 00:23:01,520 --> 00:23:03,240 IDENTIFY ALL OF THE 581 00:23:03,240 --> 00:23:03,800 TRANSLOCATIONS THAT THOSE 582 00:23:03,800 --> 00:23:06,200 PATIENTS HAVE SO NOT ONLY COPY 583 00:23:06,200 --> 00:23:08,160 NUMBER ALTERATIONS OR MUTATIONS, 584 00:23:08,160 --> 00:23:10,360 YOU CAN ALSO ADD IN THE MAIN 585 00:23:10,360 --> 00:23:11,760 DRIVER EVENT, TRANSLOCATIONS IN 586 00:23:11,760 --> 00:23:12,760 THOSE PATIENTS, CAN CALL IT OUT 587 00:23:12,760 --> 00:23:16,520 IN THOSE PATIENTS. 588 00:23:16,520 --> 00:23:16,920 NEXT SLIDE. 589 00:23:16,920 --> 00:23:19,440 THIS SHOWS WE WERE ABLE TO 590 00:23:19,440 --> 00:23:20,400 IDENTIFY IT IN EVERY SINGLE 591 00:23:20,400 --> 00:23:23,160 PATIENT AS GOOD AS BONE MARROW 592 00:23:23,160 --> 00:23:25,120 BIOPSY, EVEN MORE DATA WAS 593 00:23:25,120 --> 00:23:28,200 OBTAINED IN PERIPHERAL BLOOD, 594 00:23:28,200 --> 00:23:32,000 YOU CAN REPLACE FISH, A 595 00:23:32,000 --> 00:23:34,480 TECHNOLOGY WE'VE BEEN USING, BY 596 00:23:34,480 --> 00:23:36,160 USING CIRCULATING TUMOR CELLS, 597 00:23:36,160 --> 00:23:37,800 WHOLE GENOME SEQUENCING, YOU CAN 598 00:23:37,800 --> 00:23:39,520 REPLACE FISH AND BONE MARROW 599 00:23:39,520 --> 00:23:41,920 BIOPSY ALLOWING IN THE FUTURE TO 600 00:23:41,920 --> 00:23:45,640 BE ABLE TO SCREEN MANY MORE FOR 601 00:23:45,640 --> 00:23:47,640 RISK AT DEVELOPING AT FASTER 602 00:23:47,640 --> 00:23:48,600 PACE IN AFRICAN AMERICANS AND OF 603 00:23:48,600 --> 00:23:53,400 COURSE IN THE GENERAL 604 00:23:53,400 --> 00:23:54,520 POPULATION. 605 00:23:54,520 --> 00:23:56,240 NEXT SLIDE. 606 00:23:56,240 --> 00:23:57,680 IMMUNE CELL SEQUENCING, OVER 350 607 00:23:57,680 --> 00:23:59,880 SAMPLES OVER THE LAST COUPLE OF 608 00:23:59,880 --> 00:24:02,480 YEARS, I CAN SHOW INDEED THE 609 00:24:02,480 --> 00:24:04,160 COMPOSITIONAL CHANGES OF THE 610 00:24:04,160 --> 00:24:06,200 IMMUNE SYSTEM OCCUR AS EARLY AS 611 00:24:06,200 --> 00:24:08,080 MGUS, SURPRISING TO US BECAUSE 612 00:24:08,080 --> 00:24:10,400 WE SAW THE CHANGES WILL HAPPEN 613 00:24:10,400 --> 00:24:13,120 IN SMOLDER MYELOMA AND MGUS IS 614 00:24:13,120 --> 00:24:15,200 BENIGN, IN FACT WE FOUND EARLY 615 00:24:15,200 --> 00:24:17,720 COMPOSITIONAL CHANGES HAPPEN AS 616 00:24:17,720 --> 00:24:20,320 EARLY AS MGUS, HAS IMPLICATIONS 617 00:24:20,320 --> 00:24:21,560 FOR PEOPLE WALKING AROUND 618 00:24:21,560 --> 00:24:22,640 INCLUDING THOSE GETTING COVID 619 00:24:22,640 --> 00:24:23,520 VACCINATION, WHETHER THEY ARE 620 00:24:23,520 --> 00:24:25,800 RESPONDING TO VACCINE OR NOT. 621 00:24:25,800 --> 00:24:27,560 THE QUESTION ALSO IS WHAT ARE 622 00:24:27,560 --> 00:24:28,680 THE TRANSCRIPTIONAL CHANGES THAT 623 00:24:28,680 --> 00:24:30,200 CAN HAPPEN IN THOSE PATIENTS AND 624 00:24:30,200 --> 00:24:34,360 CAN WE IDENTIFY THEM NOT ONLY AS 625 00:24:34,360 --> 00:24:37,560 BIOMARKERS BUT ALSO FOR 626 00:24:37,560 --> 00:24:38,520 THERAPEUTIC INTERCEPTION, TCR 627 00:24:38,520 --> 00:24:40,160 SEQUENCES, IMMUNE CELLS, CAN WE 628 00:24:40,160 --> 00:24:41,360 DEFINE THEM FOR IMMUNOTHERAPY IN 629 00:24:41,360 --> 00:24:45,360 THOSE PATIENTS. 630 00:24:45,360 --> 00:24:47,400 NEXT SLIDE. 631 00:24:47,400 --> 00:24:49,080 IN THE PERIPHERAL BLOOD TRYING 632 00:24:49,080 --> 00:24:51,320 TO USE IT AS A MARKER DETECTING 633 00:24:51,320 --> 00:24:54,160 WHO IS HEALTHY AND MALIGNANT. 634 00:24:54,160 --> 00:24:55,560 IN EARLY DETECTION WE WANT TO 635 00:24:55,560 --> 00:24:56,560 IDENTIFY IMMUNE CHANGES IN 636 00:24:56,560 --> 00:24:58,880 PATIENTS AND WERE ABLE TO 637 00:24:58,880 --> 00:25:00,160 ACTUALLY GET A CLASSIFIER THAT 638 00:25:00,160 --> 00:25:02,800 TELLS HEALTHY INDIVIDUAL FROM 639 00:25:02,800 --> 00:25:03,560 SOMEONE WITH MGUS FROM 640 00:25:03,560 --> 00:25:05,200 PERIPHERAL BLOOD IMMUNE CELL 641 00:25:05,200 --> 00:25:07,440 SEQUENCING AND POTENTIALLY USE 642 00:25:07,440 --> 00:25:09,240 FOR OTHER 643 00:25:09,240 --> 00:25:10,000 [AUDIO DISTORTION] 644 00:25:10,000 --> 00:25:12,640 CAN WE USE OUR IMMUNE SYSTEM AS 645 00:25:12,640 --> 00:25:15,840 A SENSOR FOR EARLY DETECTION NOT 646 00:25:15,840 --> 00:25:16,480 ONLY FOR HEMATOLOGICAL 647 00:25:16,480 --> 00:25:17,680 MALIGNANCY BUT ALSO OTHER 648 00:25:17,680 --> 00:25:19,760 CANCERS, AND THAT COULD BE 649 00:25:19,760 --> 00:25:20,880 CRITICAL FOR PANCREATIC, BREAST, 650 00:25:20,880 --> 00:25:23,600 OTHER CANCERS WE SEE. 651 00:25:23,600 --> 00:25:25,000 NEXT SLIDE. 652 00:25:25,000 --> 00:25:26,280 AND THEN FINALLY INTERCEPTION, 653 00:25:26,280 --> 00:25:26,560 CRITICAL. 654 00:25:26,560 --> 00:25:32,120 IF WE DON'T INTERCEPT AND CHANGE 655 00:25:32,120 --> 00:25:33,440 COURSE WE SHOULDN'T BE 656 00:25:33,440 --> 00:25:34,000 SCREENING. 657 00:25:34,000 --> 00:25:34,880 FIRST ATTEMPTS HAVE BEEN 658 00:25:34,880 --> 00:25:38,240 PUBLISHED, WE KNOW PATIENTS WHO 659 00:25:38,240 --> 00:25:41,880 RECEIVE TREATMENT CAN HAVE 660 00:25:41,880 --> 00:25:43,360 IMPROVED SURVIVAL COMPARED TO 661 00:25:43,360 --> 00:25:45,400 OBSERVATION AND HAVE MOVED TO 662 00:25:45,400 --> 00:25:46,400 OTHER STUDIES IN SMOLDERING 663 00:25:46,400 --> 00:25:48,560 MYELOMA ALSO BRINGING THEM TO 664 00:25:48,560 --> 00:25:50,200 MGUS, THINKING OF IMMUNOTHERAPY 665 00:25:50,200 --> 00:25:52,160 AS WELL AS SPECIFIC PRECISION 666 00:25:52,160 --> 00:25:55,240 INTERCEPTION IN OUR PATIENTS, SO 667 00:25:55,240 --> 00:25:59,400 SOMEONE WITH A TRANSLOCATION WHY 668 00:25:59,400 --> 00:25:59,640 NOT USE 669 00:25:59,640 --> 00:26:01,400 [AUDIO DISTORTION] 670 00:26:01,400 --> 00:26:03,920 AND WE'RE TRYING TO DEVELOP 671 00:26:03,920 --> 00:26:05,440 VACCINES NOW THAT VACCINE IS 672 00:26:05,440 --> 00:26:06,520 AVAILABLE CAN WE DEVELOP 673 00:26:06,520 --> 00:26:09,520 VACCINES FOR MGUS IN OUR 674 00:26:09,520 --> 00:26:11,360 PATIENTS, IMMUNOTHERAPY SPECIFIC 675 00:26:11,360 --> 00:26:13,560 FOR MGUS AND SMOLDERING MYELOMA 676 00:26:13,560 --> 00:26:13,800 PATIENTS. 677 00:26:13,800 --> 00:26:16,720 WE'RE ALREADY TAKING MANY DRUGS 678 00:26:16,720 --> 00:26:18,360 APPROVED FOR MYELOMA, CAN WE 679 00:26:18,360 --> 00:26:22,640 DEVELOP OUR OWN THAT CAN TRULY 680 00:26:22,640 --> 00:26:22,880 INTERCEPT. 681 00:26:22,880 --> 00:26:26,160 WITH ALL THE THAT, DEFINE 682 00:26:26,160 --> 00:26:27,120 BIOMARKERS OF RESISTANCE. 683 00:26:27,120 --> 00:26:28,000 NEXT SLIDE. 684 00:26:28,000 --> 00:26:29,880 HERE ARE TWO EXAMPLES OF STUDIES 685 00:26:29,880 --> 00:26:31,680 THAT ONE IS ALREADY OPEN. 686 00:26:31,680 --> 00:26:36,560 WE HAVE ACCRUED SIX PATIENTS. 687 00:26:36,560 --> 00:26:38,640 THIS IS IMMUNOPRISM, USING 688 00:26:38,640 --> 00:26:41,480 BI-SPECIFIC ANTIBODIES INCLUDING 689 00:26:41,480 --> 00:26:44,400 ONE RECENTLY APPROVED IN OUR 690 00:26:44,400 --> 00:26:45,280 PATIENTS WITH SMOLDERING MYELOMA 691 00:26:45,280 --> 00:26:48,000 AS FIRST LINE OF THERAPY AND 692 00:26:48,000 --> 00:26:50,000 HAVE SEEN IMPRESSIVE RESPONSES 693 00:26:50,000 --> 00:26:52,280 INDICATING IN DEED YOU WITH USE 694 00:26:52,280 --> 00:26:53,400 ONE ANTIBODY, NO CHEMOTHERAPY, 695 00:26:53,400 --> 00:26:57,240 NO COMBINATION AND ACHIEVE 696 00:26:57,240 --> 00:26:58,480 AMAZING RESPONSES AS EARLY AS 697 00:26:58,480 --> 00:27:02,880 SMOLDERING MYELOMA, THE HOPE IS 698 00:27:02,880 --> 00:27:05,160 WE DON'T HAVE TO TREAT FOR A 699 00:27:05,160 --> 00:27:09,720 VERY LONG TIME OR POTENTIALLY 700 00:27:09,720 --> 00:27:11,640 THEY ACHIEVE LONG REMISSIONS. 701 00:27:11,640 --> 00:27:13,400 WE ARE BRINGING CELLULAR THERAPY 702 00:27:13,400 --> 00:27:14,600 INTO SMOLDERING MYELOMA BECAUSE 703 00:27:14,600 --> 00:27:16,440 THE BEST TIME TO USE CAR T 704 00:27:16,440 --> 00:27:18,440 THERAPY IS WHEN YOUR IMMUNE 705 00:27:18,440 --> 00:27:20,800 SYSTEM IS BETTER THAN RELAPSE 706 00:27:20,800 --> 00:27:25,200 SETTING, WITH LESS TUMOR BURDEN 707 00:27:25,200 --> 00:27:26,640 COMPARED TO HEAVILY PRE-TREATED, 708 00:27:26,640 --> 00:27:28,040 ASKING IN 20 PATIENTS THE FIRST 709 00:27:28,040 --> 00:27:30,560 PATIENT HOPEFULLY TO BE ACCRUED 710 00:27:30,560 --> 00:27:32,320 IN THE NEXT MONTH ON CAR T 711 00:27:32,320 --> 00:27:34,280 THERAPY IN PEOPLE WITH 712 00:27:34,280 --> 00:27:37,360 SMOLDERING MYELOMA, ULTRA HIGH 713 00:27:37,360 --> 00:27:39,240 RISK, MINIMAL DISEASE BURDEN 714 00:27:39,240 --> 00:27:42,840 LESS THAN 40% TO SEE IF WE CAN 715 00:27:42,840 --> 00:27:44,360 HAVE CURATIVE INTENT IN THOSE 716 00:27:44,360 --> 00:27:44,720 PATIENTS. 717 00:27:44,720 --> 00:27:47,160 I WANT TO THANK YOU FOR THIS 718 00:27:47,160 --> 00:27:48,320 OPPORTUNITY TO SHOW HOW IT 719 00:27:48,320 --> 00:27:52,360 REALLY MATTERS TO CHANGE THE WAY 720 00:27:52,360 --> 00:27:53,560 WE THINK OF MULTIPLE MYELOMA, A 721 00:27:53,560 --> 00:27:55,320 DISEASE MORE COMMON IN AFRICAN 722 00:27:55,320 --> 00:27:56,960 AMERICANS, AND CLOSE THAT GAP IN 723 00:27:56,960 --> 00:27:58,680 UNDERSTANDING WHY DO WE HAVE A 724 00:27:58,680 --> 00:27:59,600 WORSE SURVIVAL IN OUR PATIENTS 725 00:27:59,600 --> 00:28:01,680 AND IMPROVING IT BY EARLY 726 00:28:01,680 --> 00:28:02,560 DETECTION AND EARLY 727 00:28:02,560 --> 00:28:02,880 INTERCEPTION. 728 00:28:02,880 --> 00:28:04,480 I WANT TO THANK OF COURSE OUR 729 00:28:04,480 --> 00:28:07,760 AMAZING MEMBERS IN THE LAB AND 730 00:28:07,760 --> 00:28:09,360 CLINIC, MY COLLABORATORS AT THE 731 00:28:09,360 --> 00:28:10,880 BROAD WHO DOES EVERYTHING WITH 732 00:28:10,880 --> 00:28:15,560 ME AND OUR FUNDERS, STAND UP TO 733 00:28:15,560 --> 00:28:23,000 CANCER, THE LUKE AND LYMPHOMA 734 00:28:23,000 --> 00:28:24,000 SOCIETY, NCI, NIH, AND OUR 735 00:28:24,000 --> 00:28:24,720 PATIENTS. 736 00:28:24,720 --> 00:28:25,400 THANK YOU. 737 00:28:25,400 --> 00:28:26,520 >>THANKS, IRENE. 738 00:28:26,520 --> 00:28:29,600 QUESTIONS FOR DR. GHOBRIAL? 739 00:28:29,600 --> 00:28:30,440 QUESTION, OTIS? 740 00:28:30,440 --> 00:28:32,680 >>I WANT TO SAY THANK YOU FOR A 741 00:28:32,680 --> 00:28:34,200 WONDERFUL TALK. 742 00:28:34,200 --> 00:28:37,080 IT WAS REALLY GREAT. 743 00:28:37,080 --> 00:28:38,440 I DON'T WANT TO TAKE ANYTHING 744 00:28:38,440 --> 00:28:43,160 AWAY BUT BRING UP WHAT I CALL 745 00:28:43,160 --> 00:28:44,680 THE WAKEFIELD, WHICH WAS BROUGHT 746 00:28:44,680 --> 00:28:45,240 UP YESTERDAY. 747 00:28:45,240 --> 00:28:48,400 I USED TO BE AT EMORY AND INDEED 748 00:28:48,400 --> 00:28:50,040 RAN THE CANCER CENTER THERE FOR 749 00:28:50,040 --> 00:28:51,800 A WHILE. 750 00:28:51,800 --> 00:28:55,080 THERE ARE A SUBSTANTIAL NUMBER 751 00:28:55,080 --> 00:28:58,040 OF PEOPLE IN METROPOLITAN 752 00:28:58,040 --> 00:28:58,680 ATLANTA, ESPECIALLY BLACK 753 00:28:58,680 --> 00:29:01,080 PEOPLE, BUT WHITES AS WELL, WHO 754 00:29:01,080 --> 00:29:02,200 HAVE DIAGNOSED MULTIPLE MYELOMA 755 00:29:02,200 --> 00:29:06,400 AND GET NO TREATMENT WHATSOEVER. 756 00:29:06,400 --> 00:29:08,240 NOT OBSERVATION WHICH CAN BE 757 00:29:08,240 --> 00:29:08,520 APPROPRIATE. 758 00:29:08,520 --> 00:29:10,280 THESE ARE PEOPLE WHO CAN'T 759 00:29:10,280 --> 00:29:14,880 AFFORD THE VERY EXPENSIVE DRUGS. 760 00:29:14,880 --> 00:29:16,480 AND I THINK IT WOULD BE GOOD 761 00:29:16,480 --> 00:29:18,400 ESPECIALLY SINCE WE HAVE A SEER 762 00:29:18,400 --> 00:29:20,240 REGISTRY IN PLACES LIKE ATLANTA 763 00:29:20,240 --> 00:29:23,440 AND DETROIT, I THINK IT WOULD BE 764 00:29:23,440 --> 00:29:25,280 GOOD FOR THE NATIONAL CANCER 765 00:29:25,280 --> 00:29:27,560 INSTITUTE TO DO STUDIES TO 766 00:29:27,560 --> 00:29:30,320 ACTUALLY DEMONSTRATE THAT THERE 767 00:29:30,320 --> 00:29:32,280 ARE SUBSTANTIAL NUMBER OF 768 00:29:32,280 --> 00:29:33,920 AMERICAN PEOPLE WHO HAVE CANCER, 769 00:29:33,920 --> 00:29:36,120 THAT IS TREATABLE, AND THEY GET 770 00:29:36,120 --> 00:29:40,160 LESS THAN OPTIMAL TREATMENT OR 771 00:29:40,160 --> 00:29:41,120 NO TREATMENT WHATSOEVER. 772 00:29:41,120 --> 00:29:41,840 THANK YOU. 773 00:29:41,840 --> 00:29:45,400 AGAIN, THAT WAS A SUPERB TALK. 774 00:29:45,400 --> 00:29:46,520 >>THANK YOU. 775 00:29:46,520 --> 00:29:47,400 I TOTALLY AGREE. 776 00:29:47,400 --> 00:29:49,680 WE SHOULD DO MUCH BETTER THAN 777 00:29:49,680 --> 00:29:53,480 THIS. 778 00:29:53,480 --> 00:29:53,760 >>THANKS. 779 00:29:53,760 --> 00:29:55,640 CHRIS, AND I SEE KAREN'S HAND. 780 00:29:55,640 --> 00:29:57,720 >>THANK YOU FOR YOUR 781 00:29:57,720 --> 00:29:58,040 PRESENTATION. 782 00:29:58,040 --> 00:30:02,960 AS A HEMATOLOGIC HEMATOLOGIC MY 783 00:30:02,960 --> 00:30:03,640 NURSE, THE PROGRESS IS 784 00:30:03,640 --> 00:30:07,800 SUBSTANTIAL IN TERMS OF OUR 785 00:30:07,800 --> 00:30:11,760 UNDERSTANDING, YET AS WAS NOTED 786 00:30:11,760 --> 00:30:13,520 PROGRESS IS UNEQUALLY AND 787 00:30:13,520 --> 00:30:14,840 UNEVEN, AND WE PLACE MYELOMA AS 788 00:30:14,840 --> 00:30:16,800 PRIORITY FOR OUR NEXT FIVE 789 00:30:16,800 --> 00:30:17,040 YEARS. 790 00:30:17,040 --> 00:30:19,080 I WANTED TO COME BACK TO THE 791 00:30:19,080 --> 00:30:22,080 POINT MADE, ONE OF THE 792 00:30:22,080 --> 00:30:23,600 CHALLENGES HERE IS THAT THE 793 00:30:23,600 --> 00:30:25,800 TREATMENT ADVANCES HAVE BEEN 794 00:30:25,800 --> 00:30:26,880 PROFOUND, MANY COMPOUNDS ARE 795 00:30:26,880 --> 00:30:31,160 ORAL AGENTS WHICH AS WE KNOW 796 00:30:31,160 --> 00:30:33,480 CREATE STRUCTURAL INSURANCE 797 00:30:33,480 --> 00:30:36,880 ISSUES THAT PATIENTS CANNOT 798 00:30:36,880 --> 00:30:38,640 AFFORD THESE MEDICATIONS DESPITE 799 00:30:38,640 --> 00:30:40,520 CO-PAYS AND THESE PROGRAMS, AND 800 00:30:40,520 --> 00:30:41,800 THAT'S NOT AN ISSUE FOR YOU TO 801 00:30:41,800 --> 00:30:44,200 SOLVE BUT I WANT TO HIGHLIGHT 802 00:30:44,200 --> 00:30:46,080 THAT WE NEED A BETTER 803 00:30:46,080 --> 00:30:48,400 UNDERSTANDING OF THOSE ISSUES 804 00:30:48,400 --> 00:30:49,440 AND WE NEED TARGETED 805 00:30:49,440 --> 00:30:51,360 INTERVENTIONS TO MAKE SURE THAT 806 00:30:51,360 --> 00:30:54,280 PATIENTS CAN ACTUALLY RECEIVE 807 00:30:54,280 --> 00:30:58,560 AND STAY ON THESE LIFE-SAVING 808 00:30:58,560 --> 00:30:59,120 THERAPIES. 809 00:30:59,120 --> 00:31:00,760 THANK YOU. 810 00:31:00,760 --> 00:31:01,080 >>KAREN? 811 00:31:01,080 --> 00:31:01,960 >>YEAH, SO, IRENE, ALWAYS A 812 00:31:01,960 --> 00:31:03,120 PLEASURE TO SEE YOU. 813 00:31:03,120 --> 00:31:04,320 WE WORKED TOGETHER FOR A VERY 814 00:31:04,320 --> 00:31:06,320 LONG TIME ON THESE ISSUES. 815 00:31:06,320 --> 00:31:07,880 I MUST SAY I'M VERY THRILLED 816 00:31:07,880 --> 00:31:11,040 WITH THE PROGRESS YOUR TEAM HAS 817 00:31:11,040 --> 00:31:11,760 MADE. 818 00:31:11,760 --> 00:31:13,200 GOING GANG BUSTERS. 819 00:31:13,200 --> 00:31:15,000 BUT, AGAIN, THE ELEPHANT IN THE 820 00:31:15,000 --> 00:31:17,520 ROOM, YOU HAVE THIS COHORT OF 821 00:31:17,520 --> 00:31:18,920 INDIVIDUALS NOW, I DO WONDER IF 822 00:31:18,920 --> 00:31:24,560 THERE'S A WAY TO LAYER ON KIND 823 00:31:24,560 --> 00:31:27,640 OF SOME FOCUS ON ECONOMICS, 824 00:31:27,640 --> 00:31:30,600 PARTICULARLY FOR PATIENTS, YOU 825 00:31:30,600 --> 00:31:32,920 KNOW, I LOOK AT A DRUG THAT 826 00:31:32,920 --> 00:31:34,920 REVOLUTIONED THE WAY WE TREED, 827 00:31:34,920 --> 00:31:37,840 IT WENT FROM $200 A PILL, OVER 828 00:31:37,840 --> 00:31:38,920 $700 A PILL, RIGHT? 829 00:31:38,920 --> 00:31:41,240 IF WE CAN COLLECT DATA ON 830 00:31:41,240 --> 00:31:43,640 CO-PAYS, OTHER THINGS THAT MIGHT 831 00:31:43,640 --> 00:31:44,560 PRESENT, I WONDER IF THAT'S 832 00:31:44,560 --> 00:31:45,960 SOMETHING YOUR TEAM IS WORKING 833 00:31:45,960 --> 00:31:48,000 ON OR SOME MIGHT BE ABLE TO BE 834 00:31:48,000 --> 00:31:49,360 LAYERED ON THIS VERY UNIQUE 835 00:31:49,360 --> 00:31:50,200 COHORT YOU'VE DEVELOPED BECAUSE 836 00:31:50,200 --> 00:31:51,920 I DO WORRY A LITTLE BIT. 837 00:31:51,920 --> 00:31:54,440 THIS IS THE SAME KIND OF THING 838 00:31:54,440 --> 00:31:55,440 AS YESTERDAY WHEN SCREENING 839 00:31:55,440 --> 00:31:56,640 WITHOUT ATTACHING TO TREATMENT 840 00:31:56,640 --> 00:31:58,080 BUT ALSO THE FINANCIAL TOXICITY 841 00:31:58,080 --> 00:31:59,480 PIECE THAT REALLY NEEDS TO BE 842 00:31:59,480 --> 00:32:00,920 WOVEN INTO A LOT OF THESE 843 00:32:00,920 --> 00:32:03,480 LONGITUDINAL STUDIES. 844 00:32:03,480 --> 00:32:04,960 CAN YOU SPEAK TO THAT? 845 00:32:04,960 --> 00:32:06,360 >>YES, YOU'RE RIGHT. 846 00:32:06,360 --> 00:32:08,040 IT'S SO CRITICAL TO MAKE SURE 847 00:32:08,040 --> 00:32:12,560 THAT IT'S NOT JUST SCREENING AND 848 00:32:12,560 --> 00:32:17,360 TREATMENT THAT IS EXTREMELY 849 00:32:17,360 --> 00:32:17,680 EXPENSIVE BUT 850 00:32:17,680 --> 00:32:18,760 [AUDIO DISTORTION] 851 00:32:18,760 --> 00:32:21,160 WE'RE TRYING TO DO A STUDY WHERE 852 00:32:21,160 --> 00:32:24,000 WE SHOW THAT THERE IS A BENEFIT 853 00:32:24,000 --> 00:32:25,560 OF EARLY TREATMENT BECAUSE ONCE 854 00:32:25,560 --> 00:32:27,360 THE PATIENT IS DIAGNOSED WITH 855 00:32:27,360 --> 00:32:28,520 MYELOMA, AND THEY ARE LOSING 856 00:32:28,520 --> 00:32:29,480 THEIR JOB BECAUSE THEY HAVE TO 857 00:32:29,480 --> 00:32:30,840 BE OUT OF WORK, BECAUSE THEY ARE 858 00:32:30,840 --> 00:32:32,320 IN THE HOSPITAL FOR RENAL 859 00:32:32,320 --> 00:32:33,680 FAILURE, THEY HAVE A FRACTURE OF 860 00:32:33,680 --> 00:32:34,880 THEIR BONE, NOW THEY CAN NOT 861 00:32:34,880 --> 00:32:37,280 WORK ANYMORE, OR THEY HAVE TO 862 00:32:37,280 --> 00:32:39,120 HAVE TRANSPLANT, THINK OF ALL OF 863 00:32:39,120 --> 00:32:40,960 THE ECONOMICS OF THAT. 864 00:32:40,960 --> 00:32:44,480 SO WE'RE ACTUALLY TRYING TO SAY 865 00:32:44,480 --> 00:32:48,960 EARLY INTERCEPTION, IT'S LESS 866 00:32:48,960 --> 00:32:51,080 EXPENSIVE IN THE LIFETIME OF A 867 00:32:51,080 --> 00:32:54,800 PATIENT WITH MYELOMA, COMPARED 868 00:32:54,800 --> 00:32:56,080 TO A LIFETIME TREATMENT, FOR 869 00:32:56,080 --> 00:32:57,200 YEARS AND YEARS MAINTENANCE 870 00:32:57,200 --> 00:32:58,200 WITHOUT STOPPING THERAPY. 871 00:32:58,200 --> 00:32:59,800 SO IF WE TREAT INTERCEPTION 872 00:32:59,800 --> 00:33:02,360 EARLY, WE'RE DOING IT ONLY FOR 873 00:33:02,360 --> 00:33:05,240 ONE OR TWO YEARS, OR WITH CAR T 874 00:33:05,240 --> 00:33:08,360 ONCE AND YOU'RE DONE AND LEAVE 875 00:33:08,360 --> 00:33:09,480 PATIENTS ALONE, NOW IT'S NOT 876 00:33:09,480 --> 00:33:12,200 JUST ECONOMICS, IT'S THEIR LIFE. 877 00:33:12,200 --> 00:33:15,080 I THINK OF IT AS THE WIFE OF A 878 00:33:15,080 --> 00:33:17,600 PATIENT WHO HAD DIAGNOSIS OF 879 00:33:17,600 --> 00:33:18,920 LYMPHOMA, THE WHOLE FAMILY IS 880 00:33:18,920 --> 00:33:20,520 PULLED APART BECAUSE YOU GET 881 00:33:20,520 --> 00:33:21,760 CANCER EVERYONE HAS TO THINK 882 00:33:21,760 --> 00:33:26,120 ABOUT IT SO WE ALL HAVE THAT, 883 00:33:26,120 --> 00:33:27,000 EVERYTHING FELL APART WHEN 884 00:33:27,000 --> 00:33:28,560 PEOPLE ARE DIAGNOSED WITH 885 00:33:28,560 --> 00:33:30,120 CANCER, AND EARLY DETECTION 886 00:33:30,120 --> 00:33:31,280 GIVES THE BENEFIT, I CAN HAVE A 887 00:33:31,280 --> 00:33:34,080 LITTLE BIT MORE CONTROL OF MY 888 00:33:34,080 --> 00:33:35,520 LIFE, DECIDE WHEN I'M GOING TO 889 00:33:35,520 --> 00:33:36,960 BE TREATED, IT'S NOT AN 890 00:33:36,960 --> 00:33:39,440 EMERGENCY AND I'M NOT PULLING MY 891 00:33:39,440 --> 00:33:41,240 FAMILY APART OR MY WORK OR THOSE 892 00:33:41,240 --> 00:33:41,520 FACTORS. 893 00:33:41,520 --> 00:33:43,280 YOU'RE LIGHT. 894 00:33:43,280 --> 00:33:45,360 IT'S NOT JUST SURVIVAL. 895 00:33:45,360 --> 00:33:47,480 IT'S THE ECONOMICS OF IT THAT 896 00:33:47,480 --> 00:33:48,440 ARE IMPORTANT AND THE FAMILY 897 00:33:48,440 --> 00:33:50,320 LIFE BALANCE THAT WE HAVE THERE. 898 00:33:50,320 --> 00:34:00,560 >>THANKS, IRENE. 899 00:34:00,560 --> 00:34:00,920 SUSAN? 900 00:34:00,920 --> 00:34:02,680 YOU'RE MUTED. 901 00:34:02,680 --> 00:34:05,520 WE CANNOT HEAR YOU. 902 00:34:05,520 --> 00:34:11,520 903 00:34:11,520 --> 00:34:14,600 904 00:34:14,600 --> 00:34:18,680 905 00:34:18,680 --> 00:34:24,800 OUTSTANDING, IRENE. 906 00:34:24,800 --> 00:34:25,760 >>OH, PLEASE, YEAH. 907 00:34:25,760 --> 00:34:28,520 >>GREAT PRESENTATION ON THE 908 00:34:28,520 --> 00:34:28,840 SCIENCE. 909 00:34:28,840 --> 00:34:31,240 MULTIPLE MYELOMA REPRESENTS ONE 910 00:34:31,240 --> 00:34:34,360 OF THE CANCER ADVOCACY 911 00:34:34,360 --> 00:34:37,400 COMMUNITIES, MMRF, THE RESEARCH 912 00:34:37,400 --> 00:34:42,080 FOUNDATION, HOW DO WE RAISE UP 913 00:34:42,080 --> 00:34:43,640 THESE PATIENT ADVOCACY 914 00:34:43,640 --> 00:34:44,400 ORGANIZATIONS AND VIEW 915 00:34:44,400 --> 00:34:45,360 SPECTACULAR SCIENCE. 916 00:34:45,360 --> 00:34:48,520 ONE THING THAT IMPRESSED ME IS 917 00:34:48,520 --> 00:34:49,520 DATA SHARING CAPABILITIES, 918 00:34:49,520 --> 00:34:52,040 STRONG VOICES FROM THE PATIENT 919 00:34:52,040 --> 00:34:54,480 COMMUNITY ON DATA SHARING, AND 920 00:34:54,480 --> 00:34:58,920 TACKLING WHAT IS OBVIOUSLY AN 921 00:34:58,920 --> 00:34:59,520 IMPORTANT DISEASE. 922 00:34:59,520 --> 00:35:02,400 TELL ME HOW YOUR EFFORTS HAVE 923 00:35:02,400 --> 00:35:04,560 PARTNERED WITH MMRF AND HOW THE 924 00:35:04,560 --> 00:35:07,720 NCI CAN DO A BETTER JOB 925 00:35:07,720 --> 00:35:09,400 PROMOTING PATIENT ADVOCACY IN 926 00:35:09,400 --> 00:35:11,240 THE SPECTACULAR SCIENCE THAT IS 927 00:35:11,240 --> 00:35:12,120 GOING ON. 928 00:35:12,120 --> 00:35:13,000 >>YEAH, ABSOLUTELY. 929 00:35:13,000 --> 00:35:15,200 THANK YOU, MICHAEL. 930 00:35:15,200 --> 00:35:17,480 WE'VE WORKED CLOSELY WITH MMRF, 931 00:35:17,480 --> 00:35:22,480 ALSO IMF AND STAND UP TO CANCER. 932 00:35:22,480 --> 00:35:23,440 ALL OF THEM ARE WORKING HARD TO 933 00:35:23,440 --> 00:35:26,080 MAKE SURE THE PATIENT IS HEARD 934 00:35:26,080 --> 00:35:27,280 AND WE'RE GIVING THAT 935 00:35:27,280 --> 00:35:27,960 EMPOWERMENT OF OUR PATIENTS 936 00:35:27,960 --> 00:35:28,680 EARLY ON. 937 00:35:28,680 --> 00:35:33,720 WE'RE NOW WORKING WITH THEM TO 938 00:35:33,720 --> 00:35:34,360 DEVELOP 939 00:35:34,360 --> 00:35:35,560 [AUDIO DISTORTION] 940 00:35:35,560 --> 00:35:38,960 CONDITIONS, FIRST 1,000 PATIENTS 941 00:35:38,960 --> 00:35:39,520 GENOMEICALLY IDENTIFIED AND 942 00:35:39,520 --> 00:35:40,360 SEQUENCED, NOW WE'RE DEVELOPING 943 00:35:40,360 --> 00:35:42,160 IT FOR MGUS AND SMOLDERING 944 00:35:42,160 --> 00:35:44,560 MYELOMA SO WE WOULDN'T HAVE BEEN 945 00:35:44,560 --> 00:35:46,840 ABLE TO DO THOUSANDS OF SAMPLES 946 00:35:46,840 --> 00:35:49,360 WE'RE NOW COLLECTING WITHOUT 947 00:35:49,360 --> 00:35:58,800 STAND UP TO CANCER OR SEQUENCE 948 00:35:58,800 --> 00:36:02,160 300, OR 400 SAMPLES. 949 00:36:02,160 --> 00:36:03,320 WITHOUT HELP AND PHILANTHROPY, 950 00:36:03,320 --> 00:36:04,240 IT'S A COMMUNITY EFFORT, IT 951 00:36:04,240 --> 00:36:05,440 NEEDS TO BE AN EFFORT PUT 952 00:36:05,440 --> 00:36:05,880 TOGETHER. 953 00:36:05,880 --> 00:36:09,600 WE CAN CANNOT DO WHICH WITH ONR 954 00:36:09,600 --> 00:36:10,800 TWO MILLION DOLLARS OVER FIVE 955 00:36:10,800 --> 00:36:12,560 YEARS. 956 00:36:12,560 --> 00:36:16,480 IT NEEDS TO BE A HUGE EFFORT WE 957 00:36:16,480 --> 00:36:18,440 REALLY CARE ABOUT. 958 00:36:18,440 --> 00:36:20,640 LEUKEMIA AND LYMPHOMA SOCIETY IS 959 00:36:20,640 --> 00:36:22,040 WORKING WITH US, MANY OTHERS 960 00:36:22,040 --> 00:36:23,920 SAYING LET'S PUT THE EFFORT 961 00:36:23,920 --> 00:36:24,920 TOGETHER, DIFFERENT FOUNDATIONS 962 00:36:24,920 --> 00:36:26,880 WITH THE NCI HOPEFULLY AND WE 963 00:36:26,880 --> 00:36:28,560 WORK TOGETHER TO MAKE THIS 964 00:36:28,560 --> 00:36:28,800 HAPPEN. 965 00:36:28,800 --> 00:36:31,840 BUT IT DOES REQUIRE A LOT OF 966 00:36:31,840 --> 00:36:32,640 EFFORT AND ORGANIZING. 967 00:36:32,640 --> 00:36:34,440 >>WE MAY HAVE TIME FOR ONE MORE 968 00:36:34,440 --> 00:36:36,960 QUESTION FROM ANDY AND WE HAVE 969 00:36:36,960 --> 00:36:40,440 TO MOVE ON. 970 00:36:40,440 --> 00:36:40,720 >>THANKS. 971 00:36:40,720 --> 00:36:41,880 TERRIFIC. 972 00:36:41,880 --> 00:36:44,040 RELATED QUESTION TO MICHAEL'S, 973 00:36:44,040 --> 00:36:45,720 YOU'VE BEEN SUCCESSFUL IN SORT 974 00:36:45,720 --> 00:36:50,000 OF RECRUITING TO PROMISE ON THE 975 00:36:50,000 --> 00:36:52,400 BASIS OF INTEREST IN MYELOMA AND 976 00:36:52,400 --> 00:36:53,920 GETTING PATIENTS MOTIVATED BY 977 00:36:53,920 --> 00:36:55,240 EARLY DETECTION THEME. 978 00:36:55,240 --> 00:36:57,320 WHAT ARE YOUR THOUGHTS ABOUT 979 00:36:57,320 --> 00:36:59,280 BROADENING THIS APPROACH TO 980 00:36:59,280 --> 00:37:02,320 OTHER CANCERS AND THINKING ABOUT 981 00:37:02,320 --> 00:37:04,120 TRYING TO MAKE SURE WE HAVE 982 00:37:04,120 --> 00:37:06,880 EQUITABLE ENROLLMENT OF PEOPLE 983 00:37:06,880 --> 00:37:08,840 TO MSED RELATED CLINICAL TRIALS, 984 00:37:08,840 --> 00:37:15,520 HAVE YOU THOUGHT ABOUT THIS 985 00:37:15,520 --> 00:37:19,160 COHORT FOR OTHER STUDIES? 986 00:37:19,160 --> 00:37:24,560 >>WE MET TO EXPAND PROMISE INTO 987 00:37:24,560 --> 00:37:25,760 ALL BLOOD CANCERS. 988 00:37:25,760 --> 00:37:28,000 CHIP MUTATIONS CAN CAUSE NOT 989 00:37:28,000 --> 00:37:30,080 ONLY LEUKEMIA BUT ALSO CAUSE 990 00:37:30,080 --> 00:37:31,840 CARDIOVASCULAR DISEASE AND OTHER 991 00:37:31,840 --> 00:37:32,440 THINGS. 992 00:37:32,440 --> 00:37:34,800 WE'RE TALKING ABOUT WE'RE 993 00:37:34,800 --> 00:37:40,880 ALREADY SCREENING FOR MDL AND 994 00:37:40,880 --> 00:37:44,520 MSEDs, IT CAN BE DETECTED BY 995 00:37:44,520 --> 00:37:46,720 IMMUNE CELL SEQUENCING, LOOKING 996 00:37:46,720 --> 00:37:48,960 AT DANA-FARBER EARLY CANCER 997 00:37:48,960 --> 00:37:50,720 SCREENING, WHETHER WE CAN ASK 998 00:37:50,720 --> 00:37:52,120 THE QUESTION OF WHICH MSED 999 00:37:52,120 --> 00:37:53,440 METHOD IS THE BEST. 1000 00:37:53,440 --> 00:37:55,600 THERE ARE AT LEAST TEN COMPANIES 1001 00:37:55,600 --> 00:37:57,720 OUT THERE, GRAIL AND OTHERS, 1002 00:37:57,720 --> 00:38:00,320 CLAIMING TO HAVE AMAZING METHODS 1003 00:38:00,320 --> 00:38:01,760 OF SCREENING AND WE NEED TO 1004 00:38:01,760 --> 00:38:06,360 REALLY HAVE AN EFFORT THAT'S PUT 1005 00:38:06,360 --> 00:38:10,600 TOGETHER WHICH INDEED THE NCI 1006 00:38:10,600 --> 00:38:11,800 [AUDIO DISTORTION] 1007 00:38:11,800 --> 00:38:12,880 WE'RE DOING IMMUNE CELL 1008 00:38:12,880 --> 00:38:14,440 SEQUENCING BUT ALSO HOW WOULD 1009 00:38:14,440 --> 00:38:17,160 THAT BE AVAILABLE FOR ALL OF THE 1010 00:38:17,160 --> 00:38:17,760 PEOPLE ESPECIALLY EQUITY IN 1011 00:38:17,760 --> 00:38:20,120 THOSE PEOPLE SO IT'S NOT ONLY 1012 00:38:20,120 --> 00:38:22,120 THE RICH AND WEALTHY PEOPLE WHO 1013 00:38:22,120 --> 00:38:24,560 CAN GET IT. 1014 00:38:24,560 --> 00:38:26,160 IT'S EVERYONE GETTING MSED 1015 00:38:26,160 --> 00:38:29,360 DETECTION, FOR PROMISE WE'RE NOW 1016 00:38:29,360 --> 00:38:30,000 EXPANDING TO BLOOD CANCERS, EASY 1017 00:38:30,000 --> 00:38:31,440 LOW-HANGING FRUIT AND HOPEFULLY 1018 00:38:31,440 --> 00:38:33,320 CAN USE THE SAME INFRASTRUCTURE 1019 00:38:33,320 --> 00:38:37,680 IF WE OPEN IT INTO, YOU KNOW, 1020 00:38:37,680 --> 00:38:38,320 THE PHARMACIES NEARBY SO YOU 1021 00:38:38,320 --> 00:38:39,760 DON'T HAVE TO GO TO THE DOCTOR, 1022 00:38:39,760 --> 00:38:42,280 WE CAN GET IT TO NATIONWIDE ON 1023 00:38:42,280 --> 00:38:44,120 YOUR PHONE, DIRECT TO PATIENT 1024 00:38:44,120 --> 00:38:46,440 ACCESS, ALL THOSE METHODS USED 1025 00:38:46,440 --> 00:38:49,600 FOR THE CANCER SCREENING. 1026 00:38:49,600 --> 00:38:53,440 >>THANKS FOR THAT INFORMATIVE 1027 00:38:53,440 --> 00:38:54,840 PRESENTATION TO THE BOARDS. 1028 00:38:54,840 --> 00:38:58,560 SO LET'S MOVE ON TO THE NEXT 1029 00:38:58,560 --> 00:39:01,400 AGENDA ITEM, WHICH IS REPORT 1030 00:39:01,400 --> 00:39:03,840 FROM THE NCAB WORKING GROUP, AD 1031 00:39:03,840 --> 00:39:05,800 HOC WORKING GROUP REPORT ON 1032 00:39:05,800 --> 00:39:06,680 STRATEGIC APPROACHES AND 1033 00:39:06,680 --> 00:39:08,040 OPPORTUNITIES FOR RESEARCH ON 1034 00:39:08,040 --> 00:39:10,640 CANCER AMONG RACIAL AND ETHNIC 1035 00:39:10,640 --> 00:39:11,160 MINORITIES AND UNDERSERVED 1036 00:39:11,160 --> 00:39:17,920 POPULATIONS, BROUGHT TO US BY 1037 00:39:17,920 --> 00:39:21,000 THE CO-CHAIRS, DOCTORS PASKETT, 1038 00:39:21,000 --> 00:39:21,720 DOUBENI, AND MARTINEZ. 1039 00:39:21,720 --> 00:39:22,520 >>THANK YOU. 1040 00:39:22,520 --> 00:39:25,280 DR. MARTINEZ IS JOINING US, SHE 1041 00:39:25,280 --> 00:39:27,160 WILL BEGIN THE PRESENTATION 1042 00:39:27,160 --> 00:39:30,840 TODAY. 1043 00:39:30,840 --> 00:39:31,400 >>HELLO. 1044 00:39:31,400 --> 00:39:33,960 PART OF THE PRESENTATION. 1045 00:39:33,960 --> 00:39:34,840 THANK YOU, ELECTRA. 1046 00:39:34,840 --> 00:39:36,560 IT'S A PLEASURE TO BE HERE. 1047 00:39:36,560 --> 00:39:39,600 I WANT TO START BY SAYING IT'S 1048 00:39:39,600 --> 00:39:42,120 BEEN AN HONOR TO SERVE AS 1049 00:39:42,120 --> 00:39:45,320 CO-CHAIR OF THIS WORKING GROUP, 1050 00:39:45,320 --> 00:39:46,440 AND GLAD TO BE PRESENTING A 1051 00:39:46,440 --> 00:39:50,000 SYNOPSIS OF THE REPORT. 1052 00:39:50,000 --> 00:39:51,760 I'LL KEEP MY PART BRIEF TO GET 1053 00:39:51,760 --> 00:39:55,160 TO THE RESULTS AND 1054 00:39:55,160 --> 00:39:57,480 RECOMMENDATIONS PRESENTED BY 1055 00:39:57,480 --> 00:40:00,320 ELECTRA. 1056 00:40:00,320 --> 00:40:03,240 NEXT SLIDE PLEASE. 1057 00:40:03,240 --> 00:40:06,320 SO I WANT TO REMIND EVERYONE OF 1058 00:40:06,320 --> 00:40:09,280 WHAT THE CHARGE WAS TO THE 1059 00:40:09,280 --> 00:40:10,160 WORKING GROUP. 1060 00:40:10,160 --> 00:40:13,000 I'M NOT GOING TO READ IT, 1061 00:40:13,000 --> 00:40:15,320 REITERATE THAT WE WERE HERE, PUT 1062 00:40:15,320 --> 00:40:20,200 TOGETHER, AS A WORKING GROUP, 1063 00:40:20,200 --> 00:40:21,400 OPPORTUNITIES FOR RESEARCH. 1064 00:40:21,400 --> 00:40:24,280 I WANT TO UNDERLINE THAT 1065 00:40:24,280 --> 00:40:25,240 RESEARCH, ON CANCER ALONG RACIAL 1066 00:40:25,240 --> 00:40:27,520 AND ETHNIC MINORITIES AND 1067 00:40:27,520 --> 00:40:29,160 UNDERSERVED POPULATIONS. 1068 00:40:29,160 --> 00:40:30,920 AMONG THE RECOMMENDATIONS WE 1069 00:40:30,920 --> 00:40:33,520 WERE ALSO TO EVALUATE THE 1070 00:40:33,520 --> 00:40:37,480 CURRENT STATUS OF THE NCI OR NIH 1071 00:40:37,480 --> 00:40:39,360 PORTFOLIO AND IDENTIFY NEW 1072 00:40:39,360 --> 00:40:40,880 POTENTIAL STRATEGIC APPROACHES 1073 00:40:40,880 --> 00:40:45,160 AND ACTIONS TO IMPLEMENT THESE. 1074 00:40:45,160 --> 00:40:46,360 NEXT SLIDE PLEASE. 1075 00:40:46,360 --> 00:40:48,080 AFTER THIS DISCUSSIONS WITH THE 1076 00:40:48,080 --> 00:40:51,160 WORKING GROUP, EARLY IN THE 1077 00:40:51,160 --> 00:40:52,440 PROCESS, WE IDENTIFIED THESE 1078 00:40:52,440 --> 00:40:53,960 SPECIFIC GROUPS TO FOCUS ON. 1079 00:40:53,960 --> 00:40:57,200 YOU SEE THEM LISTED HERE, BLACK 1080 00:40:57,200 --> 00:40:59,480 OR AFRICAN AMERICAN, HISPANIC 1081 00:40:59,480 --> 00:41:01,560 LATINO, AMERICAN INDIAN/ALASKA 1082 00:41:01,560 --> 00:41:04,640 NATIVE, ASIAN AND PACIFIC 1083 00:41:04,640 --> 00:41:09,880 ISLANDERS, RURAL POPULATIONS, 1084 00:41:09,880 --> 00:41:11,960 OLDER ADULTS, LGBTQ, AYA CANCER 1085 00:41:11,960 --> 00:41:12,240 SURVIVORS. 1086 00:41:12,240 --> 00:41:14,040 WE RECOGNIZE DISTINCT AND SHARED 1087 00:41:14,040 --> 00:41:16,560 INEQUITIES AND DISPARITIES FACED 1088 00:41:16,560 --> 00:41:17,200 BY EACH GROUP. 1089 00:41:17,200 --> 00:41:20,280 AND IT WAS IMPORTANT FOR US TO 1090 00:41:20,280 --> 00:41:21,720 UNDERSTAND THAT AND REITERATE 1091 00:41:21,720 --> 00:41:24,520 THIS AND DESCRIBED SOME OF THESE 1092 00:41:24,520 --> 00:41:27,400 IN THE REPORT. 1093 00:41:27,400 --> 00:41:28,600 NEXT SLIDE PLEASE. 1094 00:41:28,600 --> 00:41:33,080 AS YOU HEARD, THE WORKING GROUP 1095 00:41:33,080 --> 00:41:35,560 WAS CO-CHAIRED BY ELECTRA AND 1096 00:41:35,560 --> 00:41:35,800 MYSELF. 1097 00:41:35,800 --> 00:41:38,320 I WANT TO RECOGNIZE THE MEMBERS 1098 00:41:38,320 --> 00:41:39,640 OF THE WORKING GROUP, NAMES 1099 00:41:39,640 --> 00:41:41,720 SHOWN HERE ON THE RIGHT. 1100 00:41:41,720 --> 00:41:43,360 THESE ARE EXTREMELY BUSY PEOPLE 1101 00:41:43,360 --> 00:41:44,960 WHO MADE TIME TO WORK ON THIS 1102 00:41:44,960 --> 00:41:45,640 IMPORTANT TASK. 1103 00:41:45,640 --> 00:41:48,720 THANK YOU TO ALL OF YOU. 1104 00:41:48,720 --> 00:41:51,360 I WANT TO THANK DR. PHIL CASTLE, 1105 00:41:51,360 --> 00:42:00,440 AND HIS TEAM FOR HELPING US OUT. 1106 00:42:00,440 --> 00:42:02,440 THE WORKING GROUP FOR OVER A 1107 00:42:02,440 --> 00:42:04,720 YEAR, YEAR AND A HALF, JULY 1108 00:42:04,720 --> 00:42:07,120 2021, A LONG PERIOD OF TIME. 1109 00:42:07,120 --> 00:42:10,120 WE WANTED TO MAKE SURE WE TOOK 1110 00:42:10,120 --> 00:42:13,360 ENOUGH TIME TO BE ABLE TO MEET 1111 00:42:13,360 --> 00:42:15,560 THE CHARGE OF THE TASKS. 1112 00:42:15,560 --> 00:42:19,360 FIRST MONTHLY MEETING IS JULY 1113 00:42:19,360 --> 00:42:21,160 2021, AND THIS MEETING WAS 1114 00:42:21,160 --> 00:42:22,440 ACTUALLY ATTENDED BY DR. 1115 00:42:22,440 --> 00:42:24,000 SHARPLESS, WHO PROVIDED US WITH 1116 00:42:24,000 --> 00:42:27,000 THE CHARGE, AND TOLD US NOT TO 1117 00:42:27,000 --> 00:42:30,440 TRY TO BOIL THE OPTION, I DO 1118 00:42:30,440 --> 00:42:32,600 RECALL THAT. 1119 00:42:32,600 --> 00:42:33,800 MONTHLY CO-CHAIR MEETINGS TOOK 1120 00:42:33,800 --> 00:42:39,400 PLACE WITH VERY IMPORTANT 1121 00:42:39,400 --> 00:42:41,480 SPEAKERS INCLUDING MEMBERS OF 1122 00:42:41,480 --> 00:42:44,280 THE CENTER FOR RESEARCH 1123 00:42:44,280 --> 00:42:45,200 STRATEGY, INSTRUMENTAL IN MAKING 1124 00:42:45,200 --> 00:42:47,800 ANALYSIS POSSIBLE. 1125 00:42:47,800 --> 00:42:51,320 WE ALSO HAD PRESENTATIONS FROM 1126 00:42:51,320 --> 00:42:56,720 KEY NCI INDIVIDUALS WHO 1127 00:42:56,720 --> 00:42:58,800 PRESENTED INCLUDING DR. 1128 00:42:58,800 --> 00:43:00,080 SRINIVASEN AND DR. SPRINGFIELD. 1129 00:43:00,080 --> 00:43:05,000 THANK YOU TO ALL OF YOU. 1130 00:43:05,000 --> 00:43:10,120 HERE IS THE OUTLINE OF THE 1131 00:43:10,120 --> 00:43:10,800 REPORT. 1132 00:43:10,800 --> 00:43:12,560 YOU'RE FAMILIAR WITH THE 1133 00:43:12,560 --> 00:43:14,440 FORMATS, WE'LL GET THROUGH AS 1134 00:43:14,440 --> 00:43:17,400 MANY OF THESE AS POSSIBLE IN THE 1135 00:43:17,400 --> 00:43:19,360 NEXT FEW SLIDES. 1136 00:43:19,360 --> 00:43:19,920 OKAY. 1137 00:43:19,920 --> 00:43:20,560 NEXT SLIDE PLEASE. 1138 00:43:20,560 --> 00:43:26,240 LET'S GET TO THE REPORT. 1139 00:43:26,240 --> 00:43:26,760 NEXT SLIDE. 1140 00:43:26,760 --> 00:43:28,880 IT WAS IMPORTANT FOR THE WORKING 1141 00:43:28,880 --> 00:43:30,280 GROUP, ALL OF US, TO GET ON THE 1142 00:43:30,280 --> 00:43:33,600 SAME PAGE WITH THE TERMINOLOGY 1143 00:43:33,600 --> 00:43:37,240 INCLUDING WHAT WE MEANT BY 1144 00:43:37,240 --> 00:43:38,520 DEFINITION OF DISPARITIES, 1145 00:43:38,520 --> 00:43:39,480 DEFINITION OF HEALTH 1146 00:43:39,480 --> 00:43:40,600 DISPARITIES, A COUPLE PROVIDED 1147 00:43:40,600 --> 00:43:40,960 HERE. 1148 00:43:40,960 --> 00:43:44,200 I WON'T READ THROUGH THEM. 1149 00:43:44,200 --> 00:43:46,840 THE WORKING GROUP RECOGNIZED 1150 00:43:46,840 --> 00:43:49,560 EARLY ON THERE WERE SEVERAL 1151 00:43:49,560 --> 00:43:52,120 MULTI-LEVEL FRAMEWORKS THAT SOME 1152 00:43:52,120 --> 00:43:55,160 OF YOU IN THE ROOM AND THE ZOOM 1153 00:43:55,160 --> 00:43:57,000 ARE VERY FAMILIAR WITH. 1154 00:43:57,000 --> 00:43:58,880 AND THAT HAVE BEEN DEVELOPED TO 1155 00:43:58,880 --> 00:44:00,080 SUPPORT AND GUIDE INTERVENTIONS 1156 00:44:00,080 --> 00:44:05,640 AND OTHER STRATEGIES TO ENHANCE 1157 00:44:05,640 --> 00:44:06,360 CANCER OUTCOMES, ELIMINATE 1158 00:44:06,360 --> 00:44:07,720 DISPARITIES, ACHIEVE HEALTH 1159 00:44:07,720 --> 00:44:09,160 EQUITY AMONG POPULATIONS THAT 1160 00:44:09,160 --> 00:44:10,040 EXPERIENCE THESE. 1161 00:44:10,040 --> 00:44:12,440 AND THE REPORT WE PROVIDED A 1162 00:44:12,440 --> 00:44:17,480 BRIEF OVERVIEW OF SOME OF THESE 1163 00:44:17,480 --> 00:44:17,760 FRAMEWORKS. 1164 00:44:17,760 --> 00:44:19,200 NEXT SLIDE PLEASE. 1165 00:44:19,200 --> 00:44:22,520 NOW, IN ORDER TO IDENTIFY GAPS 1166 00:44:22,520 --> 00:44:25,000 FOR PRIORITIZATION, THE WORKING 1167 00:44:25,000 --> 00:44:27,520 GROUP DECIDED TO EXAMINE 1168 00:44:27,520 --> 00:44:30,000 RESEARCH ACROSS THE CONTINUUM, 1169 00:44:30,000 --> 00:44:35,840 FOR THE POPULATIONS AS YOU CAN 1170 00:44:35,840 --> 00:44:36,400 SEE HERE. 1171 00:44:36,400 --> 00:44:38,680 NCI USE US THE CONTINUUM, WE 1172 00:44:38,680 --> 00:44:43,000 FELT THIS WAS AN IDEAL WAY TO 1173 00:44:43,000 --> 00:44:45,640 TACKLE THIS CHALLENGE OF THE 1174 00:44:45,640 --> 00:44:49,400 REPORT AND ADDRESSING THE 1175 00:44:49,400 --> 00:44:49,880 CHARGE. 1176 00:44:49,880 --> 00:44:51,320 I THINK THIS HAS PROVIDED A 1177 00:44:51,320 --> 00:44:53,560 GREAT WAY TO ASSESS THE GAPS AND 1178 00:44:53,560 --> 00:44:55,560 RESULTED IN SOME VERY 1179 00:44:55,560 --> 00:44:56,240 INTERESTING FINDINGS THAT 1180 00:44:56,240 --> 00:44:59,920 ELECTRA WILL PRESENT IN A 1181 00:44:59,920 --> 00:45:01,480 SUBSEQUENT SLIDE. 1182 00:45:01,480 --> 00:45:02,880 NEXT SLIDE PLEASE. 1183 00:45:02,880 --> 00:45:04,960 I WANT TO REMIND EVERYBODY OF 1184 00:45:04,960 --> 00:45:06,280 THE METHODOLOGY THAT THE CRS 1185 00:45:06,280 --> 00:45:09,680 TEAM USED TO CONDUCT THE 1186 00:45:09,680 --> 00:45:09,960 ANALYSIS. 1187 00:45:09,960 --> 00:45:10,800 WE PRESENTED THIS INFORMATION 1188 00:45:10,800 --> 00:45:13,080 BEFORE TO YOU ALL SO I'M NOT 1189 00:45:13,080 --> 00:45:15,000 GOING OVER IT IN TOO MUCH DETAIL 1190 00:45:15,000 --> 00:45:18,120 BUT, AGAIN, I WANT TO THANK, 1191 00:45:18,120 --> 00:45:22,080 AGAIN, THE AMAZING CRS TEAM FOR 1192 00:45:22,080 --> 00:45:22,480 THEIR GREAT WORK. 1193 00:45:22,480 --> 00:45:26,680 NEXT SLIDE PLEASE . 1194 00:45:26,680 --> 00:45:29,120 HERE A SYNOPSIS OVERVIEW OF THE 1195 00:45:29,120 --> 00:45:31,600 CRS APPROACH USED TO IDENTIFY 1196 00:45:31,600 --> 00:45:34,480 CANCER RESEARCH RELEVANT TO THE 1197 00:45:34,480 --> 00:45:36,160 WORKING GROUP'S POPULATIONS OF 1198 00:45:36,160 --> 00:45:38,200 INTEREST SHOWN ON THE SLIDE. 1199 00:45:38,200 --> 00:45:40,840 THIS APPROACH I WANT TO REMIND 1200 00:45:40,840 --> 00:45:43,360 EVERYBODY RELIED ON MACHINE 1201 00:45:43,360 --> 00:45:44,120 LEARNING ALGORITHMS, 1202 00:45:44,120 --> 00:45:47,600 SUPPLEMENTED BY SOME MANUAL 1203 00:45:47,600 --> 00:45:49,160 CURATION, THAT RESULTED FROM 1204 00:45:49,160 --> 00:45:51,320 SPECIFIC DECISIONS MADE BY THE 1205 00:45:51,320 --> 00:45:52,960 WORKING GROUP. 1206 00:45:52,960 --> 00:45:55,400 THE PROCESS BEGAN WITH 1207 00:45:55,400 --> 00:45:57,920 IDENTIFYING FY 21 NIH GRANTS, 1208 00:45:57,920 --> 00:46:03,720 THEN THESE WERE FILTERED TO 1209 00:46:03,720 --> 00:46:04,640 IDENTIFY CANCER-SPECIFIC 1210 00:46:04,640 --> 00:46:13,240 RESEARCH GRANTS. 1211 00:46:13,240 --> 00:46:15,800 THEN IDENTIFYING RESEARCH OF 1212 00:46:15,800 --> 00:46:17,320 INTEREST, RCDC, SOUNDS LIKE A 1213 00:46:17,320 --> 00:46:21,000 ROCK BAND BUT IT'S NOT. 1214 00:46:21,000 --> 00:46:21,440 RCDC. 1215 00:46:21,440 --> 00:46:24,000 WE HAVE A SLIDE SHORTLY THAT 1216 00:46:24,000 --> 00:46:25,440 DESCRIBES THIS APPROACH. 1217 00:46:25,440 --> 00:46:27,160 THERE WERE BACK AND FORTH 1218 00:46:27,160 --> 00:46:31,880 DISCUSSIONS RESULTING IN MANUAL 1219 00:46:31,880 --> 00:46:34,640 CURATION TO COME UP WITH FINAL 1220 00:46:34,640 --> 00:46:36,920 LIST OF GRANTS, A LOT OF WORK 1221 00:46:36,920 --> 00:46:47,440 TOOK PLACE BY THE CRS GROUP. 1222 00:46:48,600 --> 00:46:49,200 THANK YOU. 1223 00:46:49,200 --> 00:46:51,280 EXCLUSION CRITERIA WAS DEVELOPED 1224 00:46:51,280 --> 00:46:52,920 TO MAKE SURE WE WOULD NOT DOUBLE 1225 00:46:52,920 --> 00:46:53,120 COUNT. 1226 00:46:53,120 --> 00:46:54,920 THIS TOOK A FAIR AMOUNT OF BACK 1227 00:46:54,920 --> 00:46:56,760 AND FORTH, A LOT OF DISCUSSIONS 1228 00:46:56,760 --> 00:46:57,840 WITH THE WORKING GROUP. 1229 00:46:57,840 --> 00:46:59,520 THIS SLIDE PROVIDES A LIST OF 1230 00:46:59,520 --> 00:47:02,800 THE TYPES OF GRANTS AND GRANT 1231 00:47:02,800 --> 00:47:03,680 CATEGORIES EXCLUDED. 1232 00:47:03,680 --> 00:47:06,680 YOU HAVE THEM LISTED HERE. 1233 00:47:06,680 --> 00:47:07,480 THESE INCLUDED ALSO 1234 00:47:07,480 --> 00:47:08,280 INTERNATIONAL PROJECTS BECAUSE 1235 00:47:08,280 --> 00:47:11,320 WE FELT THAT OUR CHARGE WAS TO 1236 00:47:11,320 --> 00:47:12,640 ADVISE ON THE STRATEGIC 1237 00:47:12,640 --> 00:47:13,920 APPROACHES AND OPPORTUNITIES 1238 00:47:13,920 --> 00:47:16,360 RELATED TO RACIAL AND ETHNIC 1239 00:47:16,360 --> 00:47:17,800 MINORITIES AND UNDERSERVED 1240 00:47:17,800 --> 00:47:22,480 POPULATIONS IN THIS COUNTRY. 1241 00:47:22,480 --> 00:47:25,120 NEXT SLIDE PLEASE. 1242 00:47:25,120 --> 00:47:27,760 HERE'S AN OVERVIEW OF THE SYSTEM 1243 00:47:27,760 --> 00:47:29,840 USED BY NIH, IN ITS REPORTING 1244 00:47:29,840 --> 00:47:32,640 PROCESS, TO CATEGORIZE THE 1245 00:47:32,640 --> 00:47:35,280 FUNDING AND BIOMEDICAL RESEARCH 1246 00:47:35,280 --> 00:47:39,280 FOR EACH FISCAL YEAR BY 1247 00:47:39,280 --> 00:47:40,320 PROVIDING CONSISTENT TEXT MINING 1248 00:47:40,320 --> 00:47:42,880 METHODS APPLIED TO ALL THESE 1249 00:47:42,880 --> 00:47:44,520 CATEGORIES EACH YEAR, FOR 1250 00:47:44,520 --> 00:47:48,120 CATEGORIZATION AND REPORTING ON 1251 00:47:48,120 --> 00:47:48,560 NIH FUNDING. 1252 00:47:48,560 --> 00:47:50,400 JUST TO EMPHASIZE WE USES 1253 00:47:50,400 --> 00:47:51,080 EXISTING NIH APPROACH. 1254 00:47:51,080 --> 00:47:54,000 IF YOU WANT TO READ MORE HOW 1255 00:47:54,000 --> 00:47:54,840 THIS WORKS, THE WEBSITE FOR 1256 00:47:54,840 --> 00:48:00,680 THESE IS FOUND ON THE SLIDE. 1257 00:48:00,680 --> 00:48:01,920 NEXT SLIDE PLEASE. 1258 00:48:01,920 --> 00:48:04,440 AND THE FINAL SLIDE FOR THE 1259 00:48:04,440 --> 00:48:06,640 METHODS IS SHOWN HERE, JUST TO 1260 00:48:06,640 --> 00:48:10,000 NOTE THE INTERNATIONAL CANCER 1261 00:48:10,000 --> 00:48:11,640 RESEARCH PARTNERSHIP HAS A SET 1262 00:48:11,640 --> 00:48:13,600 OF CODING GUIDELINES REFERRED TO 1263 00:48:13,600 --> 00:48:16,440 AS THE COMMON SCIENTIFIC 1264 00:48:16,440 --> 00:48:18,640 OUTLINE, CSO, USED TO ASSESS 1265 00:48:18,640 --> 00:48:21,320 RESEARCH PORTFOLIOS. 1266 00:48:21,320 --> 00:48:23,160 SO GRANTS ARE CATEGORIZED INTO 1267 00:48:23,160 --> 00:48:26,000 CSO CODES USING MACHINE LEARNING 1268 00:48:26,000 --> 00:48:27,760 MODEL, ASSIGNED INTO CATEGORIES 1269 00:48:27,760 --> 00:48:29,200 NOTED ON THE SLIDE. 1270 00:48:29,200 --> 00:48:31,800 WE WANT TO NOTE IN SOME 1271 00:48:31,800 --> 00:48:32,880 INSTANCES THERE WAS NOT ENOUGH 1272 00:48:32,880 --> 00:48:37,600 INFORMATION TO ASSIGN A GRANT TO 1273 00:48:37,600 --> 00:48:38,600 A PARTICULAR CATEGORY, AND 1274 00:48:38,600 --> 00:48:41,080 ELECTRA IS GOING TO PROVIDE MORE 1275 00:48:41,080 --> 00:48:41,880 INFORMATION ABOUT THAT SPECIFIC 1276 00:48:41,880 --> 00:48:43,720 LIMITATION AND NOW I'M GOING TO 1277 00:48:43,720 --> 00:48:47,880 TURN IT OVER TO ELECTRA. 1278 00:48:47,880 --> 00:48:49,520 >>THANK YOU VERY MUCH, ELENA. 1279 00:48:49,520 --> 00:48:53,320 I WANT TO ECHO THE THANKS THAT 1280 00:48:53,320 --> 00:48:56,080 ELENA HAS ALREADY STATED TO THE 1281 00:48:56,080 --> 00:48:57,960 TEAM IN ALL THE HARD WORK. 1282 00:48:57,960 --> 00:49:01,200 I'M GOING TO GO NOW OVER THE 1283 00:49:01,200 --> 00:49:03,400 RESULTS IN THESE CATEGORIES, AND 1284 00:49:03,400 --> 00:49:06,240 KEEP IN MIND THE METHODOLOGY 1285 00:49:06,240 --> 00:49:07,600 THAT ELENA JUST PRESENTED AS IT 1286 00:49:07,600 --> 00:49:10,320 WILL HELP. 1287 00:49:10,320 --> 00:49:11,200 NEXT SLIDE PLEASE. 1288 00:49:11,200 --> 00:49:16,680 FIRST WE'LL LOOK AT THE FISCAL 1289 00:49:16,680 --> 00:49:17,200 21 PORTFOLIO. 1290 00:49:17,200 --> 00:49:21,400 THIS IS SORT OF HOW EVERYTHING 1291 00:49:21,400 --> 00:49:24,320 WAS DONE. 1292 00:49:24,320 --> 00:49:27,720 WE TOOK THE -- WE TOOK THE 1293 00:49:27,720 --> 00:49:31,320 FISCAL YEAR CANCER GRANTS OF ALL 1294 00:49:31,320 --> 00:49:33,840 OF NIH FOR 21. 1295 00:49:33,840 --> 00:49:37,200 AND USED THE RCDC CODE TO 1296 00:49:37,200 --> 00:49:40,360 IDENTIFY CANCER GRANTS. 1297 00:49:40,360 --> 00:49:46,680 AND WITH -- CAME UP WITH ABOUT 1298 00:49:46,680 --> 00:49:48,760 9600 BASE PROJECTS, WHICH 75% 1299 00:49:48,760 --> 00:49:52,560 WERE FROM NCI FOR A TOTAL OF 1300 00:49:52,560 --> 00:49:57,960 ABOUT 7200 PROJECTS. 1301 00:49:57,960 --> 00:50:00,400 WE THEN ADDED EXCLUSION CRITERIA 1302 00:50:00,400 --> 00:50:05,000 ALREADY DISCUSSED, AND WE CAME 1303 00:50:05,000 --> 00:50:08,480 UP WITH ABOUT NIH CANCER 1304 00:50:08,480 --> 00:50:14,160 RESEARCH PORTFOLIO OF 7300 BASE 1305 00:50:14,160 --> 00:50:16,360 PROJECTS, 74%, WHICH WERE NCI, 1306 00:50:16,360 --> 00:50:19,200 AND THEN WE INCLUDED OUR RCDC 1307 00:50:19,200 --> 00:50:21,680 CATEGORIES AND CONCEPTS FOR THE 1308 00:50:21,680 --> 00:50:23,560 POPULATION OF INTEREST TO COME 1309 00:50:23,560 --> 00:50:26,640 UP WITH WHAT YOU'LL SEE THE 1310 00:50:26,640 --> 00:50:30,920 FISCAL YEAR 21 NIH CANCER AND 1311 00:50:30,920 --> 00:50:32,200 POPULATION OF INTEREST BASE 1312 00:50:32,200 --> 00:50:35,600 PROJECTS AND THEN THE PERCENT 1313 00:50:35,600 --> 00:50:36,560 WHICH ARE NCI. 1314 00:50:36,560 --> 00:50:41,840 SO I'M NEXT GOING TO MOVE INTO 1315 00:50:41,840 --> 00:50:43,800 ACTUALLY SHOWING YOU SOME DATA. 1316 00:50:43,800 --> 00:50:45,360 SO IT WILL HELP WITH THE 1317 00:50:45,360 --> 00:50:48,200 EXPLANATION THAT I JUST GAVE. 1318 00:50:48,200 --> 00:50:50,000 NEXT SLIDE PLEASE. 1319 00:50:50,000 --> 00:50:54,160 SO, THIS IS THE FISCAL YEAR 21 1320 00:50:54,160 --> 00:50:55,000 EXTRAMURAL BASE PROJECT FOR 1321 00:50:55,000 --> 00:50:57,000 POPULATIONS OF INTEREST. 1322 00:50:57,000 --> 00:51:01,160 YOU CAN SEE THE FURTHERMOST LEFT 1323 00:51:01,160 --> 00:51:04,200 COLUMN HAS OUR POPULATIONS, AND 1324 00:51:04,200 --> 00:51:06,720 THEN TAKING THOSE BASE PROJECTS 1325 00:51:06,720 --> 00:51:12,320 FROM ALL OF NIH REMEMBER THE 1326 00:51:12,320 --> 00:51:18,440 TOTAL WAS 7327, WE PRESENT TO 1327 00:51:18,440 --> 00:51:22,400 YOU THE NUMBER CONDUCTED AMONG 1328 00:51:22,400 --> 00:51:23,680 POPULATIONS OF INTEREST, AND THE 1329 00:51:23,680 --> 00:51:30,280 FIRST YOU CAN SEE IS 310 OF 1330 00:51:30,280 --> 00:51:32,600 THOSE 7327 PROJECTS WERE 1331 00:51:32,600 --> 00:51:38,560 INDICATED TO BE CONDUCTED AMONG 1332 00:51:38,560 --> 00:51:41,640 BLACK OR AFRICAN AMERICAN 1333 00:51:41,640 --> 00:51:43,040 PARTICIPANTS. 1334 00:51:43,040 --> 00:51:44,960 AND THAT IS 4.23% OF THE TOTAL 1335 00:51:44,960 --> 00:51:45,480 NIH GRANTS. 1336 00:51:45,480 --> 00:51:48,000 IF YOU MOVE OVER TO THE NEXT 1337 00:51:48,000 --> 00:51:51,200 COLUMN, WE LOOK AT THOSE BASE 1338 00:51:51,200 --> 00:51:55,680 PROJECTS ADMINISTERED BY NCI, 1339 00:51:55,680 --> 00:51:58,520 TOTALS 5212, THERE WERE 246 OF 1340 00:51:58,520 --> 00:52:01,600 THE 310, 79%, BUT IF WE LOOK AT 1341 00:52:01,600 --> 00:52:05,320 THE TOTAL OF THOSE ADMINISTERED 1342 00:52:05,320 --> 00:52:08,480 BY NCI 5412 THAT REPRESENTS 1343 00:52:08,480 --> 00:52:08,680 4.55%. 1344 00:52:08,680 --> 00:52:10,720 YOU CAN SEE THE NUMBERS AS YOU 1345 00:52:10,720 --> 00:52:14,400 GO DOWN, EACH OF THE COLUMNS, 1346 00:52:14,400 --> 00:52:16,560 AND THE RELATIVE -- THE 1347 00:52:16,560 --> 00:52:18,960 ESTIMATED PERCENT THAT WE HAVE 1348 00:52:18,960 --> 00:52:21,520 FOR YOU. 1349 00:52:21,520 --> 00:52:25,640 NEXT SLIDE. 1350 00:52:25,640 --> 00:52:28,480 NOW, THIS ONE SHOWS YOU AGAIN 1351 00:52:28,480 --> 00:52:31,800 FISCAL YEAR 21 NIH PORTFOLIO 1352 00:52:31,800 --> 00:52:34,200 BASE PROJECT BUT CLASSIFIED 1353 00:52:34,200 --> 00:52:35,200 WITHIN THOSE CSO CATEGORIES 1354 00:52:35,200 --> 00:52:37,480 WHICH WAS THE CLOSEST WE COULD 1355 00:52:37,480 --> 00:52:40,520 GET TO THE CANCER CONTINUUM THAT 1356 00:52:40,520 --> 00:52:44,520 ELENA SHOWED YOU WHICH WAS OUR 1357 00:52:44,520 --> 00:52:46,040 DESIRE TO SHOW RESEARCH IN EACH 1358 00:52:46,040 --> 00:52:49,760 OF OUR POPULATIONS OF INTEREST 1359 00:52:49,760 --> 00:52:50,760 ACROSS THE CANCER CONTINUUM. 1360 00:52:50,760 --> 00:52:52,520 THE CONTINUUM IS THE FIRST 1361 00:52:52,520 --> 00:52:54,560 COLUMN ON THE LEFT. 1362 00:52:54,560 --> 00:52:56,440 AND I'LL GO THROUGH THE 1363 00:52:56,440 --> 00:52:58,840 COMPARATOR FOR YOU BECAUSE THIS 1364 00:52:58,840 --> 00:53:00,720 IS THE COMPARATOR. 1365 00:53:00,720 --> 00:53:05,080 SO FOR -- IN BIOLOGY AWARDS, OR 1366 00:53:05,080 --> 00:53:08,560 AWARDS FOCUSING ON BIOLOGY, 1367 00:53:08,560 --> 00:53:12,960 THERE ARE 42% OF NIH GRANTS THAT 1368 00:53:12,960 --> 00:53:15,160 FOCUS ON BIOLOGY. 1369 00:53:15,160 --> 00:53:18,240 12.9 ON ETIOLOGY, ET CETERA. 1370 00:53:18,240 --> 00:53:20,840 NOW, IF WE COMPARE AMONGST THE 1371 00:53:20,840 --> 00:53:22,440 310 PROJECTS THAT WERE CONDUCTED 1372 00:53:22,440 --> 00:53:26,880 AMONG BLACK OR AFRICAN AMERICAN 1373 00:53:26,880 --> 00:53:30,640 POPULATIONS, 26.5% OF THOSE 310 1374 00:53:30,640 --> 00:53:35,680 WERE CATEGORIZED AS FOCUSING ON 1375 00:53:35,680 --> 00:53:37,080 BIOLOGY. 1376 00:53:37,080 --> 00:53:41,240 YOU CAN SEE DOWN EACH AND ACROSS 1377 00:53:41,240 --> 00:53:42,800 THE COLUMNS. 1378 00:53:42,800 --> 00:53:44,880 WE NOW HAVE THESE PICTORIALLY, 1379 00:53:44,880 --> 00:53:53,400 AND I JUST PICKED TO SHOW YOU 1380 00:53:53,400 --> 00:53:56,600 BLACK OR AFRICAN AMERICAN 1381 00:53:56,600 --> 00:53:57,880 POPULATION, YOU CAN SEE THESE 1382 00:53:57,880 --> 00:53:59,080 BETTER IF YOU LIKE THINGS 1383 00:53:59,080 --> 00:53:59,400 VISUALLY. 1384 00:53:59,400 --> 00:54:02,560 GRAY LINE IS THE NIH CANCER 1385 00:54:02,560 --> 00:54:06,400 COMPARATOR, RED LINE IS THOSE 1386 00:54:06,400 --> 00:54:09,160 PERCENT OF THE 310 BASE PROJECTS 1387 00:54:09,160 --> 00:54:11,240 THAT ARE WITH BLACK OR AFRICAN 1388 00:54:11,240 --> 00:54:12,040 AMERICAN POPULATIONS, AND YOU 1389 00:54:12,040 --> 00:54:14,760 CAN SEE WHERE THERE ARE 1390 00:54:14,760 --> 00:54:17,720 DIFFERENCES IN BIOLOGY AND 1391 00:54:17,720 --> 00:54:19,280 TREATMENT. 1392 00:54:19,280 --> 00:54:21,680 FOR SAKE OF TIME AND YOUR EYES 1393 00:54:21,680 --> 00:54:25,600 TO SEE THESE WE'RE NOT SHOWING 1394 00:54:25,600 --> 00:54:29,200 THE OTHER GRAPHS BUT THE PATTERN 1395 00:54:29,200 --> 00:54:34,160 IS THE SAME, THAT THE BIOLOGY 1396 00:54:34,160 --> 00:54:36,440 AND THE TREATMENT RESEARCH IS 1397 00:54:36,440 --> 00:54:39,640 NOTICEABLY LESS, IN ALL OF THE 1398 00:54:39,640 --> 00:54:42,720 POPULATION GROUPS THAT WE 1399 00:54:42,720 --> 00:54:43,000 EXAMINED. 1400 00:54:43,000 --> 00:54:43,840 NEXT SLIDE PLEASE. 1401 00:54:43,840 --> 00:54:46,440 SO NOW I WANT TO GO TO OUR 1402 00:54:46,440 --> 00:54:48,160 SUMMARY AND RECOMMENDATIONS. 1403 00:54:48,160 --> 00:54:48,680 NEXT SLIDE. 1404 00:54:48,680 --> 00:54:52,080 THIS IS A SUMMARY OF OUR 1405 00:54:52,080 --> 00:54:52,880 FINDINGS. 1406 00:54:52,880 --> 00:54:55,720 AS YOU CAN SEE, THERE IS AN 1407 00:54:55,720 --> 00:54:56,720 IMBALANCE IN RESEARCH RELATIVE 1408 00:54:56,720 --> 00:54:59,200 TO THE DISTRIBUTION OF CANCER 1409 00:54:59,200 --> 00:55:01,520 DIAGNOSIS, MORBIDITY AND DEATH, 1410 00:55:01,520 --> 00:55:05,200 IN THE UNITED STATES. 1411 00:55:05,200 --> 00:55:08,800 AND RELATIVE TO THE OVERALL 1412 00:55:08,800 --> 00:55:11,600 PORTFOLIO, THE NIH COMPARATOR, 1413 00:55:11,600 --> 00:55:14,320 INVESTMENT WAS SMALL FOR 1414 00:55:14,320 --> 00:55:17,400 RESEARCH THAT FOCUSED AMONG THE 1415 00:55:17,400 --> 00:55:18,280 RACIAL/ETHNIC MINORITIES, RULE 1416 00:55:18,280 --> 00:55:24,840 POPULATIONS, OTHER GROUPS 1417 00:55:24,840 --> 00:55:25,320 EVALUATED. 1418 00:55:25,320 --> 00:55:26,600 UNDERREPRESENTATION WAS AMONG 1419 00:55:26,600 --> 00:55:30,080 CONTINUUM OF SCIENCE, CSO CODES, 1420 00:55:30,080 --> 00:55:30,760 AND LIFESPAN. 1421 00:55:30,760 --> 00:55:35,560 WE ALSO FOUND AS WE SHOWED YOU 1422 00:55:35,560 --> 00:55:38,640 THAN THERE WERE MORE PROJECTS IN 1423 00:55:38,640 --> 00:55:40,560 POPULATION SCIENCE, FEWER 1424 00:55:40,560 --> 00:55:42,920 STUDIES IN BIOLOGICAL RESEARCH 1425 00:55:42,920 --> 00:55:44,440 AND CLINICAL RESEARCH. 1426 00:55:44,440 --> 00:55:46,000 MANY OF THE PROJECTS REALLY DREW 1427 00:55:46,000 --> 00:55:48,600 ON A LIMITED NUMBER OF 1428 00:55:48,600 --> 00:55:50,680 UNDERSERVED POPULATION GROUPS, 1429 00:55:50,680 --> 00:55:53,640 LIMITING THE APPLICABILITY OF 1430 00:55:53,640 --> 00:55:55,840 CURRENT KNOWLEDGE BASE, AND 1431 00:55:55,840 --> 00:55:57,360 INFORMATION WAS LACKING OR NOT 1432 00:55:57,360 --> 00:56:03,400 AS IN DEPTH FOR SOME POPULATIONS 1433 00:56:03,400 --> 00:56:04,280 BECAUSE OF LIMITED DISAGGREGATED 1434 00:56:04,280 --> 00:56:04,840 DATA. 1435 00:56:04,840 --> 00:56:07,920 ELENA EXPLAINED THAT WE 1436 00:56:07,920 --> 00:56:12,720 DISAGGREGATED ASIAN AND PACIFIC 1437 00:56:12,720 --> 00:56:14,000 ISLANDER POPULATIONS, FOR 1438 00:56:14,000 --> 00:56:15,440 EXAMPLE, AND THERE REALLY WAS 1439 00:56:15,440 --> 00:56:20,880 NOT AS MUCH DATA IN THOSE 1440 00:56:20,880 --> 00:56:23,440 POPULATIONS. 1441 00:56:23,440 --> 00:56:25,280 OTHER POPULATIONS WERE 1442 00:56:25,280 --> 00:56:26,240 UNDERSTUDIED, LGBTQ+ POPULATION, 1443 00:56:26,240 --> 00:56:29,760 OR POPULATION WAS NOT ADEQUATELY 1444 00:56:29,760 --> 00:56:33,280 IDENTIFIABLE AS A DISTINCT GROUP 1445 00:56:33,280 --> 00:56:34,480 IN CURRENT RESEARCH INVENTORY 1446 00:56:34,480 --> 00:56:36,320 NCI MEETING WE DIDN'T HAVE CODES 1447 00:56:36,320 --> 00:56:38,720 SO WE COULDN'T PULL THOSE 1448 00:56:38,720 --> 00:56:40,920 RESEARCH GRANTS OUT OF THE 1449 00:56:40,920 --> 00:56:41,840 DATABASE. 1450 00:56:41,840 --> 00:56:46,200 FOR EXAMPLE, THE AYA POPULATION 1451 00:56:46,200 --> 00:56:47,520 AND OLDER ADULTS. 1452 00:56:47,520 --> 00:56:48,560 THIS LIMITED WORKING GROUP'S 1453 00:56:48,560 --> 00:56:50,360 ABILITY TO COMPLETE THE CHARGE 1454 00:56:50,360 --> 00:56:53,720 TO THE SAME DEGREE FOR ALL OF 1455 00:56:53,720 --> 00:56:56,800 THE POPULATIONS, THAT WE WERE 1456 00:56:56,800 --> 00:56:57,240 EXAMINING. 1457 00:56:57,240 --> 00:56:59,640 NEXT SLIDE PLEASE. 1458 00:56:59,640 --> 00:57:02,400 NOW I'M GOING TO RECOMMENDATIONS 1459 00:57:02,400 --> 00:57:04,120 IN TWO CATEGORIES, SPECIFIC AND 1460 00:57:04,120 --> 00:57:08,000 THEN THE BROAD RECOMMENDATIONS. 1461 00:57:08,000 --> 00:57:11,560 SPECIFICALLY, TO EXPAND AND/OR 1462 00:57:11,560 --> 00:57:16,360 INITIATE RFAs, FOAs, 1463 00:57:16,360 --> 00:57:17,480 INVESTIGATOR INITIATED AWARDS, 1464 00:57:17,480 --> 00:57:20,960 SUPPLEMENT OPPORTUNITIES IN 1465 00:57:20,960 --> 00:57:23,360 AREAS WITH INTENTIONAL FOCUS ON 1466 00:57:23,360 --> 00:57:24,360 ELIMINATING DISPARITIES AND 1467 00:57:24,360 --> 00:57:26,320 INEQUITIES IN THE FUNDED GRANT 1468 00:57:26,320 --> 00:57:26,640 PORTFOLIO. 1469 00:57:26,640 --> 00:57:29,480 NUMBER ONE IS MORE FUNDING FOR 1470 00:57:29,480 --> 00:57:32,240 ALL OF THOSE POPULATION GROUPS. 1471 00:57:32,240 --> 00:57:36,480 SECONDLY, IN THE AREA OF DATA 1472 00:57:36,480 --> 00:57:37,920 COLLECTION, WE RECOMMEND THAT 1473 00:57:37,920 --> 00:57:39,080 THERE IS A STANDARDIZED CHECK 1474 00:57:39,080 --> 00:57:43,160 LIST THAT IS ADOPTED FOR GRANTS 1475 00:57:43,160 --> 00:57:46,760 THAT WILL IDENTIFY POPULATIONS 1476 00:57:46,760 --> 00:57:47,880 THAT ARE INCLUDED, BEING 1477 00:57:47,880 --> 00:57:50,960 STUDIED, SET STANDARDS IN 1478 00:57:50,960 --> 00:57:54,880 REPORTING OF DISAGGREGATED DATA 1479 00:57:54,880 --> 00:57:56,200 FOR ALL RACES AND ETHNICITIES. 1480 00:57:56,200 --> 00:57:59,600 THIRD IN THE AREA OF MONITORING 1481 00:57:59,600 --> 00:58:02,640 AND EVALUATION, DEVELOP 1482 00:58:02,640 --> 00:58:04,760 EFFECTIVE AND EFFICIENT 1483 00:58:04,760 --> 00:58:06,280 STRATEGIES FOR TRACKING, 1484 00:58:06,280 --> 00:58:08,440 MONITORING, EVALUATING FEDERAL 1485 00:58:08,440 --> 00:58:10,280 INVESTMENT IN ADVANCING CANCER 1486 00:58:10,280 --> 00:58:13,280 HEALTH EQUITY TO ADDRESS GAPS IN 1487 00:58:13,280 --> 00:58:15,680 HEALTH DISPARITIES IDENTIFIED IN 1488 00:58:15,680 --> 00:58:17,000 THIS REPORT. 1489 00:58:17,000 --> 00:58:22,040 WE CAN'T MEASURE WHO WE'RE DOING 1490 00:58:22,040 --> 00:58:25,520 UNLESS WE HAVE A STRATEGY TO DO 1491 00:58:25,520 --> 00:58:26,280 THIS AUTOMATICALLY. 1492 00:58:26,280 --> 00:58:28,640 AND IF WE CAN MEASURE IT AND 1493 00:58:28,640 --> 00:58:31,560 EVALUATE IT, WE NEED TO THEN 1494 00:58:31,560 --> 00:58:34,600 REPORT IT. 1495 00:58:34,600 --> 00:58:36,040 AND CREATE ANNUAL REPORT 1496 00:58:36,040 --> 00:58:37,000 ACTIVITIES TO PROVIDE 1497 00:58:37,000 --> 00:58:38,240 CONGRESSIONAL BRIEFINGS ON THE 1498 00:58:38,240 --> 00:58:41,080 STATE OF CANCER HEALTH EQUITY. 1499 00:58:41,080 --> 00:58:44,800 NEXT SLIDE PLEASE. 1500 00:58:44,800 --> 00:58:46,320 OUR BROAD RECOMMENDATIONS 1501 00:58:46,320 --> 00:58:47,760 INCLUDE SETTING -- ESTABLISHING 1502 00:58:47,760 --> 00:58:52,240 SET OF GUIDING PRINCIPLES AND 1503 00:58:52,240 --> 00:58:53,120 PRIORITIES USING THESE 1504 00:58:53,120 --> 00:58:54,440 RECOMMENDATIONS, UTILIZE A 1505 00:58:54,440 --> 00:58:56,160 FRAMEWORK FOR RESEARCH THAT 1506 00:58:56,160 --> 00:59:00,360 RELATES TO THE SCIENCE, ART AND 1507 00:59:00,360 --> 00:59:02,520 PRACTICE OF INCLUSIVE CANCER 1508 00:59:02,520 --> 00:59:03,600 RESEARCH, IMPLEMENT STRATEGIES 1509 00:59:03,600 --> 00:59:06,920 TO INCREASE FUNDING TO DIVERSE 1510 00:59:06,920 --> 00:59:07,360 AND UNDERREPRESENTED 1511 00:59:07,360 --> 00:59:09,400 INVESTIGATORS, ENSURE A PORTION 1512 00:59:09,400 --> 00:59:13,840 OF THE GRANTS IS FOCUSED ON THIS 1513 00:59:13,840 --> 00:59:15,240 POPULATIONS WE INCLUDED IN THE 1514 00:59:15,240 --> 00:59:17,760 REPORT, IMPLEMENT A SET OF CORE 1515 00:59:17,760 --> 00:59:19,400 ELEMENTS TO FACILITATE ANALYSIS 1516 00:59:19,400 --> 00:59:22,040 AND REPORTING OF PROGRESS IN 1517 00:59:22,040 --> 00:59:25,440 RESEARCH ACROSS THE CONTINUUM BY 1518 00:59:25,440 --> 00:59:30,560 EACH OF THE POPULATIONS, AND, 1519 00:59:30,560 --> 00:59:31,160 AGAIN, INTENTIONALITY, 1520 00:59:31,160 --> 00:59:33,760 ACCELERATE RESEARCH IN THESE 1521 00:59:33,760 --> 00:59:37,080 AREAS BY OFFERING RFAs, 1522 00:59:37,080 --> 00:59:38,040 FOAs, PARS TO UNDERSTAND WHY 1523 00:59:38,040 --> 00:59:42,480 THERE ARE DISPARITIES AND HOW TO 1524 00:59:42,480 --> 00:59:46,440 ELIMINATE DISPARITY. 1525 00:59:46,440 --> 00:59:48,040 AND THEN LASTLY OUR 1526 00:59:48,040 --> 00:59:50,280 RECOMMENDATIONS CAN ONLY BE 1527 00:59:50,280 --> 00:59:54,080 FULLY REALIZED WHEN WE WORK WITH 1528 00:59:54,080 --> 00:59:55,600 OTHER ONGOING NCI EFFORTS, 1529 00:59:55,600 --> 00:59:57,480 SPECIFICALLY IN TRAINING. 1530 00:59:57,480 --> 01:00:00,160 SO THAT WE CAN INCREASE 1531 01:00:00,160 --> 01:00:04,480 DIVERSITY IN THE WORKFORCE AT 1532 01:00:04,480 --> 01:00:05,040 ALL LEVELS. 1533 01:00:05,040 --> 01:00:10,400 SO I WOULD LIKE TO CONCLUDE AND 1534 01:00:10,400 --> 01:00:13,240 SAY THAT IN POPULATION GROUPS 1535 01:00:13,240 --> 01:00:18,040 WHERE WE SEE DISPARITIES IN 1536 01:00:18,040 --> 01:00:21,640 CANCER HEALTHS OUTCOMES, WE SEE 1537 01:00:21,640 --> 01:00:22,680 DISPARITIES IN FUNDING. 1538 01:00:22,680 --> 01:00:24,840 THANK YOU VERY MUCH. 1539 01:00:24,840 --> 01:00:27,120 DR. DOUBENI IS ALSO ON. 1540 01:00:27,120 --> 01:00:31,080 SO THE THREE OF US, AND I KNOW 1541 01:00:31,080 --> 01:00:33,280 DR. CASTLE IS ALSO ON, WE'RE 1542 01:00:33,280 --> 01:00:34,240 HAPPY TO TAKE QUESTIONS. 1543 01:00:34,240 --> 01:00:36,120 MAYBE WE CAN TAKE THIS DOWN SO 1544 01:00:36,120 --> 01:00:39,360 WE CAN SEE THE QUESTIONS. 1545 01:00:39,360 --> 01:00:41,000 THANKS VERY MUCH. 1546 01:00:41,000 --> 01:00:46,320 >>WE HAVE FIVE MINUTES FOR 1547 01:00:46,320 --> 01:00:46,600 QUESTIONS. 1548 01:00:46,600 --> 01:00:50,760 CURRENTLY I SEE ANDREA AND MARK, 1549 01:00:50,760 --> 01:00:51,480 AND GLORIA. 1550 01:00:51,480 --> 01:00:55,040 LET'S GO IN THAT ORDER. 1551 01:00:55,040 --> 01:00:57,200 >>THANK YOU FOR THAT THOROUGH 1552 01:00:57,200 --> 01:00:57,960 EVALUATION ASSESSMENT AND 1553 01:00:57,960 --> 01:00:58,600 EXCELLENT JOB. 1554 01:00:58,600 --> 01:01:00,480 THE ONLY COMMENT I HAVE IS 1555 01:01:00,480 --> 01:01:02,440 REGARDING THE GRANTS AND IT MAY 1556 01:01:02,440 --> 01:01:04,960 BE SORT OF BETWEEN THE LINES BUT 1557 01:01:04,960 --> 01:01:08,120 WASN'T SPELLED OUT, EMPHASIS ON 1558 01:01:08,120 --> 01:01:12,720 YOUNG INVESTIGATOR, I SAW R01 1559 01:01:12,720 --> 01:01:13,320 AND SUPPLEMENT OPPORTUNITIES, 1560 01:01:13,320 --> 01:01:14,480 SUPPLEMENT OPPORTUNITIES IS ONE 1561 01:01:14,480 --> 01:01:16,720 OF THE MECHANISMS BUT WANT TO 1562 01:01:16,720 --> 01:01:20,600 MAKE SURE SOMEWHERE IN THE 1563 01:01:20,600 --> 01:01:24,240 DETAILS WE ARE ENCOURAGING 1564 01:01:24,240 --> 01:01:25,560 YOUNGER INVESTIGATORS. 1565 01:01:25,560 --> 01:01:26,080 >>THANKS, IN THE 1566 01:01:26,080 --> 01:01:26,960 RECOMMENDATIONS, THANKS VERY 1567 01:01:26,960 --> 01:01:28,080 MUCH, YES. 1568 01:01:28,080 --> 01:01:31,480 APPRECIATE THAT. 1569 01:01:31,480 --> 01:01:32,640 >>GREAT POINT. 1570 01:01:32,640 --> 01:01:33,760 MARK? 1571 01:01:33,760 --> 01:01:34,240 >>THANKS. 1572 01:01:34,240 --> 01:01:35,160 EXCELLENT PRESENTATION. 1573 01:01:35,160 --> 01:01:38,960 I JUST WANT TO POINT OUT ONE 1574 01:01:38,960 --> 01:01:42,000 SPECIFIC ISSUE BUT I THINK IT 1575 01:01:42,000 --> 01:01:43,480 NEEDS ATTENTION AND THIS 1576 01:01:43,480 --> 01:01:46,760 COMMITTEE MAY WANT TO ADDRESS 1577 01:01:46,760 --> 01:01:48,560 THIS TO SOME EXTENT. 1578 01:01:48,560 --> 01:01:53,680 THE AMERICAN INDIAN AND ALASKA 1579 01:01:53,680 --> 01:01:55,000 NATIVE POPULATION, AN INDIVIDUAL 1580 01:01:55,000 --> 01:01:57,200 SAY ON A THERAPEUTIC TREATMENT 1581 01:01:57,200 --> 01:02:00,160 TRIAL OR BIOLOGY STUDY, AND 1582 01:02:00,160 --> 01:02:01,120 YOU'RE NOT WITHIN THE INDIAN 1583 01:02:01,120 --> 01:02:04,320 HEALTH SERVICE TRIBAL OR URBAN 1584 01:02:04,320 --> 01:02:06,400 INDIAN HEALTH CENTER SETTING, 1585 01:02:06,400 --> 01:02:07,480 THAT COULD BE INDIVIDUAL 1586 01:02:07,480 --> 01:02:09,480 CONSENT, BUT IF YOU'RE WORKING 1587 01:02:09,480 --> 01:02:11,720 WITHIN THE INDIAN HEALTH SERVICE 1588 01:02:11,720 --> 01:02:13,840 TRIBAL OR URBAN INDIAN CLINIC 1589 01:02:13,840 --> 01:02:18,200 SETTING, THEN YOU ARE DEALING 1590 01:02:18,200 --> 01:02:19,760 WITH DOMESTIC TRIBAL SOVEREIGN 1591 01:02:19,760 --> 01:02:22,160 NATIONS AND DATA SOVEREIGNTY 1592 01:02:22,160 --> 01:02:22,480 ISSUES. 1593 01:02:22,480 --> 01:02:25,760 AND SO, YOU KNOW, THERE IS A 1594 01:02:25,760 --> 01:02:26,960 SPECIAL FEDERAL TRIBAL 1595 01:02:26,960 --> 01:02:28,800 RELATIONSHIP THAT NEEDS TO BE 1596 01:02:28,800 --> 01:02:30,040 CONSIDERED IN RELATION TO 1597 01:02:30,040 --> 01:02:30,440 RESEARCH. 1598 01:02:30,440 --> 01:02:37,880 NCI IS AWARE OF THIS. 1599 01:02:37,880 --> 01:02:39,640 WHEN YOU TALK ABOUT 1600 01:02:39,640 --> 01:02:43,920 DISAGGREGATED DATA THERE HAS TO 1601 01:02:43,920 --> 01:02:45,920 BE ALLOWANCES FOR DATA SHARING 1602 01:02:45,920 --> 01:02:47,400 AGREEMENTS THAT CAN ACCOMMODATE 1603 01:02:47,400 --> 01:02:48,840 TRIBAL SOVEREIGNTY AS WELL SO I 1604 01:02:48,840 --> 01:02:51,720 WANT TO MAKE SURE THAT THAT GETS 1605 01:02:51,720 --> 01:02:53,920 INCORPORATED INTO HOW THIS WAS 1606 01:02:53,920 --> 01:02:54,960 CONCEPTUALIZED. 1607 01:02:54,960 --> 01:02:56,440 THE OTHER QUICK POINT IS I 1608 01:02:56,440 --> 01:02:58,600 BROUGHT THIS UP I THINK 1609 01:02:58,600 --> 01:03:00,880 YESTERDAY, RURAL IN TERMS OF 1610 01:03:00,880 --> 01:03:02,200 BEING CLEAR ABOUT DEFINITIONS, 1611 01:03:02,200 --> 01:03:03,760 WHAT COUNTS, THIS WOULD BE TRUE 1612 01:03:03,760 --> 01:03:06,680 FOR OTHER GROUPS AS WELL. 1613 01:03:06,680 --> 01:03:07,560 I THINK DEFINITIONAL CLARITY IS 1614 01:03:07,560 --> 01:03:10,080 GOING TO BE IMPORTANT BECAUSE 1615 01:03:10,080 --> 01:03:14,120 PEOPLE MAY SELF-REPORT THINGS 1616 01:03:14,120 --> 01:03:14,480 THAT AREN'T -- 1617 01:03:14,480 --> 01:03:19,080 >>RIGHT, MARK, WHEN WE DID OUR 1618 01:03:19,080 --> 01:03:28,560 ANALYSIS WE DID USE OUR RUCC 1619 01:03:28,560 --> 01:03:29,640 CODE. 1620 01:03:29,640 --> 01:03:29,960 >>GLORIA? 1621 01:03:29,960 --> 01:03:30,480 >>GREAT PRESENTATION. 1622 01:03:30,480 --> 01:03:33,920 THANKS FOR ALL THE WONDERFUL 1623 01:03:33,920 --> 01:03:34,120 WORK. 1624 01:03:34,120 --> 01:03:36,560 A QUESTION THAT RELATES TO YOUR 1625 01:03:36,560 --> 01:03:38,760 RECOMMENDATION FOR REPORTING OR 1626 01:03:38,760 --> 01:03:40,280 TRACKING AND REPORTING. 1627 01:03:40,280 --> 01:03:43,480 SO RECENTLY ON A NATIONAL 1628 01:03:43,480 --> 01:03:45,240 ACADEMIES COMMITTEE ON IMPROVING 1629 01:03:45,240 --> 01:03:46,400 REPRESENTATION IN CLINICAL 1630 01:03:46,400 --> 01:03:52,760 TRIALS AND RESEARCH, WE FOCUSED 1631 01:03:52,760 --> 01:03:53,960 ON IMPROVING REPORTING IN 1632 01:03:53,960 --> 01:03:55,040 clinicaltrials.gov SPECIFICALLY 1633 01:03:55,040 --> 01:03:56,720 BECAUSE IT'S DIFFICULT TO UNDER 1634 01:03:56,720 --> 01:03:58,200 REPRESENTATION FROM DATA THAT'S 1635 01:03:58,200 --> 01:03:59,120 AVAILABLE IN 1636 01:03:59,120 --> 01:03:59,760 clinicaltrials.gov. 1637 01:03:59,760 --> 01:04:02,560 I WONDERED IF THIS COMMITTEE HAD 1638 01:04:02,560 --> 01:04:03,480 SIMILAR THOUGHTS ABOUT 1639 01:04:03,480 --> 01:04:04,360 clinicaltrials.gov BEING THE 1640 01:04:04,360 --> 01:04:06,200 RIGHT PLACE FOR THAT OR DID YOU 1641 01:04:06,200 --> 01:04:09,160 REALLY THINK ABOUT IT BEING IN A 1642 01:04:09,160 --> 01:04:11,120 DIFFERENT PLACE LIKE NIH 1643 01:04:11,120 --> 01:04:13,880 REPORTER OR SOME OTHER EXISTING 1644 01:04:13,880 --> 01:04:16,400 TRACKING SYSTEM? 1645 01:04:16,400 --> 01:04:18,280 1646 01:04:18,280 --> 01:04:24,360 >>OBVIOUSLY WE DIDN'T CONSIDER 1647 01:04:24,360 --> 01:04:24,560 THAT. 1648 01:04:24,560 --> 01:04:27,480 ELENA, DO YOU WANT TO ADD? 1649 01:04:27,480 --> 01:04:29,440 WE STILL HAVE MORE TO GO IN 1650 01:04:29,440 --> 01:04:31,720 TERMS OF WHERE THAT WOULD 1651 01:04:31,720 --> 01:04:32,520 REPORTING BE. 1652 01:04:32,520 --> 01:04:34,360 DO YOU WANT TO -- 1653 01:04:34,360 --> 01:04:37,840 >>YEAH, I THINK THAT'S A VERY 1654 01:04:37,840 --> 01:04:39,600 IMPORTANT AND CRITICAL QUESTION, 1655 01:04:39,600 --> 01:04:43,440 WITHOUT MEASURING AND TRACKING, 1656 01:04:43,440 --> 01:04:44,960 OBVIOUSLY SOMEBODY -- 1657 01:04:44,960 --> 01:04:45,640 RECOMMENDATIONS OF INCLUSIVE 1658 01:04:45,640 --> 01:04:48,360 RESEARCH ARE IMPORTANT TO TRACK. 1659 01:04:48,360 --> 01:04:51,760 RIGHT NOW WE ALL AGREE CURRENT 1660 01:04:51,760 --> 01:04:55,800 SYSTEMS ARE INADEQUATE, WHAT WE 1661 01:04:55,800 --> 01:04:59,000 RECOMMENDED IS A CHECKLIST 1662 01:04:59,000 --> 01:05:00,440 SYSTEM THAT ALLOWS FOR SYSTEMS 1663 01:05:00,440 --> 01:05:10,840 TO TRACK PERSPECTIVELY. 1664 01:05:16,360 --> 01:05:18,040 WE HAVEN'T DONE THE DEEP DIVE TO 1665 01:05:18,040 --> 01:05:20,240 SEE WHAT'S IN PLACE AND WHAT 1666 01:05:20,240 --> 01:05:20,840 YOU'RE PLANNING TO DO, CLEARLY 1667 01:05:20,840 --> 01:05:22,640 WANT TO FLAG THAT AS SOMETHING 1668 01:05:22,640 --> 01:05:25,680 IMPORTANT NCI NEEDS TO CONSIDER. 1669 01:05:25,680 --> 01:05:26,680 >>LET ME ADD SOMETHING. 1670 01:05:26,680 --> 01:05:28,760 WE DID TALK ABOUT ADDING A CHECK 1671 01:05:28,760 --> 01:05:30,600 BOX THAT WOULD BE WHEN THE GRANT 1672 01:05:30,600 --> 01:05:32,360 WAS SUBMITTED THAT THERE WOULD 1673 01:05:32,360 --> 01:05:35,120 BE A CHECK BOX AT THAT POINT, 1674 01:05:35,120 --> 01:05:37,400 THAT WOULD BE AN NIH CHECK BOX, 1675 01:05:37,400 --> 01:05:38,840 NOT NECESSARILY A CHECK BOX THAT 1676 01:05:38,840 --> 01:05:43,600 WOULD BE AT NCI LEVEL. 1677 01:05:43,600 --> 01:05:44,040 >>CORRECT, YES. 1678 01:05:44,040 --> 01:05:46,160 >>EXACTLY WHAT I WAS GOING TO 1679 01:05:46,160 --> 01:05:46,400 SAY. 1680 01:05:46,400 --> 01:05:51,520 >>PAULETTE, DO WE NEED TO VOTE? 1681 01:05:51,520 --> 01:05:52,040 >>YES. 1682 01:05:52,040 --> 01:05:58,800 ONCE THE DISCUSSION IS FINISHED 1683 01:05:58,800 --> 01:06:00,320 WE'RE AT 2:05, I'M SUPPOSED TO 1684 01:06:00,320 --> 01:06:01,480 HAND OFF TO KEITH. 1685 01:06:01,480 --> 01:06:08,480 I WAS THINK WE GO SHOULD VOTE 1686 01:06:08,480 --> 01:06:08,760 NOW. 1687 01:06:08,760 --> 01:06:10,320 >>MOVE APPROVAL. 1688 01:06:10,320 --> 01:06:12,560 >>SO DO WE HAVE -- IS THERE A 1689 01:06:12,560 --> 01:06:17,560 MOTION TO ACCEPT THE REPORT? 1690 01:06:17,560 --> 01:06:21,240 >>SO MOVED. 1691 01:06:21,240 --> 01:06:23,440 >>SECOND? 1692 01:06:23,440 --> 01:06:24,880 >>SECOND. 1693 01:06:24,880 --> 01:06:25,640 >>ANY NAYS? 1694 01:06:25,640 --> 01:06:27,000 ABSTENTIONS? 1695 01:06:27,000 --> 01:06:28,040 >>I'M GOING TO ABSTAIN BECAUSE 1696 01:06:28,040 --> 01:06:31,520 I DON'T KNOW ENOUGH ABOUT THE 1697 01:06:31,520 --> 01:06:34,080 PROCESSING OF TEXT AND HAVE 1698 01:06:34,080 --> 01:06:39,280 CONCERNS THAT THE AI/ML WAS 1699 01:06:39,280 --> 01:06:40,240 APPLIED TO STRUCTURE DATA, HARD 1700 01:06:40,240 --> 01:06:41,760 TO BELIEVE THAT THERE WASN'T 1701 01:06:41,760 --> 01:06:44,520 BIAS IN THIS DATASET SO I JUST 1702 01:06:44,520 --> 01:06:46,920 AM GOING TO ABSTAIN FROM THIS 1703 01:06:46,920 --> 01:06:52,000 ONE AS A MINORITY REPORT. 1704 01:06:52,000 --> 01:06:54,000 >>PAULETTE, YOU NOTE IT? 1705 01:06:54,000 --> 01:06:55,360 >>I HAVE IT. 1706 01:06:55,360 --> 01:07:00,600 >>IT'S BEEN PROPERLY MOVED AND 1707 01:07:00,600 --> 01:07:00,920 SECONDED. 1708 01:07:00,920 --> 01:07:04,560 1709 01:07:04,560 --> 01:07:08,320 IT'S NOT UNANIMOUS BUT -- 1710 01:07:08,320 --> 01:07:10,320 >> I THINK IT'S, WHAT, I HAVE 1711 01:07:10,320 --> 01:07:13,720 THE NUMBER, I GAVE IT TO YOU. 1712 01:07:13,720 --> 01:07:14,840 >>GREAT. 1713 01:07:14,840 --> 01:07:15,120 >>THANKS. 1714 01:07:15,120 --> 01:07:15,520 >>FANTASTIC. 1715 01:07:15,520 --> 01:07:16,920 IF THERE WERE ANY OTHER COMMENTS 1716 01:07:16,920 --> 01:07:18,560 OR QUESTIONS FEEL FREE TO SEND 1717 01:07:18,560 --> 01:07:19,800 THEM OVER TO PAULETTE AND SHE 1718 01:07:19,800 --> 01:07:21,680 CAN WORK WITH THE WORKING GROUP 1719 01:07:21,680 --> 01:07:23,320 AND SUBCOMMITTEE TO ADDRESS 1720 01:07:23,320 --> 01:07:23,840 THOSE ISSUES. 1721 01:07:23,840 --> 01:07:27,480 SO I THINK NOW I HAND THE 1722 01:07:27,480 --> 01:07:29,320 MEETING OVER TO KEITH. 1723 01:07:29,320 --> 01:07:33,480 >>THE VOTE WAS APPROVAL WITH 1724 01:07:33,480 --> 01:07:33,840 ONE ABSTENTION. 1725 01:07:33,840 --> 01:07:36,600 >>ONE ABSTENTION. 1726 01:07:36,600 --> 01:07:37,080 >>RIGHT. 1727 01:07:37,080 --> 01:07:38,360 OKAY. 1728 01:07:38,360 --> 01:07:38,760 >>OKAY. 1729 01:07:38,760 --> 01:07:39,680 THANK YOU, JOHN. 1730 01:07:39,680 --> 01:07:41,880 WE WILL PICK UP WHERE WE LEFT 1731 01:07:41,880 --> 01:07:43,520 OFF YESTERDAY. 1732 01:07:43,520 --> 01:07:45,720 FOUR CONCEPTS TO DISCUSS IN THE 1733 01:07:45,720 --> 01:07:47,360 REMAINDER OF THE BSA COMPONENT 1734 01:07:47,360 --> 01:07:49,320 OF THIS MEETING. 1735 01:07:49,320 --> 01:07:51,680 TWO NEW, TWO REISSUE CONCEPTS 1736 01:07:51,680 --> 01:07:53,680 FOR THE BOARD'S CONSIDERATION. 1737 01:07:53,680 --> 01:07:56,120 AS IN PRIOR MEETINGS, AND 1738 01:07:56,120 --> 01:08:06,640 YESTERDAY BSA MEMBERS HAVE BEEN 1739 01:08:07,640 --> 01:08:08,240 ASSIGNED. 1740 01:08:08,240 --> 01:08:09,520 IF A REISSUE, FOR TWO WE'LL BE 1741 01:08:09,520 --> 01:08:12,640 DISCUSSING TODAY, VOTE WILL BE 1742 01:08:12,640 --> 01:08:15,240 TO CONCUR, NON-CONCUR, DEFER, OR 1743 01:08:15,240 --> 01:08:17,240 ABSTAIN. 1744 01:08:17,240 --> 01:08:18,960 AS I MENTIONED YESTERDAY, WE 1745 01:08:18,960 --> 01:08:21,720 WELCOME THE BSA MEMBERS, ALL BSA 1746 01:08:21,720 --> 01:08:23,560 MEMBERS, AND NCAB MEMBERS TO 1747 01:08:23,560 --> 01:08:24,760 PARTICIPATE IN DISCUSSION BUT 1748 01:08:24,760 --> 01:08:30,040 ONLY BSA MEMBERS WILL BE VOTING. 1749 01:08:30,040 --> 01:08:31,960 FIRST IS A NEW RFA/COOPERATIVE 1750 01:08:31,960 --> 01:08:33,440 AGREEMENT, ADVANCING CANCER 1751 01:08:33,440 --> 01:08:37,400 CONTROL EQUITY RESEARCH THROUGH 1752 01:08:37,400 --> 01:08:39,040 TRANSFORMATIVE SOLUTIONS. 1753 01:08:39,040 --> 01:08:41,000 DR. APRIL OH WILL PRESENT. 1754 01:08:41,000 --> 01:08:44,840 SUBCOMMITTEE CHAIRED BY OTIS 1755 01:08:44,840 --> 01:08:48,520 BRAWLEY, SUPPORTED BY KAREN AND 1756 01:08:48,520 --> 01:08:48,760 GLORIA. 1757 01:08:48,760 --> 01:08:52,360 APRIL, GO AHEAD AND START US OFF 1758 01:08:52,360 --> 01:08:53,120 WITH YOUR PRESENTATION 1759 01:08:53,120 --> 01:08:59,520 >>ON BEHALF OF MYSELF AND 1760 01:08:59,520 --> 01:09:02,560 BRENDA, I'M PLEASED TO PRESENT 1761 01:09:02,560 --> 01:09:03,800 THIS CONCEPT. 1762 01:09:03,800 --> 01:09:06,000 DESPITE CONSIDERABLE ADVANCES IN 1763 01:09:06,000 --> 01:09:09,680 CANCER RESEARCH DISPARITIES 1764 01:09:09,680 --> 01:09:10,120 PERSIST. 1765 01:09:10,120 --> 01:09:14,080 THIS HIGHLIGHTS DISPARITIES IN 1766 01:09:14,080 --> 01:09:15,640 RURAL POPULATIONS. 1767 01:09:15,640 --> 01:09:16,680 AFRICAN AMERICAN WOMEN TWO TIMES 1768 01:09:16,680 --> 01:09:19,280 MORE LIKELY TO BE DIAGNOSED WITH 1769 01:09:19,280 --> 01:09:21,680 AND DIE FROM TRIPLE-NEGATIVE 1770 01:09:21,680 --> 01:09:22,520 BREAST CANCER, MULTIPLE MYELOMA 1771 01:09:22,520 --> 01:09:23,920 DUE TO LATE STAGE DIAGNOSIS IN 1772 01:09:23,920 --> 01:09:24,640 PART. 1773 01:09:24,640 --> 01:09:25,920 WOMEN IN RURAL AREAS ARE TWICE 1774 01:09:25,920 --> 01:09:35,640 AS LIKELY TO DIE FROM CERVICAL 1775 01:09:35,640 --> 01:09:35,920 CANCER. 1776 01:09:35,920 --> 01:09:37,200 WITHOUT ADDRESSING THESE DRIVERS 1777 01:09:37,200 --> 01:09:38,520 OR ROOT CAUSES THAT CANCER 1778 01:09:38,520 --> 01:09:40,480 CONTROL INTERVENTIONS WILL HAVE 1779 01:09:40,480 --> 01:09:42,800 MINIMAL IMPACT IN REDUCING 1780 01:09:42,800 --> 01:09:44,160 DISPARITIES AND ADVANCING 1781 01:09:44,160 --> 01:09:44,520 EQUITY. 1782 01:09:44,520 --> 01:09:46,720 AS PART OF EQUITABLE APPROACH TO 1783 01:09:46,720 --> 01:09:48,160 ADDRESSING THESE INEQUALITIES, 1784 01:09:48,160 --> 01:09:49,440 COMMUNITY PARTNERS ARE ESSENTIAL 1785 01:09:49,440 --> 01:09:52,960 FOR ENGAGEMENT AND IMPACT. 1786 01:09:52,960 --> 01:09:54,480 NEXT SLIDE. 1787 01:09:54,480 --> 01:09:57,920 ADVANCING CANCER CONTROL EQUITY 1788 01:09:57,920 --> 01:10:05,960 IS LINKED TO UNDERSTANDING SDOH, 1789 01:10:05,960 --> 01:10:08,840 AS ILLUSTRATED SOCIAL 1790 01:10:08,840 --> 01:10:11,120 DETERMINANTS HAVE A MULTI-LEVEL 1791 01:10:11,120 --> 01:10:14,520 IMPACT ON RISK FACTORS. 1792 01:10:14,520 --> 01:10:15,720 WE NEED SCIENTIFIC PROGRESS IN 1793 01:10:15,720 --> 01:10:20,640 THE FOLLOWING AREAS TO EXPAND 1794 01:10:20,640 --> 01:10:22,960 THE EVIDENCE BASE. 1795 01:10:22,960 --> 01:10:24,600 FIRST LACK OF INTERVENTION, 1796 01:10:24,600 --> 01:10:27,000 INCLUDING FOCUS ON SDOH TO 1797 01:10:27,000 --> 01:10:29,200 ADDRESS STRUCTURAL BARRIERS. 1798 01:10:29,200 --> 01:10:30,400 NOR EVIDENCE FOR HOW SOCIAL 1799 01:10:30,400 --> 01:10:31,360 DETERMINANTS OF HEALTH 1800 01:10:31,360 --> 01:10:32,920 INTERVENTIONS WORK OR MECHANISMS 1801 01:10:32,920 --> 01:10:34,520 BY WHICH STRUCTURAL 1802 01:10:34,520 --> 01:10:36,080 INTERVENTIONS CAN MAKE AN IMPACT 1803 01:10:36,080 --> 01:10:37,600 BEYOND INDIVIDUAL LEVEL TO 1804 01:10:37,600 --> 01:10:39,080 MULTI-LEVEL APPROACHES THAT 1805 01:10:39,080 --> 01:10:40,760 INCLUDE HEALTH SYSTEM COMMUNITY 1806 01:10:40,760 --> 01:10:42,440 BARRIERS AND INSTITUTIONAL 1807 01:10:42,440 --> 01:10:43,320 FACTORS THAT IMPACT 1808 01:10:43,320 --> 01:10:44,840 INEQUALITIES. 1809 01:10:44,840 --> 01:10:46,680 WE NEED TO BETTER UNDERSTAND 1810 01:10:46,680 --> 01:10:48,640 INVESTMENT AND EXPAND IN 1811 01:10:48,640 --> 01:10:49,640 COMMUNITY ENGAGEMENT 1812 01:10:49,640 --> 01:10:52,560 INTERVENTION RESEARCH TO BETTER 1813 01:10:52,560 --> 01:10:53,160 ELUCIDATE EFFECTIVE COMMUNITY 1814 01:10:53,160 --> 01:10:54,000 ENGAGEMENT STRATEGIES. 1815 01:10:54,000 --> 01:10:56,560 AND IN THESE EFFORTS WE NEED TO 1816 01:10:56,560 --> 01:10:58,200 EMPHASIZE INTEGRATION OF 1817 01:10:58,200 --> 01:10:59,840 CAPACITY BUILDING AMONGST 1818 01:10:59,840 --> 01:11:01,480 DIVERSE SCHOLARS, STAKEHOLDERS, 1819 01:11:01,480 --> 01:11:02,800 COMMUNITY PARTNERS, AND 1820 01:11:02,800 --> 01:11:04,000 INCORPORATE THE LIVED 1821 01:11:04,000 --> 01:11:06,120 EXPERIENCES OF THE UNDERSERVED. 1822 01:11:06,120 --> 01:11:07,520 NEXT SLIDE. 1823 01:11:07,520 --> 01:11:09,960 FOR THIS CONCEPT WE DEFINED 1824 01:11:09,960 --> 01:11:10,880 CANCER CONTROL EQUITY AND SOCIAL 1825 01:11:10,880 --> 01:11:12,440 DETERMINANTS OF HEALTH ON THE 1826 01:11:12,440 --> 01:11:12,680 LEFT. 1827 01:11:12,680 --> 01:11:14,520 IN RESPONSE TO THE PREVIOUSLY 1828 01:11:14,520 --> 01:11:19,000 IDENTIFIED GAPS, WHAT WE'RE 1829 01:11:19,000 --> 01:11:24,040 SEEKING TO DO VIA CENTERS 1830 01:11:24,040 --> 01:11:28,520 INITIATIVE IS TO INTEGRATE THESE 1831 01:11:28,520 --> 01:11:30,680 FOUR AREAS INTO ONE MODEL TO 1832 01:11:30,680 --> 01:11:32,480 ADVANCE CANCER CONTROL EQUITY BY 1833 01:11:32,480 --> 01:11:41,320 INTEGRATING FOUR AREAS OF 1834 01:11:41,320 --> 01:11:44,120 SCIENCE MOVING BEYOND DOCUMENT 1835 01:11:44,120 --> 01:11:47,400 HEALTH DISPARITIES. 1836 01:11:47,400 --> 01:11:49,160 WE'RE PRODUCING THROUGH 1837 01:11:49,160 --> 01:11:49,760 TRANSFORMATIVE SOLUTIONS, SEEK 1838 01:11:49,760 --> 01:11:53,600 FUNDING FOR UP TO FOUR I OF U19 1839 01:11:53,600 --> 01:11:55,480 CENTERS, ONE U24 TO ADVANCE 1840 01:11:55,480 --> 01:11:58,760 CANCER CONTROL EQUITY RESEARCH 1841 01:11:58,760 --> 01:12:00,440 BY USING COMMUNITY ENGAGEMENT TO 1842 01:12:00,440 --> 01:12:01,840 DEVELOP INTERVENTIONS THAT 1843 01:12:01,840 --> 01:12:03,520 TARGET MULTI-LEVEL PATHWAYS BY 1844 01:12:03,520 --> 01:12:05,080 WHICH SOCIAL DETERMINANTS OF 1845 01:12:05,080 --> 01:12:07,840 HEALTH IMPACT ADVERSE CANCER 1846 01:12:07,840 --> 01:12:08,080 OUTCOMES. 1847 01:12:08,080 --> 01:12:10,040 SECOND, DEVELOP MEASURES, 1848 01:12:10,040 --> 01:12:12,440 EVALUATE AND ASSESS COMMUNITY 1849 01:12:12,440 --> 01:12:14,080 LEVEL SDOH, ENGAGEMENT AND 1850 01:12:14,080 --> 01:12:15,800 CANCER CONTROL EQUITY PROCESS 1851 01:12:15,800 --> 01:12:16,480 AND OUTCOMES. 1852 01:12:16,480 --> 01:12:18,360 THIRD, BUILD COMPASS PI AMONG 1853 01:12:18,360 --> 01:12:20,520 DIVERSE SCHOLARS AND COMMUNITY 1854 01:12:20,520 --> 01:12:21,400 PARTNERS TO IMPLEMENT 1855 01:12:21,400 --> 01:12:22,800 INTERVENTIONS THAT INCORPORATE 1856 01:12:22,800 --> 01:12:24,680 THE LIVED EXPERIENCE OF THOSE 1857 01:12:24,680 --> 01:12:27,440 WHO MAY FACE CANCER 1858 01:12:27,440 --> 01:12:27,800 INEQUALITIES. 1859 01:12:27,800 --> 01:12:29,080 NEXT SLIDE. 1860 01:12:29,080 --> 01:12:30,720 WE'RE PROPOSING THE FOLLOWING 1861 01:12:30,720 --> 01:12:32,480 CENTER STRUCTURE INCLUDING ADMIN 1862 01:12:32,480 --> 01:12:35,000 CORE, RESEARCH CORE, METHODS AND 1863 01:12:35,000 --> 01:12:36,080 MEASURES AND DATA CORE, CAPACITY 1864 01:12:36,080 --> 01:12:38,600 BUILDING CORE. 1865 01:12:38,600 --> 01:12:39,480 NEXT SLIDE. 1866 01:12:39,480 --> 01:12:42,680 THROUGHOUT THIS STRUCTURE WE'RE 1867 01:12:42,680 --> 01:12:43,400 PROMOTING COMMUNITY PARTNER 1868 01:12:43,400 --> 01:12:44,840 ENGAGEMENT, FOR EXAMPLE RESEARCH 1869 01:12:44,840 --> 01:12:47,360 CORE WILL INCLUDE ENGAGEMENT IN 1870 01:12:47,360 --> 01:12:48,320 DEVELOPING INTERVENTION, METHODS 1871 01:12:48,320 --> 01:12:49,640 MEASURES AND DATA CORE 1872 01:12:49,640 --> 01:12:51,160 ENGAGEMENT OF COMMUNITY AND 1873 01:12:51,160 --> 01:12:52,720 IDENTIFYING AND TESTING EQUITY 1874 01:12:52,720 --> 01:12:55,360 METRICS AND DATA COLLECTION 1875 01:12:55,360 --> 01:12:57,000 ANALYSIS AND DISSEMINATION, 1876 01:12:57,000 --> 01:12:58,360 CAPACITY BUILDING CORE WHICH 1877 01:12:58,360 --> 01:12:59,880 WE'RE EXCITED ABOUT AN 1878 01:12:59,880 --> 01:13:01,200 OPPORTUNITY FOR JUNIOR 1879 01:13:01,200 --> 01:13:01,840 INVESTIGATORS OR NEW 1880 01:13:01,840 --> 01:13:03,680 INVESTIGATORS TO WORK WITH 1881 01:13:03,680 --> 01:13:06,240 COMMUNITY PARTNERS AND 1882 01:13:06,240 --> 01:13:07,560 PRACTITIONERS TO CO-CREATE 1883 01:13:07,560 --> 01:13:09,840 CAPACITY IN RESEARCH, COMMUNITY 1884 01:13:09,840 --> 01:13:10,840 ENGAGEMENT METHODS, LIVED 1885 01:13:10,840 --> 01:13:12,560 EXPERIENCE OF COMMUNITY AND 1886 01:13:12,560 --> 01:13:12,840 RESEARCH. 1887 01:13:12,840 --> 01:13:14,440 EACH CENTER WILL BE DESIGNED 1888 01:13:14,440 --> 01:13:16,560 AROUND PROPOSED CANCER CONTROL 1889 01:13:16,560 --> 01:13:19,120 HEALTH EQUITY RESEARCH THEME, 1890 01:13:19,120 --> 01:13:20,680 INFORMING OVERALL RESEARCH 1891 01:13:20,680 --> 01:13:21,680 AGENDA, LEVERAGING THE 1892 01:13:21,680 --> 01:13:22,760 INFRASTRUCTURE OF THE CORES, 1893 01:13:22,760 --> 01:13:25,360 CENTERS WILL CONDUCT AT LEAST 1894 01:13:25,360 --> 01:13:28,240 ONE LARGE SCALE SDOH TRIAL 1895 01:13:28,240 --> 01:13:31,120 RELATIVE TO RESEARCH THEME 1896 01:13:31,120 --> 01:13:33,960 INTERVENING ON ONE OR MORE SDOH 1897 01:13:33,960 --> 01:13:36,680 BUILDING IN FLEXIBILITY AND 1898 01:13:36,680 --> 01:13:37,440 RESPONSIVENESS TO FACILITATE 1899 01:13:37,440 --> 01:13:38,880 RESEARCH, CENTERS WILL ALSO BE 1900 01:13:38,880 --> 01:13:40,840 ABLE TO CONDUCT PILOT STUDIES 1901 01:13:40,840 --> 01:13:42,600 WITHIN THE CENTER'S BROADER 1902 01:13:42,600 --> 01:13:47,080 RESEARCH THEME TO CONTRIBUTE TO 1903 01:13:47,080 --> 01:13:49,480 AND INFORM THE SDOH 1904 01:13:49,480 --> 01:13:51,720 INTERVENTION, AN ESSENTIAL 1905 01:13:51,720 --> 01:13:53,560 COMPONENT TO APPROACH TO ALLOW 1906 01:13:53,560 --> 01:13:55,720 FOR DEVELOPMENTAL PILOT STUDIES 1907 01:13:55,720 --> 01:13:57,160 DRIVEN BY COMMUNITY IDENTIFIED 1908 01:13:57,160 --> 01:13:59,680 NEEDS, NEED TO TEST FEASIBILITY, 1909 01:13:59,680 --> 01:14:01,440 ADOPTION, AND CULTURAL 1910 01:14:01,440 --> 01:14:02,520 RELEVANCE. 1911 01:14:02,520 --> 01:14:02,800 NEXT SLIDE. 1912 01:14:02,800 --> 01:14:05,240 I WOULD LIKE TO DESCRIBE WHAT A 1913 01:14:05,240 --> 01:14:05,840 RESPONSIVE INTERVENTION WOULD 1914 01:14:05,840 --> 01:14:06,480 LOOK LIKE. 1915 01:14:06,480 --> 01:14:10,000 MOVING FROM LEFT TO RIGHT A 1916 01:14:10,000 --> 01:14:12,160 RESPONSIVE INTERVENTION WOULD 1917 01:14:12,160 --> 01:14:14,680 IDENTIFY AT LEAST ONE SDOH TO 1918 01:14:14,680 --> 01:14:15,880 DEVELOP THE MULTI-LEVEL 1919 01:14:15,880 --> 01:14:18,280 INTERVENTION AT TWO OR MORE IN 1920 01:14:18,280 --> 01:14:20,080 THE MID-OF THE FIGURE, INCLUDING 1921 01:14:20,080 --> 01:14:21,120 COMMUNITY AND ORGANIZATIONAL 1922 01:14:21,120 --> 01:14:24,200 FACTORS LIKE THE HEALTH SYSTEM, 1923 01:14:24,200 --> 01:14:25,720 FAMILIES AND HOUSEHOLDS, 1924 01:14:25,720 --> 01:14:26,520 INTERPERSONAL FACTORS, 1925 01:14:26,520 --> 01:14:26,800 INDIVIDUALS. 1926 01:14:26,800 --> 01:14:29,240 THEN TO THE RIGHT SIDE 1927 01:14:29,240 --> 01:14:29,960 ULTIMATELY ADDRESS INEQUALITIES 1928 01:14:29,960 --> 01:14:33,160 AND CANCER RISK OR OUTCOMES FOR 1929 01:14:33,160 --> 01:14:37,320 EXAMPLE CANCER-RELATED RISK, 1930 01:14:37,320 --> 01:14:38,200 HEALTH BEHAVIORS, SCREENING, 1931 01:14:38,200 --> 01:14:39,840 QUALITY OF LIFE ARE A FEW 1932 01:14:39,840 --> 01:14:41,160 EXAMPLES. 1933 01:14:41,160 --> 01:14:43,000 ONE WAY A CENTER COULD RESPOND 1934 01:14:43,000 --> 01:14:44,560 IS WORKING WITH COMMUNITY 1935 01:14:44,560 --> 01:14:46,080 PARTNERS COULD IDENTIFY FOOD 1936 01:14:46,080 --> 01:14:48,480 INSECURITY IS ONE OF THE BIGGEST 1937 01:14:48,480 --> 01:14:50,240 FACTORS IMPACTING COMMUNITY'S 1938 01:14:50,240 --> 01:14:53,960 ABILITY TO ADDRESS CANCER 1939 01:14:53,960 --> 01:14:56,160 PREVENTION THROUGH HEALTHY DIET, 1940 01:14:56,160 --> 01:14:57,920 REDUCTION IN OBESITY AND 1941 01:14:57,920 --> 01:14:58,920 SUBSEQUENTLY COULD PROPOSE 1942 01:14:58,920 --> 01:15:00,960 COMMUNITY LEVEL INTERVENTION AND 1943 01:15:00,960 --> 01:15:02,520 OUTCOMES FOR EXAMPLE FARMERS 1944 01:15:02,520 --> 01:15:05,240 MARKET, WORKING WITH CONVENIENCE 1945 01:15:05,240 --> 01:15:06,360 STORES, REFRIGERATION OF FRESH 1946 01:15:06,360 --> 01:15:08,320 FOODS, HOSPITALS ON SCREENING 1947 01:15:08,320 --> 01:15:10,080 AND REFERRALS RELATED TO SOCIAL 1948 01:15:10,080 --> 01:15:11,960 NEEDS TO REFER HUNGER OF FOOD 1949 01:15:11,960 --> 01:15:15,520 BENEFITS, INDIVIDUAL OR FAMILY 1950 01:15:15,520 --> 01:15:16,640 LEVEL NUTRITION INTERVENTIONS 1951 01:15:16,640 --> 01:15:17,640 CULTURALLY TAILORED INCLUDING 1952 01:15:17,640 --> 01:15:20,240 COOKING SKILLS AND EDUCATION TO 1953 01:15:20,240 --> 01:15:21,680 REDUCE RISK FOR CANCER ON THE 1954 01:15:21,680 --> 01:15:23,880 RIGHT SIDE. 1955 01:15:23,880 --> 01:15:25,520 NEXT SLIDE. 1956 01:15:25,520 --> 01:15:28,120 WE'RE SEEKING A CORE CENTER TO 1957 01:15:28,120 --> 01:15:30,200 ADVANCE SYNTHESIS OF EQUITY 1958 01:15:30,200 --> 01:15:31,640 RESEARCH PRODUCTS AND PRACTICES 1959 01:15:31,640 --> 01:15:33,720 PRODUCED FROM THE SUM OF THE U 1960 01:15:33,720 --> 01:15:38,880 129 CENTERS INCLUDING AND -- U19 1961 01:15:38,880 --> 01:15:39,840 CENTERS, WITH CRITICAL 1962 01:15:39,840 --> 01:15:40,960 COMPONENTS ESSENTIAL TO ADVANCE 1963 01:15:40,960 --> 01:15:42,200 CANCER HEALTH EQUITY RESEARCH 1964 01:15:42,200 --> 01:15:43,760 AND WE'VE LISTED A FEW HERE ON 1965 01:15:43,760 --> 01:15:45,440 THE SLIDE BUT I'D LIKE TO 1966 01:15:45,440 --> 01:15:47,520 HIGHLIGHT A FEW. 1967 01:15:47,520 --> 01:15:50,040 HEALTH IMPACTS OF SDOH ON 1968 01:15:50,040 --> 01:15:51,440 POPULATIONS CAN DIFFER, ONGOING 1969 01:15:51,440 --> 01:15:54,040 NEED FOR SYNTHESIS OF 1970 01:15:54,040 --> 01:15:55,600 MEASUREMENT IN HEALTH EQUITY, 1971 01:15:55,600 --> 01:15:57,120 AND TARGETING AND TAILORING 1972 01:15:57,120 --> 01:15:58,360 CULTURALLY APPROPRIATE 1973 01:15:58,360 --> 01:15:58,640 MATERIALS. 1974 01:15:58,640 --> 01:16:00,520 WE NEED TO SYNTHESIZE LEARNINGS 1975 01:16:00,520 --> 01:16:02,280 ON COMMUNITY ENGAGEMENT 1976 01:16:02,280 --> 01:16:03,400 STRATEGIES ACROSS POPULATIONS 1977 01:16:03,400 --> 01:16:05,920 AND CONTEXT, AND CENTER WOULD 1978 01:16:05,920 --> 01:16:07,120 SUPPORT DATA SHARINGS AND 1979 01:16:07,120 --> 01:16:09,520 SYNTHESIS IN WAYS ACCEPTABLE AND 1980 01:16:09,520 --> 01:16:11,560 INFORMATIVE TO LOCAL COMMUNITY. 1981 01:16:11,560 --> 01:16:12,080 FACILITATE NETWORK-WIDE 1982 01:16:12,080 --> 01:16:14,760 ASSESSMENT OF THE IMPACTS OF 1983 01:16:14,760 --> 01:16:16,320 PARTNERSHIPS, AND COORDINATE 1984 01:16:16,320 --> 01:16:18,040 EXTERNAL COLLABORATION WITH 1985 01:16:18,040 --> 01:16:21,440 OTHER RELEVANT RESEARCH 1986 01:16:21,440 --> 01:16:21,760 INITIATIVES. 1987 01:16:21,760 --> 01:16:26,400 OUR PROPOSE THE BUDGET TO FUND 1988 01:16:26,400 --> 01:16:27,920 FOUR U19 CENTERS FOR 1989 01:16:27,920 --> 01:16:30,240 $48.5 MILLION OVER FIVE YEARS, 1990 01:16:30,240 --> 01:16:32,680 ONE U24 COORDINATING CENTER FOR 1991 01:16:32,680 --> 01:16:34,040 TOTAL INVESTMENT OF $4.1 MILLION 1992 01:16:34,040 --> 01:16:36,680 OVER FIVE YEARS. 1993 01:16:36,680 --> 01:16:37,880 NEXT SLIDE. 1994 01:16:37,880 --> 01:16:38,640 SOME EVALUATION CRITERIA ARE 1995 01:16:38,640 --> 01:16:42,240 LISTED HERE AND ARE GUIDED BY 1996 01:16:42,240 --> 01:16:43,760 END GOAL OF INTERVENTION AND 1997 01:16:43,760 --> 01:16:47,720 EVIDENCE BASE TO INFORM 1998 01:16:47,720 --> 01:16:48,560 SUSTAINABILITY, ADOPTION, 1999 01:16:48,560 --> 01:16:48,800 IMPACT. 2000 01:16:48,800 --> 01:16:50,480 OVER THE COURSE OF THE 2001 01:16:50,480 --> 01:16:54,080 INITIATIVE WE ANTICIPATE SEEING 2002 01:16:54,080 --> 01:16:57,160 IMPACTS OF SDOH INTERVENTION ON 2003 01:16:57,160 --> 01:17:02,720 INEQUALITY, REDUCTION OF 2004 01:17:02,720 --> 01:17:04,040 DISPARITIES AND INTERVENTION AND 2005 01:17:04,040 --> 01:17:06,240 APPROACHES READY FOR SCALEUP. 2006 01:17:06,240 --> 01:17:10,600 WE WANT WANT TO THANK THE REVI. 2007 01:17:10,600 --> 01:17:13,320 THREE AREAS WERE RAISED FOR 2008 01:17:13,320 --> 01:17:14,760 FURTHER CLARIFICATION. 2009 01:17:14,760 --> 01:17:16,320 FIRST, ASKED TO CLARIFY 2010 01:17:16,320 --> 01:17:18,280 OPPORTUNITIES AND EXPECTATIONS 2011 01:17:18,280 --> 01:17:19,480 FOR CROSS-CENTER COLLABORATION. 2012 01:17:19,480 --> 01:17:21,960 WE SEE THESE FOUR CENTERS AND 2013 01:17:21,960 --> 01:17:23,400 COORDINATING CENTERS AS 2014 01:17:23,400 --> 01:17:25,920 OPERATING AS RESEARCH NETWORK. 2015 01:17:25,920 --> 01:17:26,800 GUIDANCE PROVIDED TO SPECIFY 2016 01:17:26,800 --> 01:17:28,320 COORDINATION BETWEEN THE CENTER 2017 01:17:28,320 --> 01:17:31,400 CORES AND COORDINATING CENTER ON 2018 01:17:31,400 --> 01:17:33,480 MEASUREMENT, SDOH MECHANISM, 2019 01:17:33,480 --> 01:17:35,240 DESIGN OF MULTI-LEVEL 2020 01:17:35,240 --> 01:17:36,240 INTERVENTIONS. 2021 01:17:36,240 --> 01:17:37,080 WE WANT TO EMPHASIZE 2022 01:17:37,080 --> 01:17:39,280 CROSS-COLLABORATION AND LEARNING 2023 01:17:39,280 --> 01:17:40,920 ARE ESSENTIAL AND SDOH FOCUSED 2024 01:17:40,920 --> 01:17:42,680 INITIATIVE, THE VALUE IS AN 2025 01:17:42,680 --> 01:17:44,560 OPPORTUNITY TO LEARN AND DEVELOP 2026 01:17:44,560 --> 01:17:47,280 AN EVIDENCE BASE ACROSS DIVERSE 2027 01:17:47,280 --> 01:17:48,680 POPULATIONS AND CONTEXT, 2028 01:17:48,680 --> 01:17:51,200 MECHANISMS OF SDOH ON CANCER, 2029 01:17:51,200 --> 01:18:00,400 ESSENTIALLY SUM TOTALS WILL 2030 01:18:00,400 --> 01:18:01,080 CONTRIBUTE. 2031 01:18:01,080 --> 01:18:03,720 SECOND, OR EQUITY RELATED 2032 01:18:03,720 --> 01:18:05,680 INVESTMENTS, HOW MIGHT THEY BE 2033 01:18:05,680 --> 01:18:06,000 CONNECTED? 2034 01:18:06,000 --> 01:18:08,840 AS U24 WE WILL PROVIDE GUIDANCE 2035 01:18:08,840 --> 01:18:10,040 TO THE COORDINATING CENTER TO 2036 01:18:10,040 --> 01:18:13,520 PROVIDE LEADERSHIP AND SUPPORT 2037 01:18:13,520 --> 01:18:15,400 TO CONNECT WITH OTHER 2038 01:18:15,400 --> 01:18:21,520 EQUITY-RELATED INITIATIVES AT 2039 01:18:21,520 --> 01:18:22,600 NCI AND ACROSS NIH. 2040 01:18:22,600 --> 01:18:23,800 FOR EXAMPLE ON DELIVERY OF 2041 01:18:23,800 --> 01:18:29,320 TRAINING AND CLICK A OF -- 2042 01:18:29,320 --> 01:18:39,880 CURRICULA OF COOL -- TOOL KITS 2043 01:18:41,360 --> 01:18:42,200 WE WILL PROVIDE GUIDANCE ON 2044 01:18:42,200 --> 01:18:43,840 OPPORTUNITIES TO USE EXISTING 2045 01:18:43,840 --> 01:18:45,560 AND DEVELOPED TRAINING TOOL KITS 2046 01:18:45,560 --> 01:18:48,480 WITH SUPPORT FROM COORDINATING 2047 01:18:48,480 --> 01:18:49,200 CENTER, LEVERAGED NETWORKS, 2048 01:18:49,200 --> 01:18:51,720 PROVIDE GUIDANCE TO CENTERS ON 2049 01:18:51,720 --> 01:18:53,920 COMPETITIVE OPPORTUNITIES TO 2050 01:18:53,920 --> 01:18:55,880 SUPPORT SCHOLARS AND COMMUNITY 2051 01:18:55,880 --> 01:18:56,520 PARTNERS TRAINING EFFORTS 2052 01:18:56,520 --> 01:18:57,960 INCLUDING EXISTING MECHANISMS 2053 01:18:57,960 --> 01:18:59,360 THAT ARE OFFERED AT NCI. 2054 01:18:59,360 --> 01:19:01,000 THANK YOU FOR THE OPPORTUNITY TO 2055 01:19:01,000 --> 01:19:01,960 SHARE THE CONCEPT. 2056 01:19:01,960 --> 01:19:06,800 WE WELCOME YOUR QUESTIONS AND 2057 01:19:06,800 --> 01:19:07,080 COMMENTS. 2058 01:19:07,080 --> 01:19:08,800 MY COLLEAGUES ARE ALSO ONLINE TO 2059 01:19:08,800 --> 01:19:12,080 ANSWER YOUR QUESTIONS. 2060 01:19:12,080 --> 01:19:12,400 >>GREAT. 2061 01:19:12,400 --> 01:19:14,840 THANK YOU, APRIL. 2062 01:19:14,840 --> 01:19:16,240 OTIS, GET US STARTED. 2063 01:19:16,240 --> 01:19:20,040 >>YEAH, FIRST I WANT TO THANK 2064 01:19:20,040 --> 01:19:24,440 DR. OH, AJAY, AND DR. BAILEY AND 2065 01:19:24,440 --> 01:19:25,520 DR. BERTAGNOLLI, THESE ARE ARE 2066 01:19:25,520 --> 01:19:28,040 THREE OF A GROUP OF VERY FINE 2067 01:19:28,040 --> 01:19:31,800 PEOPLE THAT YOU NOW LEAD AT THE 2068 01:19:31,800 --> 01:19:31,960 NCI. 2069 01:19:31,960 --> 01:19:38,000 THIS WAS A GREAT ANSWER TO DR. 2070 01:19:38,000 --> 01:19:38,880 WINKFIELD'S CONCERN RAISED 2071 01:19:38,880 --> 01:19:39,560 YESTERDAY. 2072 01:19:39,560 --> 01:19:41,760 I DON'T WANT TO UPSET PEOPLE 2073 01:19:41,760 --> 01:19:46,640 HERE BUT I THINK THERE'S TOO 2074 01:19:46,640 --> 01:19:48,600 MUCH EMPHASIS TO MINORITY 2075 01:19:48,600 --> 01:19:49,200 INCLUSION IN CLINICAL TRIALS, 2076 01:19:49,200 --> 01:19:53,760 NOT ENOUGH EMPHASIS AND GETTING 2077 01:19:53,760 --> 01:19:55,320 MINORITIES AND POOR WHITE PEOPLE 2078 01:19:55,320 --> 01:19:56,720 FOR THAT MATTER ADEQUATE 2079 01:19:56,720 --> 01:19:57,120 TREATMENT. 2080 01:19:57,120 --> 01:20:00,560 THIS IS A RESEARCH PROJECT AIMED 2081 01:20:00,560 --> 01:20:03,760 AT TRYING TO ELUCIDATE HOW YOU 2082 01:20:03,760 --> 01:20:06,160 GET ADEQUATE CARE TO HUMAN 2083 01:20:06,160 --> 01:20:06,480 BEINGS. 2084 01:20:06,480 --> 01:20:10,840 I WOULD ALSO POINT OUT THAT, YOU 2085 01:20:10,840 --> 01:20:12,960 KNOW, THE SOUTHWESTERN GROUP HAS 2086 01:20:12,960 --> 01:20:16,120 PUBLISHED WONDERFUL WORK LOOKING 2087 01:20:16,120 --> 01:20:17,840 AT THEIR OUTCOMES, FINDING EQUAL 2088 01:20:17,840 --> 01:20:20,640 TREATMENT YIELDS EQUAL OUTCOMES 2089 01:20:20,640 --> 01:20:21,720 AMONG EQUAL PEOPLE. 2090 01:20:21,720 --> 01:20:24,880 EQUAL PEOPLE IS THE KEY HERE. 2091 01:20:24,880 --> 01:20:27,480 WHEN YOU FIND BLACK-WHITE 2092 01:20:27,480 --> 01:20:29,040 DISPARITIES OR RURAL-URBAN 2093 01:20:29,040 --> 01:20:30,040 DISPARITIES IT'S ALMOST ALWAYS 2094 01:20:30,040 --> 01:20:33,320 BALLS OF -- BECAUSE OF POVERTY 2095 01:20:33,320 --> 01:20:34,360 THAT THEY HAVE THESE 2096 01:20:34,360 --> 01:20:34,800 DISPARITIES. 2097 01:20:34,800 --> 01:20:42,280 MORE WORK IN THIS AREA NEEDS TO 2098 01:20:42,280 --> 01:20:46,320 BE DONE, AND I OFTEN QUOTE THE 2099 01:20:46,320 --> 01:20:49,120 FACT IN METROPOLITAN ATLANTA 7% 2100 01:20:49,120 --> 01:20:54,560 OF BLACK WOMEN WITH LOCALIZED 2101 01:20:54,560 --> 01:20:56,440 NEWLY DIAGNOSED LOCALIZED 2102 01:20:56,440 --> 01:20:57,720 CLINICALLY LOCALIZED CURABLE 2103 01:20:57,720 --> 01:20:59,720 BREAST CANCER, 7% WILL GET NO 2104 01:20:59,720 --> 01:21:02,520 TREATMENT WITHIN THE FIRST YEAR 2105 01:21:02,520 --> 01:21:03,200 AFTER DIAGNOSIS. 2106 01:21:03,200 --> 01:21:07,480 WE NEED TO FIGURE OUT WAYS -- 2107 01:21:07,480 --> 01:21:08,160 I'LL REMIND YOU THAT THE 2108 01:21:08,160 --> 01:21:09,800 RESEARCH THAT SAYS YOU CUT THE 2109 01:21:09,800 --> 01:21:15,960 TUMOR OUT WAS DONE IN 1895. 2110 01:21:15,960 --> 01:21:17,800 AND HERE IT IS 2022. 2111 01:21:17,800 --> 01:21:21,200 7% ARE NOT GETTING TREATED. 2112 01:21:21,200 --> 01:21:23,520 SO DR. OH, DR. AJAY, DR. BAILEY, 2113 01:21:23,520 --> 01:21:28,040 THANK YOU VERY MUCH. 2114 01:21:28,040 --> 01:21:29,080 YOU WERE INCREDIBLY RESPONSIVE 2115 01:21:29,080 --> 01:21:30,960 TO THE RATHER SMALL CONCERNS 2116 01:21:30,960 --> 01:21:32,400 THAT WE HAD BECAUSE THIS WAS 2117 01:21:32,400 --> 01:21:38,320 VERY WELL WRITTEN TO BEGIN WITH. 2118 01:21:38,320 --> 01:21:40,280 I YIELD TO MY COLLEAGUES. 2119 01:21:40,280 --> 01:21:41,480 >>THIS IS GLORIA. 2120 01:21:41,480 --> 01:21:43,800 I'LL JUST ADD THAT THERE WAS A 2121 01:21:43,800 --> 01:21:46,320 LOT OF ENTHUSIASM FOR THIS 2122 01:21:46,320 --> 01:21:47,640 CONCEPT IN OUR SUBGROUP. 2123 01:21:47,640 --> 01:21:50,600 I THINK IT WAS REALLY THOUGHT 2124 01:21:50,600 --> 01:21:52,880 THAT IT WAS CAREFULLY THOUGHT 2125 01:21:52,880 --> 01:21:55,040 THROUGH, THE MECHANISM SEEMED 2126 01:21:55,040 --> 01:21:55,360 APPROPRIATE. 2127 01:21:55,360 --> 01:21:57,040 WE WERE SUPPORTIVE OF THE IDEA 2128 01:21:57,040 --> 01:21:59,120 OF HAVING A COORDINATING CENTER 2129 01:21:59,120 --> 01:22:01,640 THAT CAN SYNTHESIZE AND CULL THE 2130 01:22:01,640 --> 01:22:03,160 FINDINGS ACROSS DIFFERENT 2131 01:22:03,160 --> 01:22:04,800 RESEARCH PROJECTS AND SO IN 2132 01:22:04,800 --> 01:22:06,320 GENERAL IT WAS JUST A STRONG 2133 01:22:06,320 --> 01:22:12,000 SUPPORT FOR THIS APPLICATION. 2134 01:22:12,000 --> 01:22:15,720 SO THANK YOU FOR THE 2135 01:22:15,720 --> 01:22:16,800 PRESENTATION. 2136 01:22:16,800 --> 01:22:18,800 >>I CONCUR. 2137 01:22:18,800 --> 01:22:19,320 A WELL-WRITTEN CONCEPT, 2138 01:22:19,320 --> 01:22:21,520 APPRECIATE THE WORK THAT WAS PUT 2139 01:22:21,520 --> 01:22:22,520 INTO THIS. 2140 01:22:22,520 --> 01:22:25,600 THE MAIN CONCERN THAT I RAISED 2141 01:22:25,600 --> 01:22:28,200 WAS MAKING SURE THAT THIS 2142 01:22:28,200 --> 01:22:30,400 INITIATIVE INTERACTS WITH OTHER 2143 01:22:30,400 --> 01:22:31,720 NCI AND NIH INITIATIVES IN THIS 2144 01:22:31,720 --> 01:22:34,440 AREA SO THAT WE CAN REALLY LEARN 2145 01:22:34,440 --> 01:22:36,080 AS MUCH AS POSSIBLE. 2146 01:22:36,080 --> 01:22:37,640 AND THE TEAM HAS NICELY 2147 01:22:37,640 --> 01:22:38,720 ADDRESSED THAT. 2148 01:22:38,720 --> 01:22:40,680 SO I AM FULLY SUPPORTIVE OF THIS 2149 01:22:40,680 --> 01:22:45,160 CONCEPT. 2150 01:22:45,160 --> 01:22:48,240 2151 01:22:48,240 --> 01:22:50,000 >>THANK YOU, COMMITTEE MEMBERS. 2152 01:22:50,000 --> 01:22:51,880 WE HAVE MULTIPLE HANDS THAT SHOT 2153 01:22:51,880 --> 01:22:53,520 UP. 2154 01:22:53,520 --> 01:22:57,800 WHEN THE NCI DIRECTOR RAISES HIS 2155 01:22:57,800 --> 01:23:00,400 OR HER HAND WE SHOOT OVER TO 2156 01:23:00,400 --> 01:23:01,280 THAT SQUARE. 2157 01:23:01,280 --> 01:23:02,000 >>MONICA? 2158 01:23:02,000 --> 01:23:03,160 >>THAT DOESN'T MEAN MY COMMENTS 2159 01:23:03,160 --> 01:23:05,160 ARE MORE VALUABLE THAN ANYONE 2160 01:23:05,160 --> 01:23:07,640 ELSE'S, BUT I WANT TO THROW IN 2161 01:23:07,640 --> 01:23:10,040 THAT THE -- ONE OF THE NICE 2162 01:23:10,040 --> 01:23:12,120 THINGS ABOUT THE MOONSHOT WE'RE 2163 01:23:12,120 --> 01:23:14,800 ASKED TO CREATE AN ALL OF 2164 01:23:14,800 --> 01:23:16,080 GOVERNMENT APPROACH. 2165 01:23:16,080 --> 01:23:17,160 WE DO RESEARCH, BUT RESEARCH HAS 2166 01:23:17,160 --> 01:23:18,720 TO POINT THE WAY. 2167 01:23:18,720 --> 01:23:24,280 THERE WOULD BE NOTHING MORE 2168 01:23:24,280 --> 01:23:25,720 GRATIFYING THAN TO SAY TO THE 2169 01:23:25,720 --> 01:23:27,360 REST OF HEALTH AND HUMAN 2170 01:23:27,360 --> 01:23:29,160 SERVICES, HERE IS THE ROADMAP 2171 01:23:29,160 --> 01:23:30,720 FOR THE RIGHT WAY TO DO THIS 2172 01:23:30,720 --> 01:23:32,920 NOW, LET'S TALK ABOUT 2173 01:23:32,920 --> 01:23:34,440 IMPLEMENTATION ACROSS ALL OF 2174 01:23:34,440 --> 01:23:34,760 GOVERNMENT. 2175 01:23:34,760 --> 01:23:37,160 I REALLY LOVE THIS KIND OF WORK 2176 01:23:37,160 --> 01:23:44,200 BECAUSE WE KNOW WE CAN DO 2177 01:23:44,200 --> 01:23:46,160 SOMETHING WITH IT. 2178 01:23:46,160 --> 01:23:46,480 >>ANDREA? 2179 01:23:46,480 --> 01:23:48,240 >>YES, THANK YOU. 2180 01:23:48,240 --> 01:23:52,160 THAT'S AN EXCITING PROPOSAL. 2181 01:23:52,160 --> 01:23:54,680 I JUST WONDERED IS THERE AN 2182 01:23:54,680 --> 01:23:56,640 EXPECTATION OR REQUIREMENTS FOR 2183 01:23:56,640 --> 01:23:59,080 OTHER LANGUAGES BESIDES ENGLISH 2184 01:23:59,080 --> 01:24:00,720 IN MANY IMPOVERISHED COMMUNITIES 2185 01:24:00,720 --> 01:24:04,600 ARE MADE UP OF LATINO SPEAKING, 2186 01:24:04,600 --> 01:24:05,200 OTHER LANGUAGES BESIDE ENGLISH, 2187 01:24:05,200 --> 01:24:08,280 IT WOULD BE A SHAME TO MISS OUT 2188 01:24:08,280 --> 01:24:09,680 ON ADDRESSING THAT POPULATION. 2189 01:24:09,680 --> 01:24:12,000 IS THERE SOME SORT OF 2190 01:24:12,000 --> 01:24:13,840 EXPECTATION OR REQUIREMENT TO 2191 01:24:13,840 --> 01:24:16,040 INCLUDE MORE THAN ENGLISH IN 2192 01:24:16,040 --> 01:24:17,120 THIS PROJECT? 2193 01:24:17,120 --> 01:24:20,080 >>OH, WHAT A GREAT POINT. 2194 01:24:20,080 --> 01:24:21,400 THANK YOU FOR RAISING THAT. 2195 01:24:21,400 --> 01:24:23,120 AND THE OPPORTUNITY TO CLARIFY. 2196 01:24:23,120 --> 01:24:26,520 WE SEE THE COORDINATING CENTER 2197 01:24:26,520 --> 01:24:28,080 AS IT'S SYNTHESIZING PRODUCTS 2198 01:24:28,080 --> 01:24:30,360 ACROSS THE U19s AS THE PLACE 2199 01:24:30,360 --> 01:24:32,880 WHERE DEVELOPING THOSE TARGETED 2200 01:24:32,880 --> 01:24:33,880 AND TAILORED CULTURALLY 2201 01:24:33,880 --> 01:24:36,320 APPROPRIATE MATERIALS WOULD ALSO 2202 01:24:36,320 --> 01:24:37,000 INCLUDE LANGUAGE ACCESSIBILITY 2203 01:24:37,000 --> 01:24:44,960 SO THANK YOU FOR RAISING THAT. 2204 01:24:44,960 --> 01:24:51,520 >>THANK YOU. 2205 01:24:51,520 --> 01:24:52,920 >>THANKS, KEITH. 2206 01:24:52,920 --> 01:24:55,480 THE CONTENT IS GRATIFYING AND 2207 01:24:55,480 --> 01:24:55,800 HEARTWARMING. 2208 01:24:55,800 --> 01:24:59,520 MY QUESTION IS MORE MUNDANE, 2209 01:24:59,520 --> 01:25:01,920 CLARIFICATION MIGHT BE NEEDED. 2210 01:25:01,920 --> 01:25:04,360 THE IMPORTANCE TO DEFINE WHAT 2211 01:25:04,360 --> 01:25:05,760 COMMUNITY ENGAGEMENT MEANS 2212 01:25:05,760 --> 01:25:08,040 BECAUSE AS YOU KNOW, THIS IS A 2213 01:25:08,040 --> 01:25:10,800 TERM THAT IS USED LOOSELY BY 2214 01:25:10,800 --> 01:25:12,320 EVERYBODY, MEANS DIFFERENT 2215 01:25:12,320 --> 01:25:13,000 THINKS TO DIFFERENT PEOPLE, 2216 01:25:13,000 --> 01:25:15,600 DEPENDS WHO YOU SPEAK WITH. 2217 01:25:15,600 --> 01:25:19,240 CTSA PROGRAM AS A FAIRLY WELL 2218 01:25:19,240 --> 01:25:21,840 OILED DEFINITION THROUGH THE 2219 01:25:21,840 --> 01:25:22,560 PRINCIPLES OF COMMUNITY 2220 01:25:22,560 --> 01:25:25,240 ENGAGEMENT TO THE BOOK PUBLISHED 2221 01:25:25,240 --> 01:25:32,040 ONLINE SUGGEST THIS INITIATIVE 2222 01:25:32,040 --> 01:25:33,440 ALIGNS. 2223 01:25:33,440 --> 01:25:34,440 MONICA'S POINTS, 2224 01:25:34,440 --> 01:25:35,000 ALL-OF-GOVERNMENT APPROACH, 2225 01:25:35,000 --> 01:25:37,520 GROUPS WITH WORK IN THIS AREA 2226 01:25:37,520 --> 01:25:38,480 CAN HAVE SHARED LANGUAGE IN 2227 01:25:38,480 --> 01:25:40,560 TERMS OF WHAT IT MEANS AND ALSO 2228 01:25:40,560 --> 01:25:43,080 WHAT IT MEANS TO IMPLEMENT AND 2229 01:25:43,080 --> 01:25:45,560 MEASURE THE IMPACT OF THIS 2230 01:25:45,560 --> 01:25:45,840 INITIATIVE. 2231 01:25:45,840 --> 01:25:46,760 THANK YOU FOR DOING IT. 2232 01:25:46,760 --> 01:25:48,760 AND TO ALL OF THE TEAM FOR THIS 2233 01:25:48,760 --> 01:25:49,080 WORK. 2234 01:25:49,080 --> 01:25:54,880 THIS IS SUCH A WONDERFUL THING 2235 01:25:54,880 --> 01:25:59,600 TO SEE. 2236 01:25:59,600 --> 01:26:00,880 >>KAREN, ANNA, NELLIE. 2237 01:26:00,880 --> 01:26:01,560 >>THANK YOU. 2238 01:26:01,560 --> 01:26:02,560 FANTASTIC PROGRAM. 2239 01:26:02,560 --> 01:26:03,720 I LOVE SEEING THIS. 2240 01:26:03,720 --> 01:26:09,240 IS THIS -- THIS IS A QUESTION 2241 01:26:09,240 --> 01:26:11,560 FOR MY OWN CLARIFICATION. 2242 01:26:11,560 --> 01:26:14,160 IS YOUR VISION THAT THE CENTER 2243 01:26:14,160 --> 01:26:15,360 WILL SORT OF OPERATE MORE IN THE 2244 01:26:15,360 --> 01:26:19,000 WAY THAT A LOT OF THE CTSI 2245 01:26:19,000 --> 01:26:22,360 CENTERS OPERATE OUT OF THAT 2246 01:26:22,360 --> 01:26:24,400 PROGRAM ACROSS THE NIH WHERE 2247 01:26:24,400 --> 01:26:27,920 THERE'S A LOT OF INFRASTRUCTURE, 2248 01:26:27,920 --> 01:26:30,880 SMALLER MORE LOCALIZED RESEARCH 2249 01:26:30,880 --> 01:26:34,080 IN THESE CENTERS, WHICH THEN 2250 01:26:34,080 --> 01:26:37,120 COULD POTENTIALLY HAND OFF SOME 2251 01:26:37,120 --> 01:26:41,320 AMAZING PROBLEMS AT NCI LIKE OUR 2252 01:26:41,320 --> 01:26:43,200 NCTN GROUPS OR NCCOR GROUPS, 2253 01:26:43,200 --> 01:26:46,680 DOING A LOT OF THE CARE DELIVERY 2254 01:26:46,680 --> 01:26:48,160 WORK ALREADY, ALREADY FOCUSED ON 2255 01:26:48,160 --> 01:26:50,400 HEALTH EQUITY, OR ARE YOU SEEING 2256 01:26:50,400 --> 01:26:53,720 THIS BE LIKE ITS OWN LARGE 2257 01:26:53,720 --> 01:26:55,000 NETWORK WITH BIG CLINICAL TRIALS 2258 01:26:55,000 --> 01:26:56,880 THAT RECRUIT FROM ALL THESE 2259 01:26:56,880 --> 01:27:00,240 DIFFERENT CENTERS AS WELL? 2260 01:27:00,240 --> 01:27:01,680 I'M JUST MAKING SURE I'M ON THE 2261 01:27:01,680 --> 01:27:03,840 SAME PAGE WITH WHERE YOU GUYS 2262 01:27:03,840 --> 01:27:04,560 ARE. 2263 01:27:04,560 --> 01:27:04,840 >>SURE. 2264 01:27:04,840 --> 01:27:05,880 THANK YOU, KAREN. 2265 01:27:05,880 --> 01:27:10,600 WE SEE THIS AS A RESEARCH 2266 01:27:10,600 --> 01:27:13,840 NETWORK OF FOUR U19s AND 2267 01:27:13,840 --> 01:27:16,720 COORDINATING CENTER THAT IS 2268 01:27:16,720 --> 01:27:17,960 FACILITATING THE 2269 01:27:17,960 --> 01:27:19,120 CROSS-COLLABORATION ACROSS THE 2270 01:27:19,120 --> 01:27:20,960 U19s ON SPECIFIC SCIENTIFIC 2271 01:27:20,960 --> 01:27:22,800 AREAS SUCH AS MEASURES 2272 01:27:22,800 --> 01:27:25,760 DEVELOPMENT, AS WELL AS 2273 01:27:25,760 --> 01:27:26,280 UNDERSTANDING MULTI-LEVEL 2274 01:27:26,280 --> 01:27:27,520 INTERVENTION SCIENCE, NEW 2275 01:27:27,520 --> 01:27:30,160 METHODS AND APPROACHES, AS WELL 2276 01:27:30,160 --> 01:27:32,560 AS UNDERSTANDING THOSE 2277 01:27:32,560 --> 01:27:34,520 MECHANISMS AS THEY CAN OPERATE 2278 01:27:34,520 --> 01:27:43,280 DIFFERENTLY BASED ON DIFFERENT 2279 01:27:43,280 --> 01:27:48,720 POPULATIONS OR CONTEXTS. 2280 01:27:48,720 --> 01:27:50,920 >>GO AHEAD. 2281 01:27:50,920 --> 01:27:51,160 >>HI. 2282 01:27:51,160 --> 01:27:54,840 REALLY EXCITING. 2283 01:27:54,840 --> 01:27:57,160 WHAT I WONDERED, IT IS CANCER 2284 01:27:57,160 --> 01:27:57,920 FOCUSED. 2285 01:27:57,920 --> 01:28:00,600 WE ARE CANCER FOCUSED BUT IT'S 2286 01:28:00,600 --> 01:28:02,400 LIKELY THAT THESE INTERVENTIONS 2287 01:28:02,400 --> 01:28:04,920 WILL EXTEND BEYOND CANCER. 2288 01:28:04,920 --> 01:28:09,720 AND IT'S LIKELY THAT UNLESS 2289 01:28:09,720 --> 01:28:10,520 ENCOURAGED INVESTIGATIVE TEAM 2290 01:28:10,520 --> 01:28:12,680 WILL NOT LOOK AT OTHER DATA, 2291 01:28:12,680 --> 01:28:13,360 IMPACT ON CARDIOVASCULAR 2292 01:28:13,360 --> 01:28:15,880 DISEASE, IT'S GOING TO HAVE 2293 01:28:15,880 --> 01:28:19,120 IMPACT ON DIABETES, BONE HEALTH, 2294 01:28:19,120 --> 01:28:20,560 MOOD, ET CETERA. 2295 01:28:20,560 --> 01:28:23,200 AND SO I'M WONDERING IF THERE 2296 01:28:23,200 --> 01:28:33,760 COULD BE SOMETHING IN THERE THAT 2297 01:28:35,600 --> 01:28:36,000 WOULD SAY EXPLORATION. 2298 01:28:36,000 --> 01:28:40,160 >>THANK YOU FOR THE QUESTION. 2299 01:28:40,160 --> 01:28:44,080 IT CAN IMPACT MULTIPLE DISEASE 2300 01:28:44,080 --> 01:28:46,720 AND BEHAVIORAL OUTCOMES. 2301 01:28:46,720 --> 01:28:57,280 WE CAN PUT CLARIFICATIONS IN THE 2302 01:29:00,040 --> 01:29:00,200 CONCEPT. 2303 01:29:00,200 --> 01:29:02,960 >>IMPORTANT WORK, I HOPE IT 2304 01:29:02,960 --> 01:29:03,560 REACHES MANY INSTITUTIONS. 2305 01:29:03,560 --> 01:29:09,080 ONE CHALLENGE WITH THE U SYSTEM, 2306 01:29:09,080 --> 01:29:11,160 INS AND OUTS, CENTERS FUNDED AND 2307 01:29:11,160 --> 01:29:12,880 THOSE WHO APPLIED AND HAD GREAT 2308 01:29:12,880 --> 01:29:17,040 CONCEPTS NOT ABLE TO BE FUNDED, 2309 01:29:17,040 --> 01:29:19,040 IN THIS AREA WHETHER WE ALL WANT 2310 01:29:19,040 --> 01:29:20,360 TO MAKE PROGRESS IT MAY BE 2311 01:29:20,360 --> 01:29:22,000 HELPFUL TO BUILD IN A MECHANISM 2312 01:29:22,000 --> 01:29:31,720 OF HOW TO ENGAGE THE BROADER 2313 01:29:31,720 --> 01:29:33,560 COMMUNITY, HAVING A MECHANISM TO 2314 01:29:33,560 --> 01:29:34,760 HELP THOSE NOT SUCCESSFUL BUT 2315 01:29:34,760 --> 01:29:42,360 WANT TO MOVE FORWARD CAN 2316 01:29:42,360 --> 01:29:42,800 BENEFIT. 2317 01:29:42,800 --> 01:29:45,080 >>GREAT POINT AROUND 2318 01:29:45,080 --> 01:29:46,480 DISSEMINATION AND BROADER 2319 01:29:46,480 --> 01:29:50,440 ENGAGEMENT BEYOND THE DIRECT 2320 01:29:50,440 --> 01:29:52,080 PARTNERS WITHIN THIS INITIATIVE. 2321 01:29:52,080 --> 01:29:54,480 THIS IS WHERE COORDINATING 2322 01:29:54,480 --> 01:29:57,000 CENTER CAN COME IN AS A U 2323 01:29:57,000 --> 01:29:58,320 MECHANISM, WORK DIRECTLY WITH 2324 01:29:58,320 --> 01:30:00,640 THEM AROUND SOME OF THOSE 2325 01:30:00,640 --> 01:30:01,280 DISSEMINATION ACTIVITIES AND 2326 01:30:01,280 --> 01:30:05,160 ENGAGEMENT ACTIVITIES. 2327 01:30:05,160 --> 01:30:09,520 THANKS FOR THAT SUGGESTION. 2328 01:30:09,520 --> 01:30:09,760 >>OKAY. 2329 01:30:09,760 --> 01:30:11,080 KAREN, WOULD YOU MIND TAKING 2330 01:30:11,080 --> 01:30:14,680 YOUR HAND DOWN AS WE MOVE TO 2331 01:30:14,680 --> 01:30:14,920 VOTING? 2332 01:30:14,920 --> 01:30:19,600 OTIS, A MOTION? 2333 01:30:19,600 --> 01:30:21,800 >>I MAKE A MOTION. 2334 01:30:21,800 --> 01:30:22,080 >>OKAY. 2335 01:30:22,080 --> 01:30:24,640 MOTION TO APPROVE. 2336 01:30:24,640 --> 01:30:25,160 >>SECOND. 2337 01:30:25,160 --> 01:30:27,160 >>THANK YOU. 2338 01:30:27,160 --> 01:30:29,960 ANY FURTHER DISCUSSION? 2339 01:30:29,960 --> 01:30:33,720 2340 01:30:33,720 --> 01:30:35,760 HEARING NONE, MOTION FOR 2341 01:30:35,760 --> 01:30:36,760 APPROVAL, I'M LOOKING FOR 2342 01:30:36,760 --> 01:30:37,240 DISAPPROVALS. 2343 01:30:37,240 --> 01:30:38,760 SORRY I DIDN'T MENTION OUR 2344 01:30:38,760 --> 01:30:40,840 PROCESS, TO REMIND YOU, YOU CAN 2345 01:30:40,840 --> 01:30:42,280 RAISE YOUR HAND THROUGH THE 2346 01:30:42,280 --> 01:30:43,920 WEBEX FUNCTION OR IF THAT'S NOT 2347 01:30:43,920 --> 01:30:46,680 WORKING FOR YOU, VOICE YOUR 2348 01:30:46,680 --> 01:30:47,720 DISAPPROVAL, OTHERWISE I WILL 2349 01:30:47,720 --> 01:30:49,320 ASSUME APPROVAL AS I SCAN BACK 2350 01:30:49,320 --> 01:30:52,720 AND FORTH BETWEEN THE SCREENS. 2351 01:30:52,720 --> 01:30:55,480 2352 01:30:55,480 --> 01:30:56,880 I SEE AND HEAR NUMBER. 2353 01:30:56,880 --> 01:31:00,800 I DON'T HAVE ANY PRE-RECORDED 2354 01:31:00,800 --> 01:31:03,920 ABSTENTIONS, ANY AT THE LAST 2355 01:31:03,920 --> 01:31:05,240 MINUTE? 2356 01:31:05,240 --> 01:31:05,720 NO. 2357 01:31:05,720 --> 01:31:06,000 PAULETTE? 2358 01:31:06,000 --> 01:31:07,440 >>IT'S UNANIMOUS. 2359 01:31:07,440 --> 01:31:07,840 >>GREAT. 2360 01:31:07,840 --> 01:31:09,080 THANK YOU ALL. 2361 01:31:09,080 --> 01:31:14,760 NEXT CONCEPT ALSO A NEW 2362 01:31:14,760 --> 01:31:15,280 RFA/COOPERATIVE AGREEMENT 2363 01:31:15,280 --> 01:31:16,280 DISCOVERY AND DEVELOPMENT OF 2364 01:31:16,280 --> 01:31:18,920 NATURAL PRODUCTS FOR CANCER 2365 01:31:18,920 --> 01:31:22,640 INTERCEPTION AND PREVENTION, DR. 2366 01:31:22,640 --> 01:31:29,400 MOHAMMED PRESENTING, 2367 01:31:29,400 --> 01:31:30,840 SUBCOMMITTEE AS WELL. 2368 01:31:30,840 --> 01:31:31,680 JENNY HAD A CONFLICT TODAY AND 2369 01:31:31,680 --> 01:31:34,880 COULD NOT BE PRESENT FOR THE 2370 01:31:34,880 --> 01:31:35,080 MEETING. 2371 01:31:35,080 --> 01:31:36,520 WE WILL REPRESENT HER COMMENTS 2372 01:31:36,520 --> 01:31:40,200 WHEN WE GET TO DISCUSSION. 2373 01:31:40,200 --> 01:31:44,400 SO ALTAF, GO AHEAD WITH YOUR 2374 01:31:44,400 --> 01:31:44,760 PRESENTATION. 2375 01:31:44,760 --> 01:31:47,920 >>THANK YOU, DR. FLAHERTY. 2376 01:31:47,920 --> 01:31:51,080 A NEW FOA CONCEPT, DISCOVERY AND 2377 01:31:51,080 --> 01:31:53,600 DEVELOPMENT OF NATURAL PRODUCTS 2378 01:31:53,600 --> 01:31:54,800 FOR PRECISION PREVENTION, 2379 01:31:54,800 --> 01:31:57,320 COLLABORATIVE INITIATIVE BY TWO 2380 01:31:57,320 --> 01:32:05,520 I.C.s, NCI AND NCATS. 2381 01:32:05,520 --> 01:32:06,960 AND THREE DIVISIONS. 2382 01:32:06,960 --> 01:32:08,640 WORKING GROUP MEMBERS LISTED 2383 01:32:08,640 --> 01:32:16,240 HERE FROM THE DIVISION OF CANCER 2384 01:32:16,240 --> 01:32:19,360 PREVENTION. 2385 01:32:19,360 --> 01:32:21,880 AS WE KNOW CANCER PREVENTION AND 2386 01:32:21,880 --> 01:32:23,760 INTERCEPTION IS THE MOST 2387 01:32:23,760 --> 01:32:26,000 PROMISING STRATEGY FOR CANCER 2388 01:32:26,000 --> 01:32:27,360 SCROLL, BOTH REDUCING INCIDENCE 2389 01:32:27,360 --> 01:32:30,280 AND MORTALITY, SHOWN HERE IS A 2390 01:32:30,280 --> 01:32:32,040 SCHEMATIC OF THE ESTABLISHED 2391 01:32:32,040 --> 01:32:35,200 TIMELINE OF THE PROGRESSION OF 2392 01:32:35,200 --> 01:32:37,200 SELECTED CANCERS AND 2393 01:32:37,200 --> 01:32:37,920 PRE-MALIGNANT STAGES, MOST 2394 01:32:37,920 --> 01:32:38,840 COMMON EPITHELIAL REPRESENTING 2395 01:32:38,840 --> 01:32:42,200 THE FINAL STEP IN A LONG 2396 01:32:42,200 --> 01:32:43,080 MULTI-YEAR PROGRESSION FROM 2397 01:32:43,080 --> 01:32:45,720 TISSUE INCREASING TO NORMAL 2398 01:32:45,720 --> 01:32:52,560 LOOKING STAGES OF TO INVASIVE 2399 01:32:52,560 --> 01:32:54,040 CANCER FOR DEVELOPING 2400 01:32:54,040 --> 01:32:56,240 STRATEGIES, NEED FOR SAFER 2401 01:32:56,240 --> 01:32:59,280 CANCER INTERCEPTION AND 2402 01:32:59,280 --> 01:33:01,000 PREVENTION AGENTS IS HIGH, THIS 2403 01:33:01,000 --> 01:33:02,560 SHOWS CURRENT STATUS OF THE 2404 01:33:02,560 --> 01:33:04,560 RESEARCH AND NEED FOR NEW 2405 01:33:04,560 --> 01:33:09,640 DISCOVERY PROGRAM FOR CANCER 2406 01:33:09,640 --> 01:33:13,720 INTERCEPTION AND PREVENTION. 2407 01:33:13,720 --> 01:33:15,800 CONTINUALLY SEEING GRANTS ON THE 2408 01:33:15,800 --> 01:33:18,960 SAME NATURAL AGENTS, LACK OF 2409 01:33:18,960 --> 01:33:21,160 TARGETED NATURAL PRODUCTS. 2410 01:33:21,160 --> 01:33:22,720 SCENING GRANTS TOO EXPLORATORY 2411 01:33:22,720 --> 01:33:25,320 AND COMING TO OTHER CHALLENGES 2412 01:33:25,320 --> 01:33:27,280 DISCOVERY RESEARCH FOR 2413 01:33:27,280 --> 01:33:29,800 PREVENTION IS INHERENTLY HIGH 2414 01:33:29,800 --> 01:33:33,600 RISK AND POTENTIALLY HIGH 2415 01:33:33,600 --> 01:33:33,960 REWEAREDDING. 2416 01:33:33,960 --> 01:33:37,840 POTENTIAL FOR FLOODING MAGIC 2417 01:33:37,840 --> 01:33:39,920 BULLET -- FINDING MAGIC BULLET 2418 01:33:39,920 --> 01:33:41,040 IS LOW. 2419 01:33:41,040 --> 01:33:42,000 THERE ARE SIGNIFICANT CHALLENGES 2420 01:33:42,000 --> 01:33:43,280 TO BE ADDRESSED. 2421 01:33:43,280 --> 01:33:46,480 THERE'S A CLEAR OPPORTUNITY TO 2422 01:33:46,480 --> 01:33:50,280 EMBRACE THESE RISKS AND 2423 01:33:50,280 --> 01:33:51,080 CHALLENGES. 2424 01:33:51,080 --> 01:33:52,720 COMING TO THE NEW PROGRAM 2425 01:33:52,720 --> 01:33:55,320 JUSTIFICATION, CURRENTLY THERE 2426 01:33:55,320 --> 01:33:56,640 ARE NOR NCI PROGRAMS SUPPORTING 2427 01:33:56,640 --> 01:33:59,280 THIS TYPE OF RESEARCH 2428 01:33:59,280 --> 01:34:00,040 ACTIVITIES, UNIQUE RESOURCES 2429 01:34:00,040 --> 01:34:06,040 AVAILABLE FROM THE NCI AND 2430 01:34:06,040 --> 01:34:07,480 NCATS, DEFICIENCIES OF 2431 01:34:07,480 --> 01:34:08,440 APPROACHES, PROVIDING SAMPLES 2432 01:34:08,440 --> 01:34:11,760 QUALITY CONTROLLED AND ALSO 2433 01:34:11,760 --> 01:34:13,160 ASSOCIATED WITH SUBSTANTIAL 2434 01:34:13,160 --> 01:34:13,440 INFORMATICS. 2435 01:34:13,440 --> 01:34:14,920 NO OTHER PROGRAM IN THE 2436 01:34:14,920 --> 01:34:15,800 COMMUNITY INCLUDING PHARMA 2437 01:34:15,800 --> 01:34:19,400 COMPANIES DOING THE WORK IN THIS 2438 01:34:19,400 --> 01:34:21,280 FIELD AND CRITICAL NEED TO 2439 01:34:21,280 --> 01:34:23,680 EXPAND DISCOVERY DEVELOPMENT OF 2440 01:34:23,680 --> 01:34:28,600 THIS IS CRITICAL FOR CANCER 2441 01:34:28,600 --> 01:34:30,120 PREVENTION. 2442 01:34:30,120 --> 01:34:31,640 THE OVERALL GOAL OF THIS 2443 01:34:31,640 --> 01:34:34,920 INITIATIVE IS TO SUPPORT THE 2444 01:34:34,920 --> 01:34:36,960 DISCOVERY AND DEVELOPMENT OF 2445 01:34:36,960 --> 01:34:38,480 NATURAL PRODUCTS SAFE, 2446 01:34:38,480 --> 01:34:42,520 NON-TOXIC, EFFICACIOUS FOR 2447 01:34:42,520 --> 01:34:43,280 CANCER INTERCEPTION 2448 01:34:43,280 --> 01:34:44,200 INTERVENTION. 2449 01:34:44,200 --> 01:34:50,200 THE UG3 SELECT TARGETS AND 2450 01:34:50,200 --> 01:34:51,640 DEVELOP FOR TOXICITY SCREENING. 2451 01:34:51,640 --> 01:34:56,080 PURPOSE OF THE UH3 PHASE IS 2452 01:34:56,080 --> 01:34:57,080 SCREENING LIBRARIES, STRUCTURE 2453 01:34:57,080 --> 01:34:59,120 ELUCIDATION, FULL SCALE 2454 01:34:59,120 --> 01:34:59,680 CHARACTERIZATION, EFFICACY 2455 01:34:59,680 --> 01:35:07,680 TESTING, DEVELOPMENT OF SCREENED 2456 01:35:07,680 --> 01:35:08,920 AGENTS. 2457 01:35:08,920 --> 01:35:10,120 SEVERAL HAVE BEEN ESTABLISHED 2458 01:35:10,120 --> 01:35:13,400 BUT NCI HAS ONE OF THE LARGEST 2459 01:35:13,400 --> 01:35:15,960 COLLECTION OF NATIONAL PRODUCTS, 2460 01:35:15,960 --> 01:35:18,640 OVER 500,000 EXTRACTS COLLECTED 2461 01:35:18,640 --> 01:35:20,640 FROM PLANT AND SOURCES. 2462 01:35:20,640 --> 01:35:23,120 NCI PROGRAM FOR NATURAL PRODUCT 2463 01:35:23,120 --> 01:35:24,520 DISCOVERY CANCER MOONSHOT FUNDED 2464 01:35:24,520 --> 01:35:25,880 PROGRAM DESIGNED TO STIMULATE 2465 01:35:25,880 --> 01:35:31,080 RESEARCH IN NATURAL PRODUCTS IS 2466 01:35:31,080 --> 01:35:35,360 PRODUCING ONE MILLION NATURAL 2467 01:35:35,360 --> 01:35:36,320 PRODUCT EXTRACTIONS, THE LIBRARY 2468 01:35:36,320 --> 01:35:39,120 WITH NEW ARE AVAILABLE TO THE 2469 01:35:39,120 --> 01:35:40,560 RESEARCH COMMUNITY AT NO COST. 2470 01:35:40,560 --> 01:35:43,720 ON THE OTHER HAND, NCATS WITH 2471 01:35:43,720 --> 01:35:46,560 CUTTING EDGE TECHNOLOGIES 2472 01:35:46,560 --> 01:35:49,480 COLLABORATES WITH BOTH NIH AND 2473 01:35:49,480 --> 01:35:51,680 INVESTIGATORS TO PERFORM COMPLEX 2474 01:35:51,680 --> 01:35:52,200 PROGRAMS. 2475 01:35:52,200 --> 01:35:58,120 THIS OPPORTUNITY EXISTS TO 2476 01:35:58,120 --> 01:35:59,680 INTEGRATE EXPERTISE FOR 2477 01:35:59,680 --> 01:36:01,520 DISCOVERY OF NATURAL PRODUCTS 2478 01:36:01,520 --> 01:36:07,120 WITH ACTIVITIES USEFUL FOR 2479 01:36:07,120 --> 01:36:09,880 CANCER PREVENTION. 2480 01:36:09,880 --> 01:36:15,680 FIRST SHOWS FOA PLAN ALONG THE 2481 01:36:15,680 --> 01:36:16,560 CONTINUUM, BIPHASIC 2482 01:36:16,560 --> 01:36:17,120 MILESTONE-DRIVEN MECHANISM 2483 01:36:17,120 --> 01:36:20,600 PROVIDING UP TO THREE YEARS OF 2484 01:36:20,600 --> 01:36:24,560 SUPPORT FOR THE STUDIES, TARGET 2485 01:36:24,560 --> 01:36:27,640 SELECTION, VERIFICATION IN 2486 01:36:27,640 --> 01:36:29,040 PRE-CLINICAL SAMPLES, 2487 01:36:29,040 --> 01:36:29,880 DEVELOPMENT AND VALIDATION, 2488 01:36:29,880 --> 01:36:36,280 PROTOTYPE HTS AND PILOT 2489 01:36:36,280 --> 01:36:36,520 SCREENING. 2490 01:36:36,520 --> 01:36:38,440 UP TO TWO YEARS OF ADDITIONAL 2491 01:36:38,440 --> 01:36:42,160 SUPPORT MAY BE AWARDED FOR FULL 2492 01:36:42,160 --> 01:36:46,520 SCALE HIGH-THROUGHPUT SCREENING 2493 01:36:46,520 --> 01:36:47,560 AND ASSESSMENT. 2494 01:36:47,560 --> 01:36:49,280 PROMISING INTERVENTION, LACK OF 2495 01:36:49,280 --> 01:36:51,480 TOXICITIES ARE IDENTIFIED, THESE 2496 01:36:51,480 --> 01:36:54,560 NATURAL AGENTS CAN ENTER NCI 2497 01:36:54,560 --> 01:36:55,200 PREVENT PLAN FOR ADVANCED 2498 01:36:55,200 --> 01:36:56,280 PRE-CLINICAL DEVELOPMENT 2499 01:36:56,280 --> 01:36:59,600 FOLLOWED BY MOVING TO THE 2500 01:36:59,600 --> 01:37:01,640 CLINICAL TRIALS THROUGH THE 2501 01:37:01,640 --> 01:37:01,880 PROGRAM. 2502 01:37:01,880 --> 01:37:04,720 IN THIS SLIDE WE PROVIDE EXAMPLE 2503 01:37:04,720 --> 01:37:07,120 OF POTENTIAL MOLECULAR TARGETS 2504 01:37:07,120 --> 01:37:09,320 FOR CANCER INTERCEPTION THAT 2505 01:37:09,320 --> 01:37:19,080 PLAY KEY ROLES IN TUMORIGENESIS. 2506 01:37:19,080 --> 01:37:23,440 SEVERAL APPROACHES CAN BE 2507 01:37:23,440 --> 01:37:25,840 CONSIDERED TO OVERCOME 2508 01:37:25,840 --> 01:37:28,560 WELL-STUDIED INHIBITORS 2509 01:37:28,560 --> 01:37:32,000 ASSOCIATED TOXICITIES WHILE 2510 01:37:32,000 --> 01:37:35,160 MAINTAINING EFFICACY. 2511 01:37:35,160 --> 01:37:39,760 MPGES-1 IS RESPONSIBLE FOR INOF 2512 01:37:39,760 --> 01:37:41,200 CORRECTION, CONSIDER SAFE AND 2513 01:37:41,200 --> 01:37:48,160 EFFECTIVE FOR INTERCEPTION AND 2514 01:37:48,160 --> 01:37:48,560 TREATMENT. 2515 01:37:48,560 --> 01:37:52,440 IT COULD BE USED FOR NATURAL 2516 01:37:52,440 --> 01:37:54,280 PRODUCTS SCREENING. 2517 01:37:54,280 --> 01:37:56,040 THIS SLIDE SHOWS HIGH LEVEL 2518 01:37:56,040 --> 01:38:00,560 PROCESS FOR APPLICATION 2519 01:38:00,560 --> 01:38:05,160 SUBMISSION THROUGH FUNDING, 2520 01:38:05,160 --> 01:38:07,840 SELECTS TARGET, SUBMISSION 2521 01:38:07,840 --> 01:38:08,560 APPLICATION. 2522 01:38:08,560 --> 01:38:09,720 STAFF NEGOTIATES MILESTONES, 2523 01:38:09,720 --> 01:38:12,560 PROPOSES FUNDING PLAN. 2524 01:38:12,560 --> 01:38:16,000 STAFF MONITORS PROGRESS, 2525 01:38:16,000 --> 01:38:18,720 PROVIDES ASSISTANCE AS NEEDED. 2526 01:38:18,720 --> 01:38:19,280 RECOMMENDS AWARDS. 2527 01:38:19,280 --> 01:38:22,520 TO PROVIDE BETTER CLARITY AND 2528 01:38:22,520 --> 01:38:32,600 UPON FEEDBACK WE HAVE PROVIDED 2529 01:38:32,600 --> 01:38:33,400 THIS. 2530 01:38:33,400 --> 01:38:36,120 I HAVE SHOWN ON THIS SLIDE 2531 01:38:36,120 --> 01:38:39,640 INVESTIGATORS ARE EXPECTED TO 2532 01:38:39,640 --> 01:38:41,280 PROVIDE FOLLOWING 2533 01:38:41,280 --> 01:38:43,640 MILESTONE-BASED APPROACHES IN 2534 01:38:43,640 --> 01:38:46,520 BOTH PHASES FROM THE TARGET 2535 01:38:46,520 --> 01:38:49,560 SELECTION IN THE UG3 PHASE TO 2536 01:38:49,560 --> 01:38:52,120 EFFICACY TESTING IN UH3 PHASE. 2537 01:38:52,120 --> 01:38:56,480 AS FOR THE CONTRIBUTIONS ON THIS 2538 01:38:56,480 --> 01:39:01,560 SLIDE THE PROGRAM WILL ADVISE 2539 01:39:01,560 --> 01:39:02,480 APPLICANTS AND PROVIDE 2540 01:39:02,480 --> 01:39:03,680 ASSISTANCE BOTH ADVISORY AND 2541 01:39:03,680 --> 01:39:05,080 TECHNICAL AT VARIOUS STAGES OF 2542 01:39:05,080 --> 01:39:12,440 THE PROJECT DEVELOPMENT AND 2543 01:39:12,440 --> 01:39:18,880 IMPLEMENT APPLICATION AS NEEDED. 2544 01:39:18,880 --> 01:39:21,480 PORTFOLIO ANALYSIS, USING THE 2545 01:39:21,480 --> 01:39:25,480 NIH REPORTER, THERE WERE 88 2546 01:39:25,480 --> 01:39:27,320 UNIQUE MULTI-YEAR PROJECTS 2547 01:39:27,320 --> 01:39:28,120 IDENTIFIED USING NATURAL 2548 01:39:28,120 --> 01:39:29,840 PRODUCTS, CANCER PREVENTION AS 2549 01:39:29,840 --> 01:39:33,560 KEY WORDS. 2550 01:39:33,560 --> 01:39:35,840 OF THESE 39 PROJECTS, 2551 01:39:35,840 --> 01:39:37,520 INVESTIGATOR INITIATED R01 AND 2552 01:39:37,520 --> 01:39:38,920 OTHER GRANTS FOCUSING ON 2553 01:39:38,920 --> 01:39:40,360 SPECIFIC AGENTS. 2554 01:39:40,360 --> 01:39:42,320 SOME PROJECTS ARE THERAPEUTICS. 2555 01:39:42,320 --> 01:39:43,760 ONLY ONE PROJECT SPECIFICALLY 2556 01:39:43,760 --> 01:39:47,440 APPLIES A SCREENING PLATFORM FOR 2557 01:39:47,440 --> 01:39:51,640 THE DISCOVERY OF NOVEL 2558 01:39:51,640 --> 01:39:53,360 NON-CYTOTOXIC COMPONENTS FROM 2559 01:39:53,360 --> 01:39:54,480 CYANO BACTERIA. 2560 01:39:54,480 --> 01:39:56,760 NONE OF THESE PROJECTS FOCUS ON 2561 01:39:56,760 --> 01:39:57,880 CLEANING AND DEVELOPMENT OF 2562 01:39:57,880 --> 01:40:01,160 NATURAL PRODUCTS FOR CANCER 2563 01:40:01,160 --> 01:40:01,600 PREVENTION. 2564 01:40:01,600 --> 01:40:06,960 THE TOTAL BUDGET REQUESTED FOR 2565 01:40:06,960 --> 01:40:17,520 THIS IS $33 MILLION, LIMITED TO 2566 01:40:18,320 --> 01:40:19,640 UP TO THREE YEARS. 2567 01:40:19,640 --> 01:40:22,280 ONE RECEIPT DATE PER YEAR, THREE 2568 01:40:22,280 --> 01:40:23,600 YEARS SUPPORTING THREE GRANTS 2569 01:40:23,600 --> 01:40:29,160 PER YEAR PROVIDING TWO 2570 01:40:29,160 --> 01:40:30,080 OPPORTUNITIES FOR THE 2571 01:40:30,080 --> 01:40:36,560 SUBMISSIONS, AT LEAST TWO OF 2572 01:40:36,560 --> 01:40:39,720 THEM TO THE UH3 FACE. 2573 01:40:39,720 --> 01:40:42,000 TOTAL COSTS SET ASIDE FOR 2574 01:40:42,000 --> 01:40:44,000 COLLABORATION AND ADDITIONAL 2575 01:40:44,000 --> 01:40:47,280 NOVEL RESEARCH AREAS, SUPPORTED 2576 01:40:47,280 --> 01:40:51,440 THE MOST PROMISING PROJECTS. 2577 01:40:51,440 --> 01:40:54,640 ADDITIONAL RESOURCES WILL ENABLE 2578 01:40:54,640 --> 01:40:55,720 SPECIALIZED STUDIES IN NATURAL 2579 01:40:55,720 --> 01:41:00,080 CHEMISTRY AND SCALEUP FOR 2580 01:41:00,080 --> 01:41:02,520 EFFICACY STUDIES, SUPPORT NCATS 2581 01:41:02,520 --> 01:41:04,840 THROUGHPUT SCREENING, AND 2582 01:41:04,840 --> 01:41:06,840 RESEARCH EFFORTS TO COMPLEMENT 2583 01:41:06,840 --> 01:41:08,040 THE PROJECTS. 2584 01:41:08,040 --> 01:41:18,320 WE GO BACK TO LEADERSHIP TO 2585 01:41:18,320 --> 01:41:20,520 REQUEST ADDITIONAL FUNDS. 2586 01:41:20,520 --> 01:41:23,360 JUSTIFICATION FOR THE RFA AND 2587 01:41:23,360 --> 01:41:27,840 MECHANISM, SINCE THERE'S NO NIH 2588 01:41:27,840 --> 01:41:29,280 ANNOUNCEMENT FOR THE MECHANISM, 2589 01:41:29,280 --> 01:41:30,600 RFA WILL AVAILABLE SOLICITATION 2590 01:41:30,600 --> 01:41:41,120 OF HIGH RISK AND HIGH IMPACT, 2591 01:41:42,560 --> 01:41:48,400 RFA MECHANISM WILL ALLOW FOR 2592 01:41:48,400 --> 01:41:49,520 (INDISCERNIBLE), WITH 2593 01:41:49,520 --> 01:41:50,160 SUBSTANTIAL PROGRAMMATIC 2594 01:41:50,160 --> 01:41:56,440 INVOLVEMENT BY NCI AND NCATS IT 2595 01:41:56,440 --> 01:41:57,400 WILL REQUIRE COOPERATIVE 2596 01:41:57,400 --> 01:41:57,800 AGREEMENT. 2597 01:41:57,800 --> 01:42:02,040 BOTH STAFF WILL NEGOTIATE AND 2598 01:42:02,040 --> 01:42:04,280 MONITOR ROBUST MILESTONES FOR 2599 01:42:04,280 --> 01:42:05,520 COOPERATIVE AGREEMENTS, SUBJECT 2600 01:42:05,520 --> 01:42:09,320 MODIFICATIONS TO MEET THOSE 2601 01:42:09,320 --> 01:42:09,760 MILESTONES. 2602 01:42:09,760 --> 01:42:15,000 EVALUATE SCIENTIFIC PROGRAM FOR 2603 01:42:15,000 --> 01:42:15,360 TRANSITION. 2604 01:42:15,360 --> 01:42:16,120 SUPPORT COMMUNICATION AND 2605 01:42:16,120 --> 01:42:22,040 COLLABORATION BETWEEN THESE 2606 01:42:22,040 --> 01:42:24,680 PROGRAMS AND OTHER PROGRAMS. 2607 01:42:24,680 --> 01:42:26,640 WE THANK THE BSA MEMBERS FOR 2608 01:42:26,640 --> 01:42:32,680 MEETING WITH US AND PROVIDING 2609 01:42:32,680 --> 01:42:33,160 ADDITIONS. 2610 01:42:33,160 --> 01:42:35,840 THE SELECTED ONES WILL GO INTO 2611 01:42:35,840 --> 01:42:39,240 THE FOA LANGUAGE LISTED ON THE 2612 01:42:39,240 --> 01:42:45,080 NEXT TWO SLIDES. 2613 01:42:45,080 --> 01:42:49,760 NCI LIBRARIES WILL BE AVAILABLE. 2614 01:42:49,760 --> 01:42:51,880 STAFF WILL WORK WITH SUBMISSION 2615 01:42:51,880 --> 01:43:02,400 IN THE UG3 AND UH3 PHASES, AND 2616 01:43:04,320 --> 01:43:05,840 THE PROPOSAL DESCRIBED IN THE 2617 01:43:05,840 --> 01:43:16,360 FOA, ALSO A FEW WERE LISTED ON 2618 01:43:32,120 --> 01:43:33,640 SLIDE 11. 2619 01:43:33,640 --> 01:43:34,800 IMPORTANTLY THE BRANCH WILL 2620 01:43:34,800 --> 01:43:37,560 PROVIDE DIRECT SUPPORT FOR 2621 01:43:37,560 --> 01:43:38,520 ISOLATION, IDENTIFICATION, 2622 01:43:38,520 --> 01:43:40,680 STRUCTURAL CHARACTERIZATION OF 2623 01:43:40,680 --> 01:43:42,240 BIOACTIVE FRACTIONS/ACTIVE 2624 01:43:42,240 --> 01:43:44,560 NATURAL PRODUCTS THROUGHOUT THE 2625 01:43:44,560 --> 01:43:45,640 PURIFICATION PROCESS, SET-ASIDE 2626 01:43:45,640 --> 01:43:48,280 BUDGET ALLOCATED FOR THESE 2627 01:43:48,280 --> 01:43:48,560 ACTIVITIES. 2628 01:43:48,560 --> 01:43:52,320 AND THE BUDGET SLIDE WAS TO 2629 01:43:52,320 --> 01:43:54,720 PROVIDE BASED UPON THE 2630 01:43:54,720 --> 01:43:55,320 SUBCOMMITTEE SUGGESTIONS. 2631 01:43:55,320 --> 01:43:59,840 WITH THIS I WILL STOP HERE AND 2632 01:43:59,840 --> 01:44:02,360 BE HAPPY TO TAKE QUESTIONS ALONG 2633 01:44:02,360 --> 01:44:03,360 WITH WORKING GROUP MEMBERS ON 2634 01:44:03,360 --> 01:44:09,640 THIS CALL. 2635 01:44:09,640 --> 01:44:10,480 THANK YOU. 2636 01:44:10,480 --> 01:44:14,440 >>GET US GOING. 2637 01:44:14,440 --> 01:44:16,240 >>THANK YOU, KEITH. 2638 01:44:16,240 --> 01:44:17,920 MYSELF, KEITH AND JENNIFER, THE 2639 01:44:17,920 --> 01:44:19,680 SUBCOMMITTEE WORKING ON THIS, WE 2640 01:44:19,680 --> 01:44:23,400 WERE EXCITED ABOUT THE CONCEPT. 2641 01:44:23,400 --> 01:44:26,120 WE MET, DISCUSSED THE CONCEPT, 2642 01:44:26,120 --> 01:44:29,720 CAME UP WITH SOME QUESTIONS THAT 2643 01:44:29,720 --> 01:44:34,440 WE HAD FOR DR. MOHAMMED, 2644 01:44:34,440 --> 01:44:35,360 SCHUMAKER AND CASTLE. 2645 01:44:35,360 --> 01:44:37,160 WE MET TO DISCUSS THIS 2646 01:44:37,160 --> 01:44:41,280 AFTERWARDS, AND THEY HAVE DONE A 2647 01:44:41,280 --> 01:44:43,560 GREAT JOB IN ADDRESSING THE 2648 01:44:43,560 --> 01:44:46,480 CONCERNS AND COMMENTS THAT WE 2649 01:44:46,480 --> 01:44:47,800 HAD IN THE PRESENTATION IT WAS 2650 01:44:47,800 --> 01:44:51,960 CLEAR THEY TOOK THESE TO HEART 2651 01:44:51,960 --> 01:44:54,840 AND CLEARLY ADDRESSED ALL THE 2652 01:44:54,840 --> 01:44:55,680 MAJOR ISSUES WE HAD. 2653 01:44:55,680 --> 01:45:00,400 SOME KEY ISSUES IN TERMS OF 2654 01:45:00,400 --> 01:45:03,040 AVAILABILITY OF AMAZING RESOURCE 2655 01:45:03,040 --> 01:45:04,680 OF 500,000+ COMPOUNDS, THE ROLE 2656 01:45:04,680 --> 01:45:12,320 OF NCI AND TYPE OF SERVICES THAT 2657 01:45:12,320 --> 01:45:18,360 WOULD BE AVAILABLE, 2658 01:45:18,360 --> 01:45:19,520 INTERDIGITATING WITH OTHER 2659 01:45:19,520 --> 01:45:21,040 PROGRAMS, AS WELL AS CLEAR 2660 01:45:21,040 --> 01:45:23,040 BOUNDARIES HOW THEY WOULD BE 2661 01:45:23,040 --> 01:45:25,280 WORKING IN TERMS OF TRANSITION 2662 01:45:25,280 --> 01:45:31,200 FROM THE UG3 TO THE UH3 PART OF 2663 01:45:31,200 --> 01:45:31,840 THE PROGRAM. 2664 01:45:31,840 --> 01:45:35,360 THEY HAVE DONE A GREAT JOB 2665 01:45:35,360 --> 01:45:40,760 ADDRESSING THIS, AND I THINK WE 2666 01:45:40,760 --> 01:45:48,880 DISCUSSED IT, QUITE HAPPY WITH 2667 01:45:48,880 --> 01:45:49,440 RESPONSES. 2668 01:45:49,440 --> 01:45:50,000 KEITH? 2669 01:45:50,000 --> 01:45:52,560 >>THANKS, YOU HIT THE 2670 01:45:52,560 --> 01:45:54,160 HIGHLIGHTS. 2671 01:45:54,160 --> 01:45:56,560 I OTHER POINT, THAT WE 2672 01:45:56,560 --> 01:45:58,560 DELIBERATED ON, THIS MECHANISM 2673 01:45:58,560 --> 01:46:00,480 AS A WAY TO FILL WHAT WE THOUGHT 2674 01:46:00,480 --> 01:46:03,680 WAS A VERY CLEAR UNMET NEED, IN 2675 01:46:03,680 --> 01:46:06,960 TERMS OF APPLYING THIS APPROACH, 2676 01:46:06,960 --> 01:46:09,920 AND THE PLATFORM TECHNOLOGIES TO 2677 01:46:09,920 --> 01:46:12,400 PREVENTION RESEARCH AND ALTHOUGH 2678 01:46:12,400 --> 01:46:16,800 IT'S TYPICALLY NOT OUR PURVIEW 2679 01:46:16,800 --> 01:46:20,000 TO ADJUST MECHANISMS OR, YOU 2680 01:46:20,000 --> 01:46:24,160 KNOW, SUGGEST DIFFERENT, WE DID 2681 01:46:24,160 --> 01:46:26,480 FEEL THIS WAS A GOOD FIT ALL 2682 01:46:26,480 --> 01:46:29,840 THINGS CONSIDERED IN TERMS OF 2683 01:46:29,840 --> 01:46:34,000 WHAT'S NEEDED PARTICULARLY WHAT 2684 01:46:34,000 --> 01:46:35,960 ERLE JUST EMPHASIZED, UNIQUE 2685 01:46:35,960 --> 01:46:37,600 OFFERING OF NCI RESOURCES BEYOND 2686 01:46:37,600 --> 01:46:39,680 JUST COMPOUND LIBRARY BUT 2687 01:46:39,680 --> 01:46:41,680 EXPERTISE, NOT JUST FOR 2688 01:46:41,680 --> 01:46:43,400 CONSULTATION BUT ACTUALLY 2689 01:46:43,400 --> 01:46:46,800 COLLABORATION AND ESSENTIALLY 2690 01:46:46,800 --> 01:46:48,000 IN-KIND SERVICES, REALLY THINK 2691 01:46:48,000 --> 01:46:51,080 GOING TO VERY MUCH LEVERAGE THE 2692 01:46:51,080 --> 01:46:53,440 INVESTMENT THAT IS ALLOCATED TO 2693 01:46:53,440 --> 01:46:55,720 EXTRAMURAL INVESTIGATORS. 2694 01:46:55,720 --> 01:46:58,400 I THINK AGAIN THIS IS UNIQUE 2695 01:46:58,400 --> 01:46:59,640 UNMET NEED, UNIQUE OPPORTUNITY, 2696 01:46:59,640 --> 01:47:03,000 UNIQUE RESOURCE AT NCI. 2697 01:47:03,000 --> 01:47:04,840 WE CAME AWAY FEELING THESE ARE 2698 01:47:04,840 --> 01:47:09,120 NOTFULLY BROUGHT TOGETHER -- 2699 01:47:09,120 --> 01:47:15,920 THOUGHTFULLY BROUGHT TOGETHER, 2700 01:47:15,920 --> 01:47:17,800 AMOUNT OF SUPPORT WHICH ANYONE 2701 01:47:17,800 --> 01:47:19,640 COULD SAY MAYBE THIS IS NOT 2702 01:47:19,640 --> 01:47:22,040 ENOUGH TO MOVE ANY GIVEN PROJECT 2703 01:47:22,040 --> 01:47:25,880 FORWARD BUT THE POINT WE 2704 01:47:25,880 --> 01:47:27,640 DELIBERATED ON WITH ALTOF AND 2705 01:47:27,640 --> 01:47:32,120 TEAM IS THERE'S SO MUCH BEING 2706 01:47:32,120 --> 01:47:36,480 CORRECTED BY NCI THE COST, THE 2707 01:47:36,480 --> 01:47:37,160 INTRAMURAL COMMUNITY WILL NEED 2708 01:47:37,160 --> 01:47:39,120 IN TERMS OF THEIR COMPONENT OF 2709 01:47:39,120 --> 01:47:40,760 THE WORK, I THINK FITS WELL 2710 01:47:40,760 --> 01:47:44,480 WITHIN THE SCOPE OF WHAT'S BEEN 2711 01:47:44,480 --> 01:47:44,760 DESCRIBED. 2712 01:47:44,760 --> 01:47:45,800 WE FELT COMFORTABLE, IN THE END, 2713 01:47:45,800 --> 01:47:48,960 THAT THAT WAS THE CASE. 2714 01:47:48,960 --> 01:47:50,600 JENNY IS UNABLE TO PARTICIPATE 2715 01:47:50,600 --> 01:47:55,960 IN TODAY'S MEETING SO WE'LL MOVE 2716 01:47:55,960 --> 01:47:58,280 TO OTHER BOARD MEMBERS. 2717 01:47:58,280 --> 01:48:00,160 I SEE ANDY. 2718 01:48:00,160 --> 01:48:02,760 >>THIS IS EXCITING. 2719 01:48:02,760 --> 01:48:05,400 THERE IS REALLY A HEART FOR NEW 2720 01:48:05,400 --> 01:48:07,600 RESEARCH TO HAPPEN WITH NATURAL 2721 01:48:07,600 --> 01:48:09,240 PRODUCTS BECAUSE, YOU KNOW, THE 2722 01:48:09,240 --> 01:48:10,520 DEMAND FOR THOSE TRADITIONAL R01 2723 01:48:10,520 --> 01:48:12,000 STUDY SECTIONS ARE SUCH YOU HAVE 2724 01:48:12,000 --> 01:48:16,120 TO BE VERY, VERY DEEP INTO A FEW 2725 01:48:16,120 --> 01:48:20,480 AGENTS TO GET ANY TRACTION. 2726 01:48:20,480 --> 01:48:25,240 BUT ONE, SEEMS LIKE THIS PROGRAM 2727 01:48:25,240 --> 01:48:26,760 WOULD BE REWARDING, FOR 2728 01:48:26,760 --> 01:48:29,160 INVESTIGATORS AND GROUPS THAT 2729 01:48:29,160 --> 01:48:31,000 HAVE A PRE-DEFINED MOLECULAR 2730 01:48:31,000 --> 01:48:32,320 TARGET IN MIND, LIKE REALLY FEEL 2731 01:48:32,320 --> 01:48:34,600 IT'S GOING TO BE THE KEY TARGET, 2732 01:48:34,600 --> 01:48:36,400 BUT A LOT OF THESE NATURAL 2733 01:48:36,400 --> 01:48:43,160 PRODUCTS WITH NOT GOING TO HAVE 2734 01:48:43,160 --> 01:48:44,360 SINGLE MOLECULAR TARGETS, 2735 01:48:44,360 --> 01:48:47,360 OFFER-TARGET EFFECTS BUT STILL 2736 01:48:47,360 --> 01:48:49,400 POTENTIALLY PREVENTIVE FOR 2737 01:48:49,400 --> 01:48:50,160 CANCER, SUCCESSFUL PREVENTION 2738 01:48:50,160 --> 01:48:50,520 AGENTS. 2739 01:48:50,520 --> 01:48:53,480 WHAT'S THE THOUGHT ABOUT 2740 01:48:53,480 --> 01:48:56,120 ADDRESSING THAT KIND OF 2741 01:48:56,120 --> 01:48:56,960 POTENTIAL PROPOSAL? 2742 01:48:56,960 --> 01:49:00,040 HOW CAN WE ALSO ENSURE THAT THE 2743 01:49:00,040 --> 01:49:01,360 RIGHT KINDS OF NATURAL PRODUCTS 2744 01:49:01,360 --> 01:49:03,840 GET PUSHED FORWARD THAT MIGHT 2745 01:49:03,840 --> 01:49:04,760 HAVE LESS CLEAR MOLECULAR 2746 01:49:04,760 --> 01:49:07,920 MECHANISM BUT STILL MIGHT BE 2747 01:49:07,920 --> 01:49:15,640 EFFECTIVE AGENTS? 2748 01:49:15,640 --> 01:49:16,520 >>YEAH, YOU STATED CORRECTLY, 2749 01:49:16,520 --> 01:49:18,280 THEY DON'T HAVE A SINGLE TARGET, 2750 01:49:18,280 --> 01:49:21,360 THE IDEA IS TO SELECT A 2751 01:49:21,360 --> 01:49:22,480 CLINICALLY RELEVANT VALID TARGET 2752 01:49:22,480 --> 01:49:24,120 FOR INTERVENTION AND SCREEN THE 2753 01:49:24,120 --> 01:49:33,400 AGENTS FOR THE TARGET. 2754 01:49:33,400 --> 01:49:34,960 AND SCREENING AGENTS MAY HAVE 2755 01:49:34,960 --> 01:49:39,360 OTHER EFFECTS BUT WE'LL NOT KNOW 2756 01:49:39,360 --> 01:49:44,600 UNTIL WE GO AND EVALUATE THEM 2757 01:49:44,600 --> 01:49:45,680 WITH OTHER ASSAYS, SO BUT WILL 2758 01:49:45,680 --> 01:49:50,720 ASK FOR THE P.I.s TO COME WITH 2759 01:49:50,720 --> 01:49:52,240 CLINICALLY DEVELOPED TARGETS BUT 2760 01:49:52,240 --> 01:50:02,720 THOSE AGENTS HAVE OTHER EFFECTS 2761 01:50:02,720 --> 01:50:05,680 TOO, YEAH. 2762 01:50:05,680 --> 01:50:07,760 >>INTERESTING PROPOSAL, MY 2763 01:50:07,760 --> 01:50:10,080 QUESTION IS IT STRIKES ME A LOT 2764 01:50:10,080 --> 01:50:12,120 MUST BE INVESTED IN MAINTAINING 2765 01:50:12,120 --> 01:50:15,680 THIS LIBRARY, WE'RE GOING TO 2766 01:50:15,680 --> 01:50:17,600 INVEST MORE. 2767 01:50:17,600 --> 01:50:21,240 WHAT'S THE TRACK RECORD THAT 2768 01:50:21,240 --> 01:50:24,400 INDICATES THERE ARE ACTUALLY 2769 01:50:24,400 --> 01:50:27,040 VIABLE COMPOUNDS IN THIS LIBRARY 2770 01:50:27,040 --> 01:50:29,320 THAT CAN TURN INTO WHAT IS BEING 2771 01:50:29,320 --> 01:50:30,200 SOUGHT HERE? 2772 01:50:30,200 --> 01:50:32,840 AND WHY IS THIS SPECIFIC FOCUS, 2773 01:50:32,840 --> 01:50:35,240 WHY IS THERE SOMETHING SPECIAL 2774 01:50:35,240 --> 01:50:41,080 ABOUT NATURAL PRODUCTS THAT ARE 2775 01:50:41,080 --> 01:50:41,720 BEING CONSIDERED FOR 2776 01:50:41,720 --> 01:50:46,080 INTERCEPTION? 2777 01:50:46,080 --> 01:50:48,280 >>CAN I JUMP IN AND THEN I'LL 2778 01:50:48,280 --> 01:50:49,880 TURN IT OVER TO BARRY TO TALK 2779 01:50:49,880 --> 01:50:50,600 ABOUT SUCCESSES. 2780 01:50:50,600 --> 01:50:54,840 THIS IS ONE PLACE TO START, 2781 01:50:54,840 --> 01:50:55,440 CERTAINLY OTHER CHEMICAL 2782 01:50:55,440 --> 01:50:56,280 LIBRARIES COULD BE CONSIDERED 2783 01:50:56,280 --> 01:50:57,480 GOING DOWN. 2784 01:50:57,480 --> 01:50:58,720 WE'VE NEVER DONE THIS BEFORE. 2785 01:50:58,720 --> 01:51:05,520 I WANTED TO TAKE ADVANTAGE OF 2786 01:51:05,520 --> 01:51:06,360 RELATIONSHIPS WITH NCATS, 2787 01:51:06,360 --> 01:51:08,120 DEVELOPMENT OF NATURAL PRODUCTS, 2788 01:51:08,120 --> 01:51:10,960 THIS COULD BE CONSIDERED FOR 2789 01:51:10,960 --> 01:51:14,480 OTHER MOLECULAR ENTITIES, ALSO 2790 01:51:14,480 --> 01:51:16,760 COULD BE CONSIDERED FOR OTHER 2791 01:51:16,760 --> 01:51:17,080 APPLICATIONS. 2792 01:51:17,080 --> 01:51:18,600 I DON'T WANT TO SAY TOO MUCH, 2793 01:51:18,600 --> 01:51:22,600 BUT I'VE BEEN THINKING ABOUT 2794 01:51:22,600 --> 01:51:25,280 THIS IN A COUPLE OTHER SPACES. 2795 01:51:25,280 --> 01:51:26,520 BARRY CAN SPEAK ABOUT SPECIFIC 2796 01:51:26,520 --> 01:51:28,360 SUCCESSS OF THE PROGRAM. 2797 01:51:28,360 --> 01:51:30,240 HE PRESENTED THIS I WANT TO SAY 2798 01:51:30,240 --> 01:51:32,600 A YEAR AGO, MAYBE IT WAS A YEAR 2799 01:51:32,600 --> 01:51:35,400 AGO ABOUT WHAT THEY'VE DONE SO 2800 01:51:35,400 --> 01:51:38,120 FAR IN TERMS OF THE -- YOU KNOW, 2801 01:51:38,120 --> 01:51:41,240 THEY HAVE WORKED ON TREATMENT 2802 01:51:41,240 --> 01:51:42,320 AND THAT SPACE. 2803 01:51:42,320 --> 01:51:43,880 BARRY, MAYBE YOU COULD JUMP IN 2804 01:51:43,880 --> 01:51:45,520 AND TALK ABOUT THINGS THAT 2805 01:51:45,520 --> 01:51:47,360 HAPPENED OF HAVE BEEN SUCCESSFUL 2806 01:51:47,360 --> 01:51:49,120 FROM THIS LIBRARY. 2807 01:51:49,120 --> 01:51:49,360 >>SURE. 2808 01:51:49,360 --> 01:51:50,320 HAPPY TO. 2809 01:51:50,320 --> 01:51:52,800 SO THE LAST TIME WHEN I WAS ABLE 2810 01:51:52,800 --> 01:51:57,080 TO PRESENT THIS TOO THE NCAB WE 2811 01:51:57,080 --> 01:51:59,080 WEREN'T ABLE TO TELL SOME THINGS 2812 01:51:59,080 --> 01:51:59,640 BECAUSE IT WAS PUBLIC 2813 01:51:59,640 --> 01:52:00,960 DISSEMINATION OF THEM. 2814 01:52:00,960 --> 01:52:05,000 I CAN GIVE SOME RECENT THINGS, 2815 01:52:05,000 --> 01:52:07,400 FOR EXAMPLE, ANTI-CANCER AGENT 2816 01:52:07,400 --> 01:52:10,680 THAT WE'VE WORKED WITH, BAYLOR 2817 01:52:10,680 --> 01:52:11,800 UNIVERSITY, TEXAS CHILDREN'S, 2818 01:52:11,800 --> 01:52:14,640 FOUND A NEW NATURAL PRODUCT WE 2819 01:52:14,640 --> 01:52:17,920 WERE ABLE TO RESUPPLY IN 2820 01:52:17,920 --> 01:52:20,200 QUANTITY SHRINKING TUMORS IN 2821 01:52:20,200 --> 01:52:20,920 THEIR HANDS, ISOLATELY RECENTLY 2822 01:52:20,920 --> 01:52:23,840 THAT HAS GONE TO CLINIC 2823 01:52:23,840 --> 01:52:25,360 ANTI-SARS-COV-2 AGENTS THAT HAVE 2824 01:52:25,360 --> 01:52:27,680 BEEN SUCCESSFUL IN PHASE 1, 2825 01:52:27,680 --> 01:52:29,640 INITIAL STUDIES THERE. 2826 01:52:29,640 --> 01:52:33,240 THOSE ARE BIOLOGICS, SMALL 2827 01:52:33,240 --> 01:52:34,560 PROTEINS AND PEPTIDES. 2828 01:52:34,560 --> 01:52:36,640 ALSO RECENT DISCOVERIES OF NOVEL 2829 01:52:36,640 --> 01:52:40,040 KINASE INHIBITORS ASSOCIATED FOR 2830 01:52:40,040 --> 01:52:41,880 YOURS WITH FOHCC, IN DEVELOPMENT 2831 01:52:41,880 --> 01:52:44,960 IN THE CCR AS WELL, AGAIN A 2832 01:52:44,960 --> 01:52:46,720 NOVEL NATURAL PRODUCT. 2833 01:52:46,720 --> 01:52:48,280 OVERALL WE'RE SEEING AND WE'RE 2834 01:52:48,280 --> 01:52:49,760 COLLABORATING WITH A LOT OF 2835 01:52:49,760 --> 01:52:55,480 LABORATORIES IN THE THEY ARE -- 2836 01:52:55,480 --> 01:52:56,760 THERAPEUTIC AREA, THEY MIGHT 2837 01:52:56,760 --> 01:53:01,800 HAVE BEEN SCREENED IN CY TOE 2838 01:53:01,800 --> 01:53:03,800 TOXICITY SCREENS, 80% THAT WE'RE 2839 01:53:03,800 --> 01:53:07,520 IDENTIFYING AS ACTIVE ARE NOT 2840 01:53:07,520 --> 01:53:11,080 ACTIVE WHEN CRUDE EXTRACT WAS 2841 01:53:11,080 --> 01:53:13,240 TESTED, A LOT OF CHEMISTRY WAS 2842 01:53:13,240 --> 01:53:18,560 EARLIER MISSED IN ASSAYS. 2843 01:53:18,560 --> 01:53:19,440 MOSTLY LOOKING AT CYTOTOXICITY, 2844 01:53:19,440 --> 01:53:21,400 TRYING TO GET INTO MODALITIES 2845 01:53:21,400 --> 01:53:22,920 NOT JUST KILLING CELLS BUT 2846 01:53:22,920 --> 01:53:24,120 LOOKING AT BROADER MODALITIES 2847 01:53:24,120 --> 01:53:25,560 WITH DIFFERENT TARGETS. 2848 01:53:25,560 --> 01:53:28,120 WE THINK CHEMICAL DIVERSITY 2849 01:53:28,120 --> 01:53:29,200 PRESENT IN THIS LIBRARY WILL 2850 01:53:29,200 --> 01:53:32,040 ENABLE US TO SEE TARGETS 2851 01:53:32,040 --> 01:53:32,440 ADDRESSED HERE IN 2852 01:53:32,440 --> 01:53:33,720 CHEMOPREVENTION THAT WOULD HAVE 2853 01:53:33,720 --> 01:53:36,440 BEEN MISSED OTHERWISE OR HAVEN'T 2854 01:53:36,440 --> 01:53:42,240 BEEN LOOKED AT TO BE HONEST. 2855 01:53:42,240 --> 01:53:45,880 2856 01:53:45,880 --> 01:53:46,880 >>MIKE AND DAVE? 2857 01:53:46,880 --> 01:53:48,120 >>WHO GOES FIRST? 2858 01:53:48,120 --> 01:53:48,440 >>MIKE. 2859 01:53:48,440 --> 01:53:49,360 >>THIS WAS INTERESTING BECAUSE 2860 01:53:49,360 --> 01:53:51,680 I DO THINK THE DRUM BEAT OF 2861 01:53:51,680 --> 01:53:55,360 USING NATURAL PRODUCTS IS UPON 2862 01:53:55,360 --> 01:53:55,920 US. 2863 01:53:55,920 --> 01:53:57,120 CAN'T BE IGNORED. 2864 01:53:57,120 --> 01:53:59,400 KUDOS ON THIS WORK. 2865 01:53:59,400 --> 01:54:01,960 THE QUESTION, THERE IS AN NIH 2866 01:54:01,960 --> 01:54:03,240 CENTER AND INSTITUTE THAT'S 2867 01:54:03,240 --> 01:54:05,360 LEADING THE WAY WITH THE SCIENCE 2868 01:54:05,360 --> 01:54:08,840 IN THIS AREA, AND CONNECTIVITY. 2869 01:54:08,840 --> 01:54:13,640 I WONDER WHAT NCI'S PLANS ARE TO 2870 01:54:13,640 --> 01:54:14,440 COLLABORATE INTERAGENCY IN THIS 2871 01:54:14,440 --> 01:54:16,520 AREA? 2872 01:54:16,520 --> 01:54:19,240 >>I GUESS I CAN SPEAK TO THAT A 2873 01:54:19,240 --> 01:54:20,080 LITTLE BIT SINCE WE'RE KIND OF 2874 01:54:20,080 --> 01:54:23,280 AT THE NEXUS OF THAT. 2875 01:54:23,280 --> 01:54:25,920 WE ALREADY HAVE INTERAGENCY 2876 01:54:25,920 --> 01:54:27,000 AGREEMENT WAS NIAID, NCCIH, 2877 01:54:27,000 --> 01:54:29,520 NCATS ON A NUMBER OF DIFFERENT 2878 01:54:29,520 --> 01:54:32,800 MODALITIES FOR A NUMBER OF 2879 01:54:32,800 --> 01:54:33,600 HEALTH-RELATED SCREENING AND 2880 01:54:33,600 --> 01:54:34,560 COMPOUND IDENTIFICATION. 2881 01:54:34,560 --> 01:54:36,520 WE ARE MAKING DATA. 2882 01:54:36,520 --> 01:54:40,360 WE WILL BE PART OF THE NATURAL 2883 01:54:40,360 --> 01:54:42,400 PRODUCT OPEN DATABASE OF NMR 2884 01:54:42,400 --> 01:54:45,280 STRUCTURAL DATA THAT IS BEING 2885 01:54:45,280 --> 01:54:47,240 FUNDED BY NCCIH TO ENABLE 2886 01:54:47,240 --> 01:54:48,120 RESEARCHERS AROUND THE WORLD TO 2887 01:54:48,120 --> 01:54:50,840 HAVE ACCESS TO ALL THE DATA ON 2888 01:54:50,840 --> 01:54:52,280 THE COMPOUND STRUCTURES AND NMR 2889 01:54:52,280 --> 01:54:54,680 DATA FOR THAT AS WELL. 2890 01:54:54,680 --> 01:54:56,680 SO WE HAVE COLLABORATED WITH A 2891 01:54:56,680 --> 01:54:59,160 NUMBER OF DIFFERENT GOVERNMENT 2892 01:54:59,160 --> 01:55:00,400 AGENCIES, INCLUDING DoD, ON 2893 01:55:00,400 --> 01:55:02,920 THIS ALREADY AND HAPPY TO DO SO. 2894 01:55:02,920 --> 01:55:04,000 WE'VE WORKED OUT FACILE 2895 01:55:04,000 --> 01:55:08,560 MECHANISMS TO ENABLE US TO DO 2896 01:55:08,560 --> 01:55:11,360 EXACTLY THAT. 2897 01:55:11,360 --> 01:55:12,200 >>THANK YOU. 2898 01:55:12,200 --> 01:55:13,880 >>I APPRECIATE THE PRESENTATION 2899 01:55:13,880 --> 01:55:14,520 AND TOPIC. 2900 01:55:14,520 --> 01:55:16,800 SOME OF THE MEMBERS HAVE SAID, 2901 01:55:16,800 --> 01:55:19,760 MOST NATURAL PRODUCTS ARE POLY 2902 01:55:19,760 --> 01:55:20,560 PHARMACEUTICALS, AND THIS IS 2903 01:55:20,560 --> 01:55:22,920 WHAT'S MADE IT EXTREMELY 2904 01:55:22,920 --> 01:55:25,960 CHALLENGING TO MAKE A LOT OF 2905 01:55:25,960 --> 01:55:27,880 PROGRESS RAPIDLY. 2906 01:55:27,880 --> 01:55:30,080 I THINK SOME POINTS BARRY 2907 01:55:30,080 --> 01:55:32,840 BROUGHT UP ABOUT ACTUALLY HAVING 2908 01:55:32,840 --> 01:55:33,920 PURIFIED COMPONENTS FROM 2909 01:55:33,920 --> 01:55:35,160 EXTRACTS WERE TERRIFIC BUT IT 2910 01:55:35,160 --> 01:55:39,400 COMES BACK TO STILL A VERY LARGE 2911 01:55:39,400 --> 01:55:42,040 MOLECULE WITH MULTIPLE CENTERS 2912 01:55:42,040 --> 01:55:45,640 AND A MESSY EXPERIMENT. 2913 01:55:45,640 --> 01:55:46,760 THE SCREENING, PHENOTYPIC 2914 01:55:46,760 --> 01:55:48,560 SCREENINGS, THEY ARE AMAZING, 2915 01:55:48,560 --> 01:55:50,600 GREAT, BETTER THAN KILLING 2916 01:55:50,600 --> 01:55:55,400 CELLS, STOPPING CELL 2917 01:55:55,400 --> 01:55:56,360 PROLIFERATION. 2918 01:55:56,360 --> 01:55:57,240 ONE STEP FURTHER, THE NOBEL 2919 01:55:57,240 --> 01:56:00,200 PRIZE WAS GIVEN TEN HOURS AGO 2920 01:56:00,200 --> 01:56:01,480 FOR CLICK CHEMISTRY, HOW YOU 2921 01:56:01,480 --> 01:56:03,560 TAKE NATURAL PRODUCTS TO THAT 2922 01:56:03,560 --> 01:56:05,920 NEXT LEVEL WHERE YOU CAN 2923 01:56:05,920 --> 01:56:09,400 ACTUALLY FIGURE OUT EXACTLY WHAT 2924 01:56:09,400 --> 01:56:10,800 PROTEINS YOUR MOLECULES ARE 2925 01:56:10,800 --> 01:56:13,000 INTERACTING WITH AND DO 2926 01:56:13,000 --> 01:56:14,200 ITERATIVE CHEMISTRY TO FIND A 2927 01:56:14,200 --> 01:56:14,960 GOOD MOLECULE THAT SOMEONE'S 2928 01:56:14,960 --> 01:56:17,600 GOING TO PUT IN A PATIENT. 2929 01:56:17,600 --> 01:56:19,440 I DIDN'T HEAR ANYTHING ABOUT NEW 2930 01:56:19,440 --> 01:56:21,680 CHEMISTRY THAT YOU COULD APPLY 2931 01:56:21,680 --> 01:56:23,960 TO YOUR REALLY GREAT BESPOKE 2932 01:56:23,960 --> 01:56:24,920 COLLECTION, I WOULD ENCOURAGE 2933 01:56:24,920 --> 01:56:27,440 YOU TO PUT THAT LANGUAGE IN AND 2934 01:56:27,440 --> 01:56:34,080 YOU HAVE PEOPLE AT THE NCI, FRED 2935 01:56:34,080 --> 01:56:35,080 RICK, THE RAS PROGRAM, GET IT TO 2936 01:56:35,080 --> 01:56:38,280 THE NEXT LEVEL WHERE YOU MIGHT 2937 01:56:38,280 --> 01:56:40,120 HAVE A BIGGER IMPACT. 2938 01:56:40,120 --> 01:56:44,520 >>THANK YOU. 2939 01:56:44,520 --> 01:56:47,920 2940 01:56:47,920 --> 01:56:49,240 LET'S MOVE TO VOTING. 2941 01:56:49,240 --> 01:56:54,720 MAKING SURE THERE'S NO RESIDUAL 2942 01:56:54,720 --> 01:56:55,440 HANDS UP. 2943 01:56:55,440 --> 01:57:03,920 >>I'D LIKE TO MOTION TO MOVE 2944 01:57:03,920 --> 01:57:10,920 THE CONCEPT FORWARD. 2945 01:57:10,920 --> 01:57:12,480 >>ANY FURTHER DISCUSSION? 2946 01:57:12,480 --> 01:57:20,000 HEARING NONE, MOTION IS TO 2947 01:57:20,000 --> 01:57:20,240 APPROVE 2948 01:57:20,240 --> 01:57:21,320 , LOOKING FOR DISAPPROVAL BY 2949 01:57:21,320 --> 01:57:24,160 RAISE OF HAND OR VOICE. 2950 01:57:24,160 --> 01:57:27,000 SEEING AND HEARING NONE, I HAVE 2951 01:57:27,000 --> 01:57:28,680 NO ABSTENTIONS ON RECORD. 2952 01:57:28,680 --> 01:57:35,840 AND ANYONE NEEDS TO ABSTAIN NOW 2953 01:57:35,840 --> 01:57:41,480 PLEASE SAY SO. 2954 01:57:41,480 --> 01:57:41,880 NO. 2955 01:57:41,880 --> 01:57:42,280 OKAY, PAULETTE. 2956 01:57:42,280 --> 01:57:43,080 >>YOU'RE GOOD. 2957 01:57:43,080 --> 01:57:47,920 >>THE THIRD CONCEPT IS A 2958 01:57:47,920 --> 01:57:48,800 REISSUANCE RFA/COOPERATIVE 2959 01:57:48,800 --> 01:57:51,440 AGREEMENT, BLOOD AND MARROW 2960 01:57:51,440 --> 01:57:53,840 TRANSPLANT CLINICAL TRIALS 2961 01:57:53,840 --> 01:58:04,400 NETWORK, BMT CTN, LORI HENDERSON 2962 01:58:07,040 --> 01:58:07,400 PRESENTING. 2963 01:58:07,400 --> 01:58:09,040 THE SUBCOMMITTEE REVIEWED THIS 2964 01:58:09,040 --> 01:58:10,920 PROPOSAL AND DISCUSSED WITH THE 2965 01:58:10,920 --> 01:58:11,320 TEAM. 2966 01:58:11,320 --> 01:58:14,640 AS WE DO FOR ALL REISSUANCES, 2967 01:58:14,640 --> 01:58:16,280 DISCLOSE THAT GOING INTO THE 2968 01:58:16,280 --> 01:58:18,040 PRESENTATION AND DISCUSSION THAT 2969 01:58:18,040 --> 01:58:18,800 THE SUBCOMMITTEE'S 2970 01:58:18,800 --> 01:58:21,640 RECOMMENDATION IS FOR 2971 01:58:21,640 --> 01:58:24,400 CONCURRENCE AND PRESENTATION OF 2972 01:58:24,400 --> 01:58:27,160 THE PROPOSAL TO REISSUE. 2973 01:58:27,160 --> 01:58:30,400 SO LET'S GO AHEAD, LORI, WITH 2974 01:58:30,400 --> 01:58:31,320 YOUR PRESENTATION. 2975 01:58:31,320 --> 01:58:31,680 >>THANK YOU. 2976 01:58:31,680 --> 01:58:36,360 THE PURPOSE OF MY PRESENTATION 2977 01:58:36,360 --> 01:58:37,760 TO REQUEST FUNDS TO SUPPORT 2978 01:58:37,760 --> 01:58:39,720 CONTINUE WAILINGS OF THE BLOOD 2979 01:58:39,720 --> 01:58:41,560 AND MARROW TRANSPLANT CLINICAL 2980 01:58:41,560 --> 01:58:44,360 TRIALS NETWORK, THIS WOULD BE 2981 01:58:44,360 --> 01:58:47,720 FOR ANOTHER SEVEN YEARS. 2982 01:58:47,720 --> 01:58:49,360 BMT CTN WAS ESTABLISHED BY 2983 01:58:49,360 --> 01:58:54,120 NATIONAL HEART LUNG AND BLOOD 2984 01:58:54,120 --> 01:58:56,600 INSTITUTE, AND NCI, BACK IN 2985 01:58:56,600 --> 01:58:57,560 2001. 2986 01:58:57,560 --> 01:59:00,560 AND CURRENTLY FUNDED THROUGH 2987 01:59:00,560 --> 01:59:01,960 COOPERATIVE AGREEMENT, TWO 2988 01:59:01,960 --> 01:59:02,840 RFAs, ONE FOR DATA 2989 01:59:02,840 --> 01:59:04,920 COORDINATING CENTER, AND THE 2990 01:59:04,920 --> 01:59:07,800 OTHER TO SUPPORT CORE CLINICAL 2991 01:59:07,800 --> 01:59:08,320 CENTERS. 2992 01:59:08,320 --> 01:59:13,040 SINCE TIME IS LIMITED, I'LL JUST 2993 01:59:13,040 --> 01:59:16,680 BRIEFLY INTRODUCE THE BMT CTN, 2994 01:59:16,680 --> 01:59:17,840 DESCRIBE ACCOMPLISHING, 2995 01:59:17,840 --> 01:59:20,600 HIGHLIGHT RESEARCH AREAS THAT 2996 01:59:20,600 --> 01:59:24,560 REQUIRE REISSUANCE OF THE TWO 2997 01:59:24,560 --> 01:59:25,960 RFAs. 2998 01:59:25,960 --> 01:59:29,360 NEXT SLIDE PLEASE. 2999 01:59:29,360 --> 01:59:31,480 THE BMT CTN EMERGED AS NATIONAL 3000 01:59:31,480 --> 01:59:34,840 LEADER IN DESIGNING AND 3001 01:59:34,840 --> 01:59:35,680 SUCCESSFULLY CONDUCTING 3002 01:59:35,680 --> 01:59:37,760 TRANSPLANT TRIALS. 3003 01:59:37,760 --> 01:59:39,440 THIS IS DUE LARGELY TO 3004 01:59:39,440 --> 01:59:41,600 STRUCTURAL, HOW IT ACTUALLY 3005 01:59:41,600 --> 01:59:42,400 FUNCTIONS, AND THE CONTRIBUTIONS 3006 01:59:42,400 --> 01:59:45,120 TO THE FIELD THAT HAVE BEEN 3007 01:59:45,120 --> 01:59:46,000 MADE. 3008 01:59:46,000 --> 01:59:48,840 ITS GOAL IS TO CONDUCT PHASE 2 3009 01:59:48,840 --> 01:59:52,360 AND 3 TRIALS, THIS IS TO IMPROVE 3010 01:59:52,360 --> 01:59:55,080 OUTCOMES IN CELLULAR THERAPIES, 3011 01:59:55,080 --> 01:59:56,920 SUCH AS HEMATOPOIETIC STEM CELL 3012 01:59:56,920 --> 01:59:58,480 TRANSPLANTATION, WHICH I'LL 3013 01:59:58,480 --> 02:00:04,400 REFER TO AS HCT THROUGHOUT MY 3014 02:00:04,400 --> 02:00:05,920 TALK, CELLULAR VACCINES, CAR T 3015 02:00:05,920 --> 02:00:08,560 CELL THERAPIES TO TREAT PATIENTS 3016 02:00:08,560 --> 02:00:12,160 THAT ARE FACING LIFE-THREATENING 3017 02:00:12,160 --> 02:00:13,920 BLOOD DISORDERS. 3018 02:00:13,920 --> 02:00:15,440 MANY TRIALS IN PORTFOLIO ADDRESS 3019 02:00:15,440 --> 02:00:19,120 CHALLENGES IN THE TREATMENT AND 3020 02:00:19,120 --> 02:00:20,680 MANAGEMENT OF HEMATOLOGIC 3021 02:00:20,680 --> 02:00:23,440 MALIGNANCIES THAT CAN'T BE 3022 02:00:23,440 --> 02:00:24,520 REPLICATED ELSEWHERE. 3023 02:00:24,520 --> 02:00:26,400 THE TEAM CONSISTS OF WORLD 3024 02:00:26,400 --> 02:00:29,880 LEADERS THAT HAVE EVOLVED TO 3025 02:00:29,880 --> 02:00:31,440 MEET CURRENT MEDICAL RESEARCH 3026 02:00:31,440 --> 02:00:33,440 NEEDS AND HAVE THE EXPERTISE TO 3027 02:00:33,440 --> 02:00:36,920 IMPLEMENT CAR T CELL THERAPIES. 3028 02:00:36,920 --> 02:00:40,320 THE NETWORK HAS BECOME THE ONLY 3029 02:00:40,320 --> 02:00:44,760 U.S. GROUP FOCUSING EXCLUSIVELY 3030 02:00:44,760 --> 02:00:48,080 ON ALLOGENEIC HCT. 3031 02:00:48,080 --> 02:00:50,040 THE CENTER MEMBERSHIP AND ACTIVE 3032 02:00:50,040 --> 02:00:50,880 PARTICIPATION IN TRIALS IS 3033 02:00:50,880 --> 02:00:54,200 AVAILABLE TO ALL U.S. CENTERS 3034 02:00:54,200 --> 02:01:02,200 THAT HAVE A FACT ACCREDITATION 3035 02:01:02,200 --> 02:01:02,480 STATUS. 3036 02:01:02,480 --> 02:01:04,560 THIS FEATURE ALLOWS SMALL 3037 02:01:04,560 --> 02:01:09,160 MEDICAL CENTERS AND CONSORTIA, 3038 02:01:09,160 --> 02:01:10,800 SMALL CONSORTIA TO PARTICIPATE 3039 02:01:10,800 --> 02:01:13,160 AND HELP UNDERREPRESENTED 3040 02:01:13,160 --> 02:01:16,160 COMMUNITIES GAIN AS SAYS TO 3041 02:01:16,160 --> 02:01:19,160 TRANSPLANT TRIALS, 75 AFFILIATE 3042 02:01:19,160 --> 02:01:23,480 MEMBERS INCLUDE SEVERAL 3043 02:01:23,480 --> 02:01:24,920 NON-ACADEMIC SITES. 3044 02:01:24,920 --> 02:01:27,120 IT CONVENES IN OPEN FORUM, 3045 02:01:27,120 --> 02:01:30,640 REFERRED TO AS STATE OF THE 3046 02:01:30,640 --> 02:01:31,920 SCIENCE SYMPOSIUM, ABOUT EVERY 3047 02:01:31,920 --> 02:01:37,920 FOUR YEARS TO SEEK INPUT ON THE 3048 02:01:37,920 --> 02:01:39,920 CLINICAL NEEDS, DEVELOP HCT 3049 02:01:39,920 --> 02:01:40,480 CONCEPT, AND ESTABLISH 3050 02:01:40,480 --> 02:01:47,280 PRIORITIES IN ORDER TO HAVE A 3051 02:01:47,280 --> 02:01:49,200 HIGH MERITORIOUS RESEARCH 3052 02:01:49,200 --> 02:01:49,440 AGENDA. 3053 02:01:49,440 --> 02:01:50,800 AND UPON COMPLETION OF THE 3054 02:01:50,800 --> 02:01:53,600 STUDIES THE RESULTS ARE USED TO 3055 02:01:53,600 --> 02:01:56,600 INFORM FUTURE TRIAL DESIGNS, 3056 02:01:56,600 --> 02:02:00,280 CLINICAL PRACTICE, AND CMS 3057 02:02:00,280 --> 02:02:04,240 COVERAGE WHICH BY CONDUCTING 3058 02:02:04,240 --> 02:02:07,000 EVIDENCE DEVELOPMENT TRIALS IN 3059 02:02:07,000 --> 02:02:08,240 CANCER. 3060 02:02:08,240 --> 02:02:13,120 LAST BUT NOT LEAST BMT CTN 3061 02:02:13,120 --> 02:02:14,680 PARTICIPATE OR ENDORSES TRIALS 3062 02:02:14,680 --> 02:02:16,840 AFFILIATED WITH OTHER NIH-FUNDED 3063 02:02:16,840 --> 02:02:19,720 PROGRAMS SUCH AS NCI NATIONAL 3064 02:02:19,720 --> 02:02:24,560 CLINICAL TRIALS NETWORK, AIDS 3065 02:02:24,560 --> 02:02:26,480 MALIGNANCY CONSORTIUM, AND NIH 3066 02:02:26,480 --> 02:02:27,400 SICKLE CELL ZEALS NETWORK, 3067 02:02:27,400 --> 02:02:32,600 SUPPORTING ITS OWN MISSION. 3068 02:02:32,600 --> 02:02:34,160 SEVERAL PHARMACEUTICAL COMPANIES 3069 02:02:34,160 --> 02:02:35,680 PROVIDE SUBSTANTIAL FINANCIAL 3070 02:02:35,680 --> 02:02:38,640 SUPPORT TO EVALUATE PROMISING 3071 02:02:38,640 --> 02:02:44,320 CELL THERAPIES AND DRUGS IN 3072 02:02:44,320 --> 02:02:44,560 TRIALS. 3073 02:02:44,560 --> 02:02:46,200 NEXT SLIDE PLEASE. 3074 02:02:46,200 --> 02:02:48,720 THE PROGRAM IS CURRENTLY FUNDED 3075 02:02:48,720 --> 02:02:51,760 TO PROMOTE THE COMPARISON OF 3076 02:02:51,760 --> 02:02:53,560 TREATMENT APPROACHES IN 3077 02:02:53,560 --> 02:02:55,880 MANAGEMENT STRATEGIES FOR ADULTS 3078 02:02:55,880 --> 02:02:56,600 AND CHILDREN UNDERGOING 3079 02:02:56,600 --> 02:02:59,360 TRANSPLANT, EITHER ALONE OR IN 3080 02:02:59,360 --> 02:03:01,200 COMBINATION WITH NOVEL 3081 02:03:01,200 --> 02:03:03,280 CELL-BASED THERAPIES, AREAS OF 3082 02:03:03,280 --> 02:03:13,840 HIGH PRIORITY TO NCI ARE STUDIES 3083 02:03:15,280 --> 02:03:16,480 TARGETING LEUKEMIA, MILD 3084 02:03:16,480 --> 02:03:17,840 DYSPLASIA, HIV ASSOCIATED 3085 02:03:17,840 --> 02:03:18,080 CANCERS. 3086 02:03:18,080 --> 02:03:28,040 IT HAS ADDRESSED KEY ISSUES IN 3087 02:03:28,040 --> 02:03:30,360 DONOR AVAILABILITY, MAINTENANCE 3088 02:03:30,360 --> 02:03:34,160 THERAPY FOR DISEASE CONTROL, 3089 02:03:34,160 --> 02:03:35,240 ORGAN AND REGIMEN-RELATED 3090 02:03:35,240 --> 02:03:37,200 TOXICITIES, AND QUALITY OF LIFE 3091 02:03:37,200 --> 02:03:38,080 STUDIES. 3092 02:03:38,080 --> 02:03:41,720 THIS HAS BEEN DONE THROUGH THE 3093 02:03:41,720 --> 02:03:44,320 IMPLEMENTATION OF 60 TRIALS OF 3094 02:03:44,320 --> 02:03:47,880 WHICH 52 ARE RELEVANT TO NCI'S 3095 02:03:47,880 --> 02:03:48,560 MISSION. 3096 02:03:48,560 --> 02:03:51,480 AND THE NETWORK HAS BEEN VERY 3097 02:03:51,480 --> 02:03:54,120 PRODUCTIVE IN ACTIVATING AND 3098 02:03:54,120 --> 02:03:56,720 COMPLETING TRIALS, 35 COMPLETED, 3099 02:03:56,720 --> 02:03:58,000 WITH 22 ONGOING. 3100 02:03:58,000 --> 02:04:01,400 AMONG THE MOST NOTABLE 3101 02:04:01,400 --> 02:04:04,560 ACHIEVEMENTS FROM THE RECENT 3102 02:04:04,560 --> 02:04:06,760 PROJECT PERIOD ARE THE 7500 3103 02:04:06,760 --> 02:04:09,480 PATIENTS ACCRUED WITH SEVERAL 3104 02:04:09,480 --> 02:04:11,920 STUDIES AHEAD OF SCHEDULE, 3105 02:04:11,920 --> 02:04:14,080 CONTRIBUTIONS TO THE NCTN 3106 02:04:14,080 --> 02:04:17,400 TRIALS, TRIAL RESULTS THAT ARE 3107 02:04:17,400 --> 02:04:19,440 DEFINING CLINICAL PRACTICES, AND 3108 02:04:19,440 --> 02:04:20,960 POTENTIAL IMPACT OF PUBLICATIONS 3109 02:04:20,960 --> 02:04:24,600 IN THE FIELD. 3110 02:04:24,600 --> 02:04:26,720 NETWORK PUBLISHED 148 PAPERS 3111 02:04:26,720 --> 02:04:30,280 WITH RESULTS FROM 42 TRIALS 3112 02:04:30,280 --> 02:04:31,600 DISSEMINATED TO DATE, INCLUDING 3113 02:04:31,600 --> 02:04:35,760 29 PUBLICATIONS RESULTING FROM 3114 02:04:35,760 --> 02:04:39,000 THE SAMPLE REPOSITORY. 3115 02:04:39,000 --> 02:04:41,640 NEXT SLIDE PLEASE. 3116 02:04:41,640 --> 02:04:44,600 AMONG THE MOST NOTABLE PUBLIC 3117 02:04:44,600 --> 02:04:45,800 HEALTH CONTRIBUTIONS TRIAL 3118 02:04:45,800 --> 02:04:47,440 RESULTS THAT DEFINE CLINICAL 3119 02:04:47,440 --> 02:04:48,760 PRACTICE, LED TO PARADIGM SHIFTS 3120 02:04:48,760 --> 02:04:52,040 IN THE MANAGEMENT OF MULTIPLE 3121 02:04:52,040 --> 02:04:52,560 MYELOMA. 3122 02:04:52,560 --> 02:04:54,480 MORE THAN 12,000 DEATHS ARE 3123 02:04:54,480 --> 02:04:59,480 EXPECTED TO OCCUR FROM AMONG THE 3124 02:04:59,480 --> 02:05:01,720 31,000 AMERICANS THAT ARE 3125 02:05:01,720 --> 02:05:04,200 DIAGNOSED WITH MYELOMA EACH YEAR 3126 02:05:04,200 --> 02:05:07,040 DESPITE TREATMENT ADVANCES OVER 3127 02:05:07,040 --> 02:05:09,240 THE YEARS. 3128 02:05:09,240 --> 02:05:12,640 THIS MULTIPLE MYELOMA STUDY, THE 3129 02:05:12,640 --> 02:05:17,160 BMT CTN CONDUCTED PHASE 3 3130 02:05:17,160 --> 02:05:19,200 RANDOMIZED TRIAL COMPARING 3131 02:05:19,200 --> 02:05:20,440 SINGLE AUTOLOGOUS TRANSPLANT 3132 02:05:20,440 --> 02:05:27,480 WITH AND WITHOUT CONSOLIDATION 3133 02:05:27,480 --> 02:05:29,280 THERAPY TO TANDEM TRANSPLANT. 3134 02:05:29,280 --> 02:05:32,600 THE RESULTS SHOW NO SIGNIFICANT 3135 02:05:32,600 --> 02:05:34,440 DIFFERENCES IN THE THREE-YEAR 3136 02:05:34,440 --> 02:05:35,520 PROGRESSION-FREE SURVIVAL AMONG 3137 02:05:35,520 --> 02:05:39,360 THE THREE ARMS, AND SO THE STUDY 3138 02:05:39,360 --> 02:05:41,680 ACTUALLY PROVIDED EVIDENCE THAT 3139 02:05:41,680 --> 02:05:44,840 THE CURRENT STATE OF CARE, THAT 3140 02:05:44,840 --> 02:05:47,120 IS SINGLE AUTOLOGOUS TRANSPLANT 3141 02:05:47,120 --> 02:05:49,440 WITH MAINTENANCE IS STILL THE 3142 02:05:49,440 --> 02:05:52,800 BEST OPTION FOR TREATING THESE 3143 02:05:52,800 --> 02:05:53,840 PATIENTS. 3144 02:05:53,840 --> 02:05:55,120 AND MORE IMPORTANTLY, LED TO 3145 02:05:55,120 --> 02:05:57,240 SUBSTANTIAL DECREASE IN NUMBER 3146 02:05:57,240 --> 02:05:59,840 OF UNNECESSARY INTERVENTIONS 3147 02:05:59,840 --> 02:06:00,960 BEING PERFORMED SINCE THE 3148 02:06:00,960 --> 02:06:05,640 PUBLICATION OF THE RESULTS. 3149 02:06:05,640 --> 02:06:06,840 NEXT SLIDE PLEASE. 3150 02:06:06,840 --> 02:06:12,640 IN THE SECOND MULTIPLE MYELOMA 3151 02:06:12,640 --> 02:06:16,240 EXAMPLE, THE BMT CTN JOINED 3152 02:06:16,240 --> 02:06:21,840 DANA-FARBER TO DETERMINE IF HIGH 3153 02:06:21,840 --> 02:06:24,360 DOSE THERAPY IS STILL NECESSARY 3154 02:06:24,360 --> 02:06:27,040 IN THE INITIAL MANAGEMENT GIVEN 3155 02:06:27,040 --> 02:06:29,640 THE FACT THERE ARE NEW NOVEL 3156 02:06:29,640 --> 02:06:31,680 IMMUNOMODULATORY BASED THERAPIES 3157 02:06:31,680 --> 02:06:33,280 THAT EXIST TODAY. 3158 02:06:33,280 --> 02:06:35,680 THIS PHASE 3 STUDY WAS DESIGNED 3159 02:06:35,680 --> 02:06:40,560 TO EVALUATE THE CLINICAL BENEFIT 3160 02:06:40,560 --> 02:06:47,800 FROM TRIPLET DRUG THERAPY 3161 02:06:47,800 --> 02:06:51,080 WITHOUT METE IMMEDIATE HIGH DOSE 3162 02:06:51,080 --> 02:06:56,240 THERAPY TO THE RVD PLUS HIGH 3163 02:06:56,240 --> 02:06:59,600 DOSE THERAPY AUTOLOGOUS HCT. 3164 02:06:59,600 --> 02:07:00,280 RANDOMIZED TRIAL EXAMINES 3165 02:07:00,280 --> 02:07:02,640 EFFICACY AND SAFETY OF THE FIRST 3166 02:07:02,640 --> 02:07:06,880 LINE TREATMENT, AND PRIMARY 3167 02:07:06,880 --> 02:07:10,840 ENDPOINT WAS PROGRESSION FREE 3168 02:07:10,840 --> 02:07:11,080 SURVIVAL. 3169 02:07:11,080 --> 02:07:14,560 I'M TRYING TO DETERMINE WHY THE 3170 02:07:14,560 --> 02:07:20,920 NEXT SLIDE -- OKAY. 3171 02:07:20,920 --> 02:07:21,480 OKAY. 3172 02:07:21,480 --> 02:07:25,400 SO, THE OUTCOME OF THE -- WE'VE 3173 02:07:25,400 --> 02:07:30,640 ADVANCED TO THE RESEARCH AGENDA 3174 02:07:30,640 --> 02:07:31,520 FOR REISSUANCE. 3175 02:07:31,520 --> 02:07:34,280 THE EXTERNAL EVALUATION OF 3176 02:07:34,280 --> 02:07:36,440 PROGRAM WAS ALSO SOUGHT TO 3177 02:07:36,440 --> 02:07:43,680 ACCEPT THE PROGRESS AND NEW 3178 02:07:43,680 --> 02:07:47,320 TRIALS BEING PERFORMED, THE 3179 02:07:47,320 --> 02:07:49,600 AGENDA IS DEFINED BY THE STATE 3180 02:07:49,600 --> 02:07:51,240 OF THE SCIENCE SYMPOSIUM. 3181 02:07:51,240 --> 02:07:58,160 YOU CAN SEE SOME RESEARCH TOPICS 3182 02:07:58,160 --> 02:07:59,760 BEING PROPOSED. 3183 02:07:59,760 --> 02:08:02,480 STRATEGIES AND TRIALS REPORTED 3184 02:08:02,480 --> 02:08:03,720 AS RELEVANT AND SIGNIFICANT 3185 02:08:03,720 --> 02:08:08,760 PROGRESS, SO THE PLAN IS TO LOOK 3186 02:08:08,760 --> 02:08:10,240 AT THE RECENTLY COMPLETED PHASE 3187 02:08:10,240 --> 02:08:13,360 3 TRIALS IN HIGH PRIORITY AREAS, 3188 02:08:13,360 --> 02:08:17,480 FOCUSING ON THESE TOPICS, THREE 3189 02:08:17,480 --> 02:08:21,520 NEW STUDIES, TO SUPPORT THREE 3190 02:08:21,520 --> 02:08:22,520 IMPORTANT NCTN COLLABORATIVE 3191 02:08:22,520 --> 02:08:24,160 STUDIES FOCUSING ON DIFFUSE 3192 02:08:24,160 --> 02:08:30,120 LARGE B CELL LYMPHOMA FOR GRADE 3193 02:08:30,120 --> 02:08:32,360 3 FOLLICULAR LYMPHOMA, AND 3194 02:08:32,360 --> 02:08:34,480 CLASSICAL HODGKIN'S LYMPHOMA. 3195 02:08:34,480 --> 02:08:37,440 THE NIH PROGRAM DIRECTOR WILL 3196 02:08:37,440 --> 02:08:41,160 CONTINUE TO PARTICIPATE IN THE 3197 02:08:41,160 --> 02:08:43,920 PROGRAM PROTOCOL TEAMS, SERVE AS 3198 02:08:43,920 --> 02:08:46,640 VOTING MEMBERS ON STEERING 3199 02:08:46,640 --> 02:08:49,480 EXECUTIVE COMMITTEE AND ENSURE 3200 02:08:49,480 --> 02:08:50,920 OVERALL MANAGEMENT TO ALLOW 3201 02:08:50,920 --> 02:08:52,080 PUBLIC/PRIVATE PARTNERSHIPS TO 3202 02:08:52,080 --> 02:08:57,040 DEVELOP WITH OUTSIDE FUNDS. 3203 02:08:57,040 --> 02:08:59,560 NEXT SLIDE PLEASE. 3204 02:08:59,560 --> 02:09:06,360 SO THE NCI BUDGET REQUEST IS TO 3205 02:09:06,360 --> 02:09:12,800 SUPPORT THE RENEWAL OF 3206 02:09:12,800 --> 02:09:13,600 $3.9 MILLION. 3207 02:09:13,600 --> 02:09:24,120 THE TOTAL SEVEN-YEAR COST WOULD 3208 02:09:25,560 --> 02:09:32,360 BE 27.3 MILLION, $5.38 MILLION 3209 02:09:32,360 --> 02:09:33,840 HAS BEEN APPROVED, TOTALING $81 3210 02:09:33,840 --> 02:09:35,720 MILLION, TO SUPPORT 19 AWARDS 3211 02:09:35,720 --> 02:09:38,160 INSTEAD OF 21 IN THE CURRENT 3212 02:09:38,160 --> 02:09:39,600 PROJECT PERIOD, 18 CLINICAL CORE 3213 02:09:39,600 --> 02:09:44,840 CENTERS. 3214 02:09:44,840 --> 02:09:46,040 NEXT SLIDE PLEASE. 3215 02:09:46,040 --> 02:09:47,760 THANK YOU FOR YOUR ATTENTION. 3216 02:09:47,760 --> 02:09:50,120 I'M HAPPY TO ANSWER QUESTIONS 3217 02:09:50,120 --> 02:09:58,480 AND APOLOGIZE FOR THE DISCONNECT 3218 02:09:58,480 --> 02:10:01,200 BETWEEN THE SLIDES. 3219 02:10:01,200 --> 02:10:07,240 3220 02:10:07,240 --> 02:10:14,360 3221 02:10:14,360 --> 02:10:17,840 >>DO YOU WANT ME TO JUMP IN? 3222 02:10:17,840 --> 02:10:19,720 >>GO AHEAD. 3223 02:10:19,720 --> 02:10:25,240 >>YEAH, SO I WITH DR. LA LOW 3224 02:10:25,240 --> 02:10:27,600 AND DR. ROBERTSON WERE ASKED TWO 3225 02:10:27,600 --> 02:10:30,000 QUESTIONS, ONE WOULD WE CONCUR 3226 02:10:30,000 --> 02:10:31,840 WITH THE REVIEW THAT HAD BEEN 3227 02:10:31,840 --> 02:10:34,160 TAKING PLACE BY A PANEL OF 3228 02:10:34,160 --> 02:10:35,720 EXPERTS, ANSWER WAS YES, SHOULD 3229 02:10:35,720 --> 02:10:38,640 IT BE PRESENTED HERE, AND WE 3230 02:10:38,640 --> 02:10:40,520 FELT IT WAS A VALUABLE REVIEW 3231 02:10:40,520 --> 02:10:42,160 FOR THIS GROUP TO HEAR ABOUT 3232 02:10:42,160 --> 02:10:43,800 THIS REALLY VALUABLE PROGRAM. 3233 02:10:43,800 --> 02:10:48,440 LET ME TELL YOU WE GOT TO LOOK 3234 02:10:48,440 --> 02:10:49,800 AT A SUMMARY OF THE ACTIVITIES 3235 02:10:49,800 --> 02:10:52,000 OF THE PROGRAM OVER THE LAST 3236 02:10:52,000 --> 02:10:53,320 PERIOD BUT ALSO REVIEW WHICH WAS 3237 02:10:53,320 --> 02:10:56,680 DONE BY A PANEL OF CONTENT 3238 02:10:56,680 --> 02:11:00,440 EXPERTS FROM CTEP WHO 3239 02:11:00,440 --> 02:11:01,080 UNANIMOUSLY RECOMMENDED THIS 3240 02:11:01,080 --> 02:11:03,840 CONTINUE, BASED ON THE SCIENCE 3241 02:11:03,840 --> 02:11:05,320 OF TRANSPLANTATION, PRACTICE 3242 02:11:05,320 --> 02:11:06,760 STANDARDS, AND IMPROVEMENTS IN 3243 02:11:06,760 --> 02:11:08,880 CLINICAL MANAGEMENT. 3244 02:11:08,880 --> 02:11:10,920 YOU HEARD ABOUT SOME OF THE 3245 02:11:10,920 --> 02:11:12,480 TRIALS THIS SUPPORTS, THIS 3246 02:11:12,480 --> 02:11:14,760 SUPPORTS IMPORTANT TRIALS THAT 3247 02:11:14,760 --> 02:11:16,160 CAN'T BE DONE IN ANY OTHER 3248 02:11:16,160 --> 02:11:19,560 MECHANISM AND I WANT TO GIVE YOU 3249 02:11:19,560 --> 02:11:22,000 A FLAVOR FOR THE REVIEW THAT 3250 02:11:22,000 --> 02:11:24,560 THEY RECEIVED BECAUSE I THINK WE 3251 02:11:24,560 --> 02:11:26,840 ALL WISH WE COULD GET REVIEWS 3252 02:11:26,840 --> 02:11:28,160 LIKE THIS. 3253 02:11:28,160 --> 02:11:29,880 PRODUCTIVITY, OUTSTANDING TO 3254 02:11:29,880 --> 02:11:30,200 EXCEPTIONAL. 3255 02:11:30,200 --> 02:11:32,520 THAT'S OVER THE COVID PERIOD OF 3256 02:11:32,520 --> 02:11:34,920 TIME, POINTING OUT THIS PROGRAM 3257 02:11:34,920 --> 02:11:40,920 OVER ITS ENTIRE LONGEVITY IS 3258 02:11:40,920 --> 02:11:41,240 EXCEPTIONAL. 3259 02:11:41,240 --> 02:11:43,240 IT GOT EXEMPLAR I'VE NEVER 3260 02:11:43,240 --> 02:11:44,760 HEARD, I'VE HEARD OUTSTANDING 3261 02:11:44,760 --> 02:11:48,160 AND EXCEPTIONAL, IT GOT STELLAR 3262 02:11:48,160 --> 02:11:51,720 AS A QUALIFIER FOR SELECTION AND 3263 02:11:51,720 --> 02:11:54,600 DEVELOPMENT OF CLINICAL TRIALS. 3264 02:11:54,600 --> 02:11:57,360 EXCEPTIONAL FOR OVERALL 3265 02:11:57,360 --> 02:11:57,600 STRUCTURE. 3266 02:11:57,600 --> 02:12:01,280 WE MET TO TALK ABOUT IT, WITH 3267 02:12:01,280 --> 02:12:03,680 DR. HENDERSON, A FEW PIECES OF 3268 02:12:03,680 --> 02:12:04,600 HOW THINGS HAPPENED WE THOUGHT 3269 02:12:04,600 --> 02:12:06,880 WE WOULD LIKE TO HEAR ABOUT, ALL 3270 02:12:06,880 --> 02:12:09,080 COVERED IN THE FIRST PART OF THE 3271 02:12:09,080 --> 02:12:10,840 PRESENTATION ASKING ABOUT HOW 3272 02:12:10,840 --> 02:12:13,560 MEMBERSHIP IS DECIDED, WHO GETS 3273 02:12:13,560 --> 02:12:16,720 TO BE INVOLVED, HOW THIS PROGRAM 3274 02:12:16,720 --> 02:12:17,720 REACHES UNDERSERVED POPULATIONS, 3275 02:12:17,720 --> 02:12:24,240 WANTED TO HEAR MORE HOW STATE OF 3276 02:12:24,240 --> 02:12:25,680 SCIENCE LEADS TO THE TRIALS, HOW 3277 02:12:25,680 --> 02:12:28,400 MUCH THAT HAPPENS AT THE HIP. 3278 02:12:28,400 --> 02:12:30,360 AND ALSO HOW FOUNDING 3279 02:12:30,360 --> 02:12:32,400 PARTNERSHIP WITH NHLBI IS. 3280 02:12:32,400 --> 02:12:34,040 THAT WAS COVERED, SO I CAN SPEAK 3281 02:12:34,040 --> 02:12:36,920 FOR THE COMMITTEE THAT WE DIDN'T 3282 02:12:36,920 --> 02:12:39,840 HAVE ANY CONCERNS AND WERE 3283 02:12:39,840 --> 02:12:40,680 IMPRESSED WITH THIS IMPORTANT 3284 02:12:40,680 --> 02:12:42,360 AND THOUGHT IT WAS IMPORTANT 3285 02:12:42,360 --> 02:12:43,840 EVERYONE KNOWS ABOUT IT. 3286 02:12:43,840 --> 02:12:46,240 >>THANK YOU. 3287 02:12:46,240 --> 02:12:50,160 ANYTHING TO ADD? 3288 02:12:50,160 --> 02:12:52,480 >>KIM DID A TERRIFIC JOB 3289 02:12:52,480 --> 02:12:53,240 SUMMARIZING. 3290 02:12:53,240 --> 02:12:54,240 THE COMMITTEE WAS UNANIMOUSLY IN 3291 02:12:54,240 --> 02:12:56,960 SUPPORT BECAUSE OF THE UNIQUE 3292 02:12:56,960 --> 02:12:57,960 ASPECTS THIS PROGRAM PROVIDES A 3293 02:12:57,960 --> 02:13:00,560 AS MUCH AS THAT CANNOT BE 3294 02:13:00,560 --> 02:13:03,120 SUBSUMED BY ANY OTHER TYPE OF 3295 02:13:03,120 --> 02:13:08,400 ENTITY WITHIN THE COUNTRY AND 3296 02:13:08,400 --> 02:13:09,480 PROVIDING -- CONDUCTING PHASE 2 3297 02:13:09,480 --> 02:13:11,120 AND PHASE 3 TRIALS THAT CAN 3298 02:13:11,120 --> 02:13:12,520 ACCUMULATE LARGE NUMBERS OF 3299 02:13:12,520 --> 02:13:17,040 PATIENTS AND HAVE IDENTIFIED A 3300 02:13:17,040 --> 02:13:18,440 NUMBER OF PARADIGM-SHIFTING 3301 02:13:18,440 --> 02:13:20,960 RESULTS THAT HAVE RESULTED IN 3302 02:13:20,960 --> 02:13:22,520 IMPROVEMENTS IN CELLULAR THERAPY 3303 02:13:22,520 --> 02:13:26,120 AND OUTCOMES FOR PATIENTS WITH 3304 02:13:26,120 --> 02:13:28,960 LEUKEMIA AND MYELOMA AND REDUCE 3305 02:13:28,960 --> 02:13:31,760 TOXICITY AS WELL AS EXPENSES, 3306 02:13:31,760 --> 02:13:33,320 IT'S A UNIQUE PROGRAM THAT'S 3307 02:13:33,320 --> 02:13:40,520 HAD, AS KIM SAID, STELLAR 3308 02:13:40,520 --> 02:13:42,720 RESULTS. 3309 02:13:42,720 --> 02:13:44,360 >>JUST TO MENTION LORI AND TEAM 3310 02:13:44,360 --> 02:13:45,880 DID A GREAT JOB RESPONDING TO 3311 02:13:45,880 --> 02:13:47,440 THINGS WE RAISED. 3312 02:13:47,440 --> 02:13:49,840 A WONDERFUL CONCEPT. 3313 02:13:49,840 --> 02:13:56,160 WE STRONGLY SUPPORT IT. 3314 02:13:56,160 --> 02:13:56,920 >>SAM? 3315 02:13:56,920 --> 02:14:00,000 >>A QUICK QUESTION HOW DATA ARE 3316 02:14:00,000 --> 02:14:00,760 COLLECTED, STANDARDIZED, 3317 02:14:00,760 --> 02:14:01,560 RELATIONSHIP BETWEEN THIS 3318 02:14:01,560 --> 02:14:05,040 PROGRAM AND THE DATA THAT ARE 3319 02:14:05,040 --> 02:14:05,920 COLLECTED BY THE CIBMTR AND 3320 02:14:05,920 --> 02:14:08,880 WONDERING HOW THE DATA ARE 3321 02:14:08,880 --> 02:14:11,000 COORDINATED AND THEN USED FOR 3322 02:14:11,000 --> 02:14:13,840 SECONDARY RESEARCH IF AT ALL. 3323 02:14:13,840 --> 02:14:16,640 THANK YOU. 3324 02:14:16,640 --> 02:14:21,760 >>THE DATA IS COORDINATED 3325 02:14:21,760 --> 02:14:22,200 THROUGH THE CIBMTR. 3326 02:14:22,200 --> 02:14:23,400 THERE ARE OPPORTUNITIES WHICH 3327 02:14:23,400 --> 02:14:26,440 YOU CAN REQUEST THE DATA TO DO 3328 02:14:26,440 --> 02:14:29,720 THE SECONDARY ANALYSES. 3329 02:14:29,720 --> 02:14:30,400 THERE'S SUPPORT AND DEVELOPMENT 3330 02:14:30,400 --> 02:14:33,480 OF THE DATASET WHICH TO ACHIEVE 3331 02:14:33,480 --> 02:14:33,680 THAT. 3332 02:14:33,680 --> 02:14:36,880 >>DO YOU KNOW IF THE DATA ARE 3333 02:14:36,880 --> 02:14:39,040 COLLECTED IN THE DICTIONARY 3334 02:14:39,040 --> 02:14:40,400 FORMAT OR TRANSFORMED AFTER 3335 02:14:40,400 --> 02:14:43,560 COLLECTION AND IF NOT THERE'S 3336 02:14:43,560 --> 02:14:44,160 CERTAINLY AN OPPORTUNITY THERE 3337 02:14:44,160 --> 02:14:46,040 TO HELP IMPROVE THE WAY DATA ARE 3338 02:14:46,040 --> 02:14:48,360 COLLECTED SO THAT IT'S EASIER TO 3339 02:14:48,360 --> 02:14:50,240 TRANSMIT AND DON'T HAVE TO 3340 02:14:50,240 --> 02:14:52,760 TRANSFORM, BUT THAT MAY BE A 3341 02:14:52,760 --> 02:14:53,320 SEPARATE ISSUE. 3342 02:14:53,320 --> 02:14:56,600 >>YEAH, I DON'T KNOW THAT 3343 02:14:56,600 --> 02:14:59,880 OFFHAND. 3344 02:14:59,880 --> 02:15:01,520 3345 02:15:01,520 --> 02:15:02,080 >>THANK YOU. 3346 02:15:02,080 --> 02:15:02,720 >>ANDREA? 3347 02:15:02,720 --> 02:15:07,640 >>AT RISK OF SOUNDING LIKE A 3348 02:15:07,640 --> 02:15:09,760 NAYSAYER, SEVEN YEARS AND A LOT 3349 02:15:09,760 --> 02:15:12,760 OF MONEY, WHAT IS THE PROCESS 3350 02:15:12,760 --> 02:15:14,760 FOR EVALUATION OR UPDATES I 3351 02:15:14,760 --> 02:15:17,600 GUESS, WILL WE BE ABLE TO 3352 02:15:17,600 --> 02:15:19,360 RECEIVE A THREE TO FIVE YEAR 3353 02:15:19,360 --> 02:15:21,440 REPORT OR ANNUAL REPORT OR HOW 3354 02:15:21,440 --> 02:15:28,320 IS IT GOING TO BE COMMUNICATED? 3355 02:15:28,320 --> 02:15:31,400 >>SO, AT THE PRESENT PROGRAM 3356 02:15:31,400 --> 02:15:32,800 STAFF RECEIVABLE PROGRESS 3357 02:15:32,800 --> 02:15:36,840 REPORTS, AND WE ALSO PARTICIPATE 3358 02:15:36,840 --> 02:15:38,880 IN THE STEERING AND EXECUTIVE 3359 02:15:38,880 --> 02:15:41,320 COMMITTEE MEETINGS WHERE WE HEAR 3360 02:15:41,320 --> 02:15:43,760 ABOUT THE PROGRESS AT LEAST 3361 02:15:43,760 --> 02:15:44,160 MONTHLY. 3362 02:15:44,160 --> 02:15:45,800 WHETHER OR NOT THAT GETS 3363 02:15:45,800 --> 02:15:48,440 CONVEYED TO THIS COMMITTEE IS I 3364 02:15:48,440 --> 02:15:49,000 THINK A SEPARATE QUESTION. 3365 02:15:49,000 --> 02:15:50,520 I DON'T THINK IT'S SOMETHING 3366 02:15:50,520 --> 02:15:55,760 WE'VE DONE IN THE PAST EXCEPT 3367 02:15:55,760 --> 02:15:57,280 FOR TIMES LOOKING TOWARDS 3368 02:15:57,280 --> 02:15:58,040 REISSUING THE RFA. 3369 02:15:58,040 --> 02:15:59,960 I DON'T HAVE THAT HISTORICAL 3370 02:15:59,960 --> 02:16:04,960 KNOWLEDGE TO SAY IT'S BEEN DONE 3371 02:16:04,960 --> 02:16:06,640 OUTSIDE OF THAT. 3372 02:16:06,640 --> 02:16:07,600 >>DESIRES TO HAVE A 3373 02:16:07,600 --> 02:16:11,200 PRESENTATION THREE TO FOUR YEARS 3374 02:16:11,200 --> 02:16:15,360 OUT, PRIOR TO THE END OF THIS 3375 02:16:15,360 --> 02:16:19,880 REISSUANCE, THAT CAN BE JUMPED 3376 02:16:19,880 --> 02:16:20,400 ON. 3377 02:16:20,400 --> 02:16:20,680 >>OKAY. 3378 02:16:20,680 --> 02:16:22,680 >>SEEMS LIKE A LONG TIME, SO 3379 02:16:22,680 --> 02:16:26,200 MANY THINGS CHANGE IN SCIENCE, 3380 02:16:26,200 --> 02:16:26,480 ET CETERA. 3381 02:16:26,480 --> 02:16:28,040 SEVEN YEARS JUST SEEMS LIKE A 3382 02:16:28,040 --> 02:16:28,600 LONG TIME. 3383 02:16:28,600 --> 02:16:30,960 PERHAPS IT WOULD BE HELPFUL EVEN 3384 02:16:30,960 --> 02:16:32,640 TO THE PERSONS INVOLVED TO HAVE 3385 02:16:32,640 --> 02:16:34,880 AN EVALUATION SORT OF THREE TO 3386 02:16:34,880 --> 02:16:37,400 FOUR YEARS INTO IT. 3387 02:16:37,400 --> 02:16:39,320 >>WE CAN CERTAINLY DO THAT BUT 3388 02:16:39,320 --> 02:16:41,240 THESE ARE PHASE 3 TRIALS. 3389 02:16:41,240 --> 02:16:42,760 >>I UNDERSTAND. 3390 02:16:42,760 --> 02:16:43,400 >>YEAH, YEAH. 3391 02:16:43,400 --> 02:16:48,760 >>WE'VE GOT TO MOVE ON. 3392 02:16:48,760 --> 02:16:50,960 >>OKAY. 3393 02:16:50,960 --> 02:16:53,920 WE'LL MOVE TO VOTING. 3394 02:16:53,920 --> 02:16:54,440 REISSUANCE. 3395 02:16:54,440 --> 02:16:59,720 SAM, TAKE YOUR HAND DOWN FROM 3396 02:16:59,720 --> 02:17:00,240 QUESTIONS. 3397 02:17:00,240 --> 02:17:01,400 MOTION'S BEEN MADE. 3398 02:17:01,400 --> 02:17:04,040 KIM, IF YOU CONFIRM MOTION TO 3399 02:17:04,040 --> 02:17:04,560 CONCUR. 3400 02:17:04,560 --> 02:17:07,160 >>MOVE TO CONCUR. 3401 02:17:07,160 --> 02:17:07,520 >>AND SECOND? 3402 02:17:07,520 --> 02:17:07,960 >>SECOND. 3403 02:17:07,960 --> 02:17:10,360 >>THANK YOU. 3404 02:17:10,360 --> 02:17:15,040 FURTHER DISCUSSION? 3405 02:17:15,040 --> 02:17:15,240 OKAY. 3406 02:17:15,240 --> 02:17:18,680 HEARING NONE, MOTION IS FOR 3407 02:17:18,680 --> 02:17:20,320 CONCURRENCE, LOOKING FOR ANY 3408 02:17:20,320 --> 02:17:24,480 VOTES OF NON-CONCURRENCE. 3409 02:17:24,480 --> 02:17:25,960 3410 02:17:25,960 --> 02:17:28,200 OR VOICE STATUS IF YOU'RE UNABLE 3411 02:17:28,200 --> 02:17:29,200 TO RAISE YOUR HAND 3412 02:17:29,200 --> 02:17:29,720 ELECTRONICALLY. 3413 02:17:29,720 --> 02:17:31,640 I SEE AND HEAR NONE, NO RECORDED 3414 02:17:31,640 --> 02:17:35,560 ABSTENTIONS, IF ANYONE WOULD 3415 02:17:35,560 --> 02:17:36,960 LIKE TO ABSTAIN NOW PLEASE LET 3416 02:17:36,960 --> 02:17:38,280 ME KNOW. 3417 02:17:38,280 --> 02:17:38,600 OKAY. 3418 02:17:38,600 --> 02:17:39,800 PAULETTE, WE'RE GOOD? 3419 02:17:39,800 --> 02:17:42,880 >>WE'RE GOOD BUT WE DO HAVE ONE 3420 02:17:42,880 --> 02:17:46,680 CONFLICT, SO THE VOTE WILL BE 24 3421 02:17:46,680 --> 02:17:49,920 WITH ONE CONFLICT. 3422 02:17:49,920 --> 02:17:50,960 >>GREAT. 3423 02:17:50,960 --> 02:17:51,760 THANK YOU. 3424 02:17:51,760 --> 02:17:53,400 I'VE DONE A REASONABLY BAD JOB 3425 02:17:53,400 --> 02:17:54,960 OF KEEPING US ON TIME. 3426 02:17:54,960 --> 02:17:56,240 BUT WE HAVE THIS BUFFER PERIOD 3427 02:17:56,240 --> 02:17:59,960 OF A BREAK AND WE CAN 3428 02:17:59,960 --> 02:18:02,960 COLLECTIVELY PAY BACK FOR MY BAD 3429 02:18:02,960 --> 02:18:03,240 TIMEKEEPING. 3430 02:18:03,240 --> 02:18:05,640 >>WOULD IT BE POSSIBLE TO AVOID 3431 02:18:05,640 --> 02:18:07,960 THE BREAK AND JUST CHARGE 3432 02:18:07,960 --> 02:18:10,600 FORWARD AND STAY CLOSER TO TIME? 3433 02:18:10,600 --> 02:18:11,920 >>PAULETTE SHOULD ANSWER THAT. 3434 02:18:11,920 --> 02:18:16,840 SHE WILL SAY NO BUT I'M JUST -- 3435 02:18:16,840 --> 02:18:20,200 >>ALL OF US NEED A BREAK. 3436 02:18:20,200 --> 02:18:22,320 WE'VE BEEN AT THIS SINCE 1:00. 3437 02:18:22,320 --> 02:18:24,680 >>WE COULD COME BACK ON THE 3438 02:18:24,680 --> 02:18:28,120 SCHEDULED TIME IN 12 MINUTES. 3439 02:18:28,120 --> 02:18:30,360 >>YEAH, BUT LET'S TAKE A 3440 02:18:30,360 --> 02:18:32,520 THREE-MINUTE BREAK AND COME 3441 02:18:32,520 --> 02:18:34,960 BACK, WE'LL HAVE A TEN-MINUTE 3442 02:18:34,960 --> 02:18:36,600 ADMINISTRATIVE SESSION. 3443 02:18:36,600 --> 02:18:37,240 >>SOUNDS GREAT. 3444 02:18:37,240 --> 02:18:48,720 JUST THREE MINUTES. 3445 02:18:48,720 --> 02:18:55,280 >>FINAL CONCEPT, SBIR 2B BRIDGE 3446 02:18:55,280 --> 02:18:57,880 AWARDS TOWARDS 3447 02:18:57,880 --> 02:19:03,720 COMMERCIALIZATION. 3448 02:19:03,720 --> 02:19:05,320 DR. JONATHAN FRANCA-KOH. 3449 02:19:05,320 --> 02:19:06,360 SUBCOMMITTEE HAS REVIEWED THE 3450 02:19:06,360 --> 02:19:13,640 MATERIALS AND DISCUSSED WITH THE 3451 02:19:13,640 --> 02:19:14,600 TEAM, RECOMMENDATION FOR 3452 02:19:14,600 --> 02:19:15,960 CONCURRENCE AND PRESENTATION. 3453 02:19:15,960 --> 02:19:19,320 JONATHAN, GO AHEAD WITH THE 3454 02:19:19,320 --> 02:19:19,640 PRESENTATION. 3455 02:19:19,640 --> 02:19:22,440 >>THANK YOU SO MUCH. 3456 02:19:22,440 --> 02:19:25,920 3457 02:19:25,920 --> 02:19:29,120 I'M PRESENTING THE BRIDGE AWARD 3458 02:19:29,120 --> 02:19:32,520 RFA, AND THIS IS PART OF A 3459 02:19:32,520 --> 02:19:34,160 LARGER CONGRESSIONALLY MANDATED 3460 02:19:34,160 --> 02:19:36,240 PROGRAM FROM THE SBIR, SMALL 3461 02:19:36,240 --> 02:19:38,120 BUSINESS INNOVATION RESEARCH. 3462 02:19:38,120 --> 02:19:40,840 SO, IT DRAWS ON THESE 3463 02:19:40,840 --> 02:19:41,600 CONGRESSIONALLY MANDATED 3464 02:19:41,600 --> 02:19:44,560 SET-ASIDE FUNDS, WILL NOT IMPACT 3465 02:19:44,560 --> 02:19:47,200 RPG FUNDING. 3466 02:19:47,200 --> 02:19:49,160 FEDERAL AGENCIES THAT HAVE LARGE 3467 02:19:49,160 --> 02:19:52,760 EXTRAMURAL R&D BUDGETS ARE 3468 02:19:52,760 --> 02:19:59,320 REQUIRED TO SET ASIDE 3.65%. 3469 02:19:59,320 --> 02:20:02,440 AT THE NCI THIS AMOUNTS TO $182 3470 02:20:02,440 --> 02:20:02,720 MILLION. 3471 02:20:02,720 --> 02:20:05,280 AND THIS IS OFTEN REFERRED TO AS 3472 02:20:05,280 --> 02:20:09,400 AMERICA'S SEED FUND BECAUSE THE 3473 02:20:09,400 --> 02:20:11,920 GOAL IS TO SUPPORT EARLY STAGE 3474 02:20:11,920 --> 02:20:12,680 INNOVATESSIVE SMALL BUSINESSES, 3475 02:20:12,680 --> 02:20:23,200 USED AT THE NIH TO SUPPORT THESE 3476 02:20:23,200 --> 02:20:23,440 COMPANIES. 3477 02:20:23,440 --> 02:20:27,880 CONGRESS REAUTHORIZED FOR THREE 3478 02:20:27,880 --> 02:20:28,200 MORE YOURS. 3479 02:20:28,200 --> 02:20:29,640 WE COMMISSIONED ECONOMIC IMPACT 3480 02:20:29,640 --> 02:20:32,720 EVALUATION IN 2018, WHICH LOOKED 3481 02:20:32,720 --> 02:20:36,080 AT THE 690 PHASE 2 AWARDS MADE 3482 02:20:36,080 --> 02:20:38,280 BETWEEN 1998 AND 2010. 3483 02:20:38,280 --> 02:20:42,120 AND THEY DETERMINED THE OVERALL 3484 02:20:42,120 --> 02:20:44,560 ECONOMIC IMPACT WAS 3485 02:20:44,560 --> 02:20:45,480 $26.1 BILLION, WHICH INCLUDES 3486 02:20:45,480 --> 02:20:47,240 THE SALES OF THE PRODUCTS AND 3487 02:20:47,240 --> 02:20:51,200 SERVICES, TO DATE, AS WELL AS 3488 02:20:51,200 --> 02:20:52,360 TAX REVENUES, LABOR INCOME. 3489 02:20:52,360 --> 02:20:54,600 SO NOW I'D LIKE TO GIVE A 3490 02:20:54,600 --> 02:20:56,320 SNAPSHOT OF WHERE THE PHASE 2B 3491 02:20:56,320 --> 02:20:59,000 BRIDGE AWARD PROGRAM FITS IN 3492 02:20:59,000 --> 02:21:00,840 WITHIN THE SBIR FUNDING 3493 02:21:00,840 --> 02:21:01,120 MECHANISM. 3494 02:21:01,120 --> 02:21:04,520 THE FIRST STAGE OF FUNDING 3495 02:21:04,520 --> 02:21:07,560 CALLED PHASE 1 PROVIDES UP TO 3496 02:21:07,560 --> 02:21:08,680 $400,000 IN FUNDING FOR EARLY 3497 02:21:08,680 --> 02:21:12,080 STAGE PROOF OF CONCEPT RESEARCH. 3498 02:21:12,080 --> 02:21:13,520 AND COMPANIES SUCCESSFUL THERE 3499 02:21:13,520 --> 02:21:16,800 TO APPLY FOR PHASE 2 FUNDING, 3500 02:21:16,800 --> 02:21:19,680 WHICH OFFERS UP TO $2 MILLION. 3501 02:21:19,680 --> 02:21:21,400 AND THIS TYPICALLY SUPPORTS 3502 02:21:21,400 --> 02:21:23,800 FURTHER PRE-IND, SOMETIMES EARLY 3503 02:21:23,800 --> 02:21:24,600 CLINICAL STUDIES. 3504 02:21:24,600 --> 02:21:27,760 COMPANIES DO HAVE THE OPTION TO 3505 02:21:27,760 --> 02:21:29,280 APPLY DIRECTLY FOR PHASE 2 3506 02:21:29,280 --> 02:21:30,920 FUNDING IF THEY HAVE SUBSTANTIAL 3507 02:21:30,920 --> 02:21:32,000 DATA ON HAND. 3508 02:21:32,000 --> 02:21:34,240 AND THERE IS AN OPTION FOR 3509 02:21:34,240 --> 02:21:36,160 WHAT'S CALLED FAST TRACK 3510 02:21:36,160 --> 02:21:38,320 APPLICATION, WHICH IS COMBINED 3511 02:21:38,320 --> 02:21:41,040 PHASE 1 AND PHASE 2 APPLICATION. 3512 02:21:41,040 --> 02:21:43,880 HOWEVER, THE GOAL IS NOT JUST TO 3513 02:21:43,880 --> 02:21:45,120 SUPPORT THE COMPANY'S RESEARCH 3514 02:21:45,120 --> 02:21:48,120 AND DEVELOPMENT TO GET THEM 3515 02:21:48,120 --> 02:21:49,000 TOWARDS COMMERCIALIZATION. 3516 02:21:49,000 --> 02:21:51,840 AND THE PHASE 1 AND PHASE 2 3517 02:21:51,840 --> 02:21:52,960 GRANTS CAN TAKE COMPANIES ONLY 3518 02:21:52,960 --> 02:21:54,360 SO FAR. 3519 02:21:54,360 --> 02:21:55,240 MANY PROMISING TECHNOLOGIES FACE 3520 02:21:55,240 --> 02:21:58,080 A FUNDING GAP TO REACH THE NEXT 3521 02:21:58,080 --> 02:22:00,800 KEY VALUE INFLECTION POINT, IT 3522 02:22:00,800 --> 02:22:02,880 CAN BE CHALLENGING TO TRACT 3523 02:22:02,880 --> 02:22:03,640 INVESTMENT FOR EARLY STAGE 3524 02:22:03,640 --> 02:22:05,600 COMPANIES BECAUSE OF THE RISK 3525 02:22:05,600 --> 02:22:05,880 INVOLVED. 3526 02:22:05,880 --> 02:22:08,240 AND WITHOUT THIS FURTHER FUNDING 3527 02:22:08,240 --> 02:22:09,880 TECHNOLOGIES CAN WITHER OR FACE 3528 02:22:09,880 --> 02:22:12,320 SIGNIFICANT DELAYS. 3529 02:22:12,320 --> 02:22:14,080 THAT'S WHY THE BRIDGE AWARD 3530 02:22:14,080 --> 02:22:15,680 PROGRAM COMES IN. 3531 02:22:15,680 --> 02:22:17,120 IT ADDRESSES THE CHALLENGE BY 3532 02:22:17,120 --> 02:22:19,280 PROVIDE BE COMPANIES WITH 3533 02:22:19,280 --> 02:22:20,320 ADDITIONAL FUNDING, BUT ALSO 3534 02:22:20,320 --> 02:22:23,120 REQUIRES THEM TO RAISE MATCHING 3535 02:22:23,120 --> 02:22:25,000 FUNDS, AT LEAST 1:1 MATCH. 3536 02:22:25,000 --> 02:22:28,400 THIS WAS THE FIRST NIH SBIR 3537 02:22:28,400 --> 02:22:32,360 PROGRAM OF ITS KIND, LAUNCHED IN 3538 02:22:32,360 --> 02:22:33,320 2009 ORIGINALLY. 3539 02:22:33,320 --> 02:22:35,200 IT ALLOWS INVESTORS TO SUPPORT 3540 02:22:35,200 --> 02:22:36,520 TECHNOLOGIES VETTED BY THE PEER 3541 02:22:36,520 --> 02:22:39,560 REVIEW PROCESS AND THAT HAVE 3542 02:22:39,560 --> 02:22:42,000 BEEN DERISKED WITH NIH FUNDING 3543 02:22:42,000 --> 02:22:42,760 YOU. 3544 02:22:42,760 --> 02:22:44,400 FROM THE NCI PERSPECTIVES ALLOWS 3545 02:22:44,400 --> 02:22:46,600 US TO SUPPORT TECHNOLOGIES 3546 02:22:46,600 --> 02:22:47,880 UNDERGONE RIGOROUS DUE DILIGENCE 3547 02:22:47,880 --> 02:22:50,800 BUT TO COMPANIES THAT SHOW THEY 3548 02:22:50,800 --> 02:22:52,600 CAN ATTRACT OUTSIDE INVESTMENT. 3549 02:22:52,600 --> 02:22:54,680 THE PROGRAM IN ITS LAST 3550 02:22:54,680 --> 02:22:56,120 ITERATION PROVIDES UP TO $4 3551 02:22:56,120 --> 02:22:58,720 MILLION IN FUNDING OVER 2 OR 3 3552 02:22:58,720 --> 02:23:01,680 YEARS, AND SUPPORTS TECHNOLOGY 3553 02:23:01,680 --> 02:23:02,920 VALIDATION AND CLINICAL 3554 02:23:02,920 --> 02:23:05,840 TRANSLATION IN ALL PORTFOLIO 3555 02:23:05,840 --> 02:23:06,200 AREAS. 3556 02:23:06,200 --> 02:23:16,360 IN TERMS OF ELIGIBILITY, THEY 3557 02:23:16,360 --> 02:23:18,000 CAN APPLY PROVIDED TECHNOLOGY IS 3558 02:23:18,000 --> 02:23:20,320 RELEVANT TO THE NCI MISSION, AND 3559 02:23:20,320 --> 02:23:23,720 CLINICAL TRIALS ARE OPTIONAL BUT 3560 02:23:23,720 --> 02:23:27,000 MAJORITY OF GRANTS DO SUPPORT 3561 02:23:27,000 --> 02:23:27,520 CLINICAL TRIALS. 3562 02:23:27,520 --> 02:23:30,720 WE THINK OF THIS PROGRAM AS 3563 02:23:30,720 --> 02:23:33,880 HAVING THREE MAIN OBJECTIVES, 3564 02:23:33,880 --> 02:23:36,080 HELPING COMPANIES ACCOMPLISH 3565 02:23:36,080 --> 02:23:37,040 CRITICAL MILESTONES, HELPING 3566 02:23:37,040 --> 02:23:39,920 THEM TO ESTABLISH PARTNERSHIPS 3567 02:23:39,920 --> 02:23:42,200 WITH KEY PLAYERS IN THEIR 3568 02:23:42,200 --> 02:23:43,600 ECOSYSTEM, AND TO HELP THEM 3569 02:23:43,600 --> 02:23:46,440 LEVERAGE THE FEDERAL FUNDING TO 3570 02:23:46,440 --> 02:23:47,880 ATTRACT PRIVATE INVESTMENT THAT 3571 02:23:47,880 --> 02:23:53,360 EQUALS OR EXCEEDS NCI FUNDS. 3572 02:23:53,360 --> 02:23:56,480 THIS IS A SNAPSHOT OF AWARDS TO 3573 02:23:56,480 --> 02:24:00,320 DATE. 3574 02:24:00,320 --> 02:24:02,320 SINCE 2009, 49 AWARDS, $126 3575 02:24:02,320 --> 02:24:03,920 MILLION IN NCI FUNDING. 3576 02:24:03,920 --> 02:24:05,960 WITH THIS COMPANIES LEVERAGED TO 3577 02:24:05,960 --> 02:24:08,920 RAISE OVER $500 MILLION IN 3578 02:24:08,920 --> 02:24:10,760 MATCHING FUNDS, SOURCES INCLUDE 3579 02:24:10,760 --> 02:24:13,280 TOP VENTURE CAPITAL, STRATEGIC 3580 02:24:13,280 --> 02:24:15,280 PARTNERS, ALSO ANGEL INVESTMENT 3581 02:24:15,280 --> 02:24:15,600 GROUPS. 3582 02:24:15,600 --> 02:24:20,080 IN TERMS OF PROJECT TYPES, SPANS 3583 02:24:20,080 --> 02:24:23,600 THE RANGE WITH DEVICES, IMAGING, 3584 02:24:23,600 --> 02:24:24,360 DIAGNOSTICS, THERAPEUTICS BEING 3585 02:24:24,360 --> 02:24:25,640 EQUALLY REPRESENTED. 3586 02:24:25,640 --> 02:24:28,600 AND FROM THE 49 AWARDS SO FAR 19 3587 02:24:28,600 --> 02:24:30,360 PRODUCTS HAVE BEEN LAUNCHED BY 3588 02:24:30,360 --> 02:24:33,760 THESE COMPANIES SO THAT'S A HIT 3589 02:24:33,760 --> 02:24:35,160 RATE OF ALMOST 40%. 3590 02:24:35,160 --> 02:24:36,720 BECAUSE OF TIME I'LL JUST 3591 02:24:36,720 --> 02:24:40,560 HIGHLIGHT ONE CASE STUDY FROM 3592 02:24:40,560 --> 02:24:41,360 RECENT AWARDEES. 3593 02:24:41,360 --> 02:24:44,360 A COMPANY WAS SPUN OUT OF 3594 02:24:44,360 --> 02:24:45,160 UNIVERSITY OF PENNSYLVANIA 3595 02:24:45,160 --> 02:24:48,000 AND THEY RECEIVED A BRIDGE AWARD 3596 02:24:48,000 --> 02:24:54,120 IN 2018 TO DEVELOP A SMALL 3597 02:24:54,120 --> 02:24:55,840 MOLECULE, ORIGINALLY IDENTIFIED 3598 02:24:55,840 --> 02:24:58,000 USING R01 FUNDS. 3599 02:24:58,000 --> 02:25:00,800 THE AWARD SUPPORTED PHASE 2 3600 02:25:00,800 --> 02:25:07,200 CLINICAL TRIAL OF THEIR AGENTS, 3601 02:25:07,200 --> 02:25:09,920 RECEIVING FAST TRACK AND ORPHAN 3602 02:25:09,920 --> 02:25:11,440 DESIGNATION, THE RESULTS OF 3603 02:25:11,440 --> 02:25:16,800 CLINICAL TRIALS, THE COMPANY WAS 3604 02:25:16,800 --> 02:25:18,880 ACQUIRED BY CHIMERIX. 3605 02:25:18,880 --> 02:25:20,840 A STORY SHOWED THE CASE OF A 3606 02:25:20,840 --> 02:25:24,880 PATIENT ON ONE OF THESE TRIALS, 3607 02:25:24,880 --> 02:25:26,440 DIAGNOSED WITH DIPG, AGE 6, NOT 3608 02:25:26,440 --> 02:25:28,520 EXPECTED TO SURVIVE THE YEAR. 3609 02:25:28,520 --> 02:25:31,360 PROGNOSIS OVER FIVE YEARS WAS 1% 3610 02:25:31,360 --> 02:25:32,320 SURVIVAL. 3611 02:25:32,320 --> 02:25:34,760 THREE YEARS LATER, SHE'S NOT 3612 02:25:34,760 --> 02:25:36,200 ONLY SURVIVING BUT THRIVING WITH 3613 02:25:36,200 --> 02:25:38,280 TUMOR STABLE AT JUST 12% OF 3614 02:25:38,280 --> 02:25:39,920 ORIGINAL SIZE. 3615 02:25:39,920 --> 02:25:41,560 THE PARENTS AND DOCTORS 3616 02:25:41,560 --> 02:25:44,920 ATTRIBUTE HER SURVIVAL TO 3617 02:25:44,920 --> 02:25:45,920 ONC-201. 3618 02:25:45,920 --> 02:25:48,440 PART OF THE REISSUING PROCESS WE 3619 02:25:48,440 --> 02:25:49,960 DID GET AN EXTERNAL EVALUATION, 3620 02:25:49,960 --> 02:25:53,680 WHICH WAS IN THE BSA MATERIAL, 3621 02:25:53,680 --> 02:25:57,400 I'LL SUMMARIZE KEY RESULTS HERE. 3622 02:25:57,400 --> 02:25:58,760 SO THEY FOUND THAT THE PROGRAM 3623 02:25:58,760 --> 02:26:01,240 SUCCESSFULLY MET THE GOALS OF 3624 02:26:01,240 --> 02:26:06,680 HELPING COMPANIES ACCOMPLISH 3625 02:26:06,680 --> 02:26:09,120 MILESTONES, ESTABLISH MILESTONES 3626 02:26:09,120 --> 02:26:09,840 AND ATTRACT INVESTMENT, 2016 TO 3627 02:26:09,840 --> 02:26:13,280 2020 TO SEE THE IMPACT OF RECENT 3628 02:26:13,280 --> 02:26:14,160 BRIDGE AWARDS. 3629 02:26:14,160 --> 02:26:15,800 THEY FOUND THE MATCHING FUND 3630 02:26:15,800 --> 02:26:18,080 REQUIREMENT WAS A KEY PROGRAM 3631 02:26:18,080 --> 02:26:19,080 FEATURE, IT HELPED PUSH 3632 02:26:19,080 --> 02:26:20,960 COMPANIES TO SEEK INVESTMENT AND 3633 02:26:20,960 --> 02:26:24,200 NOT JUST RELY ON GRANTS. 3634 02:26:24,200 --> 02:26:25,960 IT DID HELP ENTICE PRIVATE 3635 02:26:25,960 --> 02:26:27,720 INVESTMENT AND COMPANIES 3636 02:26:27,720 --> 02:26:29,160 REPORTED THAT THE PRESTIGE AND 3637 02:26:29,160 --> 02:26:29,800 VALIDATION PROVIDED BY BRIDGE 3638 02:26:29,800 --> 02:26:32,120 AWARD WAS JUST AS IMPORTANT AS 3639 02:26:32,120 --> 02:26:33,520 FUNDING. 3640 02:26:33,520 --> 02:26:38,240 THIS IS A QUOTE FROM ISOPLEXIS. 3641 02:26:38,240 --> 02:26:40,720 THEY SAID NCI BACKING HELPED THE 3642 02:26:40,720 --> 02:26:41,520 VCs CONNECT DOTS AND DETERMINE 3643 02:26:41,520 --> 02:26:44,160 IT WAS A BET THEY WERE WILLING 3644 02:26:44,160 --> 02:26:48,200 TO TAKE, THE BRIDGE WAS A 3645 02:26:48,200 --> 02:26:50,320 DE-RISKING THEY NEEDED AT THAT 3646 02:26:50,320 --> 02:26:50,920 MOMENT. 3647 02:26:50,920 --> 02:26:52,480 THEY FOUND THE PROGRAM SUPPORTS 3648 02:26:52,480 --> 02:26:54,120 KEY EARLY DEVELOPMENT ACTIVITIES 3649 02:26:54,120 --> 02:26:57,040 THAT ARE BEYOND SCOPE OF A JUST 3650 02:26:57,040 --> 02:26:59,000 TRADITIONAL PHASE 2 SBIR GRANT, 3651 02:26:59,000 --> 02:27:00,560 HELPING THEM TO ATTRACT PRIVATE 3652 02:27:00,560 --> 02:27:03,080 INVESTMENT AS A STAGE THAT'S 3653 02:27:03,080 --> 02:27:05,480 DIFFICULT HENCE THE TERM VALLEY 3654 02:27:05,480 --> 02:27:06,600 OF DEATH. 3655 02:27:06,600 --> 02:27:08,040 THEY REPORTED COMPANIES ARE 3656 02:27:08,040 --> 02:27:10,080 FACING INCREASED COSTS DUE TO 3657 02:27:10,080 --> 02:27:12,040 INFLATION, AND THEY FELT IT WAS 3658 02:27:12,040 --> 02:27:13,360 IMPORTANT THE BRIDGE AWARD 3659 02:27:13,360 --> 02:27:15,040 ACCOUNT SO COMPANIES CAN 3660 02:27:15,040 --> 02:27:16,680 CONTINUE TO HIT THEIR MILESTONES 3661 02:27:16,680 --> 02:27:19,400 AND SO THEY RECOMMEND MODEST 3662 02:27:19,400 --> 02:27:20,520 INCREASE IN AWARD CENTERS. 3663 02:27:20,520 --> 02:27:21,520 PROVIDED THAT WE CAN MAINTAIN 3664 02:27:21,520 --> 02:27:23,880 THE NUMBER OF BRIDGE AWARDS PER 3665 02:27:23,880 --> 02:27:24,080 YEAR. 3666 02:27:24,080 --> 02:27:25,440 OVER THE LAST FIVE YEARS RANGES 3667 02:27:25,440 --> 02:27:28,800 HAS BEEN BETWEEN 3 AND 6 AWARDS 3668 02:27:28,800 --> 02:27:35,240 A YEAR, RECOMMENDED SUPPORTING 3669 02:27:35,240 --> 02:27:37,120 THE HIGHER END. 3670 02:27:37,120 --> 02:27:39,000 WE'RE ASKING FOR FIVE-YEAR 3671 02:27:39,000 --> 02:27:43,440 APPROVAL FROM BSA, TO MAINTAIN 3672 02:27:43,440 --> 02:27:45,560 CLINICAL TRIALS OPTIONAL, WE'RE 3673 02:27:45,560 --> 02:27:46,920 REQUESTING INCREASE IN AWARD 3674 02:27:46,920 --> 02:27:49,840 SIZE FROM $4 MILLION TO 3675 02:27:49,840 --> 02:27:51,680 $4.5 MILLION, AND WE ANTICIPATE 3676 02:27:51,680 --> 02:27:53,440 FUNDING ABOUT SIX AWARDS PER 3677 02:27:53,440 --> 02:27:55,960 YEAR, THAT WOULD MAKE THE FIRST 3678 02:27:55,960 --> 02:27:57,280 YEAR SET ASIDE OF $12 MILLION. 3679 02:27:57,280 --> 02:27:59,440 AND THE FIRST YEAR SET ASIDES 3680 02:27:59,440 --> 02:28:01,960 OVER FIVE YEARS AMOUNTING TO $60 3681 02:28:01,960 --> 02:28:02,320 MILLION. 3682 02:28:02,320 --> 02:28:06,360 AND THE EVALUATION COMMITTEE 3683 02:28:06,360 --> 02:28:07,400 RECOMMENDED PROGRAM RENEWAL. 3684 02:28:07,400 --> 02:28:13,120 SO I'LL TOUCH ON MY LAST SLIDE, 3685 02:28:13,120 --> 02:28:15,640 RFA JUSTIFICATION, SO WE THINK 3686 02:28:15,640 --> 02:28:16,440 RFA MECHANISM HELPS SIGNAL NCI 3687 02:28:16,440 --> 02:28:18,040 STRONG COMMITMENT TO THIS 3688 02:28:18,040 --> 02:28:22,880 PROGRAM AND HELPS ENCOURAGE 3689 02:28:22,880 --> 02:28:23,720 PARTICIPATION FROM AWARDEES, 3690 02:28:23,720 --> 02:28:24,880 INVESTORS, STRATEGIC PARTNERS, 3691 02:28:24,880 --> 02:28:26,200 IMPORTANT FACTOR HELPING US TO 3692 02:28:26,200 --> 02:28:30,680 ENSURE THAT THE STUDY SECTIONS 3693 02:28:30,680 --> 02:28:31,880 HAVE STRONG REPRESENTATION FOR 3694 02:28:31,880 --> 02:28:34,360 REVIEWERS TO HAVE INDUSTRY 3695 02:28:34,360 --> 02:28:36,240 BACKGROUND AND STRONG BUSINESS 3696 02:28:36,240 --> 02:28:37,160 EXPERTISE, BECAUSE THESE 3697 02:28:37,160 --> 02:28:41,720 APPLICATIONS ARE MUCH MORE 3698 02:28:41,720 --> 02:28:42,760 FOCUSEDDED ON COMMERCIALIZATION 3699 02:28:42,760 --> 02:28:44,360 WITH SPECIAL REVIEW CRITERIA 3700 02:28:44,360 --> 02:28:47,320 THAT WOULD BENEFIT FROM INDUSTRY 3701 02:28:47,320 --> 02:28:48,640 PERSPECTIVE. 3702 02:28:48,640 --> 02:28:50,040 THESE INCLUDE VERY BALANCED 3703 02:28:50,040 --> 02:28:53,000 CONSIDERATION OF BOTH TECHNICAL 3704 02:28:53,000 --> 02:28:54,960 AND COMMERCIAL MERIT, EVALUATION 3705 02:28:54,960 --> 02:28:56,680 OF INTELLECTUAL PROPERTY 3706 02:28:56,680 --> 02:28:58,800 POSITION, REGULATORY STRATEGY, 3707 02:28:58,800 --> 02:29:00,080 FUNDRAISING PLAN. 3708 02:29:00,080 --> 02:29:01,320 IN RECENT YEARS THE AVERAGE THAT 3709 02:29:01,320 --> 02:29:03,840 WE'VE HAD ON OUR BRIDGE AWARD 3710 02:29:03,840 --> 02:29:07,320 PANELS HAS BEEN AROUND 40%, FOR 3711 02:29:07,320 --> 02:29:08,080 INDUSTRY PANEL MEMBERS, COMPARED 3712 02:29:08,080 --> 02:29:18,560 TO 25% FOR THE REGULAR STUDY 3713 02:29:24,480 --> 02:29:24,800 SECTIONS. 3714 02:29:24,800 --> 02:29:26,040 AND OUR OFFICE DIRECTOR IS ON 3715 02:29:26,040 --> 02:29:28,880 THE LINE TO ANSWER QUESTIONS. 3716 02:29:28,880 --> 02:29:29,480 >>THANKS. 3717 02:29:29,480 --> 02:29:32,320 DAVE, GET US STARTED. 3718 02:29:32,320 --> 02:29:34,040 >>THANK YOU. 3719 02:29:34,040 --> 02:29:37,440 THE THREE OF US MET WITH DR. 3720 02:29:37,440 --> 02:29:39,520 FRANCA-KOH LAST YEAR TO ASK 3721 02:29:39,520 --> 02:29:40,240 QUESTIONS ABOUT THE PROGRAM, 3722 02:29:40,240 --> 02:29:44,640 LEARNED A LOT ABOUT THE HISTORY 3723 02:29:44,640 --> 02:29:45,760 OF THE PROGRAM. 3724 02:29:45,760 --> 02:29:48,800 AND JONATHAN EXPLAINED IT ALL 3725 02:29:48,800 --> 02:29:50,560 VERY WELL. 3726 02:29:50,560 --> 02:29:53,200 SYLVIA AND MYSELF WERE NOT WELL 3727 02:29:53,200 --> 02:29:59,000 AWARE OF THE SBIR PROGRAM AND 3728 02:29:59,000 --> 02:30:00,280 HOW IT PROGRESSED TO PHASE 3 OR 3729 02:30:00,280 --> 02:30:03,360 BRIDGE PROGRAM AND IMPORTANCE ON 3730 02:30:03,360 --> 02:30:06,320 DEVELOPMENT OF CERTAIN ACADEMIC 3731 02:30:06,320 --> 02:30:07,440 AND PRIVATE SECTOR 3732 02:30:07,440 --> 02:30:08,440 ACCOMPLISHMENTS INTO FULL 3733 02:30:08,440 --> 02:30:12,240 FUNDING AND MOVING FORWARD TO 3734 02:30:12,240 --> 02:30:13,000 COMMERCIALIZATION. 3735 02:30:13,000 --> 02:30:14,360 WE LEARNED ABOUT THE PROCESS, 3736 02:30:14,360 --> 02:30:16,400 HOW THE STUDY PUT TOGETHER, 3737 02:30:16,400 --> 02:30:21,120 CRITERIA FOR ASSESSING MERITS OF 3738 02:30:21,120 --> 02:30:21,560 PROPOSALS. 3739 02:30:21,560 --> 02:30:26,480 AND ALSO LEARNED FROM THE 3740 02:30:26,480 --> 02:30:28,560 ASSESSMENT OF OUTSIGNED PANEL 3741 02:30:28,560 --> 02:30:29,480 THEIR DEEP UNDERSTANDING OF HOW 3742 02:30:29,480 --> 02:30:33,840 IT MET OBJECT I WAS PUT FORTH BY 3743 02:30:33,840 --> 02:30:37,160 CONGRESS INITIALLY AS WELL AS 3744 02:30:37,160 --> 02:30:40,840 2009 OBJECTIVES, 40% RETURN ON 3745 02:30:40,840 --> 02:30:42,920 INVESTMENT, BETTER THAN ANY 3746 02:30:42,920 --> 02:30:46,200 BUSINESS MODEL I'VE HEARD OF. 3747 02:30:46,200 --> 02:30:47,680 WE ASKED, AGAIN, A FAIR NUMBER 3748 02:30:47,680 --> 02:30:48,920 OF QUESTIONS ABOUT THE PROGRAM, 3749 02:30:48,920 --> 02:30:51,480 IN THE END WE WERE SATISFIED 3750 02:30:51,480 --> 02:30:52,360 WITH THE ANSWERS. 3751 02:30:52,360 --> 02:30:53,560 THE REASON WHY WE ASKED FOR THIS 3752 02:30:53,560 --> 02:30:54,760 TO BE DISCUSSED WITH THIS WHOLE 3753 02:30:54,760 --> 02:30:57,960 GROUP IS NOT BECAUSE WE HAD 3754 02:30:57,960 --> 02:30:59,800 PROBLEMS WITH THE PROPOSAL OR 3755 02:30:59,800 --> 02:31:01,240 SERIOUS CONCERNS BUT RATHER AT 3756 02:31:01,240 --> 02:31:02,760 LEAST TWO OF THE THESE ARE 3757 02:31:02,760 --> 02:31:04,040 MEMBERS ON THE COMMITTEE WERE 3758 02:31:04,040 --> 02:31:04,920 NAIVE TO THE PROCESS IN THE 3759 02:31:04,920 --> 02:31:06,360 BEGINNING THAT THE REST OF YOU 3760 02:31:06,360 --> 02:31:10,200 HEAR ABOUT IT SO YOU CAN TELL 3761 02:31:10,200 --> 02:31:17,120 YOUR COLLEAGUES IN ACADEMIA 3762 02:31:17,120 --> 02:31:17,360 ABOUT IT. 3763 02:31:17,360 --> 02:31:18,720 THE NEXT SPEAKER IS A VETERAN OF 3764 02:31:18,720 --> 02:31:21,160 THE PROGRAM AND SPOKE TO'DED A 3765 02:31:21,160 --> 02:31:24,000 VALUE FOR HIS OWN RESEARCH AND 3766 02:31:24,000 --> 02:31:25,400 THOSE OF HILLS COLLEAGUES. 3767 02:31:25,400 --> 02:31:27,520 ONE LAST THOUGHT I'LL LEAVE YOU 3768 02:31:27,520 --> 02:31:28,600 WITH, YESTERDAY WE SAT THROUGH 3769 02:31:28,600 --> 02:31:30,440 THE FIRST, IN MY MIND, 3770 02:31:30,440 --> 02:31:32,320 EXPLANATION OF WHAT ARPA-H IS. 3771 02:31:32,320 --> 02:31:36,040 WHY DO WE HAVE ARPA-H? 3772 02:31:36,040 --> 02:31:37,040 WE HAVE IT BECAUSE PEOPLE DON'T 3773 02:31:37,040 --> 02:31:39,200 THINK WE'RE GOING TO FINISH THE 3774 02:31:39,200 --> 02:31:39,360 JOB. 3775 02:31:39,360 --> 02:31:41,680 ACTUALLY THIS PROGRAM IS ONE, 3776 02:31:41,680 --> 02:31:46,080 AGAIN, ON A SMALLER SCALE, 3777 02:31:46,080 --> 02:31:48,160 TAKING ACADEMIC DISCOVERIES INTO 3778 02:31:48,160 --> 02:31:50,320 THERAPIES, DIAGNOSIS, NEW 3779 02:31:50,320 --> 02:31:51,000 COMPUTATIONAL APPROACHES, AND SO 3780 02:31:51,000 --> 02:31:52,960 WHENEVER WE GET THAT CHANCE WE 3781 02:31:52,960 --> 02:31:53,920 SHOULD REMIND THOSE OFFICIALS 3782 02:31:53,920 --> 02:31:55,840 WHO THINK WE HAVEN'T BEEN DOING 3783 02:31:55,840 --> 02:31:57,000 IT WE'RE ACTUALLY WORKING ON 3784 02:31:57,000 --> 02:31:58,160 THIS RIGHT NOW. 3785 02:31:58,160 --> 02:32:04,000 I'M GOING TO TURN IT OVER TO DR. 3786 02:32:04,000 --> 02:32:04,240 BESICH. 3787 02:32:04,240 --> 02:32:08,640 >>THIS IS A VERY IMPORTANT 3788 02:32:08,640 --> 02:32:08,960 PROGRAM. 3789 02:32:08,960 --> 02:32:10,480 BIG T TRANSLATION MEANS OUT TO 3790 02:32:10,480 --> 02:32:13,120 THE REAL WORLD, INTO THE HANDS 3791 02:32:13,120 --> 02:32:15,640 OF HUNDREDS OF THOUSANDS AND 3792 02:32:15,640 --> 02:32:18,360 MILLIONS OF USERS IS WHAT THIS 3793 02:32:18,360 --> 02:32:19,880 PROGRAM ASPIRES TO HELP 3794 02:32:19,880 --> 02:32:20,360 ACCELERATE. 3795 02:32:20,360 --> 02:32:22,960 AGAIN, BOTH AS BEING FUNDED BY 3796 02:32:22,960 --> 02:32:24,840 SBIR CURRENTLY HAVING A FOURTH 3797 02:32:24,840 --> 02:32:25,880 START-UP, AND UNDERSTANDING HOW 3798 02:32:25,880 --> 02:32:30,520 IMPORTANT THIS IS IN THE 3799 02:32:30,520 --> 02:32:31,360 ACADEMIC ECOSYSTEM TAKING GOOD 3800 02:32:31,360 --> 02:32:33,680 IDEAS FROM THE LABORATORIES AND 3801 02:32:33,680 --> 02:32:38,400 BIG T TRANSLATING THEM INTO REAL 3802 02:32:38,400 --> 02:32:39,800 THINGS THAT MATTER IS KEY. 3803 02:32:39,800 --> 02:32:44,760 ONE THING I'D LIKE TO ADVOCATE 3804 02:32:44,760 --> 02:32:46,040 I'VE WATCHED THE NCI'S PROGRAM A 3805 02:32:46,040 --> 02:32:50,000 COUPLE DECADES, THEY HAVE A TEND 3806 02:32:50,000 --> 02:32:51,720 OF TENDENCY TO POINT INITIATIVES 3807 02:32:51,720 --> 02:32:54,800 IN THE KEY AREAS THAT IMPACT US, 3808 02:32:54,800 --> 02:32:55,720 IMAGING, GENOMICS, A.I., MACHINE 3809 02:32:55,720 --> 02:32:56,120 LEARNING. 3810 02:32:56,120 --> 02:33:01,160 THIS IS AN IMPORTANT PROGRAM, 3811 02:33:01,160 --> 02:33:06,400 AND I ENTHUSIASTICALLY ENDORSE 3812 02:33:06,400 --> 02:33:06,760 IT. 3813 02:33:06,760 --> 02:33:07,800 >>THANK YOU. 3814 02:33:07,800 --> 02:33:09,800 SYLVIA IS MARKED AS NOT BEING 3815 02:33:09,800 --> 02:33:12,400 ABLE TO PARTICIPATE, JUST 3816 02:33:12,400 --> 02:33:17,440 CONFIRMING SYLVIA IS NOT WITH 3817 02:33:17,440 --> 02:33:17,800 US. 3818 02:33:17,800 --> 02:33:22,360 WE'LL MOVE TO OTHER BOARD 3819 02:33:22,360 --> 02:33:25,760 MEMBERS. 3820 02:33:25,760 --> 02:33:26,480 >>THANK YOU, KEITH. 3821 02:33:26,480 --> 02:33:28,840 THIS SEEMS TO BE A REALLY 3822 02:33:28,840 --> 02:33:29,520 IMPORTANT CATALYST. 3823 02:33:29,520 --> 02:33:32,640 THE QUESTION I HAVE MAYBE 3824 02:33:32,640 --> 02:33:34,480 UNDERSTANDING IS EXTENT TO WHICH 3825 02:33:34,480 --> 02:33:36,040 THERE'S DIVERSITY IN THE SBIR 3826 02:33:36,040 --> 02:33:40,600 PROGRAM, ONE, BUT ALSO IN THE 3827 02:33:40,600 --> 02:33:44,800 BRIDGE PROGRAM. 3828 02:33:44,800 --> 02:33:45,600 CLEARLY IT PROVIDES 3829 02:33:45,600 --> 02:33:52,400 OPPORTUNITIES, TAKING THEM TO 3830 02:33:52,400 --> 02:33:54,920 MARKETS, MAYBE WHAT IS THE OTHER 3831 02:33:54,920 --> 02:33:58,000 PROCESS HOW YOU SEEK TO 3832 02:33:58,000 --> 02:33:59,720 DIVERSIFY THE PEOPLE WHO ARE 3833 02:33:59,720 --> 02:34:04,520 LEVERAGING THIS PROGRAM AND THE 3834 02:34:04,520 --> 02:34:05,280 SECOND QUESTION, TANGENTALLY, 3835 02:34:05,280 --> 02:34:10,560 ALMOST, HOW THIS IS GOING TO 3836 02:34:10,560 --> 02:34:10,880 BRIDGE. 3837 02:34:10,880 --> 02:34:12,120 FIRST IS ABOUT DIVERSITY AND THE 3838 02:34:12,120 --> 02:34:14,480 PROCESS YOU HAVE. 3839 02:34:14,480 --> 02:34:17,880 >>YEAH, SO WE HAVE SEVERAL 3840 02:34:17,880 --> 02:34:20,280 PROGRAMS TO HELP THE DIVERSITY. 3841 02:34:20,280 --> 02:34:23,000 I THINK RIGHT NOW IT'S FOCUS ON 3842 02:34:23,000 --> 02:34:26,040 PHASE 1, PHASE 2 GRANTS, RATHER 3843 02:34:26,040 --> 02:34:26,720 THAN THE BRIDGE. 3844 02:34:26,720 --> 02:34:31,040 SO WE HAVE A PROGRAM CALLED THE 3845 02:34:31,040 --> 02:34:35,520 APPLICATION ASSISTANCE PROGRAM, 3846 02:34:35,520 --> 02:34:39,200 WHERE WE TARGET RESEARCHERS WITH 3847 02:34:39,200 --> 02:34:40,440 UNDERREPRESENTED BACKGROUNDS, TO 3848 02:34:40,440 --> 02:34:42,160 RECEIVE ADDITIONAL HELP FROM A 3849 02:34:42,160 --> 02:34:45,120 GRANT-WRITING COMPANY THAT CAN 3850 02:34:45,120 --> 02:34:46,880 HELP THEM NAVIGATE THE 3851 02:34:46,880 --> 02:34:54,800 APPLICATION PROCESS, AND 3852 02:34:54,800 --> 02:34:59,160 DEVELOPING THEIR APPLICATIONS. 3853 02:34:59,160 --> 02:35:00,360 WE CONDUCT OUTREACH EVENTS, 3854 02:35:00,360 --> 02:35:01,560 TARGETING COMMUNITIES AND 3855 02:35:01,560 --> 02:35:03,760 ORGANIZATIONS TO HELP US BETTER 3856 02:35:03,760 --> 02:35:08,040 REACH UNDERREPRESENTED GROUPS, 3857 02:35:08,040 --> 02:35:09,360 AND THROUGH THOSE EFFORTS WE 3858 02:35:09,360 --> 02:35:12,880 PROVIDE EDUCATION AND TRAINING. 3859 02:35:12,880 --> 02:35:14,520 THE PROGRAM DIRECTORS ARE ALWAYS 3860 02:35:14,520 --> 02:35:16,800 AVAILABLE TO SPEAK WITH 3861 02:35:16,800 --> 02:35:18,760 APPLICANTS TO DISCUSS THEIR 3862 02:35:18,760 --> 02:35:20,520 APPLICATIONS PRIOR TO SUBMITTING 3863 02:35:20,520 --> 02:35:28,640 THEM. 3864 02:35:28,640 --> 02:35:32,320 AND PROVIDE GUIDANCE THERE. 3865 02:35:32,320 --> 02:35:32,960 OUR AAP, APPLICATION ASSISTANCE 3866 02:35:32,960 --> 02:35:36,480 PROGRAM, 53 OF THESE PEOPLE THAT 3867 02:35:36,480 --> 02:35:41,400 WE GAVE THAT SUPPORT TO, 53 OF 3868 02:35:41,400 --> 02:35:46,240 THEM WERE COMPANIES THAT HAD 3869 02:35:46,240 --> 02:35:47,000 FOUNDERS OF UNDERREPRESENTED 3870 02:35:47,000 --> 02:35:47,320 BACKGROUNDS. 3871 02:35:47,320 --> 02:35:52,680 >>WHAT DOES THAT MEAN EXACTLY? 3872 02:35:52,680 --> 02:35:57,400 WHAT DOES THAT ACTUALLY MEAN? 3873 02:35:57,400 --> 02:35:58,200 >>YEAH, SO UNDERREPRESENTED 3874 02:35:58,200 --> 02:36:05,040 MINORITIES IN THE LIFE SCIENCES. 3875 02:36:05,040 --> 02:36:06,360 AND ALSO WOMEN. 3876 02:36:06,360 --> 02:36:06,560 SORRY. 3877 02:36:06,560 --> 02:36:13,360 >>I THINK IT WOULD BE HELPFUL, 3878 02:36:13,360 --> 02:36:17,920 THAT'S A BIG BUCKET, IMPRESSIVE 3879 02:36:17,920 --> 02:36:20,360 BUT THE BIG BUCKET AND MORE TO 3880 02:36:20,360 --> 02:36:21,040 MY POINT TO ENCOURAGE YOU TO 3881 02:36:21,040 --> 02:36:24,320 LOOK AT HOW YOU CAN BE MORE 3882 02:36:24,320 --> 02:36:26,800 INTENTIONAL ABOUT HOW YOU -- HOW 3883 02:36:26,800 --> 02:36:28,240 THE PROGRAM IS IMPLEMENTED AND 3884 02:36:28,240 --> 02:36:29,560 DESIGNED, KNOWING THE VALUE THAT 3885 02:36:29,560 --> 02:36:33,040 IT PROVIDES, HOW THAT MIGHT BE 3886 02:36:33,040 --> 02:36:34,560 LEVERAGED TO HELP CREATE MORE 3887 02:36:34,560 --> 02:36:34,960 DIVERSITY. 3888 02:36:34,960 --> 02:36:36,680 I THINK IN PART BECAUSE IT'S 3889 02:36:36,680 --> 02:36:39,160 QUITE A BIT OF MOVEMENT 3890 02:36:39,160 --> 02:36:40,640 NATIONALLY ABOUT DIVERSITY, SO 3891 02:36:40,640 --> 02:36:45,560 WHO IS PROVIDING SERVICES AND 3892 02:36:45,560 --> 02:36:47,320 MANY EFFORTS AROUND HOW YOU LOOK 3893 02:36:47,320 --> 02:36:48,720 AT POTENTIAL PEOPLE THAT CAN BE 3894 02:36:48,720 --> 02:36:52,320 PART OF YOUR POOL, AND ACTUALLY 3895 02:36:52,320 --> 02:36:56,760 DOING OUTREACH DIRECTLY TO THEM, 3896 02:36:56,760 --> 02:36:59,040 ASSIST IN THAT PROCESS. 3897 02:36:59,040 --> 02:37:00,920 >>YES, INCREASING DIVERSITY IS 3898 02:37:00,920 --> 02:37:03,400 A BIG EFFORT OF OURS GOING 3899 02:37:03,400 --> 02:37:06,240 FORWARD, WITH OTHER PROGRAMS AND 3900 02:37:06,240 --> 02:37:06,560 INITIATIVES. 3901 02:37:06,560 --> 02:37:08,640 >>WE'RE GOING TO BE PRESSED FOR 3902 02:37:08,640 --> 02:37:11,040 TIME WITH HANDS UP. 3903 02:37:11,040 --> 02:37:12,880 KAREN, GO AHEAD. 3904 02:37:12,880 --> 02:37:14,400 >>THANKS FOR A GREAT 3905 02:37:14,400 --> 02:37:14,720 PRESENTATION. 3906 02:37:14,720 --> 02:37:15,320 INTERESTING PROGRAM. 3907 02:37:15,320 --> 02:37:17,920 I WAS WONDERING IF YOU COULD 3908 02:37:17,920 --> 02:37:22,320 COMMENT ON THE EXTENT TO WHICH 3909 02:37:22,320 --> 02:37:24,280 POPULATION HEALTH AND BEHAVIORAL 3910 02:37:24,280 --> 02:37:28,640 TECHNOLOGIES ARE ACKNOWLEDGED 3911 02:37:28,640 --> 02:37:31,400 INTO THE SBIR/STTR PROGRAM, THE 3912 02:37:31,400 --> 02:37:33,160 BRIDGE FUNDING CATEGORIES YOU 3913 02:37:33,160 --> 02:37:36,800 MENTIONED DIDN'T SEEM TO BE 3914 02:37:36,800 --> 02:37:39,200 FOCUSED ON THOSE KINDS OF 3915 02:37:39,200 --> 02:37:40,600 TECHNOLOGIES BUT IT SEEMS THERE 3916 02:37:40,600 --> 02:37:43,800 ARE MANY BEING DEVELOPED THROUGH 3917 02:37:43,800 --> 02:37:49,280 RESEARCH, mHEALTH, e-HEALTH 3918 02:37:49,280 --> 02:37:51,760 THAT COULD BE APPROPRIATE. 3919 02:37:51,760 --> 02:37:53,600 >>YEAH, THANKS. 3920 02:37:53,600 --> 02:38:02,120 I DON'T HAVE THE FIGURES ON 3921 02:38:02,120 --> 02:38:05,480 HANDP FOR THOSE CATEGORIES BUT 3922 02:38:05,480 --> 02:38:06,680 OVERALL FUNDING WE DO -- IT IS 3923 02:38:06,680 --> 02:38:08,640 AN IMPORTANT PART OF OUR 3924 02:38:08,640 --> 02:38:08,920 PORTFOLIO. 3925 02:38:08,920 --> 02:38:18,280 I THINK IN THAT KIND OF SPACE WE 3926 02:38:18,280 --> 02:38:18,960 FUND DIGITAL HEALTH, 3927 02:38:18,960 --> 02:38:20,400 SOFTWARE-BASED PROJECTS, LOOKING 3928 02:38:20,400 --> 02:38:25,120 AT DIFFERENT ASPECTS OF 3929 02:38:25,120 --> 02:38:28,360 POPULATION HEALTH, AND I CAN 3930 02:38:28,360 --> 02:38:33,960 THINK OF GRANTS WE FUNDED IN 3931 02:38:33,960 --> 02:38:36,560 TRYING TO PROMOTE DIVERSE 3932 02:38:36,560 --> 02:38:38,840 REPRESENTATION IN CLINICAL 3933 02:38:38,840 --> 02:38:40,080 TRIALS, SOFTWARE PLATFORMS TO 3934 02:38:40,080 --> 02:38:47,840 HELP PATIENTS MANAGE THEIR CARE 3935 02:38:47,840 --> 02:38:51,600 BETTER AND ACCESS PREVENTIVE 3936 02:38:51,600 --> 02:38:53,120 CARE, THINGS LIKE THAT. 3937 02:38:53,120 --> 02:38:56,200 THAT'S ABOUT 8% OF OUR PORTFOLIO 3938 02:38:56,200 --> 02:38:57,760 FROM MY UNDERSTANDING. 3939 02:38:57,760 --> 02:39:05,920 IN TERMS OF BRIDGE AWARDS, THAT 3940 02:39:05,920 --> 02:39:07,360 HAS NOT -- I DON'T THINK WE 3941 02:39:07,360 --> 02:39:17,840 FUNDED MANY IN THAT SPACE. 3942 02:39:18,360 --> 02:39:19,720 THERE HAVE BEEN APPLICATIONS BUT 3943 02:39:19,720 --> 02:39:22,440 FOR ONE REASON OR ANOTHER THEY 3944 02:39:22,440 --> 02:39:32,960 DIDN'T GET SELECTED. 3945 02:39:32,960 --> 02:39:34,400 >>HOWARD? 3946 02:39:34,400 --> 02:39:36,160 >>YOU'RE STILL MUTED, HOWARD. 3947 02:39:36,160 --> 02:39:41,560 BOB, MAYBE MOVE TO YOU. 3948 02:39:41,560 --> 02:39:41,880 >>OKAY. 3949 02:39:41,880 --> 02:39:44,400 I'M BACK. 3950 02:39:44,400 --> 02:39:44,960 >>GO AHEAD. 3951 02:39:44,960 --> 02:39:50,200 >>DO WE CARE IF FUNDED SPECIFIC 3952 02:39:50,200 --> 02:39:53,120 GOALS FOR FUNDED ORGANIZATION IS 3953 02:39:53,120 --> 02:39:54,800 FOR A POSITIVE CONTRIBUTION TO 3954 02:39:54,800 --> 02:40:00,600 THE U.S. AND PATIENT CARE WITH 3955 02:40:00,600 --> 02:40:01,600 CANCER, OF COURSE. 3956 02:40:01,600 --> 02:40:04,480 THE DATA WE'RE GIVEN ABOUT THE 3957 02:40:04,480 --> 02:40:07,800 SUCCESSES AND SUBSEQUENT FUND 3958 02:40:07,800 --> 02:40:12,840 RAISES AND EXITS THAT ARE REALLY 3959 02:40:12,840 --> 02:40:18,080 CENTERED AROUND ACHIEVING THAT 3960 02:40:18,080 --> 02:40:20,800 GOAL, I'VE SEEN TOO MANY 3961 02:40:20,800 --> 02:40:21,680 ANECDOTES WITH SBIR 3962 02:40:21,680 --> 02:40:23,000 PRESENTATIONS WHERE THERE'S A 3963 02:40:23,000 --> 02:40:25,400 DISCONNECT, A GROUP GOT A PHASE 3964 02:40:25,400 --> 02:40:26,960 2 LARGE AWARDS, WAS PRESENTED TO 3965 02:40:26,960 --> 02:40:33,520 US, HAD A BREAST CANCER GENOMIC 3966 02:40:33,520 --> 02:40:34,960 ASSAY, THEY EXITED, AND WERE 3967 02:40:34,960 --> 02:40:40,440 BOUGHT OUT BY A U.K. COMPANY. 3968 02:40:40,440 --> 02:40:43,080 U.K. NEVER BROUGHT FORWARD THE 3969 02:40:43,080 --> 02:40:45,040 BREAST CANCER GENOMIC ASSAY, 3970 02:40:45,040 --> 02:40:46,000 NEVER COMMERCIALIZED, NO BREAST 3971 02:40:46,000 --> 02:40:47,240 CANCER PATIENTS EVER GOT AN 3972 02:40:47,240 --> 02:40:48,760 ADVANTAGE OUT OF IT, AND INSTEAD 3973 02:40:48,760 --> 02:40:50,880 THEY WENT OFF AND TOOK THE MONEY 3974 02:40:50,880 --> 02:40:52,560 AND DEVELOPED A LUNG CANCER 3975 02:40:52,560 --> 02:40:52,760 PROGRAM. 3976 02:40:52,760 --> 02:40:54,360 I DON'T KNOW IF I CARE. 3977 02:40:54,360 --> 02:40:56,400 I THINK THAT'S NOT A BAD THING 3978 02:40:56,400 --> 02:40:58,720 FOR THE LUNG CANCER POPULATION, 3979 02:40:58,720 --> 02:41:04,960 BUT I'M WONDERING IF THE -- IF 3980 02:41:04,960 --> 02:41:07,040 STATISTICS WE'RE HEARING, THAT 3981 02:41:07,040 --> 02:41:13,560 IT'S NEEDED, ABOUT THE SPECIFIC 3982 02:41:13,560 --> 02:41:15,240 GOAL, YOU KNOW, SUCCESSING PART 3983 02:41:15,240 --> 02:41:20,160 OF WHERE -- SUCCESSES IS PART OF 3984 02:41:20,160 --> 02:41:23,200 WHERE THE FUNDING IS GOING. 3985 02:41:23,200 --> 02:41:26,840 3986 02:41:26,840 --> 02:41:29,120 >>PART OF THE MANDATE FROM 3987 02:41:29,120 --> 02:41:30,440 CONGRESS IS TO MAKE THAT 3988 02:41:30,440 --> 02:41:33,720 POSITIVE CONTRIBUTION TO THE 3989 02:41:33,720 --> 02:41:34,520 U.S. ECONOMY. 3990 02:41:34,520 --> 02:41:38,440 WE ALSO CARE ABOUT THE PATIENT 3991 02:41:38,440 --> 02:41:43,000 IMPACT AND FIGURE IF WE TRACK -- 3992 02:41:43,000 --> 02:41:44,440 MICHAEL, DO YOU WANT TO ADDRESS 3993 02:41:44,440 --> 02:41:46,080 THIS QUESTION? 3994 02:41:46,080 --> 02:41:47,280 >>YEAH, ACTUALLY, JONATHAN. 3995 02:41:47,280 --> 02:41:48,640 YOU CAN. 3996 02:41:48,640 --> 02:41:49,920 TALK ABOUT THE MANDATE FOR A 3997 02:41:49,920 --> 02:41:52,680 CERTAIN AMOUNT OF DOLLARS TO BE 3998 02:41:52,680 --> 02:41:53,320 OUTBOUND FOR PROGRAMS LIKE THIS 3999 02:41:53,320 --> 02:41:56,760 AS PART OF THE CONGRESSIONAL 4000 02:41:56,760 --> 02:41:57,360 BUDGET REQUIREMENTS BECAUSE I 4001 02:41:57,360 --> 02:42:00,480 THINK THAT'S THE KEY TO 4002 02:42:00,480 --> 02:42:03,200 UNDERSTANDING WHY THIS PROGRAM 4003 02:42:03,200 --> 02:42:04,400 REMAINS IMPORTANT. 4004 02:42:04,400 --> 02:42:05,720 AND DESPITE THE CHALLENGES THAT 4005 02:42:05,720 --> 02:42:08,600 I THINK ARE POINTED OUT MY 4006 02:42:08,600 --> 02:42:11,000 MEMBERS OF THIS GROUP I THINK 4007 02:42:11,000 --> 02:42:13,640 THE EDUCATION IS REALLY NEEDED 4008 02:42:13,640 --> 02:42:18,320 JUST AS A SOLUTION PIECE. 4009 02:42:18,320 --> 02:42:19,960 WE RECOGNIZE IN PITS BURKE. 4010 02:42:19,960 --> 02:42:21,360 WHAT WE'VE DONE WITH R25 TO 4011 02:42:21,360 --> 02:42:23,920 BRING BRIGHTEST MINDS TO BEAR A 4012 02:42:23,920 --> 02:42:34,480 CONNER IS RESEARCH CONNECTED TO 4013 02:42:34,480 --> 02:42:37,200 SBIR AND STTR TO BRING DIVERSE 4014 02:42:37,200 --> 02:42:39,200 FEMALE LEADERS IN THE X-RAYS TO 4015 02:42:39,200 --> 02:42:41,720 ACCOMPLISH GOALS. 4016 02:42:41,720 --> 02:42:44,560 WHY DON'T YOU COMMENT ON THE 4017 02:42:44,560 --> 02:42:48,640 ALLOCATION REQUIRED FOR THIS 4018 02:42:48,640 --> 02:42:51,320 TYPE OF COMMERCIALLY 4019 02:42:51,320 --> 02:42:52,960 OUTBOUND-RELATED ACTIVITIES. 4020 02:42:52,960 --> 02:42:56,840 >>YES, SO THE CONGRESSIONAL 4021 02:42:56,840 --> 02:42:58,920 MANDATE IS THAT 3.65% OF SET 4022 02:42:58,920 --> 02:43:00,960 ASIDE OF THE EXTRAMURAL R&D 4023 02:43:00,960 --> 02:43:02,400 BUDGET TO SUPPORT SMALL 4024 02:43:02,400 --> 02:43:05,360 BUSINESSES THROUGH THE SBIR AND 4025 02:43:05,360 --> 02:43:08,840 STTR PROGRAMS, WITH THE GOAL OF 4026 02:43:08,840 --> 02:43:11,720 HELPING INNOVATION THROUGH THESE 4027 02:43:11,720 --> 02:43:12,960 COMPANIES, IMPACT PATIENTS, AND 4028 02:43:12,960 --> 02:43:18,280 BENEFIT THE U.S. ECONOMY 4029 02:43:18,280 --> 02:43:22,480 OVERALL. 4030 02:43:22,480 --> 02:43:23,760 >>SYLVIA WANTED US TO MAKE SURE 4031 02:43:23,760 --> 02:43:29,920 WE BROUGHT THAT OUT IN THE 4032 02:43:29,920 --> 02:43:31,440 CONVERSATION SO I'M CHANNELING 4033 02:43:31,440 --> 02:43:33,000 SYLVIA RIGHT NOW. 4034 02:43:33,000 --> 02:43:33,920 >>GO, BOB. 4035 02:43:33,920 --> 02:43:34,240 >>THANKS. 4036 02:43:34,240 --> 02:43:38,440 MEASURED IS WHAT GETS DONE. 4037 02:43:38,440 --> 02:43:40,160 IF THERE'S EFFORTS TO PRIORITIZE 4038 02:43:40,160 --> 02:43:47,080 AND FUND A GROUP, BASED ON A -- 4039 02:43:47,080 --> 02:43:48,320 [AUDIO DISTORTION] 4040 02:43:48,320 --> 02:43:49,960 ACCESS TO UNDERSERVED OR 4041 02:43:49,960 --> 02:43:51,640 OVERSERVED, I DON'T CARE, ANY OF 4042 02:43:51,640 --> 02:43:53,440 THE AMERICAN POPULATION, AND 4043 02:43:53,440 --> 02:43:57,200 THEN THAT JUST DOESN'T HAPPEN 4044 02:43:57,200 --> 02:44:00,040 BECAUSE THE FUNDING GETS -- IT 4045 02:44:00,040 --> 02:44:02,520 WOULD BE NICE TO I THINK 4046 02:44:02,520 --> 02:44:05,520 UNDERSTAND THIS WHETHER, YOU 4047 02:44:05,520 --> 02:44:08,360 KNOW, HOW THE FUNDING 4048 02:44:08,360 --> 02:44:10,120 ACHIEVEMENTS SORT OF MATCH BASED 4049 02:44:10,120 --> 02:44:14,160 ON THE SPECIFIC AIMS OF WHY THEY 4050 02:44:14,160 --> 02:44:18,720 WON THAT FUNDING AND HOW THAT 4051 02:44:18,720 --> 02:44:19,200 TRANS-- 4052 02:44:19,200 --> 02:44:20,480 [AUDIO DISTORTION] 4053 02:44:20,480 --> 02:44:22,440 CARE, IMPROVING CARE OF PATIENTS 4054 02:44:22,440 --> 02:44:25,520 WITH CANCER IN OUR POPULATIONS. 4055 02:44:25,520 --> 02:44:30,440 I THINK WE CARE ABOUT THAT TOO. 4056 02:44:30,440 --> 02:44:31,520 4057 02:44:31,520 --> 02:44:33,640 >>YES, AND, YOU KNOW, OUR 4058 02:44:33,640 --> 02:44:37,160 FUNDING MANDATE IS NOT THAT OF A 4059 02:44:37,160 --> 02:44:38,440 TRADITIONAL -- NOT JUST LOOKING 4060 02:44:38,440 --> 02:44:39,000 AT ECONOMIC IMPACT. 4061 02:44:39,000 --> 02:44:41,840 AND SO WE DO HAVE PROGRAMS FOR 4062 02:44:41,840 --> 02:44:46,040 EXAMPLE ON RARE AND PEDIATRIC 4063 02:44:46,040 --> 02:44:49,120 CANCERS, PROGRAMS FUNDING, YOU 4064 02:44:49,120 --> 02:44:50,000 KNOW, HEALTH DISPARITIES, SO 4065 02:44:50,000 --> 02:44:52,400 WE'RE NOT ONLY INTERESTED IN 4066 02:44:52,400 --> 02:44:53,960 THAT WILL OVERALL RETURN. 4067 02:44:53,960 --> 02:44:56,120 THAT'S SOMETHING A LOT OF PEOPLE 4068 02:44:56,120 --> 02:44:56,440 CARE ABOUT. 4069 02:44:56,440 --> 02:44:58,320 THAT'S WHY WE COMMISSIONED THAT 4070 02:44:58,320 --> 02:44:58,640 STUDY. 4071 02:44:58,640 --> 02:45:02,360 BUT, YES, I DID NOT MEAN TO GIVE 4072 02:45:02,360 --> 02:45:03,800 THE IMPRESSION THAT'S OUR ONLY 4073 02:45:03,800 --> 02:45:04,000 GOAL. 4074 02:45:04,000 --> 02:45:05,440 YOU'RE RIGHT, WE NEED TO KEEP 4075 02:45:05,440 --> 02:45:09,120 THAT BIG PICTURE IN MIND. 4076 02:45:09,120 --> 02:45:09,400 >>OKAY. 4077 02:45:09,400 --> 02:45:11,720 WE'RE A FULL TEN MINUTES OVER. 4078 02:45:11,720 --> 02:45:14,920 BOB, REAL QUICK AND TREY AND 4079 02:45:14,920 --> 02:45:16,240 ANN, MAYBE YOU COULD SUBMIT 4080 02:45:16,240 --> 02:45:19,080 QUESTIONS THROUGH THE CHAT OR 4081 02:45:19,080 --> 02:45:19,560 COMMENTS. 4082 02:45:19,560 --> 02:45:21,520 >>REAL QUICK QUESTION FOR ME. 4083 02:45:21,520 --> 02:45:24,000 YOU KNOW, THIS IS A WONDERFUL 4084 02:45:24,000 --> 02:45:24,680 PROGRAM. 4085 02:45:24,680 --> 02:45:27,200 I SUPPORT IT COMPLETELY. 4086 02:45:27,200 --> 02:45:29,840 BUT THE ONE THING THAT'S NOT 4087 02:45:29,840 --> 02:45:32,280 BEEN DISCUSSED IS THE ECONOMIC 4088 02:45:32,280 --> 02:45:35,760 CLIMATE IN WHICH ONE HAS TO 4089 02:45:35,760 --> 02:45:38,280 CONSIDER WHETHER THESE MATCHING 4090 02:45:38,280 --> 02:45:41,680 FUNDS, INVESTMENTS FROM OUTSIDE 4091 02:45:41,680 --> 02:45:44,520 CAN BE ACHIEVED AND RIGHT NOW 4092 02:45:44,520 --> 02:45:45,720 ESPECIALLY NOW, YOU KNOW, THAT 4093 02:45:45,720 --> 02:45:49,360 VALLEY OF DEATH IS GETTING WIDER 4094 02:45:49,360 --> 02:45:51,640 AND DEEPER, AND I'M JUST 4095 02:45:51,640 --> 02:45:53,120 WONDERING HOW YOU'RE THINKING 4096 02:45:53,120 --> 02:45:55,000 ABOUT THIS IN TERMS OF SOMEHOW 4097 02:45:55,000 --> 02:45:57,120 LINKING WHAT YOU EXPECT FOR 4098 02:45:57,120 --> 02:45:59,720 MATCHING FUNDS TO BE SOMEHOW 4099 02:45:59,720 --> 02:46:00,840 LINKED TO THE INVESTMENT 4100 02:46:00,840 --> 02:46:03,640 CLIMATE. 4101 02:46:03,640 --> 02:46:05,840 >>I THINK, YES, GREAT POINT, 4102 02:46:05,840 --> 02:46:07,680 AND GIVEN THE INVESTMENT CLIMATE 4103 02:46:07,680 --> 02:46:10,320 I THINK THE BRIDGE AWARD PROGRAM 4104 02:46:10,320 --> 02:46:11,440 IS PARTICULARLY IMPACTFUL NOW 4105 02:46:11,440 --> 02:46:14,280 BECAUSE COMPANIES ARE FINDING IT 4106 02:46:14,280 --> 02:46:16,120 HARDER TO RAISE FUNDS. 4107 02:46:16,120 --> 02:46:17,560 THE CLOSEST EXPERIENCE WE HAVE 4108 02:46:17,560 --> 02:46:20,120 ARE, YOU KNOW, HOW THE PROGRAM 4109 02:46:20,120 --> 02:46:22,720 PERFORMED IN PREVIOUS ECONOMIC 4110 02:46:22,720 --> 02:46:25,000 DOWNTURNS, AND THERE WE DID FIND 4111 02:46:25,000 --> 02:46:26,640 COMPANIES WERE ABLE TO RAISE THE 4112 02:46:26,640 --> 02:46:29,760 MATCHING FUNDS. 4113 02:46:29,760 --> 02:46:32,400 I'D HAVE TO LOOK AT -- COMPARE 4114 02:46:32,400 --> 02:46:33,680 AMOUNTS PERHAPS BUT THE FEEDBACK 4115 02:46:33,680 --> 02:46:37,400 WE'RE GETTING IS THIS KIND OF 4116 02:46:37,400 --> 02:46:39,800 INCENTIVE AND ABILITY FOR 4117 02:46:39,800 --> 02:46:41,320 FEDERAL FUNDS TO LEVERAGE 4118 02:46:41,320 --> 02:46:43,160 PRIVATE INVESTMENT IS VERY 4119 02:46:43,160 --> 02:46:46,680 ATTRACTIVE IN THIS CLIMATE. 4120 02:46:46,680 --> 02:46:47,520 >>GREAT. 4121 02:46:47,520 --> 02:46:47,880 THANK YOU. 4122 02:46:47,880 --> 02:46:50,520 >>SORRY TO CUT OFF DISCUSSION. 4123 02:46:50,520 --> 02:46:53,560 LET'S MOVE TO VOTING. 4124 02:46:53,560 --> 02:46:58,160 AGAIN, THIS IS REISSUANCE, 4125 02:46:58,160 --> 02:46:59,720 SUBCOMMITTEE HAS ALREADY 4126 02:46:59,720 --> 02:47:01,120 INDICATED THEIR INTENT TO MOTION 4127 02:47:01,120 --> 02:47:02,200 FOR CONCURRENCE. 4128 02:47:02,200 --> 02:47:03,840 DAVE, CAN YOU QUICKLY CONFIRM 4129 02:47:03,840 --> 02:47:05,240 THAT? 4130 02:47:05,240 --> 02:47:06,640 >>I MOTION FOR CONCURRENCE 4131 02:47:06,640 --> 02:47:08,440 >>SECOND? 4132 02:47:08,440 --> 02:47:12,040 >>SECOND. 4133 02:47:12,040 --> 02:47:12,320 >>GREAT. 4134 02:47:12,320 --> 02:47:13,240 FURTHER DISCUSSION? 4135 02:47:13,240 --> 02:47:15,240 >>JUST THE CAVEAT ABOUT THE 4136 02:47:15,240 --> 02:47:17,040 DIVERSITY OF THE PROGRAM. 4137 02:47:17,040 --> 02:47:17,680 >>YES, NOTED. 4138 02:47:17,680 --> 02:47:18,000 THANK YOU. 4139 02:47:18,000 --> 02:47:19,480 >>JUST ON THE RECORD. 4140 02:47:19,480 --> 02:47:20,560 THAT'S ALL. 4141 02:47:20,560 --> 02:47:21,600 >>ABSOLUTELY, YEP. 4142 02:47:21,600 --> 02:47:25,320 >>I SUPPORT IT 100%. 4143 02:47:25,320 --> 02:47:25,920 >>UNDERSTOOD. 4144 02:47:25,920 --> 02:47:29,120 ANYONE ELSE? 4145 02:47:29,120 --> 02:47:29,320 OKAY. 4146 02:47:29,320 --> 02:47:32,760 LOOKING FOR ANY VOTES OF 4147 02:47:32,760 --> 02:47:34,480 NON-CONCURRENCE. 4148 02:47:34,480 --> 02:47:39,280 BY ELECTRONIC HAND OR VOICE. 4149 02:47:39,280 --> 02:47:40,520 I SEE NONE. 4150 02:47:40,520 --> 02:47:43,160 AND I DO NOT HAVE ANY RECORDED 4151 02:47:43,160 --> 02:47:43,640 ABSTENTIONS. 4152 02:47:43,640 --> 02:47:46,760 ANY LAST-MINUTE ONES? 4153 02:47:46,760 --> 02:47:48,200 4154 02:47:48,200 --> 02:47:51,600 I DO NOT SEE ANY. 4155 02:47:51,600 --> 02:47:54,760 PAULETTE, I THINK WE'RE OKAY. 4156 02:47:54,760 --> 02:47:55,880 >>IT'S UNANIMOUS. 4157 02:47:55,880 --> 02:47:56,200 >>OKAY. 4158 02:47:56,200 --> 02:47:56,960 THANKS, ALL. 4159 02:47:56,960 --> 02:47:59,520 APOLOGIES FOR THE CLOCK 4160 02:47:59,520 --> 02:47:59,920 MANAGEMENT. 4161 02:47:59,920 --> 02:48:02,960 JOHN, YOU'RE INHERITING A 4162 02:48:02,960 --> 02:48:03,520 DEFICIT. 4163 02:48:03,520 --> 02:48:06,240 BACK TO YOU. 4164 02:48:06,240 --> 02:48:08,000 >>NO PROBLEM. 4165 02:48:08,000 --> 02:48:08,440 THANKS, KEITH. 4166 02:48:08,440 --> 02:48:13,000 I THINK AT THIS POINT WE WILL BE 4167 02:48:13,000 --> 02:48:14,400 CONSIDERING ONGOING AND NEW 4168 02:48:14,400 --> 02:48:19,400 BUSINESS IN TERMS OF ONGOING 4169 02:48:19,400 --> 02:48:21,480 BUSINESS, THERE WERE THREE NCAB 4170 02:48:21,480 --> 02:48:22,680 COMMITTEE MEETINGS ON MONDAY THE 4171 02:48:22,680 --> 02:48:25,880 5th, THE CHAIRS WILL GIVE THE 4172 02:48:25,880 --> 02:48:26,480 REPORT. 4173 02:48:26,480 --> 02:48:28,240 NCAB WILL VOTE ON THOSE REPORTS. 4174 02:48:28,240 --> 02:48:32,640 I DO HAVE A QUESTION, PAULETTE. 4175 02:48:32,640 --> 02:48:34,200 THE REPORT FROM ELECTRA AND 4176 02:48:34,200 --> 02:48:35,400 ELENA WAS GIVEN THIS MORNING. 4177 02:48:35,400 --> 02:48:36,960 WE VOTED. 4178 02:48:36,960 --> 02:48:38,800 DO WE NEED TO DO IT AGAIN. 4179 02:48:38,800 --> 02:48:40,000 IT'S ON THE AGENDA. 4180 02:48:40,000 --> 02:48:41,200 >>WHAT YOU VOTED ON THIS 4181 02:48:41,200 --> 02:48:46,040 MORNING WAS THE WORKING GROUP 4182 02:48:46,040 --> 02:48:46,280 REPORT. 4183 02:48:46,280 --> 02:48:47,160 >>GOT IT. 4184 02:48:47,160 --> 02:48:48,800 >>IT'S A SUBCOMMITTEE. 4185 02:48:48,800 --> 02:48:49,880 >>GOT IT. 4186 02:48:49,880 --> 02:48:50,440 GREAT. 4187 02:48:50,440 --> 02:48:52,400 LET'S START THE FIRST 4188 02:48:52,400 --> 02:48:55,560 SUBCOMMITTEE REPORT WILL BE 4189 02:48:55,560 --> 02:49:00,920 GIVEN BY FRANCIS WHO IS CLAIRE 4190 02:49:00,920 --> 02:49:01,120 CHAIR 4191 02:49:01,120 --> 02:49:07,120 OFFED -- OF THE AD HOC COMMITTN 4192 02:49:07,120 --> 02:49:08,320 GLOBAL RESEARCH. 4193 02:49:08,320 --> 02:49:11,160 CAN YOU UNMUTE? 4194 02:49:11,160 --> 02:49:13,800 4195 02:49:13,800 --> 02:49:16,440 >>I'LL SAY I HAVE TO APOLOGIZE, 4196 02:49:16,440 --> 02:49:18,000 LAST TWO DAYS I'VE BEEN GREAT. 4197 02:49:18,000 --> 02:49:20,400 I'M OUT OF THE COUNTRY. 4198 02:49:20,400 --> 02:49:22,480 THE PAST COUPLE HOURS I'VE BEEN 4199 02:49:22,480 --> 02:49:24,320 HAVING MY INTERNET COME IN AND 4200 02:49:24,320 --> 02:49:24,760 OUT. 4201 02:49:24,760 --> 02:49:29,720 I HOPE IT WILL STAY ON. 4202 02:49:29,720 --> 02:49:33,600 CAN YOU HEAR ME? 4203 02:49:33,600 --> 02:49:33,880 >>YES. 4204 02:49:33,880 --> 02:49:34,120 >>GOOD. 4205 02:49:34,120 --> 02:49:37,760 I HOPE IT HOLDS THIS WAY. 4206 02:49:37,760 --> 02:49:39,440 THE AD HOC SUBCOMMITTEE MET TWO 4207 02:49:39,440 --> 02:49:42,800 DAYS AGO, A COPY OF THE FULL 4208 02:49:42,800 --> 02:49:43,440 SUBCOMMITTEE MEETING REPORT HAS 4209 02:49:43,440 --> 02:49:44,680 BEEN SENT TO ALL OF YOU. 4210 02:49:44,680 --> 02:49:45,920 MY PRESENTATION WILL BE A 4211 02:49:45,920 --> 02:49:47,960 SUMMARY OF SOME OF THE 4212 02:49:47,960 --> 02:49:49,680 HIGHLIGHTS OF THE MEETING AND 4213 02:49:49,680 --> 02:49:50,240 OUR DISCUSSIONS. 4214 02:49:50,240 --> 02:49:54,320 EYE REFER -- I REFER YOU TO THE 4215 02:49:54,320 --> 02:49:55,400 FULL MEETING REPORT. 4216 02:49:55,400 --> 02:49:58,440 THE CHARGE OF THE SUBCOMMITTEE 4217 02:49:58,440 --> 02:50:01,840 IN A NUTSHELL TO ADVISE NCAB AND 4218 02:50:01,840 --> 02:50:03,400 NCI DIRECTOR ON STRATEGIC 4219 02:50:03,400 --> 02:50:04,680 APPROACHES TO ENHANCE 4220 02:50:04,680 --> 02:50:07,120 CONTRIBUTION OF THE NCI TO 4221 02:50:07,120 --> 02:50:09,200 GLOBAL CANCER RESEARCH. 4222 02:50:09,200 --> 02:50:11,520 THE PROCESS, THE SUBCOMMITTEE 4223 02:50:11,520 --> 02:50:12,920 PROVIDES LEADERSHIP, EXPERTISE, 4224 02:50:12,920 --> 02:50:14,440 INPUT ON INITIATIVES, CONCEPTS, 4225 02:50:14,440 --> 02:50:16,520 PARTNERSHIPS, TO HELP IDENTIFY 4226 02:50:16,520 --> 02:50:17,160 AND PRIORITIZE CHALLENGES AND 4227 02:50:17,160 --> 02:50:19,720 NEW OPPORTUNITIES FOR THE NCI 4228 02:50:19,720 --> 02:50:22,480 AND GLOBAL CANCER RESEARCH. 4229 02:50:22,480 --> 02:50:32,960 SUBCOMMITTEE WAS PLEASED TO 4230 02:50:34,560 --> 02:50:35,160 WELCOME DR. BERTAGNOLLI, 4231 02:50:35,160 --> 02:50:36,800 EMPHASIZING GLOBAL NATURE OF 4232 02:50:36,800 --> 02:50:37,440 CANCER, SCIENTISTS AND 4233 02:50:37,440 --> 02:50:39,880 PHYSICIANS MUST ADDRESS NEEDS OF 4234 02:50:39,880 --> 02:50:44,280 THE WORLD WIDE COMMUNITY WHILE 4235 02:50:44,280 --> 02:50:46,320 ADDRESSING THEIR OWN 4236 02:50:46,320 --> 02:50:47,640 COMMUNITIES. 4237 02:50:47,640 --> 02:50:48,160 REMARKS WERE REASSURING, 4238 02:50:48,160 --> 02:50:49,600 RESTATEMENT OF THE SUPPORT 4239 02:50:49,600 --> 02:50:52,200 GLOBAL CANCER RESEARCH HAS 4240 02:50:52,200 --> 02:50:53,320 ENJOYED FROM PREVIOUS NCI 4241 02:50:53,320 --> 02:50:54,760 DIRECTORS ESPECIALLY IN THE PAST 4242 02:50:54,760 --> 02:51:03,800 DECADE FROM HAROLD VAIR VARMUSD 4243 02:51:03,800 --> 02:51:05,600 SHARPLESS AND DOUG LOWY. 4244 02:51:05,600 --> 02:51:07,320 WE LOOK FORWARD TO CONTINUED 4245 02:51:07,320 --> 02:51:07,880 SUPPORT. 4246 02:51:07,880 --> 02:51:11,680 TWO MAIN ITEMS OF BILLS FOR THE 4247 02:51:11,680 --> 02:51:14,040 SUBCOMMITTEE, FIRST WAS UPDATE 4248 02:51:14,040 --> 02:51:24,160 BY THE DIRECTOR OF THE CENTER 4249 02:51:24,160 --> 02:51:25,360 FOR GLOBAL HEALTH, AND 4250 02:51:25,360 --> 02:51:26,360 APPOINTMENT HAS NO BETTER TIME 4251 02:51:26,360 --> 02:51:30,000 THAN THE START OF THE COVID-19 4252 02:51:30,000 --> 02:51:30,240 PANDEMIC. 4253 02:51:30,240 --> 02:51:31,600 HOWEVER THE CONSTRAINTS OF THE 4254 02:51:31,600 --> 02:51:33,240 PANDEMIC WITH HIS LEADERSHIP THE 4255 02:51:33,240 --> 02:51:35,240 CENTER IS ON A VERY STRONG PATH 4256 02:51:35,240 --> 02:51:38,280 ACROSS THE INSTITUTE WITH 4257 02:51:38,280 --> 02:51:43,120 VARIOUS PARTNERS, THE VISION IN 4258 02:51:43,120 --> 02:51:44,640 LINE WITH THE STRATEGIC PLAN. 4259 02:51:44,640 --> 02:51:47,680 I BELIEVE THE STRATEGIC PLAN IS 4260 02:51:47,680 --> 02:51:50,120 AVAILABLE ONLINE, UPON REQUEST 4261 02:51:50,120 --> 02:51:57,960 FROM THE CDH. 4262 02:51:57,960 --> 02:52:00,080 KEY ELEMENTS WITH THIS WILL 4263 02:52:00,080 --> 02:52:02,800 CENTER AROUND RESEARCH, 4264 02:52:02,800 --> 02:52:04,360 TRAINING, DISSEMINATION, 4265 02:52:04,360 --> 02:52:04,880 PARTNERSHIPS, DETAILS OF 4266 02:52:04,880 --> 02:52:05,880 ACTIVITIES REPORTED TO THE 4267 02:52:05,880 --> 02:52:10,360 SUBCOMMITTEE AND EACH OF THESE 4268 02:52:10,360 --> 02:52:12,840 THEMATIC AREAS I REFER YOU TO 4269 02:52:12,840 --> 02:52:17,120 THE DETAILED REPORT. 4270 02:52:17,120 --> 02:52:21,400 TWO EXAMPLES, FIRST IS THE 4271 02:52:21,400 --> 02:52:23,040 AFFORDABLE CANCER TECHNOLOGIES 4272 02:52:23,040 --> 02:52:24,800 PROGRAM, PROVIDING GRANT SUPPORT 4273 02:52:24,800 --> 02:52:26,440 FOR LATE STAGE TESTING AND 4274 02:52:26,440 --> 02:52:32,360 VALIDATION OF CONTROL 4275 02:52:32,360 --> 02:52:33,440 TECHNOLOGIES IN LOW- AND 4276 02:52:33,440 --> 02:52:37,040 MIDDLE-INCOME COUNTRIES, 4277 02:52:37,040 --> 02:52:38,160 SUCCESSFUL PROGRAM, I'VE 4278 02:52:38,160 --> 02:52:41,320 PRESENTED EXAMPLES AT SUCCESSES 4279 02:52:41,320 --> 02:52:43,040 FOR THE PROGRAM. 4280 02:52:43,040 --> 02:52:49,120 AN RFA WAS REISSUED. 4281 02:52:49,120 --> 02:52:51,480 THE OTHER IMPORTANT THEMATIC 4282 02:52:51,480 --> 02:52:53,120 AREA THAT I'D LIKE TO MESSAGE, 4283 02:52:53,120 --> 02:52:55,880 ACTIVITIES IN THE AREA OF 4284 02:52:55,880 --> 02:52:57,600 TRAINING AND CAPACITY BUILDING 4285 02:52:57,600 --> 02:53:00,520 CARRIED OUT BOTH EXTRAMURALLY 4286 02:53:00,520 --> 02:53:01,920 AND INTRAMURALLY. 4287 02:53:01,920 --> 02:53:04,320 THE CENTER IS USING D43 AWARD 4288 02:53:04,320 --> 02:53:06,720 MECHANISM TO SUPPORT BUILDING OF 4289 02:53:06,720 --> 02:53:11,640 GLOBAL CANCER RESEARCH TRAINING 4290 02:53:11,640 --> 02:53:13,920 NETWORKS, TO ENCOURAGE LMIC 4291 02:53:13,920 --> 02:53:15,880 INSTITUTIONS TO DEVELOP 4292 02:53:15,880 --> 02:53:16,640 PARTNERSHIPS WITH NCI-DESIGNATED 4293 02:53:16,640 --> 02:53:18,840 CANCER CENTERS, THE KEY THING, 4294 02:53:18,840 --> 02:53:21,800 IT'S NOT WITHIN THE U.S. BUT AT 4295 02:53:21,800 --> 02:53:25,400 THE VARIOUS COUNTRIES, BUT 4296 02:53:25,400 --> 02:53:29,120 INTRAMURALLY HOWEVER THE 4297 02:53:29,120 --> 02:53:32,440 ACTIVITIES, ONE IS RESUMPTION OF 4298 02:53:32,440 --> 02:53:38,440 SHORT-TERM PROGRAM IN THE FALL 4299 02:53:38,440 --> 02:53:40,280 OF THIS YEAR, LMIC SCIENTISTS 4300 02:53:40,280 --> 02:53:45,120 COME TO THE NCI AND GAIN 4301 02:53:45,120 --> 02:53:47,160 TRAINING AND EXPERTISE. 4302 02:53:47,160 --> 02:53:50,440 AND THEY HAVE AWARDED FOUR -- 4303 02:53:50,440 --> 02:53:52,000 MAILED FOUR AWARDS, AND CENTER 4304 02:53:52,000 --> 02:53:54,280 FOR CANCER RESEARCH, DIVISION OF 4305 02:53:54,280 --> 02:53:55,960 CANCER EPIDEMIOLOGY AND 4306 02:53:55,960 --> 02:53:58,240 GENETICS, THE HOPE IS THESE 4307 02:53:58,240 --> 02:54:03,280 INDIVIDUALS WILL GO BACK TO THE 4308 02:54:03,280 --> 02:54:05,560 LMICs AND HOPEFULLY BUILD 4309 02:54:05,560 --> 02:54:07,320 CAPACITY THERE. 4310 02:54:07,320 --> 02:54:08,400 IN DISCUSSION THE SUBCOMMITTEE 4311 02:54:08,400 --> 02:54:14,640 NOTED SIGNIFICANT PROGRESS AND 4312 02:54:14,640 --> 02:54:21,320 REPOSITION SINCE DR. KOPAL 4313 02:54:21,320 --> 02:54:23,240 ASSUMED LEADERSHIP. 4314 02:54:23,240 --> 02:54:26,800 THE PARTNERSHIPS THAT ARE BEING 4315 02:54:26,800 --> 02:54:29,080 BUILT WITH OTHER STAKEHOLDERS 4316 02:54:29,080 --> 02:54:31,280 WITH FOGARTY INSTITUTE, NCI 4317 02:54:31,280 --> 02:54:34,560 DESIGNATED CANCER CENTERS, 4318 02:54:34,560 --> 02:54:35,200 PROFESSIONAL ORGANIZATIONS, AND 4319 02:54:35,200 --> 02:54:38,600 INDUSTRY, TO ADVANCE THE GLOBAL 4320 02:54:38,600 --> 02:54:40,200 CANCER RESEARCH PROGRAM. 4321 02:54:40,200 --> 02:54:41,560 THIS PROGRESS NOT WITH STANDING, 4322 02:54:41,560 --> 02:54:47,680 THE SUBCOMMITTEE FELT THERE WAS 4323 02:54:47,680 --> 02:54:48,800 STILL SIGNIFICANT OPPORTUNITIES 4324 02:54:48,800 --> 02:54:50,760 IN THE CANCER RESEARCH AGENDA, 4325 02:54:50,760 --> 02:54:52,080 ENCOURAGE TO CONTINUE 4326 02:54:52,080 --> 02:54:54,240 DEVELOPMENT IN THESE ACTIVITIES. 4327 02:54:54,240 --> 02:54:59,080 IMPORTANTLY, THIS WILL ALLOW THE 4328 02:54:59,080 --> 02:55:03,400 CD8 TO LEVERAGE FOR ACTIVITIES 4329 02:55:03,400 --> 02:55:04,560 SUCH AS RESEARCH INFRASTRUCTURE 4330 02:55:04,560 --> 02:55:06,240 DEVELOPMENT AND WITHOUT THAT 4331 02:55:06,240 --> 02:55:08,320 DEVELOPMENT THE COMMITTEE FELT 4332 02:55:08,320 --> 02:55:13,880 THAT THE EXPERTISE WILL HAVE 4333 02:55:13,880 --> 02:55:17,800 LIMITED IMPACT. 4334 02:55:17,800 --> 02:55:20,440 ON ANOTHER NOTE, CAPACITY 4335 02:55:20,440 --> 02:55:24,800 BUILDING WAS ENCOURAGED TO HELP 4336 02:55:24,800 --> 02:55:27,800 REDUCE AGENDA AND DISPARITY IN 4337 02:55:27,800 --> 02:55:31,960 THE WORK FORCE IN LMICs. 4338 02:55:31,960 --> 02:55:33,360 SECONDLY, LASTLY, THE 4339 02:55:33,360 --> 02:55:34,040 COMMITTEE -- ANOTHER IMPORTANT 4340 02:55:34,040 --> 02:55:36,320 SUBJECT OF BUSINESS FOR THE 4341 02:55:36,320 --> 02:55:39,040 SUBCOMMITTEE WAS REPORT ON 4342 02:55:39,040 --> 02:55:49,560 SURVEY OF GLOBAL ACTIVITIES, AT 4343 02:55:50,000 --> 02:55:54,240 NCI DESIGNATED CENTERS PRESENTED 4344 02:55:54,240 --> 02:56:04,760 BY THE HEAD OF THE PROGRAM AT 4345 02:56:05,560 --> 02:56:07,760 INDIANA UNIVERSITY, NCI 4346 02:56:07,760 --> 02:56:11,120 DESIGNATED CANCERS, ASCO, TO 4347 02:56:11,120 --> 02:56:12,240 PROVIDE OVERVIEW OF GLOBAL 4348 02:56:12,240 --> 02:56:14,480 ONCOLOGY ACTIVITIES TO ADVANCE 4349 02:56:14,480 --> 02:56:16,120 GLOBAL ONCOLOGY SUCH AS BY 4350 02:56:16,120 --> 02:56:18,720 TRACKING TRENDS IN GLOBAL 4351 02:56:18,720 --> 02:56:19,400 ONCOLOGY RESEARCH, IDENTIFY 4352 02:56:19,400 --> 02:56:23,680 AREAS AND OPPORTUNITIES FOR 4353 02:56:23,680 --> 02:56:25,240 FUNDING. 4354 02:56:25,240 --> 02:56:28,720 THE PROGRAM WAS INITIATED 2012, 4355 02:56:28,720 --> 02:56:29,600 REPEATED EVERY TWO YEARS. 4356 02:56:29,600 --> 02:56:31,760 A LARGE BODY OF DATA WAS 4357 02:56:31,760 --> 02:56:32,400 PRESENTED. 4358 02:56:32,400 --> 02:56:35,160 SOME OF IT IS SUMMARIZED IN THE 4359 02:56:35,160 --> 02:56:37,360 REPORT SO I WILL JUST MENTION 4360 02:56:37,360 --> 02:56:39,320 THIS, A FEW THINGS. 4361 02:56:39,320 --> 02:56:42,160 THIS YEAR, OR LAST YEAR, 71 4362 02:56:42,160 --> 02:56:43,600 CANCER CENTERS WERE CONTACTED TO 4363 02:56:43,600 --> 02:56:48,080 SEND IN A SURVEY, ALL BUT FOUR 4364 02:56:48,080 --> 02:56:53,120 COMPLETED, AN INCREDIBLE I THINK 4365 02:56:53,120 --> 02:56:53,720 FEAT. 4366 02:56:53,720 --> 02:56:57,160 OF THE 67, REPORTED THAT THEY 4367 02:56:57,160 --> 02:56:58,920 HAD GLOBAL ONCOLOGY ACTIVITIES, 4368 02:56:58,920 --> 02:57:03,520 SIGNIFICANT NUMBER OF THEM, 42%, 4369 02:57:03,520 --> 02:57:06,440 HAD AN OFFICE, PROGRAM DEDICATED 4370 02:57:06,440 --> 02:57:08,200 TO GLOBAL CANCER RESEARCH. 4371 02:57:08,200 --> 02:57:16,680 ONLY 9% ARE NO GLOBAL ONCOLOGY 4372 02:57:16,680 --> 02:57:17,000 ACTIVITY. 4373 02:57:17,000 --> 02:57:22,480 69% HAD NIH FUNDING, 43 HAD 4374 02:57:22,480 --> 02:57:23,680 PHILANTHROPIC FUNDING, 4375 02:57:23,680 --> 02:57:24,760 SURPRISINGLY NO GOVERNMENTAL 4376 02:57:24,760 --> 02:57:29,120 FUNDING FROM AGENCIES SUCH AS 4377 02:57:29,120 --> 02:57:31,000 CDC OR USAID 4378 02:57:31,000 --> 02:57:35,520 20%, AND U.S. CORPORATIONS 4379 02:57:35,520 --> 02:57:37,440 INDUSTRY WAS ONLY 16%. 4380 02:57:37,440 --> 02:57:38,400 ANOTHER INTERESTING FINDING WAS 4381 02:57:38,400 --> 02:57:43,160 THAT MAJORITY OF THE NIH FUNDING 4382 02:57:43,160 --> 02:57:47,000 WENT TO STUDY BIOLOGY, ETIOLOGY, 4383 02:57:47,000 --> 02:57:48,720 DIAGNOSIS/PROGNOSIS, AND 4384 02:57:48,720 --> 02:57:50,080 TREATMENT. 4385 02:57:50,080 --> 02:57:52,680 RELATIVELY LESS TO PREVENTION. 4386 02:57:52,680 --> 02:57:55,960 AND EQUALLY INTERESTING WAS MOST 4387 02:57:55,960 --> 02:57:59,000 OF THE NIH FUNDING WENT TO 4388 02:57:59,000 --> 02:58:00,440 CANCER DIAGNOSIS/PROGNOSIS AND 4389 02:58:00,440 --> 02:58:00,720 TREATMENT. 4390 02:58:00,720 --> 02:58:02,200 THESE RESULTS I THINK COULD BE 4391 02:58:02,200 --> 02:58:07,800 VERY USEFUL TO THE NCI AND CGH, 4392 02:58:07,800 --> 02:58:09,960 TO SEEK PARTNERSHIPS AND 4393 02:58:09,960 --> 02:58:13,680 COLLABORATORS, GAPS IN THE 4394 02:58:13,680 --> 02:58:15,240 GLOBAL ONCOLOGY PORTFOLIO. 4395 02:58:15,240 --> 02:58:17,760 I BELIEVE THE RESULTS OF THE 4396 02:58:17,760 --> 02:58:19,120 STUDY WILL BE PUBLISHED BUT I'M 4397 02:58:19,120 --> 02:58:21,120 SURE THEY WILL BE AVAILABLE TO 4398 02:58:21,120 --> 02:58:25,440 THOSE INTERESTED FROM THE NCI 4399 02:58:25,440 --> 02:58:26,760 UPON REQUEST. 4400 02:58:26,760 --> 02:58:27,920 LASTLY THE SUBCOMMITTEE 4401 02:58:27,920 --> 02:58:29,840 CONSIDERED BRIEFLY THE PROSPECT 4402 02:58:29,840 --> 02:58:32,720 OF LEVERAGING OPPORTUNITIES IN 4403 02:58:32,720 --> 02:58:36,160 THE NEWLY LAUNCHED MOONSHOT 2.0, 4404 02:58:36,160 --> 02:58:38,440 FOR INCREASED VISIBILITY AND 4405 02:58:38,440 --> 02:58:39,760 POTENTIALLY RESOURCES FOR THE 4406 02:58:39,760 --> 02:58:42,160 CGH AND NCI GLOBAL CANCER 4407 02:58:42,160 --> 02:58:43,560 RESEARCH AGENDA. 4408 02:58:43,560 --> 02:58:45,080 THESE DISCUSSIONS ARE IN THE 4409 02:58:45,080 --> 02:58:47,400 EARLY STAGES AND MORE 4410 02:58:47,400 --> 02:58:48,840 SPECIFICALLY INITIATIVES WILL BE 4411 02:58:48,840 --> 02:58:51,400 PRESENTED AT FUTURE MEETINGS. 4412 02:58:51,400 --> 02:58:52,760 I'LL STOP HERE AND AGAIN REFER 4413 02:58:52,760 --> 02:58:54,640 YOU TO THE MEETING REPORT YOU 4414 02:58:54,640 --> 02:58:55,640 RECEIVED FOR MORE DETAILS AND 4415 02:58:55,640 --> 02:59:00,760 ANSWER ANY QUESTIONS YOU MAY 4416 02:59:00,760 --> 02:59:00,960 HAVE. 4417 02:59:00,960 --> 02:59:02,080 >>THANKS, EXCELLENT SUMMARY OF 4418 02:59:02,080 --> 02:59:02,640 THE REPORT. 4419 02:59:02,640 --> 02:59:04,720 THANK YOU SO MUCH. 4420 02:59:04,720 --> 02:59:12,560 ARE THERE ANY QUESTIONS FOR 4421 02:59:12,560 --> 02:59:13,240 FRANCIS? 4422 02:59:13,240 --> 02:59:16,280 YES, I SEE SHELLY'S HAND. 4423 02:59:16,280 --> 02:59:19,000 >>I JUST WANT TO ASSURE THE 4424 02:59:19,000 --> 02:59:21,520 COMMITTEE THAT THE CENTER IS IN 4425 02:59:21,520 --> 02:59:23,400 EXTRAORDINARY HANDS, BY SOMEBODY 4426 02:59:23,400 --> 02:59:27,320 WHO WAS ON THE GROUND, AND 4427 02:59:27,320 --> 02:59:31,920 DEVELOPED A PROGRAM WITH 4428 02:59:31,920 --> 02:59:32,600 EXTRAORDINARY PASSION, 4429 02:59:32,600 --> 02:59:38,040 COMPETENCE, BOTH CLINICAL AND 4430 02:59:38,040 --> 02:59:40,800 SCIENTIFIC ABILITY, AN INSPIRED 4431 02:59:40,800 --> 02:59:44,840 LEADER FOR THIS GROUP. 4432 02:59:44,840 --> 02:59:45,240 >>TREMENDOUS. 4433 02:59:45,240 --> 02:59:45,680 >>THANKS, SHELLY. 4434 02:59:45,680 --> 02:59:48,120 DOROTHY, DID I SEE YOUR HAND UP? 4435 02:59:48,120 --> 02:59:50,640 >>YOU SURE DID. 4436 02:59:50,640 --> 02:59:55,480 A QUESTION REGARDING THE 4437 02:59:55,480 --> 02:59:56,800 INFRASTRUCTURE DEVELOPMENT LMIC 4438 02:59:56,800 --> 02:59:57,120 COUNTRIES. 4439 02:59:57,120 --> 02:59:58,640 WHEN YOU TALK ABOUT 4440 02:59:58,640 --> 03:00:03,000 INFRASTRUCTURE, ARE YOU THINKING 4441 03:00:03,000 --> 03:00:04,320 ABOUT DEVELOPING RESEARCH HUBS 4442 03:00:04,320 --> 03:00:05,320 WHAT CAPACITY TRAINING OCCURS, 4443 03:00:05,320 --> 03:00:08,280 PEOPLE COME IN AND LEARN 4444 03:00:08,280 --> 03:00:09,800 RESEARCH METHODOLOGIES OR 4445 03:00:09,800 --> 03:00:11,800 BUILDING LABORATORY CAPACITY? 4446 03:00:11,800 --> 03:00:13,120 WHAT IS YOUR VISION OF 4447 03:00:13,120 --> 03:00:16,600 DEVELOPING OR WHAT IS 4448 03:00:16,600 --> 03:00:19,000 COMMITTEE'S VISION OF DEVELOPING 4449 03:00:19,000 --> 03:00:21,520 THE INFRASTRUCTURE WITHIN THOSE 4450 03:00:21,520 --> 03:00:23,040 LMICs? 4451 03:00:23,040 --> 03:00:24,680 >>VERY, VERY IMPORTANT QUESTION 4452 03:00:24,680 --> 03:00:27,560 BECAUSE WE TRAIN ALL THESE 4453 03:00:27,560 --> 03:00:31,040 PEOPLE IN NEW METHODS, THEY GO 4454 03:00:31,040 --> 03:00:32,440 BACK AND CAN'T APPLY, FORGET HOW 4455 03:00:32,440 --> 03:00:36,080 OR MOVE TO OTHER THINGS. 4456 03:00:36,080 --> 03:00:40,360 SO, I THINK IT WAS GREAT VISION, 4457 03:00:40,360 --> 03:00:45,400 ABOUT FOUR OR FIVE YEARS AGO, 4458 03:00:45,400 --> 03:00:51,320 THE NCI CTA ACTUALLY HAD A 4459 03:00:51,320 --> 03:00:52,520 PROGRAM WHERE THEY WANTED AT 4460 03:00:52,520 --> 03:00:56,240 LEAST I THINK TWO OR THREE 4461 03:00:56,240 --> 03:00:57,680 COUNTRIES IN DIFFERENT REGIONS 4462 03:00:57,680 --> 03:01:03,920 OF THE LMICs TO COME TOGETHER, 4463 03:01:03,920 --> 03:01:08,640 FORM A HUB, PROVIDE SEED FUNDING 4464 03:01:08,640 --> 03:01:10,840 FOR THEM TO INITIATE SUCH AN 4465 03:01:10,840 --> 03:01:11,880 INFRASTRUCTURE TO DO EXACTLY 4466 03:01:11,880 --> 03:01:15,720 WHAT YOU JUST SAID AND MORE. 4467 03:01:15,720 --> 03:01:18,560 IN THESE DAYS OF SPECIALIZED 4468 03:01:18,560 --> 03:01:20,240 MEDICINE, YOU NEED GOOD LABS, 4469 03:01:20,240 --> 03:01:22,640 MOLECULAR LABS AND SO ON TO CARE 4470 03:01:22,640 --> 03:01:23,600 FOR THESE TUMORS. 4471 03:01:23,600 --> 03:01:26,240 RATHER THAN HAVING THEM COME 4472 03:01:26,240 --> 03:01:30,560 OVER HERE, RATHER TO ENCOURAGE 4473 03:01:30,560 --> 03:01:33,960 THEM TO SET UP THESE, IF I WERE 4474 03:01:33,960 --> 03:01:39,280 TO REDO THAT AGAIN I WOULD 4475 03:01:39,280 --> 03:01:41,120 ALMOST LIKE WHAT WE JUST SAID, 4476 03:01:41,120 --> 03:01:42,480 THE GOVERNMENTS TO ALSO HAVE A 4477 03:01:42,480 --> 03:01:46,720 CONTRIBUTION, TO MATCH THE FUNDS 4478 03:01:46,720 --> 03:01:47,600 THAT WOULD BE AVAILABLE. 4479 03:01:47,600 --> 03:01:56,200 THIS WAS BROUGHT UP AT OUR 4480 03:01:56,200 --> 03:01:58,200 MEETING, AND DR. GOPAL SAID THE 4481 03:01:58,200 --> 03:01:59,200 PROCESS, NOT CONTINUING IN THAT 4482 03:01:59,200 --> 03:02:01,080 SAME FASHION BUT RATHER WOULD 4483 03:02:01,080 --> 03:02:03,800 TAKE THEMES, SOME OF THE THEMES 4484 03:02:03,800 --> 03:02:09,480 THAT I MENTIONED, AND DEVELOP 4485 03:02:09,480 --> 03:02:12,360 PROJECTS AROUND THOSE BECAUSE 4486 03:02:12,360 --> 03:02:16,160 BUILD AN INFRASTRUCTURE IS VERY 4487 03:02:16,160 --> 03:02:17,280 EXPENSIVE, MAYBE NOT POSSIBLE 4488 03:02:17,280 --> 03:02:18,280 WITH THE RESOURCES THEY HAVE. 4489 03:02:18,280 --> 03:02:20,960 WE THOUGHT IN THE PARTNERSHIPS 4490 03:02:20,960 --> 03:02:23,160 THAT WOULD BE DEVELOPED, THERE 4491 03:02:23,160 --> 03:02:24,520 MIGHT BE ADDITIONAL STAKEHOLDERS 4492 03:02:24,520 --> 03:02:27,760 THAT WOULD BE INTERESTED IN 4493 03:02:27,760 --> 03:02:29,760 HELPING BUILD THOSE. 4494 03:02:29,760 --> 03:02:30,960 BUT FRANKLY WITHOUT AN 4495 03:02:30,960 --> 03:02:33,040 INFRASTRUCTURE TO DO THIS WORK, 4496 03:02:33,040 --> 03:02:35,880 A LOT OF TRAINING WOULD 4497 03:02:35,880 --> 03:02:38,400 EVENTUALLY JUST -- ALL THOSE 4498 03:02:38,400 --> 03:02:41,640 PEOPLE WOULD STAY BACK IN THE 4499 03:02:41,640 --> 03:02:43,840 U.S. OR OTHER COUNTRIES WHERE 4500 03:02:43,840 --> 03:02:45,680 THEY CAN PRACTICE. 4501 03:02:45,680 --> 03:02:49,080 THE INFRASTRUCTURE TRAINING 4502 03:02:49,080 --> 03:02:50,440 ALMOST LIKE GO HAND IN HAND, BUT 4503 03:02:50,440 --> 03:02:51,880 IT'S A BIG CHALLENGE BECAUSE IT 4504 03:02:51,880 --> 03:02:57,680 TAKES A LOT OF MONEY TO DO THAT. 4505 03:02:57,680 --> 03:03:00,720 >>I HAD A QUESTION. 4506 03:03:00,720 --> 03:03:02,160 I'LL ASK ANYWAY. 4507 03:03:02,160 --> 03:03:05,960 WHO DECIDES THE DESIGNATION FOR 4508 03:03:05,960 --> 03:03:08,040 LOW AND MIDDLE INCOME, HOW OFTEN 4509 03:03:08,040 --> 03:03:10,800 IS IT UPDATED? 4510 03:03:10,800 --> 03:03:13,000 THERE WERE SOME COUNTRIES WITH 4511 03:03:13,000 --> 03:03:14,960 HIGH GLOBAL ECONOMIES ON THE 4512 03:03:14,960 --> 03:03:17,520 LMIC LIST, HOW OFTEN IS THAT 4513 03:03:17,520 --> 03:03:21,080 REVIEWED, DOES THE NIH NCI HAVE 4514 03:03:21,080 --> 03:03:23,840 TO SORT OF UTILIZE A DEFINITION 4515 03:03:23,840 --> 03:03:24,880 BASED ON A DIFFERENT AGENCY? 4516 03:03:24,880 --> 03:03:29,080 I'M TRYING TO FIGURE THAT OUT. 4517 03:03:29,080 --> 03:03:32,160 >>LET ME ASK FOR PAULETTE'S 4518 03:03:32,160 --> 03:03:32,600 HELP. 4519 03:03:32,600 --> 03:03:33,800 IS THIS A TERM -- 4520 03:03:33,800 --> 03:03:37,160 >>IT'S A UNITED NATIONS 4521 03:03:37,160 --> 03:03:37,720 DESIGNATION. 4522 03:03:37,720 --> 03:03:48,000 >>OKAY, U.N. DESIGNATION, 4523 03:03:48,000 --> 03:03:48,640 GREAT. 4524 03:03:48,640 --> 03:03:52,360 >>BUT YOU'RE RIGHT, IT'S A 4525 03:03:52,360 --> 03:03:52,640 SPECTRUM. 4526 03:03:52,640 --> 03:03:55,680 SOME LIKE GHANA, NIGERIA, SOUTH 4527 03:03:55,680 --> 03:03:57,080 AFRICA HAVE INFRASTRUCTURE THAT 4528 03:03:57,080 --> 03:03:59,480 CAN BE LEVERAGES, OTHERS HAVE 4529 03:03:59,480 --> 03:04:01,480 PRACTICALLY NOTHING. 4530 03:04:01,480 --> 03:04:02,440 >>EXACTLY. 4531 03:04:02,440 --> 03:04:02,760 OKAY. 4532 03:04:02,760 --> 03:04:03,320 GREAT. 4533 03:04:03,320 --> 03:04:04,960 ANY OTHER QUESTIONS FOR FRANCIS 4534 03:04:04,960 --> 03:04:10,680 BEFORE WE GO TO VOTE? 4535 03:04:10,680 --> 03:04:15,160 SO NCAB WILL VOTE AND WE'RE 4536 03:04:15,160 --> 03:04:16,600 VOTING TO ACCEPT THE 4537 03:04:16,600 --> 03:04:17,480 SUBCOMMITTEE REPORT. 4538 03:04:17,480 --> 03:04:20,200 DO WE HAVE A MOTION TO ACCEPT 4539 03:04:20,200 --> 03:04:22,760 THE REPORT? 4540 03:04:22,760 --> 03:04:26,320 >>SO MOVED. 4541 03:04:26,320 --> 03:04:27,080 >>SECOND? 4542 03:04:27,080 --> 03:04:27,640 >>SECOND. 4543 03:04:27,640 --> 03:04:31,680 >>PROPERLY MOVED AND SECONDED. 4544 03:04:31,680 --> 03:04:32,800 QUESTIONS? 4545 03:04:32,800 --> 03:04:33,080 OKAY. 4546 03:04:33,080 --> 03:04:37,520 SO ARE THERE ANY NAYS? 4547 03:04:37,520 --> 03:04:39,800 OR ABSTENTIONS? 4548 03:04:39,800 --> 03:04:43,200 4549 03:04:43,200 --> 03:04:43,520 PAULETTE? 4550 03:04:43,520 --> 03:04:45,280 >>YOU'RE GOOD. 4551 03:04:45,280 --> 03:04:46,240 >>OKAY, GOOD. 4552 03:04:46,240 --> 03:04:50,200 WE'LL MOVE TO THE NEXT 4553 03:04:50,200 --> 03:04:53,720 SUBCOMMITTEE REPORT, GIVEN BY 4554 03:04:53,720 --> 03:04:56,880 DR. ELECTRA PASKETT, POPULATION 4555 03:04:56,880 --> 03:04:58,320 SCIENCE EPIDEMIOLOGY AND 4556 03:04:58,320 --> 03:04:58,640 DISPARITIES. 4557 03:04:58,640 --> 03:04:59,960 >>THANK YOU. 4558 03:04:59,960 --> 03:05:01,800 THE NCAB SUBCOMMITTEE ON 4559 03:05:01,800 --> 03:05:04,960 POPULATION SCIENCE EPIDEMIOLOGY 4560 03:05:04,960 --> 03:05:08,600 AND DISPARITIES MET ON MONDAY 4561 03:05:08,600 --> 03:05:12,400 AFTERNOON, AND THE 99% OF OUR 4562 03:05:12,400 --> 03:05:15,560 TIME WE SPENT REVIEWING THE 4563 03:05:15,560 --> 03:05:17,680 REPORT FROM THE WORKING GROUP 4564 03:05:17,680 --> 03:05:20,160 THAT WAS ALREADY PRESENTED TO 4565 03:05:20,160 --> 03:05:21,720 YOU ALL EARLIER THIS AFTERNOON. 4566 03:05:21,720 --> 03:05:26,200 WE HAD A LITTLE LONGER 4567 03:05:26,200 --> 03:05:27,080 PRESENTATION. 4568 03:05:27,080 --> 03:05:31,640 WE HAD ROBUST DISCUSSION. 4569 03:05:31,640 --> 03:05:32,560 VERY NICE DISCUSSION. 4570 03:05:32,560 --> 03:05:34,320 AND THE DISCUSSION IS VERY 4571 03:05:34,320 --> 03:05:39,040 NICELY CAPTURED IN THE MINUTES 4572 03:05:39,040 --> 03:05:41,080 THAT WERE CIRCULATED. 4573 03:05:41,080 --> 03:05:46,560 THE REPORT WAS THEN APPROVED BY 4574 03:05:46,560 --> 03:05:48,680 THE SUBCOMMITTEE, TO BE 4575 03:05:48,680 --> 03:05:50,160 PRESENTED TODAY TO NCAB. 4576 03:05:50,160 --> 03:05:52,680 AND PAULETTE, I DO BELIEVE THERE 4577 03:05:52,680 --> 03:05:55,440 WAS A LITTLE MIXUP WITH THE VOTE 4578 03:05:55,440 --> 03:05:57,040 THIS AFTERNOON BECAUSE IT SHOULD 4579 03:05:57,040 --> 03:06:00,120 HAVE ONLY BEEN NCAB MEMBERS THAT 4580 03:06:00,120 --> 03:06:03,200 WERE VOTING. 4581 03:06:03,200 --> 03:06:04,200 >>IT WAS 14-1. 4582 03:06:04,200 --> 03:06:06,880 >>BUT THE 1 WAS NOT AN NCAB 4583 03:06:06,880 --> 03:06:07,360 MEMBER. 4584 03:06:07,360 --> 03:06:10,280 >>OH, IS THAT RIGHT? 4585 03:06:10,280 --> 03:06:11,160 OKAY. 4586 03:06:11,160 --> 03:06:14,040 SO IT WAS 14. 4587 03:06:14,040 --> 03:06:14,280 >>YEP. 4588 03:06:14,280 --> 03:06:16,480 I WANTED TO CLEAR THAT UP, 4589 03:06:16,480 --> 03:06:19,720 PAULETTE, FOR THE MINUTES. 4590 03:06:19,720 --> 03:06:20,160 THANKS. 4591 03:06:20,160 --> 03:06:20,760 >>APPRECIATE IT, ELECTRA. 4592 03:06:20,760 --> 03:06:23,440 >>I APPRECIATE ALL THAT YOU DO, 4593 03:06:23,440 --> 03:06:24,440 I REALLY DO. 4594 03:06:24,440 --> 03:06:27,160 AND YOU KEEP US STRAIGHT SO I 4595 03:06:27,160 --> 03:06:30,000 REALLY APPRECIATE THAT. 4596 03:06:30,000 --> 03:06:32,200 SO, THE ONE THING THAT WE DIDN'T 4597 03:06:32,200 --> 03:06:36,560 HAVE A LOT OF TIME TO GET INTO 4598 03:06:36,560 --> 03:06:38,440 WAS WHAT THE SUBCOMMITTEE WOULD 4599 03:06:38,440 --> 03:06:41,600 FOCUS ON NEXT AND SO I ASKED THE 4600 03:06:41,600 --> 03:06:42,480 SUBCOMMITTEE MEMBERS TO THINK 4601 03:06:42,480 --> 03:06:46,720 ABOUT WHAT WE WOULD TALK ABOUT 4602 03:06:46,720 --> 03:06:48,920 NEXT, AND THE OPPORTUNITY THAT 4603 03:06:48,920 --> 03:06:52,760 WE DO HAVE TO MEET WE WOULD LIKE 4604 03:06:52,760 --> 03:06:58,000 TO MEET, IN THE PAST WE HAD 4605 03:06:58,000 --> 03:07:00,200 SEVERAL TOPICS ON OUR PLATE AND 4606 03:07:00,200 --> 03:07:01,960 DR. SHARPLESS HAD COUNSELED US 4607 03:07:01,960 --> 03:07:07,400 TO JUST DO ONE TOPIC AT A TIME 4608 03:07:07,400 --> 03:07:10,920 SO WE NOW COMPLETED TWO REPORTS. 4609 03:07:10,920 --> 03:07:14,320 DR. ROBISON SO CHAIRED THE ONE 4610 03:07:14,320 --> 03:07:16,360 ON THE EPIDEMIOLOGY COHORT. 4611 03:07:16,360 --> 03:07:18,360 THAT WAS WONDERFULLY DONE. 4612 03:07:18,360 --> 03:07:22,760 AND THIS IS OUR SECOND REPORT. 4613 03:07:22,760 --> 03:07:25,120 SO, I'M HAPPY TO ANSWER ANY 4614 03:07:25,120 --> 03:07:26,680 QUESTIONS IF ANYBODY HAS ANY BUT 4615 03:07:26,680 --> 03:07:28,440 I DON'T WANT TO REITERATE WHAT 4616 03:07:28,440 --> 03:07:32,040 WE'VE ALREADY TALKED ABOUT 4617 03:07:32,040 --> 03:07:34,640 TODAY. 4618 03:07:34,640 --> 03:07:36,320 4619 03:07:36,320 --> 03:07:37,200 DR. SPITZ, HELLO. 4620 03:07:37,200 --> 03:07:38,600 >>TWO ISSUES. 4621 03:07:38,600 --> 03:07:40,120 NUMBER ONE, I APOLOGIZE, I HAD 4622 03:07:40,120 --> 03:07:43,200 TO TEMPORARILY LEAVE THE MEETING 4623 03:07:43,200 --> 03:07:45,160 WHEN WE VOTED ON THE REPORT. 4624 03:07:45,160 --> 03:07:48,120 I WOULD HAVE ABSOLUTELY -- MY 4625 03:07:48,120 --> 03:07:49,280 VOTE WOULD HAVE BEEN POSITIVE 4626 03:07:49,280 --> 03:07:50,480 AND I ACCEPT IT. 4627 03:07:50,480 --> 03:07:52,960 SO PLEASE COULD THAT BE 4628 03:07:52,960 --> 03:07:53,600 RECORDED. 4629 03:07:53,600 --> 03:07:59,400 NUMBER TWO, ELECTRA YOU'VE DONE 4630 03:07:59,400 --> 03:08:00,720 A FANTASTIC JOB, I CAN'T THINK 4631 03:08:00,720 --> 03:08:02,560 OF ANYONE WHO WOULD HAVE DONE IT 4632 03:08:02,560 --> 03:08:05,000 AS WELL OR CAREFULLY AND 4633 03:08:05,000 --> 03:08:05,960 EFFICIENTLY AS YOU. 4634 03:08:05,960 --> 03:08:08,800 ONE POINT WE BROUGHT UP SEVERAL 4635 03:08:08,800 --> 03:08:11,360 TIMES, WHICH PERHAPS WE COULD 4636 03:08:11,360 --> 03:08:15,240 CONSIDER ADDRESSING IS THE ISSUE 4637 03:08:15,240 --> 03:08:18,320 OF FUNDING OPPORTUNITIES FOR 4638 03:08:18,320 --> 03:08:20,760 TRAINEES IN POPULATION SCIENCE. 4639 03:08:20,760 --> 03:08:24,600 AS WE KNOW, THE KO 7 HAS GONE 4640 03:08:24,600 --> 03:08:27,640 AWAY, R25 HAS BEEN EXTENSIVELY 4641 03:08:27,640 --> 03:08:28,280 CHANGED. 4642 03:08:28,280 --> 03:08:31,360 AND WE HAVE BROUGHT THIS UP ONCE 4643 03:08:31,360 --> 03:08:33,880 WITH I RECALL DR. SHARPLESS, HE 4644 03:08:33,880 --> 03:08:35,080 AGREED IT WAS IMPORTANT, PERHAPS 4645 03:08:35,080 --> 03:08:37,240 THAT'S SOMETHING WE COULD 4646 03:08:37,240 --> 03:08:39,680 CONSIDER FOR DISCUSSION BUT I 4647 03:08:39,680 --> 03:08:40,640 OBVIOUSLY RESPECT WHATEVER THE 4648 03:08:40,640 --> 03:08:43,040 COMMITTEE DECIDES TO DO NEXT. 4649 03:08:43,040 --> 03:08:43,360 >>RIGHT. 4650 03:08:43,360 --> 03:08:46,440 FIRST LET ME THANK YOU, 4651 03:08:46,440 --> 03:08:47,320 MARGARET. 4652 03:08:47,320 --> 03:08:48,880 YOU'RE SO NICE WITH YOUR 4653 03:08:48,880 --> 03:08:49,200 COMPLIMENTS. 4654 03:08:49,200 --> 03:08:52,720 I DO HAVE TO SAY THAT IT WAS AN 4655 03:08:52,720 --> 03:08:54,440 ENTIRE COMMITTEE WORK, AND THE 4656 03:08:54,440 --> 03:08:56,920 CO-CHAIRS AND DR. CASTLE REALLY, 4657 03:08:56,920 --> 03:09:02,560 REALLY CONTRIBUTED AND I CAN'T 4658 03:09:02,560 --> 03:09:05,080 THANK ENOUGH ALL OF THEIR 4659 03:09:05,080 --> 03:09:06,360 ASSISTANCE IN PUTTING THAT ALL 4660 03:09:06,360 --> 03:09:06,640 TOGETHER. 4661 03:09:06,640 --> 03:09:07,920 SO IT REALLY WAS A GROUP 4662 03:09:07,920 --> 03:09:09,000 ACTIVITY. 4663 03:09:09,000 --> 03:09:10,640 THANK YOU VERY MUCH. 4664 03:09:10,640 --> 03:09:13,520 I DO REMEMBER THAT WE TALKED 4665 03:09:13,520 --> 03:09:18,520 ABOUT THAT BECAUSE A LOT OF THE 4666 03:09:18,520 --> 03:09:20,040 OPPORTUNITIES FOR TRAINEE 4667 03:09:20,040 --> 03:09:22,160 FUNDING HAS GONE AWAY. 4668 03:09:22,160 --> 03:09:24,320 AND SO WE DID TALK ABOUT THAT. 4669 03:09:24,320 --> 03:09:26,280 I MADE A LIST. 4670 03:09:26,280 --> 03:09:27,480 AND I THINK, MARGARET, YOU MIGHT 4671 03:09:27,480 --> 03:09:30,120 REMEMBER ONE OF THE OTHER IDEAS 4672 03:09:30,120 --> 03:09:33,920 WAS TALKING ABOUT CLINICAL TRIAL 4673 03:09:33,920 --> 03:09:36,080 ACRUCIAL. -- ACCRUAL. 4674 03:09:36,080 --> 03:09:38,440 >>BROUGHT UP BY DR. SHARPLESS. 4675 03:09:38,440 --> 03:09:40,720 THOSE WERE THE THREE BIG AREAS 4676 03:09:40,720 --> 03:09:42,520 THAT WE HAD DISCUSSED. 4677 03:09:42,520 --> 03:09:43,720 OBVIOUSLY WE FOCUSED FIRST ON 4678 03:09:43,720 --> 03:09:46,760 THE ONES YOU'VE ALREADY DONE. 4679 03:09:46,760 --> 03:09:47,840 >>YES, RIGHT. 4680 03:09:47,840 --> 03:09:48,160 OKAY, THANKS. 4681 03:09:48,160 --> 03:09:51,480 I MADE A NOTE OF BOTH OF THOSE. 4682 03:09:51,480 --> 03:09:55,880 THAT'S WONDERFUL. 4683 03:09:55,880 --> 03:09:56,440 THANK YOU, MARGARET. 4684 03:09:56,440 --> 03:09:56,840 >>DOROTHY? 4685 03:09:56,840 --> 03:09:59,600 >>IS IT OKAY IF I CALL ON 4686 03:09:59,600 --> 03:10:00,040 PEOPLE? 4687 03:10:00,040 --> 03:10:03,080 >>YES, SURE. 4688 03:10:03,080 --> 03:10:05,080 >>OKAY. 4689 03:10:05,080 --> 03:10:05,400 DOROTHY? 4690 03:10:05,400 --> 03:10:06,800 >>OKAY. 4691 03:10:06,800 --> 03:10:09,000 I'M UNMUTED. 4692 03:10:09,000 --> 03:10:10,320 SO, ELECTRA, A REALLY WONDERFUL 4693 03:10:10,320 --> 03:10:10,520 REPORT. 4694 03:10:10,520 --> 03:10:12,160 I GUESS ONE OF THE THINGS THAT 4695 03:10:12,160 --> 03:10:19,040 YOU POINTED OUT THE FACT THAT 4696 03:10:19,040 --> 03:10:23,760 THE BIOLOGY AND TREATMENT, NOT 4697 03:10:23,760 --> 03:10:27,480 VERY MANY PROJECTS THAT HAD 4698 03:10:27,480 --> 03:10:28,360 REPRESENTATION OF THE 4699 03:10:28,360 --> 03:10:29,040 UNDERREPRESENTED, AND I'M 4700 03:10:29,040 --> 03:10:32,480 WONDERING I THINK YOU TALKED 4701 03:10:32,480 --> 03:10:33,480 ABOUT THE RECOMMENDATION YOU 4702 03:10:33,480 --> 03:10:37,560 TALKED ABOUT REALLY WAS TO 4703 03:10:37,560 --> 03:10:40,840 FACILITATE MORE RESEARCH OVERALL 4704 03:10:40,840 --> 03:10:41,680 AMONG THE UNDERREPRESENTED 4705 03:10:41,680 --> 03:10:44,080 POPULATION BUT IT SEEMS LIKE THE 4706 03:10:44,080 --> 03:10:47,360 WHOLE BIOLOGY AREA IN PARTICULAR 4707 03:10:47,360 --> 03:10:50,480 AND PROBABLY TREATMENT IT LOOKS 4708 03:10:50,480 --> 03:10:53,120 LIKE REALLY STRUGGLE WITH 4709 03:10:53,120 --> 03:10:53,960 RECRUITING UNDERREPRESENTED 4710 03:10:53,960 --> 03:10:55,200 POPULATIONS AND I'M WONDERING 4711 03:10:55,200 --> 03:10:57,480 WHETHER THAT MIGHT NOT BE AN 4712 03:10:57,480 --> 03:11:01,960 IMPORTANT FOCUS BECAUSE I KNOW 4713 03:11:01,960 --> 03:11:04,480 ON CCSGs THAT'S A CHALLENGE, A 4714 03:11:04,480 --> 03:11:06,560 TOPIC THAT COMES UP AS A 4715 03:11:06,560 --> 03:11:06,840 CHALLENGE. 4716 03:11:06,840 --> 03:11:09,840 >>YES, THANK YOU, DOROTHY. 4717 03:11:09,840 --> 03:11:13,200 YOU ADEQUATELY CHARACTERIZED OUR 4718 03:11:13,200 --> 03:11:16,440 SUMMARIES, AND I THINK AS I 4719 03:11:16,440 --> 03:11:19,120 EXPLAINED, WE DIDN'T ASSESS 4720 03:11:19,120 --> 03:11:21,800 CLINICAL TRIAL ACCRUAL. 4721 03:11:21,800 --> 03:11:24,840 SO, WE LOOKED AT ARE THERE 4722 03:11:24,840 --> 03:11:27,680 RESEARCH PROJECTS GOING ON IN 4723 03:11:27,680 --> 03:11:29,120 THE AREA OF TREATMENT BASED ON, 4724 03:11:29,120 --> 03:11:31,760 YOU KNOW, THE DATA MINING WE 4725 03:11:31,760 --> 03:11:35,360 COULD IDENTIFY IN THOSE CFO 4726 03:11:35,360 --> 03:11:36,880 CODES, AND THOSE POPULATIONS. 4727 03:11:36,880 --> 03:11:40,040 AND BUT I DO BELIEVE THAT YOUR 4728 03:11:40,040 --> 03:11:42,040 COMMENTS ARE LENDING SUPPORT TO 4729 03:11:42,040 --> 03:11:43,120 WHAT MARGARET AND I TALKED ABOUT 4730 03:11:43,120 --> 03:11:47,080 FOR ONE OF THE AREAS THAT DR. 4731 03:11:47,080 --> 03:11:48,280 SHARPLESS MENTIONED, THIS 4732 03:11:48,280 --> 03:11:50,480 COMMITTEE COULD LOOK INTO, 4733 03:11:50,480 --> 03:11:57,680 CLINICAL TRIAL ACCRUAL OF THESE 4734 03:11:57,680 --> 03:12:03,160 POPULATIONS. 4735 03:12:03,160 --> 03:12:04,360 THANK YOU, DOROTHY. 4736 03:12:04,360 --> 03:12:06,880 I DON'T SEE ANY MORE HANDS 4737 03:12:06,880 --> 03:12:11,840 UNLESS I'M MESSING MESS -- MISM 4738 03:12:11,840 --> 03:12:12,880 ON THE SECOND PAGE. 4739 03:12:12,880 --> 03:12:15,440 >>JOHN, IS A QUESTION OKAY? 4740 03:12:15,440 --> 03:12:23,320 A QUICK ONE. 4741 03:12:23,320 --> 03:12:26,520 I'M WONDERING IF IMMUNOTHERAPY, 4742 03:12:26,520 --> 03:12:34,120 CANCER TREATMENT, IS THAT 4743 03:12:34,120 --> 03:12:38,320 SOMETHING YOU DISCUSS A LOT? 4744 03:12:38,320 --> 03:12:41,480 >>IN OUR SUBCOMMITTEE WE 4745 03:12:41,480 --> 03:12:43,360 HAVEN'T SPECIFICALLY CALLED OUT 4746 03:12:43,360 --> 03:12:46,440 IMMUNOTHERAPY BUT I DO KNOW -- 4747 03:12:46,440 --> 03:12:47,960 >>OR IMMUNO-ONCOLOGY IN 4748 03:12:47,960 --> 03:12:49,360 GENERAL. 4749 03:12:49,360 --> 03:12:52,880 >>I DO KNOW IMMUNO-ONCOLOGY HAS 4750 03:12:52,880 --> 03:12:54,280 INCLUDED POPULATION SCIENTISTS 4751 03:12:54,280 --> 03:12:58,560 IN A VARIETY OF ASPECTS. 4752 03:12:58,560 --> 03:13:01,680 SO, FOR EXAMPLE, LOOKING AT 4753 03:13:01,680 --> 03:13:03,280 SYMPTOMS, HOW TO MANAGE 4754 03:13:03,280 --> 03:13:05,120 SYMPTOMS, FOR EXAMPLE, ADHERENCE 4755 03:13:05,120 --> 03:13:06,360 COULD BE, YOU KNOW, ANOTHER 4756 03:13:06,360 --> 03:13:10,280 THING BUT I DO KNOW THERE IS A 4757 03:13:10,280 --> 03:13:17,200 ROLE TO INCLUDE POPULATION 4758 03:13:17,200 --> 03:13:22,680 SCIENCE IN THAT AREA. 4759 03:13:22,680 --> 03:13:22,880 MARK? 4760 03:13:22,880 --> 03:13:25,280 >>JUST ONE COMMENT, WHEN YOU 4761 03:13:25,280 --> 03:13:27,800 THINK ABOUT -- IF THIS SHIFTS IN 4762 03:13:27,800 --> 03:13:29,240 THE FUTURE TO CLINICAL TRIALS 4763 03:13:29,240 --> 03:13:31,160 ENROLLMENT OR TREATMENT TRIALS 4764 03:13:31,160 --> 03:13:33,160 ENROLLMENT OR BIOLOGY, ANY OF 4765 03:13:33,160 --> 03:13:35,120 THOSE, A WISE PERSON, WE HAVE 4766 03:13:35,120 --> 03:13:35,720 SEVERAL COMMUNITY ADVISORY 4767 03:13:35,720 --> 03:13:39,040 BOARDS, ONE IS A TRIBAL ADVISORY 4768 03:13:39,040 --> 03:13:39,960 COUNCIL, AND THIS COMMENT WAS 4769 03:13:39,960 --> 03:13:42,040 FOCUS SHOULDN'T JUST BE ON THE 4770 03:13:42,040 --> 03:13:44,000 POPULATION, SHOULD ALSO BE ON 4771 03:13:44,000 --> 03:13:47,800 THE RESEARCHERS. 4772 03:13:47,800 --> 03:13:51,240 AND THE RESEARCHERS NEED INPUT 4773 03:13:51,240 --> 03:13:53,040 ON THE COMMUNITIES. 4774 03:13:53,040 --> 03:13:56,440 IT'S BIDIRECTIONAL. 4775 03:13:56,440 --> 03:13:57,480 AND THE COMMUNITIES FEEL THE 4776 03:13:57,480 --> 03:13:58,560 RESEARCHES SAY WE WANT YOUR 4777 03:13:58,560 --> 03:14:00,200 DATA, SO AS YOU THINK ABOUT THAT 4778 03:14:00,200 --> 03:14:02,520 GOING FORWARD THINK ABOUT 4779 03:14:02,520 --> 03:14:03,360 OUTREACH TO THE RESEARCH 4780 03:14:03,360 --> 03:14:07,840 COMMUNITY AS WELL AS THE 4781 03:14:07,840 --> 03:14:10,120 POPULATIONS. 4782 03:14:10,120 --> 03:14:10,640 >>THANKS. 4783 03:14:10,640 --> 03:14:12,800 SORT OF WHAT THE HEART OF COE 4784 03:14:12,800 --> 03:14:15,040 IS, RIGHT, MARK? 4785 03:14:15,040 --> 03:14:20,520 >>YEAH, EXACTLY. 4786 03:14:20,520 --> 03:14:23,480 4787 03:14:23,480 --> 03:14:25,080 >>NO FURTHER QUESTIONS, THE 4788 03:14:25,080 --> 03:14:27,640 NCAB MEMBERS SHOULD VOTE TO 4789 03:14:27,640 --> 03:14:28,600 ACCEPT THE REPORT. 4790 03:14:28,600 --> 03:14:34,120 IS THERE A MOTION TO ACCEPT? 4791 03:14:34,120 --> 03:14:35,280 >>I MOVE. 4792 03:14:35,280 --> 03:14:36,200 >>SECOND? 4793 03:14:36,200 --> 03:14:36,600 >>SECOND. 4794 03:14:36,600 --> 03:14:41,640 >>PROPERLY MOVED AND SECOND. 4795 03:14:41,640 --> 03:14:43,960 A QUESTION? 4796 03:14:43,960 --> 03:14:48,440 >>GO AHEAD. 4797 03:14:48,440 --> 03:14:53,120 >>IF NOT, WE CAN -- NCAB 4798 03:14:53,120 --> 03:14:54,320 MEMBERS SHOULD VOTE. 4799 03:14:54,320 --> 03:14:57,480 ANY NAYS? 4800 03:14:57,480 --> 03:15:00,360 ANY ABSTENTIONS? 4801 03:15:00,360 --> 03:15:00,640 PAULETTE? 4802 03:15:00,640 --> 03:15:01,440 >>IT'S UNANIMOUS. 4803 03:15:01,440 --> 03:15:04,720 >>COULD I ASK A QUESTION? 4804 03:15:04,720 --> 03:15:05,440 >>UH-HUH. 4805 03:15:05,440 --> 03:15:06,080 >>YOU CAN. 4806 03:15:06,080 --> 03:15:08,160 >>PAULETTE, THE REPORT THAT WE 4807 03:15:08,160 --> 03:15:10,240 SUBMITTED, I'VE HAD SEVERAL 4808 03:15:10,240 --> 03:15:13,200 PEOPLE ASK ME WHEN THAT WILL BE 4809 03:15:13,200 --> 03:15:15,520 MADE PUBLIC OR AT LEAST BE ABLE 4810 03:15:15,520 --> 03:15:16,160 TO REFERENCE. 4811 03:15:16,160 --> 03:15:18,760 DO YOU KNOW WHAT THE PROCESS IS 4812 03:15:18,760 --> 03:15:21,880 WITH THE REPORTS? 4813 03:15:21,880 --> 03:15:25,160 >>IT WILL BE POSTED ON THE 4814 03:15:25,160 --> 03:15:27,880 WEBSITE WITHIN THE NEXT 24-48 4815 03:15:27,880 --> 03:15:28,200 HOURS. 4816 03:15:28,200 --> 03:15:28,440 >>OKAY. 4817 03:15:28,440 --> 03:15:32,400 THANK YOU VERY MUCH. 4818 03:15:32,400 --> 03:15:34,800 APPRECIATE THAT. 4819 03:15:34,800 --> 03:15:35,080 >>OKAY. 4820 03:15:35,080 --> 03:15:36,440 >>THANK YOU. 4821 03:15:36,440 --> 03:15:37,640 THE LAST AND FINAL REPORT 4822 03:15:37,640 --> 03:15:39,520 SUBCOMMITTEE REPORT TO BE 4823 03:15:39,520 --> 03:15:43,520 PRESENTED WILL BE BROUGHT TO 4824 03:15:43,520 --> 03:15:46,040 BROUGHT US BY 4825 03:15:46,040 --> 03:15:55,440 DR. AZAD, CLINICAL 4826 03:15:55,440 --> 03:15:57,040 INVESTIGATIONS. 4827 03:15:57,040 --> 03:15:59,960 >>THE SUBCOMMITTEE MET MONDAY, 4828 03:15:59,960 --> 03:16:01,600 5th, DECIDED TO LOOK AT THE 4829 03:16:01,600 --> 03:16:04,560 SURVEY THAT HAD BEEN 4830 03:16:04,560 --> 03:16:07,400 ADMINISTERED TO NCTN SITES TO 4831 03:16:07,400 --> 03:16:09,480 REALLY UNDERSTAND HOW THE SYSTEM 4832 03:16:09,480 --> 03:16:11,240 HAD BEEN OPERATING SO THE 4833 03:16:11,240 --> 03:16:12,520 RECOMPETE FOR THE FOLLOWING 4834 03:16:12,520 --> 03:16:15,080 YEAR, HOW THAT COULD BE CRAFTED 4835 03:16:15,080 --> 03:16:16,920 TO ADDRESS ANY CONCERNS AS WELL 4836 03:16:16,920 --> 03:16:20,720 AS CONTINUE TO CAPITALIZE ON 4837 03:16:20,720 --> 03:16:21,320 SUCCESSES. 4838 03:16:21,320 --> 03:16:23,360 THE SUBCOMMITTEE ON CLINICAL 4839 03:16:23,360 --> 03:16:25,240 INVESTIGATIONS, THE FULL REPORT, 4840 03:16:25,240 --> 03:16:27,080 ALL OF YOU RECEIVED THIS MORNING 4841 03:16:27,080 --> 03:16:30,240 BUT AS A BRIEF SUMMARY, OUR 4842 03:16:30,240 --> 03:16:33,520 MISSION IS TO FOCUS ON HOW TO 4843 03:16:33,520 --> 03:16:35,600 ADVISE NCAB AND NCI ON TRIALS 4844 03:16:35,600 --> 03:16:38,600 THAT ARE FOCUSED ON DETECTION, 4845 03:16:38,600 --> 03:16:39,320 PREVENTION, DIAGNOSTICS, 4846 03:16:39,320 --> 03:16:40,640 MANAGEMENT, AND TREATMENT. 4847 03:16:40,640 --> 03:16:42,480 WE'RE RESPONSIBLE FOR A BROAD 4848 03:16:42,480 --> 03:16:45,360 RANGE OF CONCERNS, HOW TO 4849 03:16:45,360 --> 03:16:46,760 IMPROVE CLINICAL INVESTIGATIONS 4850 03:16:46,760 --> 03:16:48,880 IN HUMAN BEINGS. 4851 03:16:48,880 --> 03:16:53,280 WE ALSO INVITE -- ADVICE ON THE 4852 03:16:53,280 --> 03:16:54,920 NCTN PROGRAM, AND AS I MENTIONED 4853 03:16:54,920 --> 03:16:58,080 THIS YEAR IS THE YEAR THAT THE 4854 03:16:58,080 --> 03:17:01,200 RECOMPETE FOR THE NCTN 4855 03:17:01,200 --> 03:17:02,120 REFORMATTED PROGRAM IS MOVING 4856 03:17:02,120 --> 03:17:05,080 FORWARD SO THE SURVEY THAT WAS 4857 03:17:05,080 --> 03:17:06,320 CONDUCTED WAS CONDUCTED 4858 03:17:06,320 --> 03:17:08,120 REGARDING THE PERFORMANCE OF THE 4859 03:17:08,120 --> 03:17:11,400 NCTN OVER THE PAST THREE YEARS 4860 03:17:11,400 --> 03:17:13,160 FROM MARCH OF 2019 THROUGH JULY 4861 03:17:13,160 --> 03:17:14,840 OF 2022. 4862 03:17:14,840 --> 03:17:16,880 WE INVITED DR. MOONEY, ASSOCIATE 4863 03:17:16,880 --> 03:17:19,960 DIRECTOR OF THE CANCER THERAPY 4864 03:17:19,960 --> 03:17:21,400 EVALUATION PROGRAM, CTEP, TO 4865 03:17:21,400 --> 03:17:25,760 PRESENT RESULTS OF THE SURVEY. 4866 03:17:25,760 --> 03:17:27,640 SHE FIRST BEGAN WITH A SUMMARY 4867 03:17:27,640 --> 03:17:29,280 OF THE PROGRAM SO THIS IS A 4868 03:17:29,280 --> 03:17:33,640 PROGRAM THAT WAS FOUNDED IN 4869 03:17:33,640 --> 03:17:36,480 2014, NCTN PROGRAM, 4870 03:17:36,480 --> 03:17:38,160 RECONFIGURATION OF COOPERATIVE 4871 03:17:38,160 --> 03:17:41,840 GROUPS TO HARMONIZE PROCESSES 4872 03:17:41,840 --> 03:17:42,600 AND PROMOTE COLLABORATIONS, 4873 03:17:42,600 --> 03:17:43,960 INVIGORATE NCI CLINICAL TRIALS 4874 03:17:43,960 --> 03:17:48,440 PORTFOLIO WHICH HAD BEEN HAVING 4875 03:17:48,440 --> 03:17:50,080 CHALLENGES PRIOR TO THIS. 4876 03:17:50,080 --> 03:17:51,280 OBJECTIVES WERE TO CONTINUE 4877 03:17:51,280 --> 03:17:53,440 FOCUSING ON QUESTIONS THAT ARE 4878 03:17:53,440 --> 03:17:57,080 NOT PARTICULARLY WELL SUPPORTED 4879 03:17:57,080 --> 03:17:57,840 IN NORMAL COMMERCIAL 4880 03:17:57,840 --> 03:17:59,520 ENVIRONMENTS PRIORITIZED STUDIES 4881 03:17:59,520 --> 03:18:01,680 THAT INCORPORATE BOTH INNOVATIVE 4882 03:18:01,680 --> 03:18:03,400 SCIENCE BUT ALSO LOOKING AT 4883 03:18:03,400 --> 03:18:05,280 LARGE SCALE TESTING OF SMALL 4884 03:18:05,280 --> 03:18:07,720 SUBSETS OF MOLECULAR DEFINED 4885 03:18:07,720 --> 03:18:09,680 CANCERS TO BE NCI MATCH TRIAL IS 4886 03:18:09,680 --> 03:18:12,280 AN EXAMPLE OF THAT KIND OF 4887 03:18:12,280 --> 03:18:13,520 INITIATIVE THAT WAS UNDERTAKEN 4888 03:18:13,520 --> 03:18:15,440 THROUGH THE NCTN SO LARGE SCALE 4889 03:18:15,440 --> 03:18:18,080 TESTING OF SMALL SUBSETS OF 4890 03:18:18,080 --> 03:18:19,520 MOLECULAR DEFINED PATIENTS AND 4891 03:18:19,520 --> 03:18:21,920 ALSO LOOKING AT RARE TUMORS 4892 03:18:21,920 --> 03:18:25,600 WHICH IS A CHALLENGE TO DO AND 4893 03:18:25,600 --> 03:18:28,480 MORE TRADITIONAL CLINICAL TRIAL 4894 03:18:28,480 --> 03:18:31,440 NETWORKS OR IN COMMERCIAL 4895 03:18:31,440 --> 03:18:31,720 ENTITIES. 4896 03:18:31,720 --> 03:18:37,680 THE NCTN IS COMPOSED OF SEVERAL 4897 03:18:37,680 --> 03:18:38,800 CENTRALIZED FUNCTIONS, THERE'S A 4898 03:18:38,800 --> 03:18:40,000 REVIEW BOARD, CLINICAL TRIALS 4899 03:18:40,000 --> 03:18:41,960 SUPPORT UNIT, RADIATION THERAPY 4900 03:18:41,960 --> 03:18:43,720 AND IMAGING CORE CENTER, 4901 03:18:43,720 --> 03:18:46,320 STEERING REVIEW COMMITTEE, THAT 4902 03:18:46,320 --> 03:18:49,040 CAN BE TUMOR BASED OR COMMON 4903 03:18:49,040 --> 03:18:51,040 HISTOLOGY BASED, COMMON DATA 4904 03:18:51,040 --> 03:18:52,080 MANAGEMENT SYSTEMS. 4905 03:18:52,080 --> 03:18:55,480 EACH NCTN GROUP HAS ITS OWN LEAD 4906 03:18:55,480 --> 03:18:57,480 ACADEMIC SITE AS WELL AS 4907 03:18:57,480 --> 03:18:59,120 STATISTICS AND DATA MANAGEMENT, 4908 03:18:59,120 --> 03:19:01,240 OPERATIONS, AND ITS OWN TUMOR 4909 03:19:01,240 --> 03:19:02,480 BANK. 4910 03:19:02,480 --> 03:19:05,000 SO THE SURVEY THAT WAS GIVEN WAS 4911 03:19:05,000 --> 03:19:09,640 OPEN FROM JULY 25 THROUGH AUGUST 4912 03:19:09,640 --> 03:19:11,400 26, 2022, 335 INDIVIDUALS 4913 03:19:11,400 --> 03:19:15,840 RESPONDED TO THE SURVEY. 4914 03:19:15,840 --> 03:19:17,440 AND 254 COMPLETED THE SURVEY IN 4915 03:19:17,440 --> 03:19:19,160 ITS ENTIRETY. 4916 03:19:19,160 --> 03:19:20,000 WHAT'S IMPORTANT ABOUT WHAT'S 4917 03:19:20,000 --> 03:19:21,800 HAPPENED OVER THE LAST FEW YEARS 4918 03:19:21,800 --> 03:19:24,400 EVEN IN THE ERA OF COVID, AFTER 4919 03:19:24,400 --> 03:19:27,120 A FEW MONTHS OF HAVING DECREASED 4920 03:19:27,120 --> 03:19:30,440 ACCRUALS ON THE NCTN WE HAD 4921 03:19:30,440 --> 03:19:32,440 MAINTAINED ACCRUALS ACROSS THE 4922 03:19:32,440 --> 03:19:34,520 NCTN THAT WAS CONSISTENT BEFORE 4923 03:19:34,520 --> 03:19:36,120 AND AFTER COVID. 4924 03:19:36,120 --> 03:19:37,920 THE SURVEY RESULTS OVERALL 4925 03:19:37,920 --> 03:19:40,880 SHOWED THAT THERE WAS GREAT 4926 03:19:40,880 --> 03:19:42,680 SATISFACTION IN THE PROGRAM, 4927 03:19:42,680 --> 03:19:43,920 ESPECIALLY COMPARED TO THE YEARS 4928 03:19:43,920 --> 03:19:49,160 BEFORE SO IF WE LOOK AT DECEMBER 4929 03:19:49,160 --> 03:19:53,000 2016 TO AUGUST 20, 22, THERE WAS 4930 03:19:53,000 --> 03:19:55,520 AN INCREASE IN SATISFACTION FOR 4931 03:19:55,520 --> 03:19:56,840 THE PROGRAM AND OVERALL THE 4932 03:19:56,840 --> 03:19:59,040 REPORT FROM THE SURVEY WAS QUITE 4933 03:19:59,040 --> 03:19:59,960 POSITIVE. 4934 03:19:59,960 --> 03:20:02,760 BUT THERE WERE RECURRENT AREAS 4935 03:20:02,760 --> 03:20:04,640 THAT WERE POTENTIAL PLACES FOR 4936 03:20:04,640 --> 03:20:06,160 OPTIMIZATION ESPECIALLY AS WE 4937 03:20:06,160 --> 03:20:09,680 LOOK FORWARD TO THE NEXT YEAR. 4938 03:20:09,680 --> 03:20:13,120 THIS INCLUDES HOW WE COULD 4939 03:20:13,120 --> 03:20:14,600 IMPROVE ENROLLMENT OF DIVERSE 4940 03:20:14,600 --> 03:20:15,800 POPULATIONS, LOOKING OVER THE 4941 03:20:15,800 --> 03:20:18,160 LAST TEN YEARS THERE HAS BEEN AN 4942 03:20:18,160 --> 03:20:21,360 INCREASE IN BOTH THE ABSOLUTE 4943 03:20:21,360 --> 03:20:22,040 NUMBER AND PERCENTAGES OF 4944 03:20:22,040 --> 03:20:25,320 MINORITY PATIENTS THAT HAVE BEEN 4945 03:20:25,320 --> 03:20:28,040 ENROLLED IN NCTN BUT STILL 4946 03:20:28,040 --> 03:20:29,000 HASN'T REACHED THE LEVEL OF THE 4947 03:20:29,000 --> 03:20:30,640 POPULATION WITHIN THE UNITED 4948 03:20:30,640 --> 03:20:34,160 STATES SO THERE'S STILL GREAT 4949 03:20:34,160 --> 03:20:35,600 OPPORTUNITY FOR CONTINUED 4950 03:20:35,600 --> 03:20:37,480 ENHANCEMENT OF ENROLLING DIVERSE 4951 03:20:37,480 --> 03:20:38,240 POPULATIONS AND VULNERABLE 4952 03:20:38,240 --> 03:20:41,920 PATIENTS THAT ARE NOT RECEIVING 4953 03:20:41,920 --> 03:20:42,920 ADEQUATE CARE. 4954 03:20:42,920 --> 03:20:46,080 MULTIPLE SITES ALSO TALKED ABOUT 4955 03:20:46,080 --> 03:20:49,520 THE IMPORTANCE OF HARMONIZING 4956 03:20:49,520 --> 03:20:51,760 DATA COLLECTION AND MINIMIZING 4957 03:20:51,760 --> 03:20:52,440 DATA COLLECTION, MINIMIZING 4958 03:20:52,440 --> 03:20:53,800 REDUNDANCY OF DATA COLLECTION, 4959 03:20:53,800 --> 03:20:57,560 AND HOW WE CAN STREAMLINE ISSUES 4960 03:20:57,560 --> 03:20:59,960 SO STAFF ARE ABLE TO OPEN MORE 4961 03:20:59,960 --> 03:21:01,920 TRIALS AND CLOSE MORE TRIALS 4962 03:21:01,920 --> 03:21:05,120 WHICH IS ALSO A CHALLENGE THAT 4963 03:21:05,120 --> 03:21:06,640 DIFFERENT SITES MENTIONED. 4964 03:21:06,640 --> 03:21:09,600 ANOTHER AREA OF POTENTIAL 4965 03:21:09,600 --> 03:21:11,440 OPTIMIZATION INCLUDES HOW MORE 4966 03:21:11,440 --> 03:21:13,840 JUNIOR FACULTY AND EARLY CAREER 4967 03:21:13,840 --> 03:21:16,200 INVESTIGATORS CAN BE INVOLVED IN 4968 03:21:16,200 --> 03:21:17,760 LEADERSHIP IN CLINICAL TRIALS 4969 03:21:17,760 --> 03:21:20,880 AND IN THE NCTN. 4970 03:21:20,880 --> 03:21:21,440 SOME SUGGESTIONS INCLUDED 4971 03:21:21,440 --> 03:21:24,920 LIMITING THE NUMBER OF TRIALS 4972 03:21:24,920 --> 03:21:26,960 THAT A PERSON CAN CHAIR AND 4973 03:21:26,960 --> 03:21:28,520 CONSIDERING TERM LIMITS FOR 4974 03:21:28,520 --> 03:21:30,400 COMMITTEE CHAIR ROLES AS WELL AS 4975 03:21:30,400 --> 03:21:32,520 INITIATIVES THAT HAPPEN, FOR 4976 03:21:32,520 --> 03:21:34,600 EXAMPLE, IN THE NCI MATCH WHEN 4977 03:21:34,600 --> 03:21:37,200 EARLY CAREER AND LATER CAREER 4978 03:21:37,200 --> 03:21:38,000 INVESTIGATOR WAS INVOLVED IN 4979 03:21:38,000 --> 03:21:41,240 EACH ARM OF THE TRIAL. 4980 03:21:41,240 --> 03:21:43,720 THERE WERE CONCERNS ABOUT 4981 03:21:43,720 --> 03:21:47,480 FUNDING IN THE NCTN SO 4982 03:21:47,480 --> 03:21:50,080 CENTRALIZED SERVICES HELP 4983 03:21:50,080 --> 03:21:51,920 SOMEWHAT BUT THERE'S 4984 03:21:51,920 --> 03:21:53,120 SIGNIFICANTLY LARGE COSTS 4985 03:21:53,120 --> 03:21:54,440 ASSOCIATED WITH BIOSPECIMEN 4986 03:21:54,440 --> 03:21:56,520 COLLECTION THAT IS REALLY NOT 4987 03:21:56,520 --> 03:21:59,280 WELL FUNDED, AS WELL AS FOR THE 4988 03:21:59,280 --> 03:22:01,880 PULL CONDUCT OF CORRELATIVE 4989 03:22:01,880 --> 03:22:02,320 SCIENCE. 4990 03:22:02,320 --> 03:22:05,400 DR. MOONEY I THINK DID A VERY 4991 03:22:05,400 --> 03:22:07,200 NICE JOB OF EXPLAINING WHAT 4992 03:22:07,200 --> 03:22:12,920 WE'RE ALL AWARE OF THAT INDUSTRY 4993 03:22:12,920 --> 03:22:17,960 SPONSORED STUDIES FOR MORE THAN 4994 03:22:17,960 --> 03:22:19,600 NCTN STUDIES ARE PRIORITIZED 4995 03:22:19,600 --> 03:22:21,480 HAVING FINANCIAL STRAIN AND THIS 4996 03:22:21,480 --> 03:22:23,600 IS FURTHER MAGNIFIED BY 4997 03:22:23,600 --> 03:22:25,960 WORKFORCE ISSUES THAT HAVE COME 4998 03:22:25,960 --> 03:22:27,520 UP DURING COVID BUT CONTINUE 4999 03:22:27,520 --> 03:22:30,680 WHEN IT COMES TO WORKFORCE AND 5000 03:22:30,680 --> 03:22:33,400 STAFF TURNOVER. 5001 03:22:33,400 --> 03:22:36,600 THERE WAS SOME UNCERTAINTY OR 5002 03:22:36,600 --> 03:22:38,200 DISCREPANCY BETWEEN SOME SITES 5003 03:22:38,200 --> 03:22:40,360 THAT WANTED MORE EARLY STAGE AND 5004 03:22:40,360 --> 03:22:41,520 EARLY PHASE CLINICAL TRIALS AND 5005 03:22:41,520 --> 03:22:43,160 OTHER SITES THAT WANTED MORE 5006 03:22:43,160 --> 03:22:46,320 LATE STAGE OR LATE PHASE TRIALS, 5007 03:22:46,320 --> 03:22:48,160 AND SO THAT LIKELY IS BASED ON 5008 03:22:48,160 --> 03:22:50,120 THE DIFFERENCE BETWEEN EACH 5009 03:22:50,120 --> 03:22:51,120 INDIVIDUAL SITE, AND IS REALLY 5010 03:22:51,120 --> 03:22:52,560 ABOUT TRYING TO HAVE A BALANCE 5011 03:22:52,560 --> 03:22:54,120 OF DIFFERENT KINDS OF STUDIES 5012 03:22:54,120 --> 03:22:57,520 THAT CAN SERVICE NEEDS OF A VERY 5013 03:22:57,520 --> 03:22:59,760 LARGE TRIAL PORTFOLIO AND SITE 5014 03:22:59,760 --> 03:23:01,320 PORTFOLIO WHERE EACH SITE MIGHT 5015 03:23:01,320 --> 03:23:03,520 HAVE DIFFERENT KINDS OF TRIALS 5016 03:23:03,520 --> 03:23:06,560 THAT IT MIGHT MOST ACTIVELY 5017 03:23:06,560 --> 03:23:07,880 ENROLL TO. 5018 03:23:07,880 --> 03:23:08,880 COVID-19 CREATED SOME 5019 03:23:08,880 --> 03:23:09,160 CHALLENGES. 5020 03:23:09,160 --> 03:23:12,400 THERE WERE SIX MONTHS OF 5021 03:23:12,400 --> 03:23:16,000 DECREASED ACCRUALS DURING THE 5022 03:23:16,000 --> 03:23:17,240 INITIAL PERIOD BUT MULTIPLE 5023 03:23:17,240 --> 03:23:19,640 POSITIVE THINGS CAME OUT OF OUR 5024 03:23:19,640 --> 03:23:21,160 ADAPTING TO THE COVID-19 5025 03:23:21,160 --> 03:23:22,280 PANDEMIC, AND THAT INCLUDED 5026 03:23:22,280 --> 03:23:25,120 BEING ABLE TO DO TELEHEALTH FOR 5027 03:23:25,120 --> 03:23:26,240 STUDY VISITS, ALLOWING PRIMARY 5028 03:23:26,240 --> 03:23:29,040 CARE PROVIDERS OR LOCAL HEALTH 5029 03:23:29,040 --> 03:23:30,680 PROVIDERS TO PERFORM STUDY 5030 03:23:30,680 --> 03:23:31,680 ACTIVITIES, REMOTE CONSENTING, 5031 03:23:31,680 --> 03:23:34,080 SHIPPING ORAL AGENTS TO 5032 03:23:34,080 --> 03:23:36,800 PATIENTS, REMOTE AUDITING, AND 5033 03:23:36,800 --> 03:23:38,520 ALL OF THESE ARE NOT NEW 5034 03:23:38,520 --> 03:23:40,840 STRATEGIES THAT COULD BE 5035 03:23:40,840 --> 03:23:43,360 UTILIZED GOING FORWARD, BOTH TO 5036 03:23:43,360 --> 03:23:46,320 HELP ENROLL MORE DIVERSE 5037 03:23:46,320 --> 03:23:47,600 POPULATIONS AS BEING ON A 5038 03:23:47,600 --> 03:23:49,920 CLINICAL TRIAL CAN BE BOTH 5039 03:23:49,920 --> 03:23:51,640 FINANCIALLY AND TIME-WISE A 5040 03:23:51,640 --> 03:23:53,720 STRAIN FOR PATIENTS. 5041 03:23:53,720 --> 03:23:54,960 BUT ALSO ALLOW DECREASING AMOUNT 5042 03:23:54,960 --> 03:23:59,000 OF STRAIN ON STAFF AS WELL. 5043 03:23:59,000 --> 03:24:00,640 SO OVERALL, PEOPLE HAVE BEEN 5044 03:24:00,640 --> 03:24:02,920 HAPPY BASED ON THE SURVEY, AND 5045 03:24:02,920 --> 03:24:05,240 ADVANCES THAT HAPPENED WITH THE 5046 03:24:05,240 --> 03:24:05,440 NCTN. 5047 03:24:05,440 --> 03:24:07,720 THERE ARE MANY THINGS FROM THE 5048 03:24:07,720 --> 03:24:11,040 LAST FIVE YEARS THAT SHOULD BE 5049 03:24:11,040 --> 03:24:12,040 MAINTAINED AND CONTINUED, BUT 5050 03:24:12,040 --> 03:24:13,440 THERE ARE OPPORTUNITIES THAT WE 5051 03:24:13,440 --> 03:24:16,320 REALLY NEED TO TAKE ADVANTAGE OF 5052 03:24:16,320 --> 03:24:21,200 IN A NEW RFA THAT WE MAY WANT TO 5053 03:24:21,200 --> 03:24:23,400 IMPROVE ON, AND THAT INVOLVES 5054 03:24:23,400 --> 03:24:25,840 WAYS THAT WE CAN DECREASE THE 5055 03:24:25,840 --> 03:24:29,800 DATA BURDEN ON DIFFERENT SITES, 5056 03:24:29,800 --> 03:24:33,280 CREATE EFFICIENCY WITH 5057 03:24:33,280 --> 03:24:34,440 CENTRALIZATION, PRIORITIZE 5058 03:24:34,440 --> 03:24:37,080 JUNIOR FACULTY INVOLVEMENT AS 5059 03:24:37,080 --> 03:24:41,800 WELL AS DIFFERENT INITIATIVES O 5060 03:24:41,800 --> 03:24:48,600 INCREASE DIVOT TRIALS -- DIFFER, 5061 03:24:48,600 --> 03:24:50,040 - DIVERSITY, ON THE 5062 03:24:50,040 --> 03:24:50,440 TRIALS. 5063 03:24:50,440 --> 03:24:53,760 WE HAD COMMENTS FROM COMMITTEE 5064 03:24:53,760 --> 03:24:57,160 MEMBERS, AS WELL AS NCAB AND BSA 5065 03:24:57,160 --> 03:24:59,560 MEMBERS THAT FOCUSED ON MULTIPLE 5066 03:24:59,560 --> 03:25:01,400 ISSUES THAT WERE COMING OUT OF 5067 03:25:01,400 --> 03:25:02,600 THE SURVEY. 5068 03:25:02,600 --> 03:25:05,880 THERE WAS A COMMON CONSENSUS 5069 03:25:05,880 --> 03:25:07,320 THAT NCAB MEMBERS UNDERSTAND 5070 03:25:07,320 --> 03:25:10,360 THAT MORE FUNDING IS REALLY 5071 03:25:10,360 --> 03:25:12,120 NECESSARY, AND THERE WAS 5072 03:25:12,120 --> 03:25:13,320 CONVERSATION REGARDING TRYING TO 5073 03:25:13,320 --> 03:25:16,280 DO SOME MORE DATA ANALYSIS 5074 03:25:16,280 --> 03:25:18,240 AROUND WHAT COSTS ARE FOR 5075 03:25:18,240 --> 03:25:19,360 CONDUCTING TRIALS, SO HOW WE 5076 03:25:19,360 --> 03:25:22,560 MIGHT BE ABLE TO BETTER ADVOCATE 5077 03:25:22,560 --> 03:25:25,440 FOR MORE FUNDING FOR THE NCTN 5078 03:25:25,440 --> 03:25:27,560 STUDIES, AS WELL AS POTENTIALLY 5079 03:25:27,560 --> 03:25:30,080 HOW WE MIGHT REJIGGER THE WAY 5080 03:25:30,080 --> 03:25:31,640 TRIALS ARE FUNDED. 5081 03:25:31,640 --> 03:25:33,360 THERE WAS A CONSENSUS ON THE 5082 03:25:33,360 --> 03:25:36,240 NEED TO FOCUS ON HOW WE MIGHT 5083 03:25:36,240 --> 03:25:38,160 CONTINUE TO IMPROVE ACCESS OF 5084 03:25:38,160 --> 03:25:41,000 THESE TRIALS TO PATIENTS THAT 5085 03:25:41,000 --> 03:25:45,360 ARE DIVERSE INCLUDING PATIENTS 5086 03:25:45,360 --> 03:25:46,160 WITH DIFFERENT SOCIOECONOMIC 5087 03:25:46,160 --> 03:25:49,120 ISSUES AND SO WE HAD A VERY 5088 03:25:49,120 --> 03:25:50,160 ROBUST DISCUSSION, AND I'LL 5089 03:25:50,160 --> 03:25:52,960 LEAVE THE REST OF THIS TO MORE 5090 03:25:52,960 --> 03:25:55,160 DETAILED READING OF THE MINUTES 5091 03:25:55,160 --> 03:25:57,800 FROM THAT MEETING. 5092 03:25:57,800 --> 03:26:03,840 5093 03:26:03,840 --> 03:26:04,200 >>FANTASTIC. 5094 03:26:04,200 --> 03:26:05,040 THANKS, NILO. 5095 03:26:05,040 --> 03:26:07,880 DO WE HAVE ANY QUESTIONS FOR 5096 03:26:07,880 --> 03:26:10,320 NILO? 5097 03:26:10,320 --> 03:26:12,720 5098 03:26:12,720 --> 03:26:14,800 YOU CAN MANAGE THE Q&A IF YOU 5099 03:26:14,800 --> 03:26:16,920 CAN SEE THE HANDS. 5100 03:26:16,920 --> 03:26:17,960 >>KAREN? 5101 03:26:17,960 --> 03:26:20,600 >>THANK YOU FOR THAT GREAT 5102 03:26:20,600 --> 03:26:21,000 OVERVIEW. 5103 03:26:21,000 --> 03:26:21,760 THAT WAS WONDERFUL. 5104 03:26:21,760 --> 03:26:23,240 >>IT GOT REALLY DARK AFTER I 5105 03:26:23,240 --> 03:26:23,600 SPOKE. 5106 03:26:23,600 --> 03:26:26,280 I DON'T KNOW IF THAT SAYS 5107 03:26:26,280 --> 03:26:26,720 SOMETHING ABOUT THE 5108 03:26:26,720 --> 03:26:27,040 PRESENTATION. 5109 03:26:27,040 --> 03:26:29,000 >>, YEAH WE WON'T COMMENT ON 5110 03:26:29,000 --> 03:26:29,200 THAT. 5111 03:26:29,200 --> 03:26:32,200 SO, ONE OF THE THINGS THAT I 5112 03:26:32,200 --> 03:26:35,000 THINK IS RELEVANT TO YOUR 5113 03:26:35,000 --> 03:26:36,360 PRESENTATION AND ALSO THE 5114 03:26:36,360 --> 03:26:37,880 CONVERSATION AROUND CLINICAL 5115 03:26:37,880 --> 03:26:39,760 TRIAL ENROLLMENT IS TO REALLY 5116 03:26:39,760 --> 03:26:40,600 THINK ABOUT THE DIFFERENT TIMES 5117 03:26:40,600 --> 03:26:44,440 OF PARTNERSHIPS AS YOU MAY BE 5118 03:26:44,440 --> 03:26:45,960 AWARE, THE WYNN SCHOLARSHIP 5119 03:26:45,960 --> 03:26:48,480 PROGRAM IS FOCUSED ON IMPROVING 5120 03:26:48,480 --> 03:26:53,080 NOT ONLY WORKFORCE DIVERSITY 5121 03:26:53,080 --> 03:26:54,400 WITH RESPECT TO CLINICAL 5122 03:26:54,400 --> 03:26:56,320 TRIALISTS BUT TRYING TO IMPROVE 5123 03:26:56,320 --> 03:27:02,520 PARTICIPATION, AND THERE IS AN 5124 03:27:02,520 --> 03:27:04,480 UPCOMING PARTNERSHIP WITH ASCO 5125 03:27:04,480 --> 03:27:05,480 WORKING WITH COOPERATIVE GROUPS, 5126 03:27:05,480 --> 03:27:06,800 INDIVIDUALS MAY BE TRAINED AS A 5127 03:27:06,800 --> 03:27:12,040 WIN 5128 03:27:12,040 --> 03:27:14,000 -- WYNN SCHOLAR TO THINK ABOUT 5129 03:27:14,000 --> 03:27:22,080 A GROUP THAT COULD BE A JUMPOFF 5130 03:27:22,080 --> 03:27:23,080 POINT FOR PEOPLE TRAINED. 5131 03:27:23,080 --> 03:27:27,680 I JUST WANTED TO MENTION THAT. 5132 03:27:27,680 --> 03:27:31,600 ASCO AND AAAC PARTNERED AROUND 5133 03:27:31,600 --> 03:27:35,000 DOING BASELINE DATA COLLECTION 5134 03:27:35,000 --> 03:27:37,440 AT DIFFERENT INSTITUTIONS AROUND 5135 03:27:37,440 --> 03:27:39,080 INCLUSIVE PARTICIPATION. 5136 03:27:39,080 --> 03:27:40,040 [AUDIO DISTORTION] 5137 03:27:40,040 --> 03:27:41,920 ANY OF THAT DATA WAS PART OF 5138 03:27:41,920 --> 03:27:44,440 YOUR ENVIRONMENTAL SCAN AS YOU 5139 03:27:44,440 --> 03:27:48,920 GUYS WERE THINKING OR DISCUSSING 5140 03:27:48,920 --> 03:27:50,240 ANY OF YOUR PROGRAMS. 5141 03:27:50,240 --> 03:27:53,400 >>SO THAT WAS NOT PART OF THIS 5142 03:27:53,400 --> 03:27:54,280 SURVEY OR CONVERSATION GOING 5143 03:27:54,280 --> 03:27:56,120 FORWARD BUT I THINK IT 5144 03:27:56,120 --> 03:27:57,080 ABSOLUTELY MAKES SENSE TO 5145 03:27:57,080 --> 03:27:58,720 INCORPORATE THAT. 5146 03:27:58,720 --> 03:28:05,880 I THINK OUR NEXT MEETING SHOULD 5147 03:28:05,880 --> 03:28:11,360 BE A HIGHLIGHTED TOPIC. 5148 03:28:11,360 --> 03:28:13,200 >>I JUST HAD A QUESTION. 5149 03:28:13,200 --> 03:28:15,080 YOU MENTIONED BRIEFLY ABOUT DATA 5150 03:28:15,080 --> 03:28:16,040 STREAMLINING AND I DON'T WANT TO 5151 03:28:16,040 --> 03:28:17,600 SPEND TOO MUCH TIME ON IT BUT 5152 03:28:17,600 --> 03:28:19,800 DID YOU COME UP WITH ANY 5153 03:28:19,800 --> 03:28:21,520 SOLUTIONS ABOUT HOW TO 5154 03:28:21,520 --> 03:28:23,160 CENTRALIZE AND STREAMLINE THE 5155 03:28:23,160 --> 03:28:23,840 DATA? 5156 03:28:23,840 --> 03:28:25,360 THAT'S ONE OF THE REALLY 5157 03:28:25,360 --> 03:28:28,840 CRITICAL ISSUES BEING ABLE TO BE 5158 03:28:28,840 --> 03:28:30,880 EFFICIENT IN THESE CLINICAL 5159 03:28:30,880 --> 03:28:32,120 TRIALS, LARGE AND SMALL SCALE. 5160 03:28:32,120 --> 03:28:34,720 >>YEAH, SO AT THE END OF THAT 5161 03:28:34,720 --> 03:28:35,800 CONVERSATION WE BEGAN TALKING 5162 03:28:35,800 --> 03:28:38,520 ABOUT HOW WE MIGHT BE ABLE TO 5163 03:28:38,520 --> 03:28:40,280 ADAPT THE RFA THAT'S GOING OUT 5164 03:28:40,280 --> 03:28:42,640 AS WELL AS HOW WE INSTRUCT THE 5165 03:28:42,640 --> 03:28:45,040 STEERING COMMITTEES AND WHO HELP 5166 03:28:45,040 --> 03:28:46,360 WITH THE PROTOCOL FORMATION. 5167 03:28:46,360 --> 03:28:48,200 TO STREAMLINE BOTH WHAT DATA IS 5168 03:28:48,200 --> 03:28:49,840 COLLECTED BUT THEN STILL 5169 03:28:49,840 --> 03:28:52,640 CONTINUE TO PRIORITIZE SOME DATA 5170 03:28:52,640 --> 03:28:53,520 THAT SOMETIMES ISN'T EVEN 5171 03:28:53,520 --> 03:28:53,840 COLLECTED. 5172 03:28:53,840 --> 03:28:55,360 THERE'S A BALANCE THERE. 5173 03:28:55,360 --> 03:28:56,360 SOME DEMOGRAPHIC DATA THAT WE'RE 5174 03:28:56,360 --> 03:28:58,080 NOT DOING A GOOD JOB OF 5175 03:28:58,080 --> 03:28:59,880 COLLECTING, BUT THEN THERE'S 5176 03:28:59,880 --> 03:29:02,360 LONG-TERM DATA THAT'S BEING 5177 03:29:02,360 --> 03:29:03,120 COLLECTED, I THINK THERE'S 5178 03:29:03,120 --> 03:29:06,720 THINGS THAT ARE NILES TO -- NICE 5179 03:29:06,720 --> 03:29:09,800 TO HAVE AND PUT A HUGE AMOUNT OF 5180 03:29:09,800 --> 03:29:12,320 BURDEN ON THE STAFF SO MOST OF 5181 03:29:12,320 --> 03:29:13,400 THAT IS TO -- DOESN'T APPEAR TO 5182 03:29:13,400 --> 03:29:16,160 BE PART OF THE NEW RFA BUT 5183 03:29:16,160 --> 03:29:18,240 SHOULD BE ABOUT THE BEST 5184 03:29:18,240 --> 03:29:19,520 OPERATING PRACTICES THAT ARE 5185 03:29:19,520 --> 03:29:22,320 ALSO -- THEY ARE THE NEXT THING 5186 03:29:22,320 --> 03:29:26,040 THAT THE CLINICAL INVESTIGATION 5187 03:29:26,040 --> 03:29:27,240 COMMITTEE IS PLANNING TO TAKE 5188 03:29:27,240 --> 03:29:32,480 YOU THE, DOING STANDARD 5189 03:29:32,480 --> 03:29:33,560 OPERATING PROCEDURES AROUND 5190 03:29:33,560 --> 03:29:38,640 CENTRAL FUNCTIONS OF THE NCTN, 5191 03:29:38,640 --> 03:29:40,920 THEY DO HAVE CONTROL OVER AND 5192 03:29:40,920 --> 03:29:42,520 COULD BE MODIFIED, WE JUST NEED 5193 03:29:42,520 --> 03:29:45,800 TO MAKE THAT A PRIORITY. 5194 03:29:45,800 --> 03:29:48,920 >>AND THEY ARE ALL USING THE 5195 03:29:48,920 --> 03:29:49,680 SAME SOFTWARE, RIGHT? 5196 03:29:49,680 --> 03:29:51,680 IT'S A MATTER OF STREAMLINING 5197 03:29:51,680 --> 03:29:55,360 DATA POINTS BEING COLLECTED? 5198 03:29:55,360 --> 03:29:56,240 >>YES AND THE TIMELINE OF HOW 5199 03:29:56,240 --> 03:30:00,080 LONG THEY HAVE TO BE COLLECTED. 5200 03:30:00,080 --> 03:30:01,040 >>THANK YOU. 5201 03:30:01,040 --> 03:30:03,720 >>A QUICK QUESTION. 5202 03:30:03,720 --> 03:30:05,560 I COULDN'T COME WHEN YOU HAD THE 5203 03:30:05,560 --> 03:30:05,800 MEETING. 5204 03:30:05,800 --> 03:30:07,400 A GREAT SUMMARY. 5205 03:30:07,400 --> 03:30:08,920 IT'S ABOUT THE PANDEMIC 5206 03:30:08,920 --> 03:30:09,880 EXPERIENCE, YOU TALKED ABOUT 5207 03:30:09,880 --> 03:30:10,800 SEVERAL THINGS IN CLINICAL 5208 03:30:10,800 --> 03:30:13,000 TRIALS THAT ARE BETTER, NOW 5209 03:30:13,000 --> 03:30:14,080 COULD BE DONE. 5210 03:30:14,080 --> 03:30:15,160 IT FELT SOFT. 5211 03:30:15,160 --> 03:30:17,680 I WASN'T SURE IF THERE'S A PLAN 5212 03:30:17,680 --> 03:30:20,960 TO FOLLOW WHAT YOU WERE SAYING 5213 03:30:20,960 --> 03:30:25,160 TO WRITE UP SOPs, CODIFY 5214 03:30:25,160 --> 03:30:26,560 TELEMEDICINE CAN BE USED IN THIS 5215 03:30:26,560 --> 03:30:28,200 SITUATION, YOU CAN USE PRIMARY 5216 03:30:28,200 --> 03:30:29,600 CARE PROVIDER TO DO EXAMS, YOU 5217 03:30:29,600 --> 03:30:31,040 CAN DO THE LABORATORIES, BECAUSE 5218 03:30:31,040 --> 03:30:32,240 I THINK THERE'S A REGRESSION 5219 03:30:32,240 --> 03:30:34,160 BACK TO OUR OLD PATTERNS OF 5220 03:30:34,160 --> 03:30:35,520 BEHAVIOR WHEN PEOPLE DON'T KNOW 5221 03:30:35,520 --> 03:30:39,120 WHAT'S REALLY OKAY AND WHAT'S 5222 03:30:39,120 --> 03:30:39,640 NOT. 5223 03:30:39,640 --> 03:30:41,680 >>SO I THINK THAT THERE WERE 5224 03:30:41,680 --> 03:30:44,080 MORE DETAILS IN THE PRESENTATION 5225 03:30:44,080 --> 03:30:45,280 AND THAT THOSE ABSOLUTELY ARE 5226 03:30:45,280 --> 03:30:47,560 GOING TO BE CODIFIED. 5227 03:30:47,560 --> 03:30:50,600 BOTH IN THE RFA GOING OUT BUT 5228 03:30:50,600 --> 03:30:54,000 MAYBE GOING BACK TO WHAT WE 5229 03:30:54,000 --> 03:30:57,600 TALKED ABOUT ANDREA, ALSO ABOUT 5230 03:30:57,600 --> 03:31:02,200 SOPs OF NCTN WITHIN 5231 03:31:02,200 --> 03:31:02,840 CENTRALIZED SERVICES COOPERATIVE 5232 03:31:02,840 --> 03:31:04,040 GROUPS ARE DOING, ABOUT 5233 03:31:04,040 --> 03:31:09,520 PROVIDING THAT CONTEXT AND THAT 5234 03:31:09,520 --> 03:31:11,200 OVERVIEW AND OVERSIGHT, AND THEY 5235 03:31:11,200 --> 03:31:13,880 ARE COMMITTED TO DOING IT. 5236 03:31:13,880 --> 03:31:22,920 AND I'VE SEEN IN MY OWN PROGRAM 5237 03:31:22,920 --> 03:31:24,880 THAT'S IN THE NEW ONES MOVING 5238 03:31:24,880 --> 03:31:29,160 FORWARD AS WELL. 5239 03:31:29,160 --> 03:31:33,040 5240 03:31:33,040 --> 03:31:39,440 >>ANYBODY ELSE? 5241 03:31:39,440 --> 03:31:41,480 >>WE CAN'T HEAR YOU. 5242 03:31:41,480 --> 03:31:43,360 >>ARE YOU CALLING FOR THE VOTE? 5243 03:31:43,360 --> 03:31:45,320 >>THERE WAS ONE MORE HAND. 5244 03:31:45,320 --> 03:31:50,040 >>HOWARD'S HAND IS UP. 5245 03:31:50,040 --> 03:31:52,320 >>THANK YOU. 5246 03:31:52,320 --> 03:31:54,080 I'M WONDERING ABOUT WHAT GETS 5247 03:31:54,080 --> 03:31:57,680 MEASURED IS WHAT GETS DONE, AND 5248 03:31:57,680 --> 03:31:59,880 TO MEASURE THESE MEMBERS BY 5249 03:31:59,880 --> 03:32:03,280 INVITING A SURVEY AND HEARING 5250 03:32:03,280 --> 03:32:05,560 ABOUT THEIR PLACE IS FINE 5251 03:32:05,560 --> 03:32:10,840 ALTHOUGH WE REALIZE IN THE 5252 03:32:10,840 --> 03:32:12,280 RANKING OF DATA, DECISION-MAKING 5253 03:32:12,280 --> 03:32:14,040 DATA, THAT'S LOW ON THE LIST, 5254 03:32:14,040 --> 03:32:14,920 RIGHT? 5255 03:32:14,920 --> 03:32:15,920 >>YES. 5256 03:32:15,920 --> 03:32:18,720 >>SURVEY IN GENERAL. 5257 03:32:18,720 --> 03:32:20,480 BUT THAT BEING SAID WONDERING 5258 03:32:20,480 --> 03:32:23,120 ABOUT OTHER QUESTIONS THAT MIGHT 5259 03:32:23,120 --> 03:32:26,400 BE ASKED THAT WOULD THEN HELP 5260 03:32:26,400 --> 03:32:30,560 REINFORCE BOTH THE QUALITY AND 5261 03:32:30,560 --> 03:32:33,840 DESIRABILITY OF PARTNERSHIPS OR 5262 03:32:33,840 --> 03:32:34,400 INDUSTRY PARTNERSHIPS, I'M 5263 03:32:34,400 --> 03:32:37,440 THINKING FOR EXAMPLE THERE WAS A 5264 03:32:37,440 --> 03:32:38,680 EUROPEAN COOPERATIVE GROUP WHERE 5265 03:32:38,680 --> 03:32:42,520 A VERY LARGE -- A U.S. COMPANY 5266 03:32:42,520 --> 03:32:44,320 HAD PROBLEMS WITH THOUSANDS OF 5267 03:32:44,320 --> 03:32:45,560 UNANSWERED QUERIES AND THEY WERE 5268 03:32:45,560 --> 03:32:46,880 TRYING TO PARTNER WITH THEM BUT 5269 03:32:46,880 --> 03:32:48,960 IT TOOK MONTHS AND MONTHS, A 5270 03:32:48,960 --> 03:32:53,440 YEAR PLUS TO GET ALL THESE 5271 03:32:53,440 --> 03:32:55,160 QUERIES ANSWERED. 5272 03:32:55,160 --> 03:32:57,080 AND THEN THE DATA SHARING 5273 03:32:57,080 --> 03:33:00,640 INITIATIVES THAT I THINK THEY 5274 03:33:00,640 --> 03:33:06,360 ARE OBLIGATED TO DO AND THERE'S 5275 03:33:06,360 --> 03:33:09,160 BEEN MULTIPLE PUBLICATIONS AT 5276 03:33:09,160 --> 03:33:09,760 clinicaltrials.gov AND PROJECT 5277 03:33:09,760 --> 03:33:15,120 DATASPHERE HAVE A LOT OF MISSING 5278 03:33:15,120 --> 03:33:17,440 DATA SETS FROM NCCTN TRIALS. 5279 03:33:17,440 --> 03:33:20,040 DIFFERENT THINGS REQUIRED IN THE 5280 03:33:20,040 --> 03:33:22,240 PROTOCOL, COLLECTED, NOT 5281 03:33:22,240 --> 03:33:22,520 UPLOADED. 5282 03:33:22,520 --> 03:33:25,200 SO QUALITY, IF YOU ASK ABOUT 5283 03:33:25,200 --> 03:33:26,720 QUALITY AND TRACK QUALITY, YOU 5284 03:33:26,720 --> 03:33:31,320 KNOW, IN MY VIEW THAT'S THE WAY 5285 03:33:31,320 --> 03:33:32,520 TO GET IT. 5286 03:33:32,520 --> 03:33:34,720 I'M INTERESTED BECAUSE I CARE 5287 03:33:34,720 --> 03:33:36,480 ABOUT EFFECTIVE PARTNERSHIPS. 5288 03:33:36,480 --> 03:33:41,160 WE BROUGHT UP BEFORE HOW 5289 03:33:41,160 --> 03:33:43,040 BRINGING BEVACIZUMAB -- 5290 03:33:43,040 --> 03:33:43,440 [AUDIO DISTORTION] 5291 03:33:43,440 --> 03:33:47,440 LED TO ONE OF THE BEST FASTEST 5292 03:33:47,440 --> 03:33:49,920 ACCRUALS ON RECORD, FROM WHAT I 5293 03:33:49,920 --> 03:33:51,920 RECALL, BECAUSE THE INDUSTRY 5294 03:33:51,920 --> 03:33:54,000 PEOPLE THAT HAD BEVACIZUMAB 5295 03:33:54,000 --> 03:33:55,720 REALLY DID WORK WELL AND 5296 03:33:55,720 --> 03:33:59,240 COLLABORATE WELL TO GET THE 5297 03:33:59,240 --> 03:34:02,200 QUALITY OUT OF THE 5298 03:34:02,200 --> 03:34:04,160 COLLABORATION. 5299 03:34:04,160 --> 03:34:07,280 THAT'S MY OWN FEELING. 5300 03:34:07,280 --> 03:34:08,200 THANK YOU. 5301 03:34:08,200 --> 03:34:09,880 >>I THINK WE'LL TAKE THAT 5302 03:34:09,880 --> 03:34:10,760 COMMENT. 5303 03:34:10,760 --> 03:34:13,720 I WILL SAY THAT BECAUSE THESE 5304 03:34:13,720 --> 03:34:16,080 STUDIES ARE ACTUALLY MONITORED 5305 03:34:16,080 --> 03:34:17,320 BY THE SAME ENTITY, I THINK 5306 03:34:17,320 --> 03:34:19,400 THERE'S THE OPPORTUNITY TO BE 5307 03:34:19,400 --> 03:34:20,680 ABLE TO LOOK AT THE DATA QUALITY 5308 03:34:20,680 --> 03:34:23,000 AND TO LOOK AT IT OVER TIME TO 5309 03:34:23,000 --> 03:34:24,960 GET A SENSE OF SOME OF THAT SO 5310 03:34:24,960 --> 03:34:27,960 WHEN WE THEN MOVE TOWARDS THESE 5311 03:34:27,960 --> 03:34:29,240 PRIVATE PARTNERSHIPS THAT WE'VE 5312 03:34:29,240 --> 03:34:32,320 GOT SOME DATA IN HAND REGARDING 5313 03:34:32,320 --> 03:34:34,400 HOW WELL THE GROUPS ARE DOING IN 5314 03:34:34,400 --> 03:34:37,280 CAPTURING ALL THE DATA AND HOW 5315 03:34:37,280 --> 03:34:44,360 CLEAN THAT DATA IS, YOU KNOW. 5316 03:34:44,360 --> 03:34:47,960 >>THE OTHER THING THAT I -- 5317 03:34:47,960 --> 03:34:48,600 [AUDIO DISTORTION] 5318 03:34:48,600 --> 03:34:51,040 COMPLETERS, WE TALK ABOUT 5319 03:34:51,040 --> 03:34:52,960 ACCRUAL OF UNDERSERVED AND 5320 03:34:52,960 --> 03:34:54,200 MINORITY, BUT I THINK IT COULD 5321 03:34:54,200 --> 03:34:56,800 WELL BE IT'S ONE ON ONE FOR WHO 5322 03:34:56,800 --> 03:34:59,240 FINISHES THE STUDY AND PROVIDES 5323 03:34:59,240 --> 03:35:00,560 DATA THAT'S MEANINGFUL TO 5324 03:35:00,560 --> 03:35:00,840 ANALYZE. 5325 03:35:00,840 --> 03:35:02,560 BUT MAYBE IT'S NOT. 5326 03:35:02,560 --> 03:35:03,640 AND I THINK, AGAIN, YOU KNOW, 5327 03:35:03,640 --> 03:35:05,360 WHAT YOU ASK FOR, WHAT YOU 5328 03:35:05,360 --> 03:35:08,800 MEASURE, IS THE BEST WAY TO GET 5329 03:35:08,800 --> 03:35:10,120 SOMETHING AND SHOW PEOPLE YOU 5330 03:35:10,120 --> 03:35:12,640 VALUE IT. 5331 03:35:12,640 --> 03:35:18,640 5332 03:35:18,640 --> 03:35:19,760 >>GREAT POINT, HOWARD. 5333 03:35:19,760 --> 03:35:24,800 THERE BEING NO OTHER DISCUSSION, 5334 03:35:24,800 --> 03:35:28,160 IT'S TIME FOR NCAB TO VOTE TO 5335 03:35:28,160 --> 03:35:28,920 ACCEPT THE REPORT. 5336 03:35:28,920 --> 03:35:33,760 IS THERE A MOTION TO ACCEPT? 5337 03:35:33,760 --> 03:35:34,480 >>SO MOVED. 5338 03:35:34,480 --> 03:35:36,800 >>SECOND? 5339 03:35:36,800 --> 03:35:37,320 >>SECOND. 5340 03:35:37,320 --> 03:35:37,640 >>SECOND. 5341 03:35:37,640 --> 03:35:41,240 >>NOW IT'S BEEN PROPERLY MOVED 5342 03:35:41,240 --> 03:35:42,600 AND SECONDED. 5343 03:35:42,600 --> 03:35:43,480 QUESTIONS? 5344 03:35:43,480 --> 03:35:45,560 LET'S VOTE. 5345 03:35:45,560 --> 03:35:46,560 ARE THERE ANY NAYS? 5346 03:35:46,560 --> 03:35:53,160 DOES ANYONE NEED TO ABSTAIN? 5347 03:35:53,160 --> 03:35:54,920 PAULETTE? 5348 03:35:54,920 --> 03:35:56,560 >>IT'S UNANIMOUS VOTE. 5349 03:35:56,560 --> 03:35:58,960 >>THANK YOU. 5350 03:35:58,960 --> 03:36:01,240 SO MOVING ON, WE HAVE ROUGHLY 5351 03:36:01,240 --> 03:36:04,320 TEN MINUTES ON THE FORMAL 5352 03:36:04,320 --> 03:36:06,440 AGENDA, MOVING TO OTHER 5353 03:36:06,440 --> 03:36:08,800 BUSINESS, THE ANNUAL BSA CONCEPT 5354 03:36:08,800 --> 03:36:12,760 REVIEW REPORT IS POSTED ON THE 5355 03:36:12,760 --> 03:36:13,720 BSA ONLY WEBSITE. 5356 03:36:13,720 --> 03:36:16,880 AND SO THE MEMBERS ONLY WEBSITE. 5357 03:36:16,880 --> 03:36:18,760 AS REQUESTED PRIOR YEARS OF THE 5358 03:36:18,760 --> 03:36:19,800 REPORT HAVE BEEN ARCHIVED. 5359 03:36:19,800 --> 03:36:24,800 SO YOU CAN NOW HAVE ACCESS TO 5360 03:36:24,800 --> 03:36:26,880 THOSE TO REVIEW. 5361 03:36:26,880 --> 03:36:30,360 I GUESS NOW WE ASK ARE THERE 5362 03:36:30,360 --> 03:36:31,120 THOUGHTS, ISSUES, CONCERNS, 5363 03:36:31,120 --> 03:36:34,520 RECOMMENDATIONS THAT ANYONE 5364 03:36:34,520 --> 03:36:37,680 WOULD LIKE TO SHARE TODAY THAT 5365 03:36:37,680 --> 03:36:39,440 THE BOARDS AND NCI SHOULD 5366 03:36:39,440 --> 03:36:42,040 CONSIDER GOING FORWARD? 5367 03:36:42,040 --> 03:36:45,120 5368 03:36:45,120 --> 03:36:45,360 5369 03:36:45,360 --> 03:36:46,880 I THINK FOR ME ONE THING IS WE 5370 03:36:46,880 --> 03:36:49,960 SHOULD TRY TO ENSURE THAT THE 5371 03:36:49,960 --> 03:36:51,120 PRESENTATIONS ALLOW FOR ADEQUATE 5372 03:36:51,120 --> 03:36:52,600 TIME FOR DISCUSSION. 5373 03:36:52,600 --> 03:36:54,760 I KNOW THERE'S A 30-MINUTE SLOT 5374 03:36:54,760 --> 03:36:57,160 SOMETIMES A PRESENTATION WILL GO 5375 03:36:57,160 --> 03:36:58,360 25, 28 MINUTES, WE DON'T HAVE 5376 03:36:58,360 --> 03:36:59,280 ENOUGH TIME. 5377 03:36:59,280 --> 03:37:00,760 I'M NOT QUITE SURE HOW WE DO 5378 03:37:00,760 --> 03:37:04,080 THAT BUT IT WOULD BE GOOD IF 5379 03:37:04,080 --> 03:37:06,480 DURING THE PLANNING THAT 5380 03:37:06,480 --> 03:37:07,920 THERE'S, YOU KNOW, CLEARER 5381 03:37:07,920 --> 03:37:09,640 INSTRUCTIONS IN TERMS OF THE 5382 03:37:09,640 --> 03:37:11,960 TIME OF THE PRESENTATION VERSUS 5383 03:37:11,960 --> 03:37:12,240 DISCUSSION. 5384 03:37:12,240 --> 03:37:13,480 THAT'S ONE QUESTION OR COMMENT 5385 03:37:13,480 --> 03:37:15,120 THAT I HAD. 5386 03:37:15,120 --> 03:37:16,960 MARGARET, I SEE YOUR HAND. 5387 03:37:16,960 --> 03:37:18,240 >>THANK YOU. 5388 03:37:18,240 --> 03:37:20,080 THIS IS JUST A THOUGHT. 5389 03:37:20,080 --> 03:37:22,080 YOU CAN THINK IT'S NOT 5390 03:37:22,080 --> 03:37:24,480 APPROPRIATE, BUT I WAS WONDERING 5391 03:37:24,480 --> 03:37:26,200 IF WHEN DIVISIONS AND SO ON 5392 03:37:26,200 --> 03:37:28,920 PRESENT THEIR REPORTS, WE ALL 5393 03:37:28,920 --> 03:37:30,560 KNOW THEY ARE DOING OUTSTANDING 5394 03:37:30,560 --> 03:37:32,760 JOBS, HIGHLY PRODUCTIVE, AND I'M 5395 03:37:32,760 --> 03:37:37,200 WOUND EARNING IF -- WONDERING IF 5396 03:37:37,200 --> 03:37:38,440 THERE SHOULDN'T BE A SMALL 5397 03:37:38,440 --> 03:37:40,200 SECTION ON ISSUES, CHALLENGES 5398 03:37:40,200 --> 03:37:42,600 THEY ARE FACING AND GAPS AND 5399 03:37:42,600 --> 03:37:43,960 WAYS IN WHICH BESIDES JUST 5400 03:37:43,960 --> 03:37:44,920 LAUDING THEM FOR THEIR REALLY 5401 03:37:44,920 --> 03:37:47,040 GOOD WORK WE CAN ACTUALLY DO 5402 03:37:47,040 --> 03:37:50,080 SOMETHING TO HELP THEM. 5403 03:37:50,080 --> 03:37:51,720 >>THAT'S A GOOD POINT. 5404 03:37:51,720 --> 03:37:56,440 AGAIN, THAT ALSO SPEAKS TO 5405 03:37:56,440 --> 03:37:59,920 FRAMING THE PRESENTATIONS 5406 03:37:59,920 --> 03:38:00,240 APPROPRIATELY. 5407 03:38:00,240 --> 03:38:00,920 >>IN TERMS OF PRESENTATIONS, 5408 03:38:00,920 --> 03:38:07,000 THEY ARE GIVE AN SET TIME TO 5409 03:38:07,000 --> 03:38:10,840 PRESENT, A SET TIME WHEN FOR 5410 03:38:10,840 --> 03:38:12,480 QUESTIONS TO BE CONSIDERED. 5411 03:38:12,480 --> 03:38:16,640 IF THE PRESENTERS GO PAST THAT 5412 03:38:16,640 --> 03:38:17,840 TIME THERE'S NO CONTROL. 5413 03:38:17,840 --> 03:38:21,080 >>I DON'T KNOW IF CAN SEE IF 5414 03:38:21,080 --> 03:38:23,240 IT'S 20 AND 10 OR 25 AND 5 TO 5415 03:38:23,240 --> 03:38:23,760 KNOW. 5416 03:38:23,760 --> 03:38:25,400 I HAVE NO PROBLEMS CUTTING 5417 03:38:25,400 --> 03:38:26,600 PEOPLE OFF. 5418 03:38:26,600 --> 03:38:30,040 >>I WILL LET THE CHAIR KNOW. 5419 03:38:30,040 --> 03:38:32,760 >>THAT WOULD BE GREAT. 5420 03:38:32,760 --> 03:38:34,360 5421 03:38:34,360 --> 03:38:36,480 THANK YOU, PAULETTE. 5422 03:38:36,480 --> 03:38:37,120 THAT'S GREAT. 5423 03:38:37,120 --> 03:38:38,560 AND THANK YOU, MARGARET, IN 5424 03:38:38,560 --> 03:38:40,120 TERMS OF THE COMMENT ABOUT THEM, 5425 03:38:40,120 --> 03:38:43,480 YOU KNOW, TALKING ABOUT 5426 03:38:43,480 --> 03:38:44,160 CHALLENGES AND ISSUES AND 5427 03:38:44,160 --> 03:38:45,240 BARRIERS TO PROGRESS. 5428 03:38:45,240 --> 03:38:53,120 IT'S A GREAT POINT. 5429 03:38:53,120 --> 03:38:57,880 FIRST I SAW NELLIE'S HAND. 5430 03:38:57,880 --> 03:38:58,840 >>ALONG THOSE LINES, QUICKLY, 5431 03:38:58,840 --> 03:39:00,120 HELPFUL TO HAVE THE 5432 03:39:00,120 --> 03:39:01,040 PRESENTATIONS BEFOREHAND TO MAKE 5433 03:39:01,040 --> 03:39:03,000 NOTES ON THEM. 5434 03:39:03,000 --> 03:39:05,200 IF THAT'S REASONABLE, JUST A 5435 03:39:05,200 --> 03:39:07,560 THOUGHT. 5436 03:39:07,560 --> 03:39:13,600 AND THEN I'M A NEW BSA MEMBER. 5437 03:39:13,600 --> 03:39:14,560 >>LET ME RESPOND. 5438 03:39:14,560 --> 03:39:15,720 WE DON'T GET THE PRESENTATIONS 5439 03:39:15,720 --> 03:39:16,760 UNTIL THE EVENING BEFORE OR DAY 5440 03:39:16,760 --> 03:39:18,000 OF THE PRESENTATION. 5441 03:39:18,000 --> 03:39:19,200 >>I'M NOT SURPRISED. 5442 03:39:19,200 --> 03:39:22,400 >>OKAY. 5443 03:39:22,400 --> 03:39:24,040 SO LET'S MOVE ON. 5444 03:39:24,040 --> 03:39:25,760 >>A MORE INFORMED DISCUSSION. 5445 03:39:25,760 --> 03:39:27,400 >>I GET IT. 5446 03:39:27,400 --> 03:39:28,600 >>LET'S MOVE ON. 5447 03:39:28,600 --> 03:39:29,440 >>MINE OTHER POINT WAS 5448 03:39:29,440 --> 03:39:32,680 SOMETHING I DON'T KNOW WHETHER 5449 03:39:32,680 --> 03:39:35,080 WE ARE ALLOWED TO PROPOSE TOPICS 5450 03:39:35,080 --> 03:39:37,160 BUT IF WE ARE THEN I WOULD LIKE 5451 03:39:37,160 --> 03:39:39,880 TO PUT SOMETHING ON OUR HORIZON 5452 03:39:39,880 --> 03:39:42,320 THAT WORRIES ME. 5453 03:39:42,320 --> 03:39:44,720 THAT IS THERE'S LIKE THIS -- 5454 03:39:44,720 --> 03:39:48,320 REQUESTS FROM THE, I DON'T KNOW, 5455 03:39:48,320 --> 03:39:51,280 LEGISLATURE ABOUT DATA SHARING 5456 03:39:51,280 --> 03:39:52,680 AND IMMEDIATE PUBLICATION OF 5457 03:39:52,680 --> 03:39:56,560 RESEARCH THAT MAY BE COMING DOWN 5458 03:39:56,560 --> 03:39:57,520 THE PIKE. 5459 03:39:57,520 --> 03:39:58,960 AND WHY THAT WORRIES ME AND I 5460 03:39:58,960 --> 03:40:01,840 THINK MONICA IS GOING TO GET 5461 03:40:01,840 --> 03:40:07,480 ASKED TO DISCUSS THAT WITH THE 5462 03:40:07,480 --> 03:40:08,640 LEGISLATOR, IS THAT IF 5463 03:40:08,640 --> 03:40:10,200 PUBLICATIONS NEED TO BE 5464 03:40:10,200 --> 03:40:11,520 IMMEDIATELY PUBLISHED WHAT WILL 5465 03:40:11,520 --> 03:40:14,560 HAPPEN IS THAT A LOT OF JOURNAL 5466 03:40:14,560 --> 03:40:15,520 IT'S, THEIR ENTIRE BUSINESS 5467 03:40:15,520 --> 03:40:17,640 MODEL IS GONE AND THEY HAVE TO 5468 03:40:17,640 --> 03:40:19,160 CHARGE OPEN ACCESS FEES FOR 5469 03:40:19,160 --> 03:40:21,560 EVERYBODY WHO IS WORKING FOR THE 5470 03:40:21,560 --> 03:40:22,440 NIH. 5471 03:40:22,440 --> 03:40:26,720 IF THEY CHARGE OPEN ACCESS FEES 5472 03:40:26,720 --> 03:40:29,000 THOSE CAN RANGE BETWEEN $3,000 5473 03:40:29,000 --> 03:40:30,320 OR $15,000 OR $20,000, THAT 5474 03:40:30,320 --> 03:40:32,640 COMES BACK TO US, P.I.s, AND 5475 03:40:32,640 --> 03:40:34,480 IT COMES BACK TO TWO THINGS THAT 5476 03:40:34,480 --> 03:40:35,600 WORRY ME SPECIFICALLY. 5477 03:40:35,600 --> 03:40:38,280 ONE IS I'M NOT GOING TO ASK MY 5478 03:40:38,280 --> 03:40:39,560 UNDERGRAD STUDENT TO WRITE THEIR 5479 03:40:39,560 --> 03:40:43,800 OWN PAPER ANYMORE IF IT COSTS ME 5480 03:40:43,800 --> 03:40:44,680 $5,000, RIGHT? 5481 03:40:44,680 --> 03:40:47,080 SO IT MEANS TRAINEES WILL BE 5482 03:40:47,080 --> 03:40:48,520 DISADVANTAGED BECAUSE WE'LL BE 5483 03:40:48,520 --> 03:40:50,240 THINKING MORE CAREFULLY ABOUT 5484 03:40:50,240 --> 03:40:53,160 HOW MUCH DOES IT COST US TO 5485 03:40:53,160 --> 03:40:54,680 PUBLISH AND TRAINEES AND THEY 5486 03:40:54,680 --> 03:41:00,000 WILL NOT HAVE FIRST AUTHOR 5487 03:41:00,000 --> 03:41:00,440 PUBLICATIONS. 5488 03:41:00,440 --> 03:41:01,760 SECOND PROBLEM WITH THIS IF WEEP 5489 03:41:01,760 --> 03:41:05,040 IN THE -- IF WE IN THE UNITED 5490 03:41:05,040 --> 03:41:06,040 STATES WITH NIH FUNDING HAVE TO 5491 03:41:06,040 --> 03:41:07,560 DO THAT BUT LET'S SAY OTHER 5492 03:41:07,560 --> 03:41:08,600 COUNTRIES DON'TS HAVE THAT 5493 03:41:08,600 --> 03:41:11,440 REQUIREMENT IT PUTS THE U.S. 5494 03:41:11,440 --> 03:41:13,080 SCIENTISTS AT A DISADVANTAGE 5495 03:41:13,080 --> 03:41:15,040 BECAUSE, AGAIN, WE WILL THINK 5496 03:41:15,040 --> 03:41:16,680 TWICE WHEN WE PUBLISH AND WILL 5497 03:41:16,680 --> 03:41:20,560 PROBABLY WAIT A LITTLE BIT 5498 03:41:20,560 --> 03:41:21,400 LONGER BEFORE SUBMITTING 5499 03:41:21,400 --> 03:41:23,280 SOMETHING AND MAYBE CHINA, 5500 03:41:23,280 --> 03:41:24,920 JAPAN, WHATEVER, CAN GET THEIR 5501 03:41:24,920 --> 03:41:25,920 STUFF OUT. 5502 03:41:25,920 --> 03:41:30,040 OF 5503 03:41:30,040 --> 03:41:31,160 MAYBE I'M PARANOID, I'M WORRIED 5504 03:41:31,160 --> 03:41:34,320 ABOUT THIS BEING SOMETHING THAT 5505 03:41:34,320 --> 03:41:36,800 COULD IMPACT US IN VERY 5506 03:41:36,800 --> 03:41:40,880 UNEXPECTED WAYS THAT WE DON'T 5507 03:41:40,880 --> 03:41:42,640 WANT TO HAVE HAPPEN. 5508 03:41:42,640 --> 03:41:44,280 >>THAT'S A FUTURE AGENDA ITEM. 5509 03:41:44,280 --> 03:41:44,560 >>YES. 5510 03:41:44,560 --> 03:41:47,880 I WAS GOING TO GET TO THAT. 5511 03:41:47,880 --> 03:41:48,200 IT'S OKAY. 5512 03:41:48,200 --> 03:41:49,240 IT'S OKAY, NELI. 5513 03:41:49,240 --> 03:41:50,120 I APPRECIATE THE COMMENTS. 5514 03:41:50,120 --> 03:41:51,840 IT'S A REALLY GOOD ONE. 5515 03:41:51,840 --> 03:41:54,560 DOUG, I WASN'T SURE IF YOUR HAND 5516 03:41:54,560 --> 03:41:56,320 WAS TO RESPOND. 5517 03:41:56,320 --> 03:42:02,800 >>YES, I WANTED TO GIVE A BRIEF 5518 03:42:02,800 --> 03:42:04,880 PRELIMINARY RESPONSE TO NELI. 5519 03:42:04,880 --> 03:42:09,800 NIH LEADERSHIP IS GOING TO BE 5520 03:42:09,800 --> 03:42:14,560 MAKING A RESPONSE TO OSTP IN 5521 03:42:14,560 --> 03:42:15,040 FEBRUARY. 5522 03:42:15,040 --> 03:42:19,080 AND THERE WILL THEN BE ADEQUATE 5523 03:42:19,080 --> 03:42:21,160 TIME FOR A RESPONSE. 5524 03:42:21,160 --> 03:42:24,720 AND WHAT NIH LEADERSHIP HAS TOLD 5525 03:42:24,720 --> 03:42:28,840 ME IS THAT THEY MAKE A 5526 03:42:28,840 --> 03:42:30,360 DISTINCTION BETWEEN SOMETHING 5527 03:42:30,360 --> 03:42:32,920 BEING PUBLICLY AVAILABLE AND 5528 03:42:32,920 --> 03:42:37,040 SOMETHING BEING OPEN ACCESS. 5529 03:42:37,040 --> 03:42:38,800 5530 03:42:38,800 --> 03:42:40,200 >>VERY GOOD. 5531 03:42:40,200 --> 03:42:41,840 ADIN, DO YOU HAVE ADDITIONAL 5532 03:42:41,840 --> 03:42:42,280 COMMENTS ABOUT THAT. 5533 03:42:42,280 --> 03:42:45,040 >>I WAS GOING TO MAKE THE SAME 5534 03:42:45,040 --> 03:42:45,600 COMMENT. 5535 03:42:45,600 --> 03:42:47,120 THANKS, JOHN. 5536 03:42:47,120 --> 03:42:48,200 >>GREAT. 5537 03:42:48,200 --> 03:42:48,760 THANKS. 5538 03:42:48,760 --> 03:42:49,520 A GREAT POINT. 5539 03:42:49,520 --> 03:42:52,840 SHOULD BE A FUTURE AGENDA ITEM. 5540 03:42:52,840 --> 03:42:59,640 >>I JUST HAD A QUESTION ABOUT 5541 03:42:59,640 --> 03:43:00,000 IN-PERSON TIME. 5542 03:43:00,000 --> 03:43:01,920 >>IN-PERSON TIME? 5543 03:43:01,920 --> 03:43:11,840 >>YES, CAN IT BE VIRTUAL 5544 03:43:11,840 --> 03:43:13,520 FOREVER? 5545 03:43:13,520 --> 03:43:13,800 [LAUGHTER] 5546 03:43:13,800 --> 03:43:15,240 >>OKAY, NCAB MEETING IN 5547 03:43:15,240 --> 03:43:19,400 FEBRUARY IS VIRTUAL DUE TO THE 5548 03:43:19,400 --> 03:43:19,640 WEATHER. 5549 03:43:19,640 --> 03:43:22,400 BSA MEETING IN MARCH WILL BE 5550 03:43:22,400 --> 03:43:23,120 VIRTUAL. 5551 03:43:23,120 --> 03:43:27,080 BUT HOPEFULLY WE CAN MOVE 5552 03:43:27,080 --> 03:43:29,120 TOWARDS FACE-TO-FACE IN REGARDS 5553 03:43:29,120 --> 03:43:33,120 TO THE JUNE 23 MEETING. 5554 03:43:33,120 --> 03:43:34,000 OKAY? 5555 03:43:34,000 --> 03:43:34,320 >>GOT IT. 5556 03:43:34,320 --> 03:43:36,920 >>I APPRECIATE THAT COMMENT. 5557 03:43:36,920 --> 03:43:38,640 I'VE BEEN SNOWED IN MARYLAND FOR 5558 03:43:38,640 --> 03:43:40,040 A STUDY SECTION BEFORE. 5559 03:43:40,040 --> 03:43:41,440 I GET IT. 5560 03:43:41,440 --> 03:43:41,960 OKAY. 5561 03:43:41,960 --> 03:43:42,160 GREAT. 5562 03:43:42,160 --> 03:43:45,960 NOW WE'RE GOING TO MOVE TO 5563 03:43:45,960 --> 03:43:46,960 ACTUAL SUGGESTIONS FOR FUTURE 5564 03:43:46,960 --> 03:43:48,160 AGENDA ITEMS. 5565 03:43:48,160 --> 03:43:51,640 ONE THAT I MENTIONED WAS NCI 5566 03:43:51,640 --> 03:43:52,000 FREDERICK. 5567 03:43:52,000 --> 03:43:54,720 ARE THERE OTHER -- NELI PROVIDED 5568 03:43:54,720 --> 03:43:54,880 ONE. 5569 03:43:54,880 --> 03:43:57,560 ARE THERE OTHERS? 5570 03:43:57,560 --> 03:44:02,200 5571 03:44:02,200 --> 03:44:05,040 YOUR HAND IS STILL UP. 5572 03:44:05,040 --> 03:44:05,320 OKAY. 5573 03:44:05,320 --> 03:44:07,800 >>YEAH, THIS IS HOWARD. 5574 03:44:07,800 --> 03:44:09,440 WE TALKED ONCE ABOUT GETTING AN 5575 03:44:09,440 --> 03:44:15,560 UPDATE ON WHAT'S GOING ON WITH 5576 03:44:15,560 --> 03:44:16,120 THE CIMACs AND 5577 03:44:16,120 --> 03:44:18,320 IMMUNO-ONCOLOGYP. 5578 03:44:18,320 --> 03:44:20,760 5579 03:44:20,760 --> 03:44:21,800 [AUDIO DISTORTION] 5580 03:44:21,800 --> 03:44:22,360 BEING DEVELOPED. 5581 03:44:22,360 --> 03:44:24,320 JOHN, AT THE LAST MEETING YOU 5582 03:44:24,320 --> 03:44:26,320 LIKED THAT IDEA GOING FORWARD 5583 03:44:26,320 --> 03:44:27,840 BUT THEY ARE STARTING TO 5584 03:44:27,840 --> 03:44:29,240 PUBLISH, THREE OR FOUR 5585 03:44:29,240 --> 03:44:32,440 PUBLICATIONS HAVE NOW COME OUT 5586 03:44:32,440 --> 03:44:34,480 OF THE CIMACs, AND BUT IT'S A 5587 03:44:34,480 --> 03:44:38,560 BIT HARD TO DIGEST AND SOMEBODY 5588 03:44:38,560 --> 03:44:41,400 LIKE DINAH SINGER, WHO HAS GREAT 5589 03:44:41,400 --> 03:44:43,480 PRESENTATION SKILLS, OR SOMEONE, 5590 03:44:43,480 --> 03:44:47,520 YOU KNOW, COULD PROBABLY DO A 5591 03:44:47,520 --> 03:44:49,480 GREAT JOB SUMMARIZING WHERE 5592 03:44:49,480 --> 03:44:49,680 THE -- 5593 03:44:49,680 --> 03:44:50,920 [AUDIO DISTORTION] 5594 03:44:50,920 --> 03:44:53,000 >>I LOVE THAT IDEA. 5595 03:44:53,000 --> 03:44:55,400 >>ALSO HOW THESE GRANTS SHOULD 5596 03:44:55,400 --> 03:44:56,800 BE GOING THEM, IMMUNO-ONCOLOGY 5597 03:44:56,800 --> 03:45:01,120 GRANTS, I'M NOT SEEING THEM 5598 03:45:01,120 --> 03:45:06,040 QUOTING OR BUILDING ON THOSE 5599 03:45:06,040 --> 03:45:07,440 INVESTMENTS. 5600 03:45:07,440 --> 03:45:08,040 >>GREAT POINT. 5601 03:45:08,040 --> 03:45:10,360 AND I THINK THAT WOULD BE A 5602 03:45:10,360 --> 03:45:12,240 REALLY GOOD FUTURE AGENDA ITEM 5603 03:45:12,240 --> 03:45:18,160 FOR BOTH NCAB AND BSA. 5604 03:45:18,160 --> 03:45:18,800 KAREN? 5605 03:45:18,800 --> 03:45:20,440 >>YEAH, SO ONE IDEA OR 5606 03:45:20,440 --> 03:45:23,360 SUGGESTION I WOULD HAVE FOR A 5607 03:45:23,360 --> 03:45:25,160 FUTURE MEETING IS SOMETHING 5608 03:45:25,160 --> 03:45:28,200 AROUND ALL OF THE CREDIBLE DATA 5609 03:45:28,200 --> 03:45:29,840 SHARING POLICIES THAT SEEM TO BE 5610 03:45:29,840 --> 03:45:33,840 COMING OUT OF EVERY WHICH WAY WE 5611 03:45:33,840 --> 03:45:37,400 TURN AROUND, PARTICULARLY IF YOU 5612 03:45:37,400 --> 03:45:41,120 LOOK FOR THE NEW NIH-WIDE 5613 03:45:41,120 --> 03:45:42,760 POLICIES THAT WE'RE ALL EXPECTED 5614 03:45:42,760 --> 03:45:44,720 TO IMPLEMENT AS OF JANUARY 25 5615 03:45:44,720 --> 03:45:48,560 THAT PEOPLE ARE TALKING ABOUT 5616 03:45:48,560 --> 03:45:49,640 SETTING UP REPOSITORIES AND 5617 03:45:49,640 --> 03:45:51,120 INSTITUTIONS, AND, YOU KNOW, 5618 03:45:51,120 --> 03:45:52,080 ACTUALLY EVEN POTENTIALLY HAVING 5619 03:45:52,080 --> 03:45:55,360 YOUR DATA BEFORE YOU PUBLISH AN 5620 03:45:55,360 --> 03:45:58,760 ARTICLE, THERE'S A LOT OF THINGS 5621 03:45:58,760 --> 03:46:00,840 TO INTERPRET IN THESE POLICIES. 5622 03:46:00,840 --> 03:46:02,920 AND IT WOULD BE REALLY GREAT TO 5623 03:46:02,920 --> 03:46:07,040 HEAR NCI'S PERSPECTIVE ON 5624 03:46:07,040 --> 03:46:08,240 POLICIES TO KIND OF THINK ABOUT 5625 03:46:08,240 --> 03:46:09,360 WHERE THEY SHOULD BE GOING, 5626 03:46:09,360 --> 03:46:11,320 WHERE WE SHOULD BE GOING, THINGS 5627 03:46:11,320 --> 03:46:11,600 LIKE THAT. 5628 03:46:11,600 --> 03:46:13,120 I JUST THINK IT WOULD BE 5629 03:46:13,120 --> 03:46:14,920 INFORMATIVE FOR US TO HEAR, 5630 03:46:14,920 --> 03:46:20,080 MAYBE WE CAN HAVE SOME GOOD 5631 03:46:20,080 --> 03:46:23,240 INPUT ON ALL OF THIS. 5632 03:46:23,240 --> 03:46:24,880 >>GREAT POINT. 5633 03:46:24,880 --> 03:46:26,320 AND HOPEFULLY THAT'S NOTED AND 5634 03:46:26,320 --> 03:46:26,840 CAPTURED. 5635 03:46:26,840 --> 03:46:29,280 IF THERE ARE ANY OTHER TOPICS, 5636 03:46:29,280 --> 03:46:31,800 PLEASE FEEL FREE TO SEND THEM 5637 03:46:31,800 --> 03:46:33,000 FROM THE JOINT COMMITTEE, FEEL 5638 03:46:33,000 --> 03:46:35,840 FREE TO SEND THEM TO KEITH OR 5639 03:46:35,840 --> 03:46:41,120 PAULETTE OR MYSELF, INDIVIDUAL 5640 03:46:41,120 --> 03:46:45,480 BOARD AGENDA SUGGESTIONS TO 5641 03:46:45,480 --> 03:46:46,600 PAULETTE OR THE CHAIR. 5642 03:46:46,600 --> 03:46:48,680 I THANK YOU FOR AN AMAZING 5643 03:46:48,680 --> 03:46:50,520 MEETING GETTING TO HEAR FROM OUR 5644 03:46:50,520 --> 03:46:53,280 NEW NCI DIRECTOR AS WELL AS 5645 03:46:53,280 --> 03:46:55,680 INAUGURAL ARPA-H DIRECTOR WAS TO 5646 03:46:55,680 --> 03:46:58,080 ME AN ABSOLUTE TREAT. 5647 03:46:58,080 --> 03:47:00,360 THE QUESTIONS, COMMENTS, 5648 03:47:00,360 --> 03:47:02,560 FEEDBACK WERE INSIGHTFUL OVER 5649 03:47:02,560 --> 03:47:03,880 THE LAST COUPLE DAYS. 5650 03:47:03,880 --> 03:47:06,400 I THINK NCI IS GOING TO BE 5651 03:47:06,400 --> 03:47:08,600 BETTER FROM THESE MEETINGS AND 5652 03:47:08,600 --> 03:47:09,800 THESE DISCUSSIONS AND WE'RE ALL 5653 03:47:09,800 --> 03:47:11,080 ANXIOUS ABOUT WATCHING OUT FOR 5654 03:47:11,080 --> 03:47:12,840 THE BUDGETS AND HOW THAT'S GOING 5655 03:47:12,840 --> 03:47:15,040 TO PLAY OUT IN TERMS OF THE C.R. 5656 03:47:15,040 --> 03:47:17,560 OVER THE NEXT UPCOMING MONTHS 5657 03:47:17,560 --> 03:47:19,280 BUT I FEEL THAT THESE MEETINGS 5658 03:47:19,280 --> 03:47:19,640 WERE AMAZING. 5659 03:47:19,640 --> 03:47:23,480 KEITH, I DON'T KNOW IF YOU HAVE 5660 03:47:23,480 --> 03:47:24,240 FINAL COMMENTS? 5661 03:47:24,240 --> 03:47:26,200 >>NO, ECHO THOSE THOUGHTS, 5662 03:47:26,200 --> 03:47:27,160 JOHN. 5663 03:47:27,160 --> 03:47:28,080 REALLY APPRECIATE THE VIGOROUS 5664 03:47:28,080 --> 03:47:31,440 PARTICIPATION OF THE PAST COUPLE 5665 03:47:31,440 --> 03:47:32,080 DAYS' DISCUSSIONS. 5666 03:47:32,080 --> 03:47:36,920 >>SO THERE BEING NO FURTHER 5667 03:47:36,920 --> 03:47:38,560 BUSINESS, WE WILL ADJOURN. 5668 03:47:38,560 --> 03:47:42,920 >>HAVE A GREAT HOLIDAY SEASON. 5669 03:47:42,920 --> 03:47:50,240 >>AND I'LL SEE THE NCAB MEMBERS 5670 03:47:50,240 --> 00:00:00,000 VIRTUALLY IN FEBRUARY.